BRCA1	O	NOUN	B
is	O	AUX	O
secreted	O	VERB	B
and	O	CCONJ	O
exhibits	O	VERB	O
properties	O	NOUN	B
of	O	ADP	O
a	O	DET	O
granin	O	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
BRCA1	O	NOUN	B
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
most	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
function	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
protein	O	NOUN	I
has	O	AUX	O
remained	O	VERB	O
elusive	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
encodes	O	VERB	B
a	O	DET	O
190	O	NUM	O
-	O	PUNCT	O
kD	O	NOUN	B
protein	O	NOUN	I
with	O	ADP	O
sequence	O	NOUN	B
homology	O	NOUN	I
and	O	CCONJ	O
biochemical	O	ADJ	B
analogy	O	NOUN	B
to	O	PART	O
the	O	DET	O
granin	O	NOUN	B
protein	O	NOUN	I
family	O	NOUN	O
.	O	PUNCT	O


Interestingly	O	ADV	O
,	O	PUNCT	O
BRCA2	O	NOUN	B
also	O	ADV	O
includes	O	VERB	O
a	O	DET	O
motif	O	NOUN	B
similar	O	ADJ	O
to	O	PART	O
the	O	DET	O
granin	O	NOUN	B
consensus	O	NOUN	B
at	O	ADP	O
the	O	DET	O
C	O	NOUN	O
terminus	O	NOUN	O
of	O	ADP	O
the	O	DET	O
protein	O	NOUN	B
.	O	PUNCT	O


Both	O	CCONJ	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
granins	O	NOUN	B
localize	O	VERB	O
to	O	PART	O
secretory	O	ADJ	B
vesicles	O	NOUN	I
,	O	PUNCT	O
are	O	AUX	O
secreted	O	VERB	B
by	O	ADP	O
a	O	DET	O
regulated	O	VERB	O
pathway	O	NOUN	O
,	O	PUNCT	O
are	O	AUX	O
post	O	NOUN	B
-	O	PUNCT	O
translationally	O	ADV	B
glycosylated	O	VERB	B
and	O	CCONJ	O
are	O	AUX	O
responsive	O	ADJ	B
to	O	PART	O
hormones	O	NOUN	B
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
regulated	O	VERB	O
secretory	O	ADJ	B
protein	O	NOUN	I
,	O	PUNCT	O
BRCA1	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
function	O	VERB	B
by	O	ADP	O
a	O	DET	O
mechanism	O	NOUN	B
not	O	PART	O
previously	O	ADV	O
described	O	VERB	O
for	O	ADP	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
products	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
risk	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
carriers	O	NOUN	B
is	O	AUX	O
modified	O	VERB	B
by	O	ADP	O
the	O	DET	O
HRAS1	O	NOUN	B
variable	O	ADJ	B
number	O	NOUN	I
of	O	ADP	O
tandem	O	ADJ	O
repeat	O	NOUN	O
(	O	PUNCT	O
VNTR	O	NOUN	O
)	O	PUNCT	O
locus	O	NOUN	O
.	O	PUNCT	O


Women	O	NOUN	B
who	O	PRON	O
carry	O	VERB	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
on	O	ADP	O
chromosome	O	NOUN	B
17q21	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
have	O	AUX	O
an	O	DET	O
80	O	NUM	O
%	O	NOUN	O
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
40	O	NUM	O
%	O	NOUN	O
risk	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
by	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
70	O	NUM	O
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
variable	O	ADJ	B
penetrance	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
genetic	O	ADJ	B
and	O	CCONJ	O
non	O	ADJ	B
-	O	PUNCT	O
genetic	O	ADJ	B
factors	O	NOUN	I
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
tumourigenesis	O	NOUN	B
in	O	ADP	O
these	O	DET	O
individuals	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
HRAS1	O	NOUN	B
variable	O	ADJ	B
number	O	NOUN	I
of	O	ADP	O
tandem	O	ADJ	B
repeats	O	NOUN	I
(	O	PUNCT	I
VNTR	O	NOUN	B
)	O	PUNCT	O
polymorphism	O	NOUN	B
,	O	PUNCT	O
located	O	ADJ	O
1	O	NUM	O
kilobase	O	NOUN	O
(	O	PUNCT	O
kb	O	NOUN	O
)	O	PUNCT	O
downstream	O	ADJ	B
of	O	ADP	O
the	O	DET	O
HRAS1	O	NOUN	B
proto	O	NOUN	I
-	O	PUNCT	O
oncogene	O	NOUN	B
(	O	PUNCT	O
chromosome	O	NOUN	B
11p15	O	NOUN	I
.	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
one	O	NUM	O
possible	O	ADJ	O
genetic	O	ADJ	B
modifier	O	NOUN	I
of	O	ADP	O
cancer	B-Disease	NOUN	B
penetrance	O	NOUN	B
.	O	PUNCT	O


Individuals	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
rare	O	ADJ	B
alleles	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VNTR	O	NOUN	B
have	O	AUX	O
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
certain	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
cancers	B-Disease	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
2	O	NUM	O
-	O	SYM	O
4	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
rare	O	ADJ	B
HRAS1	O	NOUN	B
alleles	O	NOUN	B
increases	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
typed	O	VERB	B
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
307	O	NUM	O
female	O	ADJ	B
BRCA1	O	NOUN	B
carriers	O	NOUN	B
at	O	ADP	O
this	O	DET	O
locus	O	NOUN	B
using	O	VERB	O
a	O	DET	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
technique	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
2	O	NUM	O
.	O	PUNCT	O


11	O	NUM	O
times	O	NOUN	O
greater	O	ADJ	O
for	O	ADP	O
BRCA1	O	NOUN	B
carriers	O	NOUN	B
harbouring	O	VERB	O
one	O	NUM	O
or	O	CCONJ	O
two	O	NUM	O
rare	O	ADJ	O
HRAS1	O	NOUN	B
alleles	O	NOUN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
carriers	O	NOUN	B
with	O	ADP	O
only	O	ADV	O
common	O	ADJ	O
alleles	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
015	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
magnitude	O	NOUN	B
of	O	ADP	O
the	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
rare	O	ADJ	B
HRAS1	O	NOUN	B
allele	O	NOUN	B
was	O	AUX	O
not	O	PART	O
altered	O	VERB	O
by	O	ADP	O
adjusting	O	VERB	O
for	O	ADP	O
the	O	DET	O
other	O	ADJ	O
known	O	ADJ	O
risk	O	NOUN	B
factors	O	NOUN	I
for	O	ADP	O
hereditary	B-Disease	ADJ	B
ovarian	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Susceptibility	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
did	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
affected	O	VERB	B
by	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
rare	O	ADJ	B
HRAS1	O	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
to	O	PART	O
show	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
modifying	O	VERB	O
gene	O	NOUN	B
on	O	ADP	O
the	O	DET	O
penetrance	O	NOUN	B
of	O	ADP	O
an	O	DET	O
inherited	B-Disease	VERB	B
cancer	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I


A	O	DET	O
novel	O	ADJ	O
homeodomain	O	NOUN	B
-	O	PUNCT	O
encoding	O	VERB	B
gene	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
large	O	ADJ	O
CpG	O	NOUN	B
island	O	NOUN	O
interrupted	O	VERB	B
by	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
unstable	O	ADJ	I
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
trinucleotide	O	NOUN	B
repeat	O	NOUN	I
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
kinase	O	NOUN	I
-	O	PUNCT	O
encoding	O	VERB	B
gene	O	NOUN	B
,	O	PUNCT	O
DMPK	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
maps	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	B
19q13	O	NOUN	I
.	O	PUNCT	O


3	O	X	O
.	O	PUNCT	O


Characterisation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
in	O	ADP	O
patient	O	NOUN	B
tissues	O	NOUN	I
has	O	AUX	O
thus	O	ADV	O
far	O	ADV	O
generated	O	VERB	O
conflicting	O	VERB	O
data	O	NOUN	B
on	O	ADP	O
alterations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
steady	O	ADJ	B
state	O	NOUN	I
levels	O	NOUN	O
of	O	ADP	O
DMPK	O	NOUN	B
mRNA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
final	O	ADJ	O
DMPK	O	NOUN	B
protein	O	NOUN	O
levels	O	NOUN	O
in	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
expansion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
DM	B-Disease	NOUN	B
region	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	O
19	O	NUM	O
is	O	AUX	O
gene	O	NOUN	B
rich	O	ADJ	I
,	O	PUNCT	O
and	O	CCONJ	O
it	O	PRON	O
is	O	AUX	O
possible	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
repeat	O	NOUN	O
expansion	O	NOUN	B
may	O	AUX	O
lead	O	VERB	O
to	O	PART	O
dysfunction	O	NOUN	B
of	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
transcription	O	NOUN	B
units	O	NOUN	I
in	O	ADP	O
the	O	DET	O
vicinity	O	NOUN	B
,	O	PUNCT	O
perhaps	O	ADV	O
as	O	ADP	O
a	O	DET	O
consequence	O	NOUN	O
of	O	ADP	O
chromatin	O	NOUN	B
disruption	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
genes	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
CpG	O	NOUN	B
island	O	NOUN	I
at	O	ADP	O
the	O	DET	O
3	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
DMPK	O	NOUN	B
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
this	O	DET	O
region	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
island	O	NOUN	B
extends	O	VERB	O
over	O	ADP	O
3	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
kb	O	NOUN	O
and	O	CCONJ	O
is	O	AUX	O
interrupted	O	VERB	B
by	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
genomic	O	ADJ	B
sequences	O	NOUN	I
downstream	O	ADJ	I
(	O	PUNCT	O
centromeric	O	ADJ	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
repeat	O	NOUN	O
in	O	ADP	O
human	O	ADJ	B
and	O	CCONJ	O
mouse	O	NOUN	B
identified	O	VERB	O
regions	O	NOUN	O
of	O	ADP	O
significant	O	ADJ	O
homology	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
correspond	O	VERB	O
to	O	PART	O
exons	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
predicted	O	VERB	O
to	O	PART	O
encode	O	VERB	B
a	O	DET	O
homeodomain	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
analysis	O	NOUN	B
shows	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
gene	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
we	O	PRON	O
have	O	AUX	O
called	O	VERB	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
homeodomain	O	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
DMAHP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
tissues	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
,	O	PUNCT	O
heart	O	NOUN	B
and	O	CCONJ	O
brain	O	NOUN	B
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
the	O	DET	O
27	O	NUM	O
exons	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
promoter	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
familial	B-Disease	ADJ	B
or	I-Disease	CCONJ	O
sporadic	I-Disease	ADJ	B
bilateral	I-Disease	ADJ	O
retinoblastoma	I-Disease	NOUN	O
by	O	ADP	O
using	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


For	O	ADP	O
improvement	O	NOUN	B
over	O	ADP	O
previous	O	ADJ	O
studies	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
new	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
primers	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
designed	O	VERB	O
,	O	PUNCT	O
which	O	DET	O
allow	O	VERB	O
for	O	ADP	O
amplification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
coding	O	NOUN	B
and	O	CCONJ	O
splicing	O	NOUN	B
sequences	O	NOUN	I
only	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
positioning	O	NOUN	B
of	O	ADP	O
the	O	DET	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
(	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
primers	O	NOUN	O
was	O	AUX	O
such	O	ADJ	O
that	O	SCONJ	O
the	O	DET	O
resulting	O	VERB	O
PCR	O	NOUN	B
products	O	NOUN	I
were	O	AUX	O
of	O	ADP	O
different	O	ADJ	O
sizes	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
analyze	O	VERB	B
two	O	NUM	O
different	O	ADJ	O
exons	O	NOUN	B
simultaneously	O	ADV	B
and	O	CCONJ	O
still	O	ADV	O
distinguish	O	VERB	O
between	O	ADP	O
the	O	DET	O
banding	O	NOUN	B
profiles	O	NOUN	B
for	O	ADP	O
both	O	DET	O
(	O	PUNCT	O
biplex	O	ADJ	B
analysis	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
using	O	VERB	O
this	O	DET	O
approach	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
identify	O	VERB	O
mutation	O	NOUN	B
in	O	ADP	O
22	O	NUM	O
new	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
overall	O	ADJ	O
efficiency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
procedure	O	NOUN	B
when	O	SCONJ	O
we	O	PRON	O
used	O	VERB	O
a	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
pass	O	NOUN	B
regimen	O	NOUN	B
was	O	AUX	O
only	O	ADV	O
48	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mutations	O	NOUN	B
were	O	AUX	O
small	O	ADJ	O
insertions	O	NOUN	B
and	O	CCONJ	O
deletions	O	NOUN	B
and	O	CCONJ	O
point	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
roughly	O	ADV	O
equal	O	ADJ	O
proportions	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Type	B-Disease	NOUN	B
II	I-Disease	NUM	I
human	I-Disease	ADJ	I
complement	I-Disease	NOUN	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
(	O	PUNCT	O
Ser189	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Phe	O	NOUN	B
;	O	PUNCT	O
Gly444	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Arg	O	NOUN	B
)	O	PUNCT	O
cause	O	VERB	O
impaired	O	VERB	B
C2	O	NOUN	O
secretion	O	NOUN	O
.	O	PUNCT	O


Type	B-Disease	NOUN	B
II	I-Disease	NUM	I
complement	I-Disease	NOUN	I
protein	I-Disease	NOUN	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
selective	O	ADJ	O
block	O	NOUN	O
in	O	ADP	O
C2	O	NOUN	O
secretion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Type	O	NOUN	B
II	O	NUM	I
C2	O	NOUN	I
null	O	NOUN	I
allele	O	NOUN	I
(	O	PUNCT	I
C2Q0	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
linked	O	VERB	O
to	O	PART	O
two	O	NUM	O
major	O	ADJ	O
histocompatibility	O	NOUN	B
haplotypes	O	NOUN	I
(	O	PUNCT	O
MHC	O	NOUN	B
)	O	PUNCT	O
that	O	PRON	O
differ	O	VERB	O
from	O	ADP	O
the	O	DET	O
MHC	O	NOUN	B
of	O	ADP	O
the	O	DET	O
more	O	ADV	O
common	O	ADJ	O
Type	B-Disease	NOUN	B
I	I-Disease	NUM	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
Type	B-Disease	NOUN	B
II	I-Disease	NUM	I
deficiency	I-Disease	NOUN	I
the	O	DET	O
two	O	NUM	O
Type	O	NOUN	B
II	O	NUM	I
C2Q0	O	NOUN	I
genes	O	NOUN	I
were	O	AUX	O
isolated	O	VERB	B
and	O	CCONJ	O
transfected	O	VERB	B
separately	O	ADV	O
into	O	ADP	O
L	O	NOUN	B
-	O	PUNCT	O
cells	O	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
molecular	O	ADJ	B
biology	O	NOUN	I
,	O	PUNCT	O
biosynthetic	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
immunofluorescence	O	NOUN	B
studies	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
C2	O	NOUN	B
secretion	O	NOUN	I
is	O	AUX	O
impaired	O	ADJ	B
in	O	ADP	O
Type	B-Disease	NOUN	B
II	I-Disease	NUM	I
C2	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
because	O	SCONJ	O
of	O	ADP	O
different	O	ADJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
at	O	ADP	O
highly	O	ADV	O
conserved	O	VERB	O
residues	O	NOUN	O
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
C2Q0	O	NOUN	B
alleles	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
is	O	AUX	O
in	O	ADP	O
exon	O	NOUN	B
5	O	NUM	I
(	O	PUNCT	O
nucleotide	O	NOUN	B
C566	O	NOUN	I
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
;	O	PUNCT	O
Ser189	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
Phe	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
C2Q0	O	NOUN	B
gene	O	NOUN	I
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
MHC	O	NOUN	B
haplotype	O	NOUN	O
A11	O	NOUN	O
,	O	PUNCT	O
B35	O	NOUN	B
,	O	PUNCT	O
DRw1	O	NOUN	B
,	O	PUNCT	O
BFS	O	PROPN	B
,	O	PUNCT	O
C4A0B1	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
other	O	ADJ	O
is	O	AUX	O
in	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
(	O	PUNCT	O
G1930	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
;	O	PUNCT	O
Gly444	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Arg	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
C2Q0	O	NOUN	B
gene	O	NOUN	I
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
MHC	O	NOUN	B
haplotype	O	NOUN	O
A2	O	NOUN	O
,	O	PUNCT	O
B5	O	NOUN	B
,	O	PUNCT	O
DRw4	O	NOUN	B
,	O	PUNCT	O
BFS	O	PROPN	B
,	O	PUNCT	O
C4A3B1	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
mutant	O	ADJ	B
C2	O	NOUN	I
gene	O	NOUN	I
product	O	NOUN	I
is	O	AUX	O
retained	O	VERB	O
early	O	ADV	B
in	O	ADP	O
the	O	DET	O
secretory	O	ADJ	B
pathway	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
mutants	O	NOUN	B
provide	O	VERB	O
models	O	NOUN	B
for	O	ADP	O
elucidating	O	VERB	O
the	O	DET	O
C2	O	NOUN	B
secretory	O	ADJ	I
pathway	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Defective	O	ADJ	B
dimerization	O	NOUN	O
of	O	ADP	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
subunits	O	NOUN	I
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
Cys	O	NOUN	B
-	O	PUNCT	O
>	O	X	O
Arg	O	NOUN	B
mutation	O	NOUN	O
in	O	ADP	O
type	B-Disease	NOUN	B
IID	I-Disease	NOUN	I
von	I-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
same	O	ADJ	O
heterozygous	O	ADJ	B
T	O	NOUN	B
-	O	PUNCT	O
>	O	X	O
C	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
nt	O	NOUN	O
8567	O	NUM	O
of	O	ADP	O
the	O	DET	O
von	B-Disease	NOUN	B
Willebrand	I-Disease	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
vWF	O	NOUN	B
)	O	PUNCT	O
transcript	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
two	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
type	B-Disease	NOUN	B
IID	I-Disease	NOUN	I
von	I-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
other	O	ADJ	O
apparent	O	ADJ	B
abnormality	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
alleles	O	NOUN	B
were	O	AUX	O
normal	O	ADJ	O
in	O	ADP	O
the	O	DET	O
parents	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
sister	O	NOUN	B
;	O	PUNCT	O
thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
mutation	O	NOUN	B
originated	O	VERB	O
de	O	X	O
novo	O	X	O
in	O	ADP	O
the	O	DET	O
proposita	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
patient	O	NOUN	B
also	O	ADV	O
had	O	AUX	O
asymptomatic	O	ADJ	B
parents	O	NOUN	B
who	O	PRON	O
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
were	O	AUX	O
not	O	PART	O
available	O	ADJ	O
for	O	ADP	O
study	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
structural	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	O
the	O	DET	O
identified	O	VERB	B
mutation	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
the	O	DET	O
CyS2010	O	PROPN	B
-	O	PUNCT	O
>	O	X	O
Arg	O	NOUN	B
substitution	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
vWF	O	NOUN	B
carboxyl	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
domain	O	NOUN	B
containing	O	VERB	O
residues	O	NOUN	B
1366	O	NUM	O
-	O	SYM	O
2050	O	NUM	O
.	O	PUNCT	O


Insect	O	ADJ	B
cells	O	NOUN	I
infected	O	VERB	B
with	O	ADP	O
recombinant	O	ADJ	B
baculovirus	O	NOUN	I
expressing	O	VERB	B
normal	O	ADJ	O
vWF	O	NOUN	B
sequence	O	NOUN	O
secreted	O	VERB	B
a	O	DET	O
disulfide	O	NOUN	B
linked	O	VERB	O
dimeric	O	ADJ	B
molecule	O	NOUN	I
with	O	ADP	O
an	O	DET	O
apparent	O	ADJ	B
molecular	O	ADJ	B
mass	O	NOUN	I
of	O	ADP	O
150	O	NUM	O
kDa	O	NOUN	O
before	O	ADP	O
reduction	O	NOUN	B
,	O	PUNCT	O
yielding	O	VERB	O
a	O	DET	O
single	O	ADJ	O
band	O	NOUN	O
of	O	ADP	O
80	O	NUM	O
kDa	O	NOUN	O
after	O	ADP	O
disulfide	O	NOUN	B
bond	O	NOUN	I
reduction	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
cells	O	NOUN	B
expressing	O	VERB	B
the	O	DET	O
mutant	O	ADJ	B
fragment	O	NOUN	O
secreted	O	VERB	B
a	O	DET	O
monomeric	O	ADJ	B
molecule	O	NOUN	I
of	O	ADP	O
apparent	O	ADJ	B
molecular	O	ADJ	B
mass	O	NOUN	I
of	O	ADP	O
80	O	NUM	O
kDa	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
remained	O	VERB	O
unchanged	O	ADJ	B
after	O	ADP	O
reduction	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
CyS2010	O	NOUN	B
is	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	B
dimerization	O	NOUN	I
of	O	ADP	O
vWF	O	NOUN	B
subunits	O	NOUN	I
through	O	ADP	O
disulfide	O	NOUN	B
bonding	O	NOUN	I
of	O	ADP	O
carboxyl	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
domains	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
a	O	DET	O
heterozygous	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
codon	O	NOUN	B
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
defective	O	ADJ	B
multimer	O	NOUN	B
formation	O	NOUN	O
in	O	ADP	O
type	B-Disease	NOUN	B
IID	I-Disease	NOUN	I
von	I-Disease	NOUN	I
Willebrand	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
novel	O	ADJ	O
effector	O	NOUN	B
for	O	ADP	O
the	O	DET	O
GTPase	O	NOUN	B
CDC42Hs	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
actin	O	NOUN	B
polymerization	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Rho	O	NOUN	B
family	O	NOUN	B
of	O	ADP	O
GTPases	O	NOUN	B
control	O	VERB	B
diverse	O	ADJ	O
biological	O	ADJ	B
processes	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
cell	O	NOUN	B
morphology	O	NOUN	I
and	O	CCONJ	O
mitogenesis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	O
WASP	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
protein	O	NOUN	B
that	O	PRON	O
is	O	AUX	O
defective	O	ADJ	B
in	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
effector	O	NOUN	B
for	O	ADP	O
CDC42Hs	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
for	O	ADP	O
the	O	DET	O
other	O	ADJ	O
Rho	O	NOUN	B
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
Rac	O	NOUN	B
and	O	CCONJ	O
Rho	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
interaction	O	NOUN	B
is	O	AUX	O
dependent	O	ADJ	B
on	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
G	O	NOUN	B
protein	O	NOUN	I
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	I
.	O	PUNCT	O


Cellular	O	ADJ	B
expression	O	NOUN	I
of	O	ADP	O
epitope	O	NOUN	B
-	O	PUNCT	O
tagged	O	VERB	B
WASP	O	PROPN	B
produces	O	VERB	O
clusters	O	NOUN	B
of	O	ADP	O
WASP	O	PROPN	B
that	O	PRON	O
are	O	AUX	O
highly	O	ADV	O
enriched	O	VERB	O
in	O	ADP	O
polymerized	O	ADJ	B
actin	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
clustering	O	NOUN	B
is	O	AUX	O
not	O	PART	O
observed	O	VERB	O
with	O	ADP	O
a	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminally	O	ADV	B
deleted	O	VERB	B
WASP	O	PROPN	B
and	O	CCONJ	O
is	O	AUX	O
inhibited	O	VERB	B
by	O	ADP	O
coexpression	O	NOUN	B
with	O	ADP	O
dominant	O	ADJ	B
negative	O	ADJ	B
CDC42Hs	O	NOUN	B
-	O	PUNCT	O
N17	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
with	O	ADP	O
dominant	O	ADJ	B
negative	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
Rac	O	NOUN	B
or	O	CCONJ	O
Rho	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
WASP	O	PROPN	B
provides	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
link	O	NOUN	O
between	O	ADP	O
CDC42Hs	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
actin	O	NOUN	B
cytoskeleton	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
suggests	O	VERB	O
a	O	DET	O
molecular	O	ADJ	B
mechanism	O	NOUN	I
for	O	ADP	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
abnormalities	O	NOUN	I
in	O	ADP	O
WAS	B-Disease	PROPN	B
.	O	PUNCT	O


The	O	DET	O
WASP	O	NOUN	B
sequence	O	NOUN	B
contains	O	VERB	O
two	O	NUM	O
novel	O	ADJ	O
domains	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
homologous	O	ADJ	B
to	O	PART	O
other	O	ADJ	O
proteins	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
action	O	NOUN	B
organization	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
idiopathic	O	ADJ	B
Addison	B-Disease	NOUN	I
'	I-Disease	PART	O
s	I-Disease	NOUN	O
disease	I-Disease	NOUN	B
in	O	ADP	O
young	O	ADJ	B
adult	O	ADJ	I
male	O	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
Linked	I-Disease	VERB	B
adrenoleukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
ALD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
genetic	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
demyelination	B-Disease	NOUN	B
of	I-Disease	ADP	O
the	I-Disease	DET	O
central	I-Disease	ADJ	B
nervous	I-Disease	ADJ	I
system	I-Disease	NOUN	I
,	O	PUNCT	O
adrenal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
accumulation	O	NOUN	B
of	O	ADP	O
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
in	O	ADP	O
tissue	O	NOUN	B
and	O	CCONJ	O
body	O	NOUN	B
fluids	O	NOUN	I
.	O	PUNCT	O


ALD	B-Disease	NOUN	B
is	O	AUX	O
due	O	ADJ	O
to	O	PART	O
mutation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
located	O	ADJ	O
in	O	ADP	O
Xq28	O	NOUN	B
that	O	PRON	O
encodes	O	VERB	B
a	O	DET	O
peroxisomal	O	ADJ	B
transporter	O	NOUN	I
protein	O	NOUN	I
of	O	ADP	O
unknown	O	ADJ	O
function	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
phenotype	O	NOUN	B
of	O	ADP	O
ALD	B-Disease	NOUN	B
is	O	AUX	O
the	O	DET	O
cerebral	O	ADJ	B
form	O	NOUN	I
(	O	PUNCT	O
45	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
that	O	PRON	O
develops	O	VERB	O
in	O	ADP	O
boys	O	NOUN	B
between	O	ADP	O
5	O	NUM	O
-	O	SYM	O
12	O	NUM	O
yr	O	NOUN	O
.	O	PUNCT	O


Adrenomyeloneuropathy	B-Disease	NOUN	B
(	O	PUNCT	O
AMN	B-Disease	NOUN	B
)	O	PUNCT	O
involves	O	VERB	O
the	O	DET	O
spinal	O	ADJ	B
cord	O	NOUN	I
and	O	CCONJ	O
peripheral	O	ADJ	B
nerves	O	NOUN	I
in	O	ADP	O
young	O	ADJ	B
adults	O	NOUN	I
(	O	PUNCT	O
35	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Adrenal	B-Disease	ADJ	B
insufficiency	I-Disease	NOUN	I
(	O	PUNCT	O
Addisons	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
)	O	PUNCT	O
is	O	AUX	O
frequently	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
AMN	B-Disease	NOUN	B
or	O	CCONJ	O
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
remain	O	VERB	O
the	O	DET	O
only	O	ADJ	O
clinical	O	ADJ	B
expression	O	NOUN	O
of	O	ADP	O
ALD	B-Disease	NOUN	B
(	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
cases	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
ALD	B-Disease	NOUN	B
among	O	ADP	O
adults	O	NOUN	B
with	O	ADP	O
Addisons	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
remains	O	VERB	O
unknown	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
evaluate	O	VERB	B
this	O	DET	O
prevalence	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
performed	O	VERB	O
biochemical	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	ADJ	O
acids	O	NOUN	O
in	O	ADP	O
14	O	NUM	O
male	O	NOUN	B
patients	O	NOUN	B
(	O	PUNCT	O
age	O	NOUN	B
ranging	O	VERB	O
from	O	ADP	O
12	O	NUM	O
-	O	SYM	O
45	O	NUM	O
yr	O	NOUN	O
at	O	ADP	O
diagnosis	O	NOUN	B
)	O	PUNCT	O
previously	O	ADV	O
diagnosed	O	VERB	B
as	O	ADP	O
having	O	VERB	O
primary	O	ADJ	O
idiopathic	O	ADJ	B
adrenocortical	B-Disease	ADJ	I
insufficiency	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
5	O	NUM	O
of	O	ADP	O
14	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
35	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
elevated	O	ADJ	B
plasma	O	NOUN	B
concentrations	O	NOUN	B
of	O	ADP	O
very	O	ADV	O
long	O	ADJ	O
chain	O	NOUN	O
fatty	O	NOUN	O
acids	O	NOUN	O
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
adrenocortical	O	ADJ	B
antibodies	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
electrophysiological	O	ADJ	B
tests	O	NOUN	I
and	O	CCONJ	O
magnetic	O	ADJ	B
resonance	O	NOUN	I
imaging	O	NOUN	I
it	O	PRON	O
was	O	AUX	O
determined	O	VERB	O
that	O	SCONJ	O
two	O	NUM	O
patients	O	NOUN	B
had	O	AUX	O
cerebral	B-Disease	ADJ	B
ALD	I-Disease	NOUN	I
,	O	PUNCT	O
one	O	PRON	O
had	O	AUX	O
adrenomyeloneuropathy	B-Disease	NOUN	B
with	O	ADP	O
cerebral	O	ADJ	B
involvement	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
had	O	AUX	O
preclinical	O	ADJ	B
AMN	B-Disease	PROPN	B
.	O	PUNCT	O


Our	O	PRON	O
data	O	NOUN	B
support	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
ALD	B-Disease	NOUN	B
is	O	AUX	O
a	O	DET	O
frequent	O	ADJ	B
cause	O	NOUN	B
of	O	ADP	O
idiopathic	O	ADJ	B
Addisons	B-Disease	NOUN	I
disease	I-Disease	NOUN	I
in	O	ADP	O
children	O	NOUN	B
and	O	CCONJ	O
adults	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Tumor	B-Disease	NOUN	B
suppression	O	NOUN	B
and	O	CCONJ	O
apoptosis	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
prostate	B-Disease	NOUN	O
carcinoma	I-Disease	NOUN	O
mediated	O	VERB	O
by	O	ADP	O
a	O	DET	O
genetic	O	ADJ	B
locus	O	NOUN	I
within	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
10pter	O	NOUN	O
-	O	PUNCT	O
q11	O	NOUN	B
.	O	PUNCT	O


Prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
is	O	AUX	O
the	O	DET	O
second	O	ADJ	O
leading	O	NOUN	O
cause	O	NOUN	O
of	O	ADP	O
male	O	NOUN	B
cancer	B-Disease	NOUN	O
deaths	O	NOUN	B
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
States	O	PROPN	I
.	O	PUNCT	O


Yet	O	ADV	O
,	O	PUNCT	O
despite	O	SCONJ	O
a	O	DET	O
large	O	ADJ	O
international	O	ADJ	B
effort	O	NOUN	B
,	O	PUNCT	O
little	O	ADJ	O
is	O	AUX	O
known	O	VERB	O
about	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
that	O	PRON	O
underlie	O	VERB	O
this	O	DET	O
devastating	O	ADJ	O
disease	O	NOUN	B
.	O	PUNCT	O


Prostate	O	NOUN	B
secretory	O	ADJ	I
epithelial	O	ADJ	B
cells	O	NOUN	I
and	O	CCONJ	O
androgen	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
prostate	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
undergo	O	VERB	O
apoptosis	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
androgen	O	NOUN	B
deprivation	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
furthermore	O	ADV	O
,	O	PUNCT	O
most	O	ADJ	O
prostate	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
become	O	VERB	O
androgen	O	NOUN	B
independent	O	ADJ	B
and	O	CCONJ	O
refractory	O	ADJ	B
to	O	PART	O
further	O	ADJ	O
therapeutic	O	ADJ	B
manipulations	O	NOUN	I
during	O	ADP	O
disease	O	NOUN	B
progression	O	NOUN	I
.	O	PUNCT	O


Definition	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
events	O	NOUN	I
that	O	PRON	O
trigger	O	VERB	B
apoptosis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prostate	O	NOUN	B
could	O	AUX	O
provide	O	VERB	O
important	O	ADJ	O
insights	O	NOUN	O
into	O	ADP	O
critical	O	ADJ	B
pathways	O	NOUN	I
in	O	ADP	O
normal	O	ADJ	B
development	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
elucidate	O	VERB	O
the	O	DET	O
perturbations	O	NOUN	B
of	O	ADP	O
those	O	DET	O
key	O	ADJ	O
pathways	O	NOUN	B
in	O	ADP	O
neoplastic	O	ADJ	B
transformation	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
functional	O	ADJ	B
definition	O	NOUN	B
of	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
genetic	O	ADJ	B
locus	O	NOUN	I
within	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
10pter	O	NOUN	O
-	O	PUNCT	O
q11	O	NOUN	B
that	O	PRON	O
mediates	O	VERB	O
both	O	CCONJ	O
in	O	X	B
vivo	O	X	I
tumor	O	NOUN	B
suppression	O	NOUN	B
and	O	CCONJ	O
in	O	X	B
vitro	O	X	I
apoptosis	O	NOUN	B
of	O	ADP	O
prostatic	B-Disease	ADJ	B
adenocarcinoma	I-Disease	NOUN	I
cells	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
defined	O	VERB	O
fragment	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	O
10	O	NUM	O
was	O	AUX	O
transferred	O	VERB	B
via	O	ADP	O
microcell	O	NOUN	B
fusion	O	NOUN	I
into	O	ADP	O
a	O	DET	O
prostate	B-Disease	NOUN	B
adenocarcinoma	I-Disease	NOUN	I
cell	O	NOUN	B
line	O	NOUN	I
.	O	PUNCT	O


Microcell	O	ADJ	B
hybrids	O	NOUN	I
containing	O	VERB	O
only	O	ADV	O
the	O	DET	O
region	O	NOUN	B
10pter	O	NOUN	O
-	O	PUNCT	O
q11	O	NOUN	B
were	O	AUX	O
suppressed	O	VERB	B
for	O	ADP	O
tumorigenicity	O	NOUN	B
following	O	VERB	O
injection	O	NOUN	B
of	O	ADP	O
microcell	O	NOUN	B
hybrids	O	NOUN	I
into	O	ADP	O
nude	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
complemented	O	VERB	B
hybrids	O	NOUN	B
undergo	O	VERB	O
programmed	O	VERB	B
cell	O	NOUN	I
death	O	NOUN	I
in	O	X	B
vitro	O	X	I
via	O	ADP	O
a	O	DET	O
mechanism	O	NOUN	B
that	O	PRON	O
does	O	AUX	O
not	O	PART	O
require	O	VERB	O
nuclear	O	ADJ	B
localization	O	NOUN	I
of	O	ADP	O
p53	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
functionally	O	ADV	O
define	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
genetic	O	ADJ	B
locus	O	NOUN	I
,	O	PUNCT	O
designated	O	VERB	O
PAC1	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
prostate	O	NOUN	B
adenocarcinoma	O	NOUN	I
1	O	NUM	I
,	O	PUNCT	O
involved	O	VERB	O
in	O	ADP	O
tumor	O	NOUN	B
suppression	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
prostate	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
furthermore	O	ADV	O
strongly	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
cell	O	NOUN	B
death	O	NOUN	I
pathway	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
functionally	O	ADV	O
restored	O	VERB	B
in	O	ADP	O
prostatic	B-Disease	ADJ	B
adenocarcinoma	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
BRCA2	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
breast	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
cancers	B-Disease	NOUN	B
.	O	PUNCT	O


Inherited	O	VERB	B
mutant	O	ADJ	O
alleles	O	NOUN	O
of	O	ADP	O
familial	O	ADJ	B
tumour	B-Disease	NOUN	I
suppressor	O	NOUN	I
genes	O	NOUN	I
predispose	O	VERB	O
individuals	O	NOUN	B
to	O	ADP	O
particular	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
cancer	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
an	O	DET	O
involvement	O	NOUN	B
in	O	ADP	O
inherited	O	VERB	B
susceptibility	O	NOUN	B
to	O	PART	O
cancer	B-Disease	NOUN	B
,	O	PUNCT	O
these	O	DET	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
genes	O	NOUN	I
are	O	AUX	O
targets	O	NOUN	B
for	O	ADP	O
somatic	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
sporadic	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
type	O	NOUN	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
familial	O	ADJ	B
forms	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
exception	O	NOUN	B
is	O	AUX	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
contributes	O	VERB	O
to	O	PART	O
a	O	DET	O
significant	O	ADJ	O
fraction	O	NOUN	B
of	O	ADP	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
undergoes	O	VERB	O
mutation	O	NOUN	B
at	O	ADP	O
very	O	ADV	O
low	O	ADJ	O
rates	O	NOUN	B
in	O	ADP	O
sporadic	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


This	O	DET	O
finding	O	NOUN	O
suggests	O	VERB	O
that	O	SCONJ	O
other	O	ADJ	O
genes	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
the	O	DET	O
principal	O	ADJ	B
targets	O	NOUN	B
for	O	ADP	O
somatic	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
breast	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
second	O	NOUN	O
,	O	PUNCT	O
recently	O	ADV	O
identified	O	VERB	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
gene	O	NOUN	O
,	O	PUNCT	O
BRCA2	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
5	O	NUM	O
-	O	SYM	O
8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
accounts	O	VERB	O
for	O	ADP	O
a	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
roughly	O	ADV	O
equal	O	ADJ	O
to	O	PART	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


Like	O	ADP	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
BRCA2	O	NOUN	B
behaves	O	VERB	O
as	O	ADP	O
a	O	DET	O
dominantly	O	ADV	O
inherited	O	VERB	B
tumour	B-Disease	NOUN	O
suppressor	O	NOUN	O
gene	O	NOUN	O
.	O	PUNCT	O


Individuals	O	NOUN	B
who	O	PRON	O
inherit	O	VERB	O
one	O	NUM	O
mutant	O	ADJ	B
allele	O	NOUN	B
are	O	AUX	O
at	O	ADP	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
tumours	B-Disease	NOUN	B
they	O	PRON	O
develop	O	VERB	O
lose	O	VERB	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
by	O	ADP	O
heterozygous	O	ADJ	B
deletion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
BRCA2	O	NOUN	B
coding	O	NOUN	B
sequence	O	NOUN	I
is	O	AUX	O
huge	O	ADJ	O
,	O	PUNCT	O
composed	O	VERB	O
of	O	ADP	O
26	O	NUM	O
exons	O	NOUN	B
that	O	PRON	O
span	O	VERB	O
10	O	NUM	O
,	O	PUNCT	O
443	O	NUM	O
bp	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
investigate	O	VERB	B
the	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
BRCA2	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
sporadic	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancers	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
cell	O	NOUN	B
lines	O	NOUN	I
that	O	PRON	O
represent	O	VERB	O
twelve	O	NUM	O
other	O	ADJ	O
tumour	B-Disease	NOUN	B
types	O	NOUN	I
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA2	O	NOUN	B
are	O	AUX	O
infrequent	O	ADJ	B
in	O	ADP	O
cancers	B-Disease	NOUN	B
including	O	VERB	O
breast	B-Disease	NOUN	B
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
probable	O	ADJ	O
germline	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
pancreatic	B-Disease	ADJ	B
tumour	I-Disease	NOUN	I
cell	O	NOUN	I
line	O	NOUN	I
suggests	O	VERB	O
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
BRCA2	O	NOUN	B
in	O	ADP	O
susceptibility	O	NOUN	B
to	O	PART	O
pancreatic	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Founding	O	NOUN	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
southern	O	ADJ	B
Sweden	O	PROPN	I
.	O	PUNCT	O


Nine	O	NUM	O
different	O	ADJ	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
15	O	NUM	O
of	O	ADP	O
47	O	NUM	O
kindreds	O	NOUN	B
from	O	ADP	O
southern	O	ADJ	B
Sweden	O	PROPN	I
,	O	PUNCT	O
by	O	ADP	O
use	O	NOUN	O
of	O	ADP	O
SSCP	O	NOUN	B
and	O	CCONJ	O
heteroduplex	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
all	O	DET	O
exons	O	NOUN	B
and	O	CCONJ	O
flanking	O	ADJ	B
intron	O	NOUN	I
region	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
-	O	PUNCT	O
truncation	O	NOUN	B
test	O	NOUN	I
for	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
direct	O	ADJ	B
sequencing	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
but	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
give	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
premature	O	ADJ	B
translation	O	NOUN	I
termination	O	NOUN	I
and	O	CCONJ	O
include	O	VERB	O
seven	O	NUM	O
frameshift	O	NOUN	B
insertions	O	NOUN	I
or	O	CCONJ	O
deletions	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
nonsense	O	NOUN	B
mutation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
splice	O	NOUN	B
acceptor	O	NOUN	I
site	O	NOUN	I
mutation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
mutation	O	NOUN	B
is	O	AUX	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
Cys61Gly	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
zinc	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
motif	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
novel	O	ADJ	O
Swedish	O	ADJ	B
founding	O	NOUN	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
the	O	DET	O
nucleotide	O	NOUN	B
2595	O	NUM	O
deletion	O	NOUN	B
A	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
five	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
C	O	NOUN	B
1806	O	NUM	I
T	O	NOUN	I
nonsense	O	NOUN	I
mutation	O	NOUN	I
in	O	ADP	O
three	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
3166	O	NUM	O
insertion	O	NOUN	B
TGAGA	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
families	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
nucleotide	O	NOUN	B
1201	O	NUM	O
deletion	O	NOUN	B
11	O	NUM	O
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intragenic	O	ADJ	B
polymorphism	O	NOUN	B
D17S855	O	NOUN	B
supports	O	VERB	O
common	O	ADJ	O
origins	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
.	O	PUNCT	O


Eleven	O	NOUN	O
of	O	ADP	O
the	O	DET	O
15	O	NUM	O
kindreds	O	NOUN	B
manifesting	O	VERB	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
,	O	PUNCT	O
several	O	ADJ	O
of	O	ADP	O
them	O	PRON	O
with	O	ADP	O
a	O	DET	O
predominant	O	ADJ	B
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
phenotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
set	O	NOUN	O
of	O	ADP	O
32	O	NUM	O
families	O	NOUN	B
in	O	ADP	O
which	O	DET	O
no	O	DET	O
BRCA1	O	NOUN	B
alterations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
included	O	VERB	O
1	O	NUM	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
kindred	O	NOUN	B
manifesting	O	VERB	O
clear	O	ADJ	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
BRCA1	O	NOUN	B
region	O	NOUN	B
and	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
chromosome	O	NOUN	B
in	O	ADP	O
associated	O	VERB	O
tumors	B-Disease	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
tumor	B-Disease	NOUN	B
types	O	NOUN	I
found	O	VERB	O
in	O	ADP	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
/	O	PUNCT	O
haplotype	O	NOUN	B
carriers	O	NOUN	B
included	O	VERB	O
prostatic	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
pancreas	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
skin	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
lung	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
malignant	B-Disease	ADJ	B
melanoma	I-Disease	NOUN	I
,	O	PUNCT	O
an	O	DET	O
oligodendroglioma	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
carcinosarcoma	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
,	O	PUNCT	O
12	O	NUM	O
of	O	ADP	O
16	O	NUM	O
kindreds	O	NOUN	B
manifesting	O	VERB	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
or	O	CCONJ	O
linkage	O	NOUN	B
contained	O	VERB	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
only	O	ADV	O
6	O	NUM	O
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
31	O	NUM	O
families	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
confirms	O	VERB	O
the	O	DET	O
involvement	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
in	O	ADP	O
disease	O	NOUN	B
predisposition	O	NOUN	I
for	O	ADP	O
a	O	DET	O
subset	O	NOUN	O
of	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
families	O	NOUN	B
often	O	ADV	O
characterized	O	VERB	B
by	O	ADP	O
ovarian	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


Rapid	O	ADJ	B
detection	O	NOUN	B
of	O	ADP	O
regionally	O	ADV	B
clustered	O	VERB	I
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
by	O	ADP	O
multiplex	O	ADJ	B
heteroduplex	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


UKCCCR	O	PROPN	B
Familial	O	ADJ	B
Ovarian	B-Disease	ADJ	I
Cancer	I-Disease	PROPN	I
Study	O	PROPN	I
Group	O	PROPN	I
.	O	PUNCT	O


Germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
a	O	DET	O
substantial	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
multiple	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Since	O	SCONJ	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
last	O	ADJ	O
year	O	NOUN	B
,	O	PUNCT	O
>	O	X	O
65	O	NUM	O
distinct	O	ADJ	O
mutations	O	NOUN	B
scattered	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
,	O	PUNCT	O
making	O	VERB	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
time	O	NOUN	I
consuming	O	NOUN	O
and	O	CCONJ	O
technically	O	ADV	O
challenging	O	ADJ	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
a	O	DET	O
multiplex	O	ADJ	B
heteroduplex	O	NOUN	I
analysis	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
designed	O	VERB	O
to	O	PART	O
analyze	O	VERB	B
one	O	NUM	O
-	O	PUNCT	O
quarter	O	NOUN	B
of	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
in	O	ADP	O
a	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
step	O	NOUN	B
screening	O	NOUN	B
procedure	O	NOUN	I
and	O	CCONJ	O
that	O	DET	O
will	O	AUX	O
detect	O	VERB	B
approximately	O	ADV	O
50	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
so	O	ADV	O
far	O	ADV	O
reported	O	VERB	O
in	O	ADP	O
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
families	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
this	O	DET	O
technique	O	NOUN	B
to	O	PART	O
analyze	O	VERB	O
BRCA1	O	NOUN	B
in	O	ADP	O
162	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
identified	O	VERB	B
12	O	NUM	O
distinct	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
35	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
previously	O	ADV	O
undescribed	O	ADJ	O
mutation	O	NOUN	B
within	O	ADP	O
the	O	DET	O
tetramerisation	O	NOUN	B
domain	O	NOUN	O
of	O	ADP	O
TP53	O	NOUN	B
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
details	O	NOUN	O
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
classic	O	ADJ	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
which	O	DET	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
codon	O	NOUN	B
344	O	NUM	I
of	O	ADP	O
the	O	DET	O
tumour	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
TP53	O	NOUN	B
.	O	PUNCT	O


Codon	O	NOUN	B
344	O	NUM	I
is	O	AUX	O
a	O	DET	O
key	O	ADJ	O
residue	O	NOUN	B
within	O	ADP	O
the	O	DET	O
tetramerisation	O	NOUN	B
domain	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
substitution	O	NOUN	B
of	O	ADP	O
a	O	DET	O
proline	O	NOUN	B
for	O	ADP	O
a	O	DET	O
leucine	O	NOUN	B
is	O	AUX	O
predicted	O	VERB	O
to	O	PART	O
have	O	AUX	O
profound	O	ADJ	O
implications	O	NOUN	O
for	O	ADP	O
tetramerisation	O	NOUN	B
and	O	CCONJ	O
potentially	O	ADV	O
DNA	O	NOUN	B
binding	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
a	O	DET	O
mutation	O	NOUN	B
at	O	ADP	O
this	O	DET	O
residue	O	NOUN	B
in	O	ADP	O
either	O	CCONJ	O
sporadic	B-Disease	ADJ	B
tumours	I-Disease	NOUN	I
or	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
germline	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
first	O	ADJ	O
report	O	NOUN	O
of	O	ADP	O
a	O	DET	O
germline	O	NOUN	B
mutation	O	NOUN	I
within	O	ADP	O
the	O	DET	O
tetramerisation	O	NOUN	B
domain	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
family	O	NOUN	B
does	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
remarkable	O	ADJ	O
in	O	ADP	O
the	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
tumours	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
there	O	PRON	O
is	O	AUX	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
in	O	ADP	O
a	O	DET	O
leiomyosarcoma	B-Disease	NOUN	B
from	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
cell	O	NOUN	B
line	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
established	O	VERB	O
from	O	ADP	O
the	O	DET	O
tumour	B-Disease	NOUN	B
of	O	ADP	O
the	O	DET	O
proband	O	NOUN	B
and	O	CCONJ	O
cytogenetic	O	ADJ	B
and	O	CCONJ	O
molecular	O	ADJ	B
studies	O	NOUN	I
carried	O	VERB	O
out	O	ADP	O
,	O	PUNCT	O
providing	O	VERB	O
an	O	DET	O
extensive	O	ADJ	B
analysis	O	NOUN	B
in	O	ADP	O
this	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
spectrum	O	NOUN	B
of	O	ADP	O
RB1	O	NOUN	B
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
hereditary	B-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
searched	O	VERB	O
for	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
RB1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
119	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
hereditary	B-Disease	ADJ	B
retinoblastoma	I-Disease	NOUN	I
.	O	PUNCT	O


Previous	O	ADJ	O
investigations	O	NOUN	B
by	O	ADP	O
Southern	O	NOUN	B
blot	O	NOUN	I
hybridization	O	NOUN	I
and	O	CCONJ	O
PCR	O	NOUN	B
fragment	O	NOUN	I
-	O	PUNCT	O
length	O	NOUN	B
analysis	O	NOUN	B
had	O	AUX	O
revealed	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
48	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
on	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
remaining	O	VERB	O
71	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
applying	O	VERB	O
heteroduplex	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
nonisotopic	O	ADJ	B
SSCP	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
direct	O	ADJ	B
sequencing	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
detected	O	VERB	B
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
resulting	O	VERB	O
in	O	ADP	O
premature	O	ADJ	B
termination	O	NOUN	I
codons	O	NOUN	I
or	O	CCONJ	O
disruption	O	NOUN	B
of	O	ADP	O
splice	O	NOUN	B
signals	O	NOUN	I
in	O	ADP	O
51	O	NUM	O
(	O	PUNCT	O
72	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
71	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


Four	O	NUM	O
patients	O	NOUN	B
also	O	ADV	O
showed	O	VERB	O
rare	O	ADJ	B
sequence	O	NOUN	B
variants	O	NOUN	B
.	O	PUNCT	O


No	O	DET	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
preferentially	O	ADV	O
involved	O	VERB	O
in	O	ADP	O
single	O	ADJ	B
base	O	NOUN	I
substitutions	O	NOUN	I
.	O	PUNCT	O


Recurrent	O	ADJ	B
transitions	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
at	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
14	O	NUM	O
codons	O	NOUN	B
within	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
mutation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
exons	O	NOUN	B
25	O	NUM	O
-	O	SYM	O
27	O	NUM	O
,	O	PUNCT	O
although	O	SCONJ	O
this	O	DET	O
region	O	NOUN	B
contains	O	VERB	O
two	O	NUM	O
CGA	O	NOUN	B
codons	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
mutations	O	NOUN	B
within	O	ADP	O
the	O	DET	O
3	O	NUM	O
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RB1	O	NOUN	B
gene	O	NOUN	I
may	O	AUX	O
not	O	PART	O
be	O	AUX	O
oncogenic	O	ADJ	B
.	O	PUNCT	O


When	O	SCONJ	O
these	O	DET	O
data	O	NOUN	B
were	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
the	O	DET	O
results	O	NOUN	B
of	O	ADP	O
our	O	PRON	O
previous	O	ADJ	O
investigations	O	NOUN	B
,	O	PUNCT	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
99	O	NUM	O
(	O	PUNCT	O
83	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
119	O	NUM	O
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
spectrum	O	NOUN	B
comprises	O	VERB	O
15	O	NUM	O
%	O	NOUN	O
large	O	ADJ	O
deletions	O	NOUN	B
,	O	PUNCT	O
26	O	NUM	O
%	O	NOUN	O
small	O	ADJ	B
length	O	NOUN	B
alterations	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
42	O	NUM	O
%	O	NOUN	O
base	O	NOUN	B
substitutions	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
correlation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
location	O	NOUN	B
of	O	ADP	O
frameshift	O	NOUN	B
or	O	CCONJ	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
and	O	CCONJ	O
phenotypic	O	ADJ	B
features	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
age	O	NOUN	B
at	O	ADP	O
diagnosis	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
tumor	B-Disease	NOUN	B
foci	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
manifestation	O	NOUN	B
of	O	ADP	O
nonocular	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
was	O	AUX	O
observed	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


Phenotypic	O	ADJ	B
characterization	O	NOUN	B
of	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
30	O	NUM	O
-	O	SYM	O
40	O	NUM	O
CAG	O	NOUN	B
repeats	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Huntington	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
reveals	O	VERB	O
HD	B-Disease	NOUN	B
cases	O	NOUN	B
with	O	ADP	O
36	O	NUM	O
repeats	O	NOUN	B
and	O	CCONJ	O
apparently	O	ADV	O
normal	O	ADJ	O
elderly	O	ADJ	B
individuals	O	NOUN	B
with	O	ADP	O
36	O	NUM	O
-	O	PUNCT	O
39	O	NUM	O
repeats	O	NOUN	B
.	O	PUNCT	O


Abnormal	O	ADJ	B
CAG	O	NOUN	B
expansions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
IT	O	PROPN	B
-	O	PUNCT	O
15	O	NUM	O
gene	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
diagnostic	O	ADJ	B
setting	O	NOUN	I
it	O	PRON	O
is	O	AUX	O
necessary	O	ADJ	O
to	O	PART	O
define	O	VERB	O
the	O	DET	O
limits	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
size	O	NOUN	I
ranges	O	VERB	B
on	O	ADP	O
normal	O	ADJ	B
and	O	CCONJ	O
HD	B-Disease	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
chromosomes	O	NOUN	O
.	O	PUNCT	O


Most	O	ADV	O
large	O	ADJ	O
analyses	O	NOUN	B
that	O	PRON	O
defined	O	VERB	O
the	O	DET	O
limits	O	NOUN	B
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
pathological	O	ADJ	B
size	O	NOUN	O
ranges	O	NOUN	B
employed	O	VERB	O
PCR	O	NOUN	B
assays	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
included	O	VERB	O
the	O	DET	O
CAG	O	NOUN	B
repeats	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
CCG	O	NOUN	B
repeat	O	NOUN	I
tract	O	NOUN	I
that	O	PRON	O
was	O	AUX	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
invariant	O	ADJ	B
.	O	PUNCT	O


Many	O	ADJ	O
of	O	ADP	O
these	O	DET	O
experiments	O	NOUN	B
found	O	VERB	O
an	O	DET	O
overlap	O	NOUN	B
between	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
disease	O	NOUN	B
size	O	NOUN	I
ranges	O	VERB	I
.	O	PUNCT	O


Subsequent	O	ADJ	O
findings	O	NOUN	B
that	O	SCONJ	O
the	O	DET	O
CCG	O	NOUN	B
repeats	O	NOUN	I
vary	O	VERB	O
by	O	ADP	O
8	O	NUM	O
trinucleotide	O	NOUN	B
lengths	O	NOUN	B
suggested	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
limits	O	NOUN	B
of	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
disease	O	NOUN	B
size	O	NOUN	I
ranges	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
reevaluated	O	VERB	O
with	O	ADP	O
assays	O	NOUN	B
that	O	PRON	O
exclude	O	VERB	O
the	O	DET	O
CCG	O	NOUN	B
polymorphism	O	NOUN	B
.	O	PUNCT	O


Since	O	SCONJ	O
patients	O	NOUN	B
with	O	ADP	O
between	O	ADP	O
30	O	NUM	O
and	O	CCONJ	O
40	O	NUM	O
repeats	O	NOUN	B
are	O	AUX	O
rare	O	ADJ	B
,	O	PUNCT	O
a	O	DET	O
consortium	O	NOUN	B
was	O	AUX	O
assembled	O	VERB	O
to	O	PART	O
collect	O	VERB	O
such	O	ADJ	O
individuals	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
178	O	NUM	O
samples	O	NOUN	B
were	O	AUX	O
reanalyzed	O	VERB	B
in	O	ADP	O
Cambridge	O	PROPN	O
by	O	ADP	O
using	O	VERB	O
assays	O	NOUN	B
specific	O	ADJ	B
for	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
repeats	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
optimized	O	VERB	O
methods	O	NOUN	B
for	O	ADP	O
reliable	O	ADJ	O
sizing	O	NOUN	B
of	O	ADP	O
CAG	O	NOUN	B
repeats	O	NOUN	I
and	O	CCONJ	O
show	O	VERB	O
cases	O	NOUN	B
that	O	PRON	O
demonstrate	O	VERB	O
the	O	DET	O
dangers	O	NOUN	B
of	O	ADP	O
using	O	VERB	O
PCR	O	NOUN	B
assays	O	NOUN	I
that	O	PRON	O
include	O	VERB	O
both	O	CCONJ	O
the	O	DET	O
CAG	O	NOUN	B
and	O	CCONJ	O
CCG	O	NOUN	B
polymorphisms	O	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
HD	B-Disease	NOUN	B
patients	O	NOUN	B
had	O	AUX	O
36	O	NUM	O
repeats	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
confirms	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
allele	O	NOUN	B
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
disease	O	NOUN	B
.	O	PUNCT	O


Individuals	O	NOUN	B
without	O	ADP	O
apparent	O	ADJ	B
symptoms	O	NOUN	B
or	O	CCONJ	O
signs	O	NOUN	O
of	O	ADP	O
HD	B-Disease	NOUN	B
were	O	AUX	O
found	O	VERB	O
at	O	ADP	O
36	O	NUM	O
repeats	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
74	O	NUM	O
,	O	PUNCT	O
78	O	NUM	O
,	O	PUNCT	O
79	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
87	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
37	O	NUM	O
repeats	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
69	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
38	O	NUM	O
repeats	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
69	O	NUM	O
and	O	CCONJ	O
90	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
39	O	NUM	O
repeats	O	NOUN	B
(	O	PUNCT	O
aged	O	ADJ	B
67	O	NUM	O
,	O	PUNCT	O
90	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
95	O	NUM	O
years	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
detailed	O	ADJ	O
case	O	NOUN	B
histories	O	NOUN	I
of	O	ADP	O
an	O	DET	O
exceptional	O	ADJ	B
case	O	NOUN	O
from	O	ADP	O
this	O	DET	O
series	O	NOUN	O
will	O	AUX	O
be	O	AUX	O
presented	O	VERB	O
a	O	DET	O
95	O	NUM	O
-	O	PUNCT	O
year	O	NOUN	B
-	O	PUNCT	O
old	O	ADJ	B
man	O	NOUN	B
with	O	ADP	O
39	O	NUM	O
repeats	O	NOUN	B
who	O	PRON	O
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
classical	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
apparently	O	ADV	O
healthy	O	ADJ	B
survival	O	NOUN	B
into	O	ADP	O
old	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
some	O	DET	O
individuals	O	NOUN	B
with	O	ADP	O
36	O	NUM	O
-	O	PUNCT	O
39	O	NUM	O
repeats	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
HD	B-Disease	NOUN	B
mutation	O	NOUN	B
may	O	AUX	O
not	O	PART	O
always	O	ADV	O
be	O	AUX	O
fully	O	ADV	O
penetrant	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
and	O	CCONJ	O
expression	O	NOUN	B
of	O	ADP	O
eight	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
among	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
is	O	AUX	O
inherited	O	VERB	B
as	O	ADP	O
an	O	DET	O
autosomal	O	ADJ	B
recessive	O	ADJ	B
trait	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
aspartoacylase	I-Disease	NOUN	B
(	O	PUNCT	O
ASPA	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
are	O	AUX	O
from	O	ADP	O
an	O	DET	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
background	O	NOUN	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
ASPA	O	PROPN	B
that	O	PRON	O
lead	O	VERB	O
to	O	PART	O
loss	O	NOUN	B
of	O	ADP	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
E285A	O	NOUN	B
and	O	CCONJ	O
Y231X	O	NOUN	B
are	O	AUX	O
the	O	DET	O
two	O	NUM	O
predominant	O	ADJ	B
mutations	O	NOUN	B
that	O	PRON	O
account	O	VERB	O
for	O	ADP	O
97	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I
in	O	ADP	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
aimed	O	VERB	O
at	O	ADP	O
finding	O	VERB	B
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
in	O	ADP	O
25	O	NUM	O
independent	O	ADJ	O
patients	O	NOUN	B
of	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
Jewish	O	ADJ	B
background	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
novel	O	ADJ	B
and	O	CCONJ	O
three	O	NUM	O
previously	O	ADV	O
characterized	O	VERB	B
mutations	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
80	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
40	O	NUM	O
/	O	SYM	O
50	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
A305E	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
accounted	O	VERB	O
for	O	ADP	O
48	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
24	O	NUM	O
/	O	SYM	O
50	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
mutant	O	ADJ	B
chromosomes	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
of	O	ADP	O
western	O	ADJ	B
European	O	ADJ	B
descent	O	NOUN	I
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
predominant	O	ADJ	O
Jewish	O	ADJ	B
mutations	O	NOUN	B
each	O	DET	O
accounted	O	VERB	O
for	O	ADP	O
a	O	DET	O
single	O	ADJ	O
mutant	O	ADJ	B
chromosome	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
eight	O	NUM	O
novel	O	ADJ	B
mutations	O	NOUN	B
identified	O	VERB	B
included	O	VERB	O
1	O	NUM	O
-	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	B
-	O	PUNCT	O
bp	O	NOUN	B
deletions	O	NOUN	B
(	O	PUNCT	O
32	O	NUM	O
deltaT	O	NOUN	O
and	O	CCONJ	O
876	O	NUM	O
deltaAGAA	O	ADV	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
I16T	O	NOUN	B
,	O	PUNCT	O
G27R	O	NOUN	B
,	O	PUNCT	O
D114E	O	NOUN	O
,	O	PUNCT	O
G123E	O	NOUN	O
,	O	PUNCT	O
C152Y	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
R168C	O	NOUN	B
missense	O	NOUN	I
mutations	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
homozygous	O	ADJ	B
32	O	NUM	O
deltaT	O	NOUN	O
deletion	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
only	O	ADV	O
known	O	ADJ	O
patient	O	NOUN	B
of	O	ADP	O
African	O	ADJ	B
-	O	PUNCT	O
American	O	ADJ	B
origin	O	NOUN	B
with	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
heterozygosity	O	NOUN	B
for	O	ADP	O
876	O	NUM	O
deltaAGAA	O	X	B
mutation	O	NOUN	B
was	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
three	O	NUM	O
independent	O	ADJ	B
patients	O	NOUN	B
from	O	ADP	O
England	O	PROPN	B
.	O	PUNCT	O


Six	O	NUM	O
single	O	ADJ	B
-	O	PUNCT	O
base	O	NOUN	B
changes	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
from	O	ADP	O
Turkey	O	PROPN	B
(	O	PUNCT	O
D114E	O	NOUN	O
,	O	PUNCT	O
R168C	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
The	O	DET	O
Netherlands	O	PROPN	B
(	O	PUNCT	O
I16T	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
Germany	O	PROPN	B
(	O	PUNCT	O
G27R	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
Ireland	O	PROPN	B
(	O	PUNCT	O
C152Y	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
Canada	O	PROPN	B
(	O	PUNCT	O
G123E	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
PCR	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
protocol	O	NOUN	B
is	O	AUX	O
described	O	VERB	O
that	O	PRON	O
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
introduce	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
expression	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
cDNA	O	NOUN	B
clones	O	NOUN	I
demonstrated	O	VERB	O
that	O	SCONJ	O
all	O	DET	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
ASPA	I-Disease	NOUN	B
and	O	CCONJ	O
should	O	AUX	O
therefore	O	ADV	O
result	O	VERB	O
in	O	ADP	O
Canavan	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
and	O	CCONJ	O
chromosomal	O	ADJ	B
localization	O	NOUN	I
of	O	ADP	O
Atm	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mouse	O	NOUN	B
homolog	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Atm	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mouse	O	NOUN	B
homolog	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
ATM	O	NOUN	O
gene	O	NOUN	O
defective	O	ADJ	B
in	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
entire	O	ADJ	O
coding	O	VERB	B
sequence	O	NOUN	I
of	O	ADP	O
the	O	DET	O
Atm	O	NOUN	B
transcript	O	NOUN	B
was	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
found	O	VERB	O
to	O	PART	O
contain	O	VERB	O
an	O	DET	O
open	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
encoding	O	VERB	B
a	O	DET	O
protein	O	NOUN	B
of	O	ADP	O
3066	O	NUM	O
amino	O	NOUN	B
acids	O	NOUN	I
with	O	ADP	O
84	O	NUM	O
%	O	NOUN	O
overall	O	ADJ	B
identity	O	NOUN	B
and	O	CCONJ	O
91	O	NUM	O
%	O	NOUN	O
similarity	O	NOUN	B
to	O	PART	O
the	O	DET	O
human	O	ADJ	B
ATM	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Variable	O	ADJ	B
levels	O	NOUN	I
of	O	ADP	O
expression	O	NOUN	B
of	O	ADP	O
Atm	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
different	O	ADJ	O
tissues	O	NOUN	B
.	O	PUNCT	O


Fluorescence	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
and	O	CCONJ	O
linkage	O	NOUN	B
analysis	O	NOUN	I
located	O	VERB	O
the	O	DET	O
Atm	O	NOUN	B
gene	O	NOUN	I
on	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
9	O	NUM	I
,	O	PUNCT	O
band	O	NOUN	B
9C	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
region	O	NOUN	B
homologous	O	ADJ	B
to	O	PART	O
the	O	DET	O
ATM	O	NOUN	B
region	O	NOUN	O
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
11q22	O	NOUN	I
-	O	PUNCT	O
q23	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mouse	O	NOUN	B
homolog	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
WASP	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
is	O	AUX	O
highly	O	ADV	O
conserved	O	VERB	B
and	O	CCONJ	O
maps	O	NOUN	B
near	O	ADP	O
the	O	DET	O
scurfy	O	NOUN	O
(	O	PUNCT	O
sf	O	NOUN	O
)	O	PUNCT	O
mutation	O	NOUN	B
on	O	ADP	O
the	O	DET	O
X	O	NOUN	B
chromosome	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mouse	O	NOUN	B
WASP	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
homolog	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
isolated	O	VERB	B
and	O	CCONJ	O
sequenced	O	VERB	B
.	O	PUNCT	O
the	O	DET	O
predicted	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
is	O	AUX	O
86	O	NUM	O
%	O	NOUN	O
identical	O	ADJ	B
to	O	PART	O
the	O	DET	O
human	O	ADJ	B
WASP	O	NOUN	B
sequence	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
distinct	O	ADJ	O
feature	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
an	O	DET	O
expanded	O	VERB	O
polymorphic	O	ADJ	B
GGA	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
that	O	PRON	O
codes	O	VERB	B
for	O	ADP	O
polyglycine	O	NOUN	B
and	O	CCONJ	O
varies	O	VERB	O
from	O	ADP	O
15	O	NUM	O
to	O	PART	O
17	O	NUM	O
triplets	O	NOUN	B
in	O	ADP	O
different	O	ADJ	O
Mus	O	NOUN	B
musculus	O	ADJ	I
strains	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
genomic	O	ADJ	B
structure	O	NOUN	I
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
WASP	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
expressed	O	VERB	B
as	O	ADP	O
an	O	DET	O
approximately	O	ADV	O
2	O	NUM	O
.	O	PUNCT	O


4	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
mRNA	O	NOUN	B
in	O	ADP	O
thymus	O	NOUN	B
and	O	CCONJ	O
spleen	O	NOUN	B
.	O	PUNCT	O


Chromosomal	O	ADJ	B
mapping	O	NOUN	I
in	O	ADP	O
an	O	DET	O
interspecific	O	ADJ	B
M	O	NOUN	I
.	O	PUNCT	O


Musculus	O	PROPN	B
/	O	SYM	O
M	O	PROPN	B
.	O	PUNCT	O
spretus	O	ADJ	B
backcross	O	NOUN	I
placed	O	VERB	O
the	O	DET	O
Wasp	O	PROPN	B
locus	O	NOUN	I
near	O	ADP	O
the	O	DET	O
centromere	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
X	O	NOUN	O
chromosome	O	NOUN	O
,	O	PUNCT	O
inseparable	O	ADJ	O
from	O	ADP	O
Gata1	O	NOUN	B
,	O	PUNCT	O
Tcfe3	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
scurfy	O	NOUN	B
(	O	PUNCT	O
sf	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


This	O	DET	O
localization	O	NOUN	B
makes	O	VERB	O
Wasp	O	PROPN	B
a	O	DET	O
candidate	O	NOUN	O
for	O	ADP	O
involvement	O	NOUN	B
in	O	ADP	O
scurfy	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
T	O	NOUN	B
cell	O	NOUN	I
-	O	PUNCT	O
mediated	O	VERB	B
fatal	B-Disease	ADJ	B
lymphoreticular	I-Disease	ADJ	O
disease	I-Disease	NOUN	O
of	O	ADP	O
mice	O	NOUN	B
that	O	PRON	O
has	O	AUX	O
previously	O	ADV	O
been	O	AUX	O
proposed	O	VERB	O
as	O	ADP	O
a	O	DET	O
mouse	O	NOUN	B
homolog	O	NOUN	B
of	O	ADP	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Northern	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
sf	O	NOUN	O
tissue	O	NOUN	B
samples	O	NOUN	O
indicated	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
WASP	O	NOUN	B
mRNA	O	NOUN	B
in	O	ADP	O
liver	O	NOUN	B
and	O	CCONJ	O
skin	O	NOUN	B
,	O	PUNCT	O
presumably	O	ADV	O
as	O	ADP	O
a	O	DET	O
consequence	O	NOUN	O
of	O	ADP	O
lymphocytic	O	ADJ	B
infiltration	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
non	O	ADJ	B
abnormalities	O	NOUN	I
in	O	ADP	O
the	O	DET	O
amount	O	NOUN	B
or	O	CCONJ	O
size	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
present	O	ADJ	O
.	O	PUNCT	O


Colchicine	O	NOUN	B
in	O	ADP	O
breast	O	NOUN	B
milk	O	NOUN	I
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
.	O	PUNCT	O


To	O	PART	O
clarify	O	VERB	O
whether	O	SCONJ	O
colchicine	O	NOUN	B
is	O	AUX	O
excreted	O	VERB	B
in	O	ADP	O
breast	O	NOUN	B
milk	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
to	O	PART	O
compare	O	VERB	B
its	O	PRON	O
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
and	O	CCONJ	O
breast	O	NOUN	B
milk	O	NOUN	I
of	O	ADP	O
lactating	O	VERB	B
women	O	NOUN	B
who	O	PRON	O
have	O	AUX	O
familial	B-Disease	ADJ	B
Mediterranean	I-Disease	ADJ	I
fever	I-Disease	NOUN	I
(	O	PUNCT	O
FMF	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
a	O	DET	O
specific	O	ADJ	O
radioimmunoassay	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
determined	O	VERB	O
colchicine	O	NOUN	B
concentrations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
and	O	CCONJ	O
breast	O	NOUN	B
milk	O	NOUN	I
of	O	ADP	O
4	O	NUM	O
patients	O	NOUN	B
at	O	ADP	O
various	O	ADJ	O
time	O	NOUN	B
points	O	NOUN	I
,	O	PUNCT	O
following	O	VERB	O
oral	O	ADJ	B
administration	O	NOUN	I
of	O	ADP	O
the	O	DET	O
drug	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
4	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
FMF	B-Disease	NOUN	B
who	O	PRON	O
had	O	AUX	O
been	O	AUX	O
taking	O	VERB	O
colchicine	O	NOUN	B
on	O	ADP	O
a	O	DET	O
long	O	ADJ	B
-	O	PUNCT	O
term	O	NOUN	B
basis	O	NOUN	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
.	O	PUNCT	O


Colchicine	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
excreted	O	VERB	B
in	O	ADP	O
breast	O	NOUN	B
milk	O	NOUN	I
.	O	PUNCT	O


Its	O	PRON	O
levels	O	NOUN	B
ranged	O	VERB	O
between	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
ng	O	NOUN	O
/	O	PUNCT	O
ml	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
were	O	AUX	O
similar	O	ADJ	O
to	O	PART	O
those	O	DET	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
serum	O	NOUN	B
(	O	PUNCT	O
parallel	O	ADJ	O
concentration	O	NOUN	O
time	O	NOUN	O
curves	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
considerable	O	ADJ	O
variation	O	NOUN	B
in	O	ADP	O
colchicine	O	NOUN	B
milk	O	NOUN	B
concentration	O	NOUN	B
among	O	ADP	O
the	O	DET	O
different	O	ADJ	O
patients	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
might	O	AUX	O
be	O	AUX	O
related	O	ADJ	O
to	O	PART	O
individual	O	ADJ	B
breast	O	NOUN	B
milk	O	NOUN	I
composition	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
possibly	O	ADV	O
,	O	PUNCT	O
to	O	PART	O
other	O	ADJ	O
nutritional	O	ADJ	B
or	O	CCONJ	O
metabolic	O	ADJ	B
factors	O	NOUN	I
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
extensive	O	ADJ	O
peripheral	O	ADJ	B
tissue	O	NOUN	O
binding	O	NOUN	O
and	O	CCONJ	O
relatively	O	ADV	O
low	O	ADJ	B
concentration	O	NOUN	B
of	O	ADP	O
colchicine	O	NOUN	B
in	O	ADP	O
breast	O	NOUN	B
milk	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
amount	O	NOUN	B
ingested	O	VERB	B
by	O	ADP	O
the	O	DET	O
infant	O	NOUN	B
is	O	AUX	O
small	O	ADJ	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
based	O	VERB	O
on	O	ADP	O
our	O	PRON	O
clinical	O	ADJ	B
experience	O	NOUN	B
,	O	PUNCT	O
nursing	O	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
safe	O	ADJ	O
for	O	ADP	O
lactating	O	VERB	B
women	O	NOUN	B
with	O	ADP	O
FMF	B-Disease	NOUN	B
who	O	PRON	O
continue	O	VERB	O
to	O	PART	O
take	O	VERB	O
colchicine	O	NOUN	B
.	O	PUNCT	O


Abnormal	O	ADJ	B
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
protein	O	NOUN	I
kinase	O	NOUN	I
levels	O	NOUN	B
produce	O	VERB	O
only	O	ADV	O
mild	O	ADJ	B
myopathy	B-Disease	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
commonly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
CTG	O	NOUN	B
repeat	O	NOUN	I
expansions	O	NOUN	I
within	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
DM	O	NOUN	B
-	O	PUNCT	O
protein	O	NOUN	B
kinase	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
altered	O	ADJ	O
expression	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
DMPK	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
ubiquitously	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
all	O	DET	O
muscle	O	NOUN	B
cell	O	NOUN	I
lineages	O	NOUN	O
during	O	ADP	O
development	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
disrupting	O	VERB	B
the	O	DET	O
endogenous	O	ADJ	B
Dmpk	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
overexpressing	O	VERB	B
a	O	DET	O
normal	O	ADJ	O
human	O	ADJ	B
DMPK	O	NOUN	B
transgene	O	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Nullizygous	O	ADJ	B
(	O	PUNCT	O
-	O	PUNCT	O
/	O	SYM	O
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
showed	O	VERB	O
only	O	ADV	O
inconsistent	O	ADJ	B
and	O	CCONJ	O
minor	O	ADJ	B
size	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
head	O	NOUN	B
and	O	CCONJ	I
neck	O	NOUN	I
muscle	O	NOUN	I
fibres	O	NOUN	I
at	O	ADP	O
older	O	ADJ	B
age	O	NOUN	I
,	O	PUNCT	O
animals	O	NOUN	B
with	O	ADP	O
the	O	DET	O
highest	O	ADJ	B
DMPK	O	NOUN	B
transgene	O	NOUN	B
expression	O	NOUN	B
showed	O	VERB	O
hypertrophic	B-Disease	ADJ	B
cardiomyopathy	I-Disease	NOUN	I
and	O	CCONJ	O
enhanced	O	VERB	B
neonatal	O	ADJ	B
mortality	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
both	O	DET	O
models	O	NOUN	B
lack	O	VERB	O
other	O	ADJ	O
frequent	O	ADJ	B
DM	B-Disease	NOUN	B
symptoms	O	NOUN	B
including	O	VERB	O
the	O	DET	O
fibre	O	NOUN	B
-	O	PUNCT	O
type	O	NOUN	B
dependent	O	ADJ	O
atrophy	B-Disease	NOUN	B
,	O	PUNCT	O
myotonia	B-Disease	NOUN	B
,	O	PUNCT	O
cataract	B-Disease	NOUN	B
and	O	CCONJ	O
male	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
infertility	I-Disease	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
strengthen	O	VERB	O
the	O	DET	O
contention	O	NOUN	O
that	O	SCONJ	O
simple	O	ADJ	O
loss	O	NOUN	B
-	O	PUNCT	O
or	O	CCONJ	O
gain	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	O
-	O	PUNCT	O
expression	O	NOUN	B
of	O	ADP	O
DMPK	O	NOUN	B
is	O	AUX	O
not	O	PART	O
the	O	DET	O
only	O	ADV	O
crucial	O	ADJ	O
requirement	O	NOUN	B
for	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mice	O	NOUN	B
lacking	O	VERB	B
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
protein	O	NOUN	I
kinase	O	NOUN	I
develop	O	VERB	O
a	O	DET	O
late	O	ADJ	O
onset	O	NOUN	O
progressive	O	ADJ	O
myopathy	B-Disease	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disorder	I-Disease	NOUN	O
resulting	O	VERB	O
from	O	ADP	O
the	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
a	O	DET	O
putative	O	ADJ	B
protein	O	NOUN	I
kinase	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
DMPK	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
pathogenesis	O	NOUN	B
we	O	PRON	O
have	O	AUX	O
developed	O	VERB	O
Dmpk	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
(	O	PUNCT	O
Dmpk	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
.	O	PUNCT	O


Dmpk	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
develop	O	VERB	O
a	O	DET	O
late	O	ADJ	B
-	O	PUNCT	O
onset	O	NOUN	B
,	O	PUNCT	O
progressive	B-Disease	ADJ	B
skeletal	I-Disease	ADJ	B
myopathy	I-Disease	NOUN	I
that	O	PRON	O
shares	O	VERB	O
some	O	DET	O
pathological	O	ADJ	B
features	O	NOUN	B
with	O	ADP	O
DM	B-Disease	NOUN	B
.	O	PUNCT	O


Muscles	O	NOUN	B
from	O	ADP	O
mature	O	ADJ	B
mice	O	NOUN	B
show	O	VERB	O
variation	O	NOUN	B
in	O	ADP	O
fibre	O	NOUN	B
size	O	NOUN	I
,	O	PUNCT	O
increased	O	VERB	B
fibre	B-Disease	NOUN	B
degeneration	I-Disease	NOUN	I
and	O	CCONJ	O
fibrosis	B-Disease	NOUN	B
.	O	PUNCT	O


Adult	O	ADJ	B
Dmpk	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
show	O	VERB	O
ultrastructural	O	ADJ	B
changes	O	NOUN	B
in	O	ADP	O
muscle	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
50	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
force	O	NOUN	B
generation	O	NOUN	B
compared	O	VERB	O
to	O	PART	O
young	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
DMPK	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
necessary	O	ADJ	O
for	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
structure	O	NOUN	O
and	O	CCONJ	O
function	O	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
DMPK	O	NOUN	B
levels	O	NOUN	B
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
DM	B-Disease	NOUN	B
pathology	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
Brca1	O	NOUN	B
is	O	AUX	O
required	O	VERB	O
for	O	ADP	O
embryonic	O	ADJ	B
cellular	O	ADJ	B
proliferation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gone	O	VERB	O
in	O	ADP	O
humans	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
predisposition	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
here	O	ADV	O
that	O	SCONJ	O
Brca1	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
are	O	AUX	O
normal	O	ADJ	B
and	O	CCONJ	O
fertile	O	ADJ	B
and	O	CCONJ	O
lack	O	NOUN	B
tumors	B-Disease	NOUN	B
by	O	ADP	O
age	O	NOUN	B
eleven	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


Homozygous	O	ADJ	B
Brca1	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
mutant	O	ADJ	B
mice	O	NOUN	O
die	O	VERB	B
before	O	ADP	O
day	O	NOUN	B
7	O	NUM	O
.	O	PUNCT	O


5	O	NUM	O
of	O	ADP	O
embryogenesis	O	NOUN	B
.	O	PUNCT	O


Mutant	O	ADJ	B
embryos	O	NOUN	B
are	O	AUX	O
poorly	O	ADV	O
developed	O	VERB	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
mesoderm	O	NOUN	B
formation	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
extraembryonic	O	ADJ	B
region	O	NOUN	I
is	O	AUX	O
abnormal	O	ADJ	B
,	O	PUNCT	O
but	O	CCONJ	O
aggregation	O	NOUN	B
with	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
tetraploid	O	ADJ	B
embryos	O	NOUN	B
does	O	AUX	O
not	O	PART	O
rescue	O	VERB	O
the	O	DET	O
lethality	O	NOUN	B
.	O	PUNCT	O


In	O	X	B
vivo	O	X	I
,	O	PUNCT	O
mutant	O	ADJ	B
embryos	O	NOUN	B
do	O	AUX	O
not	O	PART	O
exhibit	O	VERB	O
increased	O	VERB	B
apoptosis	O	NOUN	B
but	O	CCONJ	O
show	O	VERB	O
reduced	O	VERB	B
cell	O	NOUN	B
proliferation	O	NOUN	I
accompanied	O	VERB	O
by	O	ADP	O
decreased	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
cyclin	O	NOUN	B
E	O	NOUN	I
and	O	CCONJ	O
mdm	O	PROPN	B
-	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
regulator	O	NOUN	B
of	O	ADP	O
p53	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
cyclin	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
kinase	O	NOUN	B
inhibitor	O	NOUN	I
p21	O	NOUN	B
is	O	AUX	O
dramatically	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
embryos	O	NOUN	B
.	O	PUNCT	O


Buttressing	O	VERB	B
these	O	DET	O
in	O	X	B
vivo	O	X	I
observations	O	NOUN	B
is	O	AUX	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
mutant	O	ADJ	B
blastocyst	O	NOUN	O
growth	O	NOUN	O
is	O	AUX	O
grossly	O	ADV	O
impaired	O	ADJ	B
in	O	X	B
vitro	O	X	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
death	O	NOUN	B
of	O	ADP	O
Brca1	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
mutant	O	ADJ	B
embryos	O	NOUN	B
prior	O	ADJ	O
to	O	PART	O
gastrulation	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
a	O	DET	O
failure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proliferative	O	ADJ	B
burst	O	NOUN	O
required	O	VERB	O
for	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
different	O	ADJ	O
germ	O	NOUN	B
layers	O	NOUN	I
.	O	PUNCT	O


Increased	O	VERB	B
coronary	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
in	O	ADP	O
Japanese	O	ADJ	B
-	O	PUNCT	O
American	O	ADJ	B
men	O	NOUN	B
with	O	ADP	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
gene	O	NOUN	I
despite	O	SCONJ	O
increased	O	VERB	B
HDL	O	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


Plasma	O	NOUN	B
high	O	ADJ	B
density	O	NOUN	I
lipoprotein	O	NOUN	I
(	O	PUNCT	I
HDL	O	NOUN	O
)	O	PUNCT	O
levels	O	NOUN	B
are	O	AUX	O
strongly	O	ADV	O
genetically	O	ADV	B
determined	O	VERB	O
and	O	CCONJ	O
show	O	VERB	O
a	O	DET	O
general	O	ADJ	O
inverse	O	ADJ	O
relationship	O	NOUN	B
with	O	ADP	O
coronary	B-Disease	ADJ	B
heart	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
(	O	PUNCT	O
CHD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
cholesteryl	O	NOUN	B
ester	O	NOUN	I
transfer	O	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
CETP	O	NOUN	B
)	O	PUNCT	O
mediates	O	VERB	O
the	O	DET	O
transfer	O	NOUN	B
of	O	ADP	O
cholesteryl	O	NOUN	B
esters	O	NOUN	I
from	O	ADP	O
HDL	O	NOUN	B
to	O	PART	O
other	O	ADJ	O
lipoproteins	O	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
a	O	DET	O
key	O	ADJ	O
participant	O	NOUN	B
in	O	ADP	O
the	O	DET	O
reverse	O	ADJ	B
transport	O	NOUN	I
of	O	ADP	I
cholesterol	O	NOUN	B
from	O	ADP	O
the	O	DET	O
periphery	O	NOUN	B
to	O	PART	O
the	O	DET	O
liver	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
high	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
different	O	ADJ	O
CETP	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
(	O	PUNCT	O
D442G	O	NOUN	B
,	O	PUNCT	O
5	O	NUM	O
.	O	PUNCT	O
1	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
intron	O	NOUN	B
14G	O	NOUN	O
A	O	NOUN	O
,	O	PUNCT	O
0	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
469	O	NUM	O
men	O	NOUN	B
of	O	ADP	O
Japanese	O	ADJ	B
ancestry	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Honolulu	O	PROPN	B
Heart	O	PROPN	I
Program	O	PROPN	I
and	O	CCONJ	O
mutations	O	NOUN	B
were	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
decreased	O	VERB	B
CETP	O	NOUN	B
(	O	PUNCT	O
-	O	PUNCT	O
35	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
increased	O	VERB	B
HDL	O	NOUN	B
chol	O	NOUN	I
levels	O	NOUN	I
(	O	PUNCT	O
+	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
D442G	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	O
prevalence	O	NOUN	B
of	O	ADP	O
definite	O	ADJ	O
CHD	B-Disease	NOUN	B
was	O	AUX	O
21	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
men	O	NOUN	B
with	O	ADP	O
mutations	O	NOUN	B
and	O	CCONJ	O
16	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
men	O	NOUN	B
without	O	ADP	O
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
relative	O	ADJ	B
risk	O	NOUN	I
(	O	PUNCT	O
RR	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
CHD	B-Disease	NOUN	B
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


43	O	NUM	O
in	O	ADP	O
men	O	NOUN	B
with	O	ADP	O
mutations	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.	O	PUNCT	O
05	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
after	O	ADP	O
adjustment	O	NOUN	B
for	O	ADP	O
CHD	B-Disease	NOUN	B
risk	O	NOUN	I
factors	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
RR	O	NOUN	B
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


55	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
02	O	NUM	O
)	O	PUNCT	O
;	O	PUNCT	O
after	O	ADP	O
additional	O	ADJ	O
adjustment	O	NOUN	B
for	O	ADP	O
HDL	O	NOUN	B
levels	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
RR	O	NOUN	B
was	O	AUX	O
1	O	NUM	O
.	O	PUNCT	O


68	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.	O	PUNCT	O
008	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Similar	O	ADJ	O
RR	O	NOUN	B
values	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
for	O	ADP	O
the	O	DET	O
D442G	O	NOUN	B
mutation	O	NOUN	B
alone	O	ADV	O
.	O	PUNCT	O


Increased	O	VERB	B
CHD	B-Disease	NOUN	B
in	O	ADP	O
men	O	NOUN	B
with	O	ADP	O
mutations	O	NOUN	B
was	O	AUX	O
primarily	O	ADV	O
observed	O	VERB	O
for	O	ADP	O
HDL	O	NOUN	B
chol	O	NOUN	I
41	O	NUM	O
-	O	PUNCT	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
;	O	PUNCT	O
for	O	ADP	O
HDL	O	NOUN	B
chol	O	NOUN	I
>	O	X	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	NOUN	B
men	O	NOUN	B
with	O	ADP	O
and	O	CCONJ	O
without	O	ADP	O
mutations	O	NOUN	B
had	O	AUX	O
low	O	ADJ	B
CHD	B-Disease	NOUN	B
prevalence	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
genetic	O	ADJ	B
CETP	B-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
risk	O	NOUN	B
factor	O	NOUN	I
for	O	ADP	O
CHD	B-Disease	NOUN	B
,	O	PUNCT	O
primarily	O	ADV	O
due	O	ADP	O
to	O	PART	O
increased	O	VERB	B
CHD	B-Disease	NOUN	B
prevalence	O	NOUN	B
in	O	ADP	O
men	O	NOUN	B
with	O	ADP	O
the	O	DET	O
D442G	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
HDL	O	NOUN	B
cholesterol	O	NOUN	I
between	O	ADP	O
41	O	NUM	O
and	O	CCONJ	O
60	O	NUM	O
mg	O	NOUN	O
/	O	SYM	O
dl	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
HDL	O	NOUN	B
concentration	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
dynamics	O	NOUN	B
of	O	ADP	O
cholesterol	O	NOUN	B
transport	O	NOUN	I
through	O	ADP	O
HDL	O	NOUN	B
(	O	PUNCT	O
i	O	NOUN	O
.	O	PUNCT	O
e	O	X	O
.	O	PUNCT	O
,	O	PUNCT	O
reverse	O	ADJ	B
cholesterol	O	NOUN	I
transport	O	NOUN	I
)	O	PUNCT	O
determine	O	VERB	O
the	O	DET	O
anti	O	ADJ	B
-	O	PUNCT	O
atherogenicity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HDL	O	NOUN	B
fraction	O	NOUN	I
.	O	PUNCT	O


Mapping	O	VERB	B
the	O	DET	O
homolog	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
Rb1	O	NOUN	B
gene	O	NOUN	I
to	O	PART	O
chromosome	O	NOUN	O
14	O	NUM	O
of	O	ADP	O
higher	O	ADJ	B
primates	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Rb1	O	NOUN	B
gene	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
with	O	ADP	O
retinoblastoma	B-Disease	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
located	O	ADJ	O
on	O	ADP	O
human	O	ADJ	B
Chromosome	O	NOUN	I
(	O	PUNCT	O
Chr	O	NOUN	O
)	O	PUNCT	O
13q14	O	NOUN	O
.	O	PUNCT	O


2	O	NUM	O
2	O	NUM	O
.	O	PUNCT	O


A	O	DET	O
unique	O	ADJ	O
sequence	O	NOUN	B
human	O	ADJ	B
Rb1	O	NOUN	B
cosmid	O	NOUN	I
DNA	O	NOUN	B
probe	O	NOUN	I
has	O	AUX	O
been	O	AUX	O
used	O	VERB	O
to	O	PART	O
localize	O	VERB	B
this	O	DET	O
region	O	NOUN	B
on	O	ADP	O
apes	O	NOUN	B
Chr	O	NOUN	B
14	O	NUM	O
by	O	ADP	O
the	O	DET	O
FISH	O	NOUN	B
technique	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
conservation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Rb1	O	NOUN	B
gene	O	NOUN	O
in	O	ADP	O
higher	O	ADJ	B
primates	O	NOUN	B
at	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
equivalent	O	ADJ	O
chromosome	O	NOUN	B
locus	O	NOUN	I
(	O	PUNCT	O
14q14	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
human	O	NOUN	B
may	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
phylogenetic	O	ADJ	B
marker	O	NOUN	I
to	O	PART	O
further	O	ADJ	O
trace	O	VERB	O
the	O	DET	O
evolutionary	O	ADJ	B
pathway	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
descent	O	NOUN	I
.	O	PUNCT	O


Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
no	O	DET	O
strict	O	ADJ	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
but	O	CCONJ	O
clustering	O	NOUN	B
of	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
protein	O	NOUN	I
(	O	PUNCT	O
WASP	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
presenting	O	VERB	O
with	O	ADP	O
WAS	B-Disease	PROPN	B
and	O	CCONJ	O
in	O	ADP	O
patients	O	NOUN	B
showing	O	VERB	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	B
.	O	PUNCT	O


Mutation	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
19	O	NUM	O
families	O	NOUN	B
of	O	ADP	O
German	O	ADJ	B
,	O	PUNCT	O
Swiss	O	ADJ	B
and	O	CCONJ	O
Turkish	O	ADJ	B
descent	O	NOUN	B
by	O	ADP	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
and	O	CCONJ	O
sequencing	O	NOUN	B
resulted	O	VERB	O
in	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
seven	O	NUM	O
novel	O	ADJ	B
and	O	CCONJ	O
10	O	NUM	O
known	O	ADJ	O
mutations	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
striking	O	ADJ	O
clustering	O	NOUN	B
of	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
four	O	NUM	O
exons	O	NOUN	B
contrasted	O	VERB	O
with	O	ADP	O
a	O	DET	O
random	O	ADJ	B
distribution	O	NOUN	B
of	O	ADP	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
.	O	PUNCT	O


More	O	ADJ	O
than	O	ADP	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
all	O	DET	O
known	O	VERB	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
localized	O	ADJ	B
in	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
stretch	O	NOUN	B
of	O	ADP	O
the	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
;	O	PUNCT	O
this	O	DET	O
region	O	NOUN	B
contained	O	VERB	O
a	O	DET	O
mutational	O	ADJ	B
hot	O	ADJ	O
spot	O	NOUN	O
at	O	ADP	O
codon	O	NOUN	B
86	O	NUM	O
.	O	PUNCT	O


No	O	DET	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlation	O	NOUN	B
emerged	O	VERB	O
after	O	ADP	O
a	O	DET	O
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
identified	O	VERB	B
mutations	O	NOUN	B
with	O	ADP	O
the	O	DET	O
resulting	O	VERB	O
clinical	O	ADJ	B
picture	O	NOUN	I
for	O	ADP	O
a	O	DET	O
classical	O	ADJ	O
WAS	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
substitution	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
86	O	NUM	O
resulted	O	VERB	O
in	O	ADP	O
an	O	DET	O
extremely	O	ADV	B
variable	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Swiss	O	ADJ	B
family	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
extended	O	ADJ	O
homology	O	NOUN	B
search	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
distant	O	ADJ	O
relationship	O	NOUN	B
of	O	ADP	O
this	O	DET	O
stretch	O	NOUN	B
to	O	ADP	O
the	O	DET	O
vasodilator	O	NOUN	B
-	O	PUNCT	O
stimulated	O	VERB	B
phosphoprotein	O	NOUN	B
(	O	PUNCT	O
VASP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
of	O	ADP	O
cyto	O	NOUN	B
-	O	PUNCT	O
architecture	O	NOUN	B
by	O	ADP	O
interacting	O	VERB	B
with	O	ADP	O
actin	O	NOUN	B
-	O	PUNCT	O
like	O	ADJ	B
filaments	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Influence	O	NOUN	B
of	O	ADP	O
PAX6	O	NOUN	B
gene	O	NOUN	B
dosage	O	NOUN	I
on	O	ADP	O
development	O	NOUN	B
:	O	PUNCT	O
overexpression	O	NOUN	B
causes	O	VERB	O
severe	O	ADJ	B
eye	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


Aniridia	B-Disease	NOUN	B
in	O	ADP	O
man	O	NOUN	B
and	O	CCONJ	O
Small	O	ADJ	B
eye	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
are	O	AUX	O
semidominant	B-Disease	ADJ	B
developmental	I-Disease	ADJ	I
disorders	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
within	O	ADP	O
the	O	DET	O
paired	O	ADJ	O
box	O	NOUN	O
gene	O	NOUN	O
PAX6	O	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
heterozygotes	O	NOUN	B
suffer	O	VERB	O
from	O	ADP	O
iris	B-Disease	ADJ	B
hypoplasia	I-Disease	NOUN	I
,	O	PUNCT	O
homozygous	O	ADJ	B
mice	O	NOUN	B
lack	O	VERB	B
eyes	O	NOUN	B
and	O	CCONJ	O
nasal	O	ADJ	B
cavities	O	NOUN	I
and	O	CCONJ	O
exhibit	O	VERB	O
brain	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
gene	O	NOUN	B
dosage	O	NOUN	I
in	O	ADP	O
more	O	ADJ	O
detail	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
generated	O	VERB	O
yeast	O	NOUN	B
artificial	O	ADJ	B
chromosome	O	NOUN	I
transgenic	O	ADJ	B
mice	O	NOUN	I
carrying	O	VERB	O
the	O	DET	O
human	O	ADJ	B
PAX6	O	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
crossed	O	VERB	B
onto	O	ADP	O
the	O	DET	O
Small	O	ADJ	B
eye	O	NOUN	I
background	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
transgene	O	NOUN	B
rescues	O	VERB	B
the	O	DET	O
mutant	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


Strikingly	O	ADV	B
,	O	PUNCT	O
mice	O	NOUN	B
carrying	O	VERB	O
multiple	O	ADJ	B
copies	O	NOUN	B
on	O	ADP	O
a	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
background	O	NOUN	B
show	O	VERB	O
specific	O	ADJ	O
developmental	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	O
of	I-Disease	ADP	O
the	I-Disease	DET	O
eye	I-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
of	O	ADP	O
other	O	ADJ	O
tissues	O	NOUN	B
expressing	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
at	O	ADP	O
least	O	ADJ	O
five	O	NUM	O
different	O	ADJ	O
eye	O	NOUN	B
phenotypes	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
changes	O	NOUN	B
in	O	ADP	O
PAX6	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
provide	O	VERB	O
evidence	O	NOUN	B
that	O	SCONJ	O
not	O	PART	O
only	O	ADV	O
reduced	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
increased	O	VERB	B
levels	O	NOUN	B
of	O	ADP	O
transcriptional	O	ADJ	B
regulators	O	NOUN	I
can	O	AUX	O
cause	O	VERB	O
developmental	B-Disease	ADJ	B
defects	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Heterodimer	O	NOUN	B
formation	O	NOUN	B
and	O	CCONJ	O
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
enzyme	O	NOUN	B
galactose	O	NOUN	I
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridylyltransferase	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
of	O	ADP	O
the	O	DET	O
fundamental	O	ADJ	O
questions	O	NOUN	O
concerning	O	VERB	O
expression	O	NOUN	B
and	O	CCONJ	O
function	O	NOUN	B
of	O	ADP	O
dimeric	O	ADJ	B
enzymes	O	NOUN	I
involves	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
naturally	O	ADV	O
occurring	O	VERB	O
mutations	O	NOUN	B
on	O	ADP	O
subunit	O	NOUN	B
assembly	O	NOUN	I
and	O	CCONJ	O
heterodimer	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
question	O	NOUN	O
is	O	AUX	O
of	O	ADP	O
particular	O	ADJ	O
interest	O	NOUN	O
for	O	ADP	O
the	O	DET	O
human	O	ADJ	B
enzyme	O	NOUN	B
galactose	O	NOUN	I
-	O	PUNCT	O
l	O	NOUN	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridylyl	O	ADJ	B
-	O	PUNCT	O
transferase	O	NOUN	B
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
impairment	O	NOUN	B
of	O	ADP	O
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
metabolic	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
galactosemia	B-Disease	NOUN	B
,	O	PUNCT	O
because	O	SCONJ	O
many	O	ADJ	O
if	O	SCONJ	O
not	O	PART	O
most	O	ADJ	O
patients	O	NOUN	B
studied	O	VERB	O
to	O	PART	O
date	O	NOUN	B
are	O	AUX	O
compound	O	NOUN	B
heterozygotes	O	NOUN	B
rather	O	ADV	O
than	O	ADP	O
true	O	ADJ	O
molecular	O	ADJ	B
homozygotes	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
broad	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
phenotypic	O	ADJ	B
severity	O	NOUN	B
observed	O	VERB	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
raises	O	VERB	O
the	O	DET	O
possibility	O	NOUN	O
that	O	SCONJ	O
allelic	O	ADJ	B
combination	O	NOUN	B
,	O	PUNCT	O
not	O	PART	O
just	O	ADV	O
allelic	O	ADJ	B
constitution	O	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
play	O	VERB	O
some	O	DET	O
role	O	NOUN	O
in	O	ADP	O
determining	O	VERB	O
outcome	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
work	O	NOUN	O
described	O	VERB	O
herein	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
selected	O	VERB	O
two	O	NUM	O
distinct	O	ADJ	O
naturally	O	ADV	O
occurring	O	VERB	O
null	O	ADJ	B
mutations	O	NOUN	I
of	O	ADP	O
GALT	O	NOUN	B
,	O	PUNCT	O
Q188R	O	NOUN	B
and	O	CCONJ	O
R333W	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
asked	O	VERB	O
the	O	DET	O
questions	O	NOUN	B
(	O	PUNCT	O
i	O	X	O
)	O	PUNCT	O
what	O	PRON	O
are	O	AUX	O
the	O	DET	O
impacts	O	NOUN	B
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
on	O	ADP	O
subunit	O	NOUN	B
assembly	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
ii	O	X	O
)	O	PUNCT	O
if	O	SCONJ	O
heterodimers	O	NOUN	B
do	O	AUX	O
form	O	NOUN	O
,	O	PUNCT	O
are	O	AUX	O
they	O	PRON	O
active	O	ADJ	B
?	O	PUNCT	O


To	O	PART	O
answer	O	VERB	O
these	O	DET	O
questions	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
established	O	VERB	O
a	O	DET	O
yeast	O	NOUN	B
system	O	NOUN	I
for	O	ADP	O
the	O	DET	O
coexpression	O	NOUN	B
of	O	ADP	O
epitope	O	NOUN	B
-	O	PUNCT	O
tagged	O	VERB	B
alleles	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
GALT	O	NOUN	B
and	O	CCONJ	O
investigated	O	VERB	B
both	O	CCONJ	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
specific	O	ADJ	O
GALT	O	NOUN	B
subunit	O	NOUN	B
interactions	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
defined	O	VERB	O
heterodimer	O	NOUN	B
pools	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
found	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
homodimers	O	NOUN	B
and	O	CCONJ	O
heterodimers	O	NOUN	B
do	O	AUX	O
form	O	VERB	O
involving	O	VERB	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
subunits	O	NOUN	I
tested	O	VERB	B
and	O	CCONJ	O
that	O	SCONJ	O
both	O	CCONJ	O
heterodimer	O	NOUN	B
pools	O	NOUN	B
retain	O	VERB	O
substantial	O	ADJ	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
are	O	AUX	O
significant	O	ADJ	O
not	O	PART	O
only	O	ADV	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
their	O	PRON	O
implications	O	NOUN	O
for	O	ADP	O
furthering	O	VERB	O
our	O	PRON	O
understanding	O	NOUN	O
of	O	ADP	O
galactosemia	B-Disease	NOUN	B
and	O	CCONJ	O
GALT	O	NOUN	B
holoenzyme	O	NOUN	B
structure	O	NOUN	B
-	O	PUNCT	O
function	O	NOUN	B
relationships	O	NOUN	B
but	O	CCONJ	O
also	O	ADV	O
because	O	SCONJ	O
the	O	DET	O
system	O	NOUN	B
described	O	VERB	O
may	O	AUX	O
serve	O	VERB	O
as	O	ADP	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
similar	O	ADJ	O
studies	O	NOUN	B
of	O	ADP	O
other	O	ADJ	O
complexes	O	NOUN	B
composed	O	VERB	O
of	O	ADP	O
multiple	O	ADJ	B
subunits	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Cleavage	O	NOUN	B
of	O	ADP	O
huntingtin	O	NOUN	B
by	O	ADP	O
apopain	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
proapoptotic	O	ADJ	B
cysteine	O	NOUN	I
protease	O	NOUN	I
,	O	PUNCT	O
is	O	AUX	O
modulated	O	VERB	B
by	O	ADP	O
the	O	DET	O
polyglutamine	O	NOUN	B
tract	O	NOUN	I
.	O	PUNCT	O


Apoptosis	O	NOUN	B
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
recognized	O	VERB	O
as	O	ADP	O
a	O	DET	O
mode	O	NOUN	B
of	O	ADP	O
cell	O	NOUN	B
death	O	NOUN	I
in	O	ADP	O
Huntington	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Apopain	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
human	O	ADJ	B
counterpart	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nematode	O	NOUN	B
cysteine	O	NOUN	B
protease	O	NOUN	I
death	O	NOUN	B
-	O	PUNCT	O
gene	O	NOUN	B
product	O	NOUN	I
,	O	PUNCT	O
CED	O	PROPN	B
-	O	PUNCT	O
3	O	NUM	B
,	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
key	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
proteolytic	O	ADJ	B
events	O	NOUN	I
leading	O	VERB	O
to	O	PART	O
apoptosis	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
apoptotic	O	ADJ	B
extracts	O	NOUN	I
and	O	CCONJ	O
apopain	O	NOUN	B
itself	O	PRON	O
specifically	O	ADV	O
cleave	O	VERB	B
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
,	O	PUNCT	O
huntingtin	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rate	O	NOUN	B
of	O	ADP	O
cleavage	O	NOUN	B
increases	O	NOUN	B
with	O	ADP	O
the	O	DET	O
length	O	NOUN	B
of	O	ADP	O
the	O	DET	O
huntingtin	O	NOUN	B
polyglutamine	O	NOUN	I
tract	O	NOUN	I
,	O	PUNCT	O
providing	O	VERB	O
an	O	DET	O
explanation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
gain	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	O
-	O	PUNCT	O
function	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
CAG	O	NOUN	B
expansion	O	NOUN	B
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
huntingtin	O	NOUN	B
is	O	AUX	O
cleaved	O	VERB	B
by	O	ADP	O
cysteine	O	NOUN	B
proteases	O	NOUN	I
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
HD	B-Disease	NOUN	B
might	O	AUX	O
be	O	AUX	O
a	O	DET	O
disorder	B-Disease	NOUN	B
of	I-Disease	ADP	O
inappropriate	I-Disease	ADJ	O
apoptosis	I-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
5	O	NUM	O
'	O	PART	O
end	O	NOUN	O
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
lies	O	VERB	O
within	O	ADP	O
a	O	DET	O
duplicated	O	ADJ	B
region	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
17q21	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
begin	O	VERB	O
to	O	PART	O
address	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
abnormal	O	ADJ	B
regulation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
BRCA1	O	NOUN	B
is	O	AUX	O
a	O	DET	O
critical	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
sporadic	O	ADJ	B
breast	O	NOUN	B
/	O	PUNCT	O
ovarian	O	ADJ	B
tumorigenesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
the	O	DET	O
detailed	O	ADJ	O
structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
genomic	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
region	O	NOUN	O
of	O	ADP	O
the	O	DET	O
genome	O	NOUN	B
contains	O	VERB	O
a	O	DET	O
tandem	O	ADJ	B
duplication	O	NOUN	I
of	O	ADP	O
approximately	O	ADV	O
30	O	NUM	O
kilobases	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
results	O	VERB	B
in	O	ADP	O
two	O	NUM	O
copies	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
exons	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
2	O	NUM	O
,	O	PUNCT	O
of	O	ADP	O
exons	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
3	O	NUM	O
of	O	ADP	O
the	O	DET	O
adjacent	O	ADJ	B
1A1	O	NOUN	B
-	O	PUNCT	O
3B	O	NOUN	B
gene	O	NOUN	B
and	O	CCONJ	O
of	O	ADP	O
the	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
295	O	NUM	O
base	O	NOUN	B
pair	O	NOUN	I
intergenic	O	ADJ	O
region	O	NOUN	O
.	O	PUNCT	O


Sequence	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
duplicated	O	ADJ	B
exons	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
1A1	O	NOUN	B
-	O	PUNCT	O
3B	O	NOUN	B
and	O	CCONJ	O
flanking	O	ADJ	B
genomic	O	ADJ	B
DNA	O	NOUN	I
reveals	O	VERB	O
maintenance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
intron	O	NOUN	B
-	O	PUNCT	O
exon	O	NOUN	B
structure	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
high	O	ADJ	O
degree	O	NOUN	B
of	O	ADP	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
identity	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
are	O	AUX	O
non	O	ADV	B
-	O	PUNCT	O
processed	O	VERB	B
pseudogenes	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
duplication	O	NOUN	B
is	O	AUX	O
a	O	DET	O
recent	O	ADJ	O
event	O	NOUN	B
in	O	ADP	O
evolutionary	O	ADJ	B
terms	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
show	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
processed	O	VERB	O
pseudogene	O	NOUN	B
of	O	ADP	O
the	O	DET	O
acidic	O	ADJ	B
ribosomal	O	ADJ	O
phosphoprotein	O	NOUN	O
P1	O	NOUN	O
(	O	PUNCT	O
ARPP1	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
inserted	O	VERB	B
directly	O	ADV	O
upstream	O	ADV	B
of	O	ADP	O
pseudo	O	ADJ	B
-	O	PUNCT	O
BRCA1	O	NOUN	B
exon	O	NOUN	B
1A	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
believe	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
findings	O	NOUN	B
could	O	AUX	O
not	O	PART	O
only	O	ADV	O
confound	O	VERB	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
could	O	AUX	O
have	O	AUX	O
implications	O	NOUN	O
for	O	ADP	O
the	O	DET	O
normal	O	ADJ	B
and	O	CCONJ	O
abnormal	O	ADJ	B
regulation	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
transcription	O	NOUN	B
,	O	PUNCT	O
translation	O	NOUN	B
and	O	CCONJ	O
function	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Deletion	O	NOUN	B
of	O	ADP	O
small	O	ADJ	B
nuclear	O	ADJ	I
ribonucleoprotein	O	NOUN	I
polypeptide	O	NOUN	I
N	O	NOUN	I
(	O	PUNCT	O
SNRPN	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
detected	O	VERB	B
by	O	ADP	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
:	O	PUNCT	O
two	O	NUM	O
sibs	O	NOUN	B
with	O	ADP	O
the	O	DET	O
typical	O	ADJ	O
phenotype	O	NOUN	B
without	O	ADP	O
a	O	DET	O
cytogenetic	O	ADJ	B
deletion	O	NOUN	I
in	O	ADP	O
chromosome	O	NOUN	B
15q	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
small	O	ADJ	O
nuclear	O	ADJ	B
ribonucleoprotein	O	NOUN	I
polypeptide	O	NOUN	I
N	O	NOUN	I
(	O	PUNCT	O
SNRPN	O	NOUN	O
)	O	PUNCT	O
gene	O	NOUN	O
is	O	AUX	O
regarded	O	VERB	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
candidates	O	NOUN	O
for	O	ADP	O
Prader	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Willi	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
PWS	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
two	O	NUM	O
sibs	O	NOUN	B
with	O	ADP	O
typical	O	ADJ	O
PWS	B-Disease	NOUN	B
presenting	O	NOUN	O
deletion	O	NOUN	B
of	O	ADP	O
SNRPN	O	NOUN	B
detected	O	VERB	B
by	O	ADP	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
(	O	PUNCT	O
FISH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Neither	O	CCONJ	O
a	O	DET	O
cytogenetically	O	ADV	B
detectable	O	ADJ	B
15q12	O	NOUN	O
deletion	O	NOUN	B
nor	O	CCONJ	O
a	O	DET	O
deletion	O	NOUN	B
for	O	ADP	O
the	O	DET	O
D15S11	O	NOUN	B
,	O	PUNCT	O
D15S10	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
GABRB3	O	NOUN	B
cosmid	O	NOUN	I
probes	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
either	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
implies	O	VERB	O
a	O	DET	O
smaller	O	ADJ	O
deletion	O	NOUN	B
limited	O	ADJ	O
to	O	PART	O
the	O	DET	O
PWS	B-Disease	NOUN	B
critical	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


FISH	O	NOUN	B
with	O	ADP	O
a	O	DET	O
SNRPN	O	NOUN	B
probe	O	NOUN	I
will	O	AUX	O
permit	O	VERB	O
analysis	O	NOUN	B
of	O	ADP	O
PWS	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
limited	O	ADJ	O
deletions	O	NOUN	B
not	O	PART	O
detectable	O	ADJ	B
with	O	ADP	O
other	O	ADJ	O
probes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
tumour	I-Disease	NOUN	O
suppressor	O	NOUN	O
gene	O	NOUN	O
during	O	ADP	O
human	O	ADJ	B
embryogenesis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
von	B-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
(	I-Disease	PUNCT	O
VHL	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
disease	I-Disease	NOUN	O
product	O	NOUN	O
is	O	AUX	O
thought	O	VERB	O
to	O	ADP	O
down	O	VERB	B
-	O	PUNCT	O
regulate	O	VERB	B
transcription	O	NOUN	B
by	O	ADP	O
antagonizing	O	VERB	O
elongin	O	NOUN	B
-	O	PUNCT	O
enhanced	O	VERB	B
transcriptional	O	ADJ	B
elongation	O	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
VHL	B-Disease	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
predispose	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
retinal	B-Disease	ADJ	B
,	I-Disease	PUNCT	O
cerebellar	I-Disease	ADJ	B
and	I-Disease	CCONJ	O
spinal	I-Disease	ADJ	B
haemangioblastomas	I-Disease	NOUN	I
,	O	PUNCT	O
renal	B-Disease	ADJ	B
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
phaeochromocytoma	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
somatic	O	ADJ	B
Inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
frequent	O	ADJ	B
in	O	ADP	O
sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
haemangioblastoma	B-Disease	NOUN	B
.	O	PUNCT	O


Regulation	O	NOUN	B
of	O	ADP	O
transcript	O	NOUN	B
elongation	O	NOUN	B
is	O	AUX	O
an	O	DET	O
important	O	ADJ	O
control	O	NOUN	B
mechanism	O	NOUN	B
for	O	ADP	O
gene	O	NOUN	B
expression	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
might	O	AUX	O
modify	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
proto	O	NOUN	B
-	O	PUNCT	O
oncogenes	O	NOUN	B
and	O	CCONJ	O
growth	O	NOUN	B
suppressor	O	NOUN	I
genes	O	NOUN	I
during	O	ADP	O
embryogenesis	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
investigated	O	VERB	B
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
VHL	B-Disease	NOUN	B
mRNA	O	NOUN	B
during	O	ADP	O
human	O	ADJ	B
embryogenesis	O	NOUN	B
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
studies	O	NOUN	B
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
weeks	O	NOUN	B
post	O	NOUN	B
conception	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
VHL	B-Disease	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
germ	O	NOUN	B
layers	O	NOUN	I
,	O	PUNCT	O
strong	O	ADJ	O
expression	O	NOUN	B
was	O	AUX	O
noted	O	VERB	O
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
nervous	O	ADJ	I
system	O	NOUN	I
,	O	PUNCT	O
kidneys	O	NOUN	B
,	O	PUNCT	O
testis	O	NOUN	B
and	O	CCONJ	O
lung	O	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
the	O	DET	O
kidney	O	NOUN	B
,	O	PUNCT	O
VHL	B-Disease	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
differentially	O	ADV	O
expressed	O	VERB	B
within	O	ADP	O
renal	O	ADJ	B
tubules	O	NOUN	I
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
specific	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
kidney	O	NOUN	B
development	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
alternatively	O	ADV	O
spliced	O	VERB	B
VHL	B-Disease	NOUN	B
mRNAs	O	NOUN	B
characterized	O	VERB	B
by	O	ADP	O
inclusion	O	NOUN	B
(	O	PUNCT	O
isoform	O	NOUN	B
I	O	NUM	I
)	O	PUNCT	O
or	O	CCONJ	O
exclusion	O	NOUN	B
(	O	PUNCT	O
isoform	O	NOUN	B
II	O	NUM	I
)	O	PUNCT	O
of	O	ADP	O
exon	O	NOUN	B
2	O	NUM	I
are	O	AUX	O
transcribed	O	VERB	B
in	O	ADP	O
adult	O	ADJ	B
tissues	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
if	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
isoforms	O	NOUN	B
are	O	AUX	O
differentially	O	ADV	O
expressed	O	VERB	B
during	O	ADP	O
embryogenesis	O	NOUN	B
,	O	PUNCT	O
VHL	B-Disease	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
reverse	O	ADJ	B
transcribed	O	VERB	I
from	O	ADP	O
13	O	NUM	O
fetal	O	ADJ	B
tissues	O	NOUN	I
(	O	PUNCT	O
8	O	NUM	O
-	O	SYM	O
10	O	NUM	O
weeks	O	NOUN	B
gestation	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
quantitative	O	ADJ	B
distribution	O	NOUN	B
of	O	ADP	O
VHL	B-Disease	NOUN	B
mRNA	O	NOUN	B
within	O	ADP	O
fetal	O	ADJ	B
tissues	O	NOUN	I
reflected	O	VERB	O
that	O	SCONJ	O
seen	O	VERB	O
by	O	ADP	O
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
ratio	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
VHL	B-Disease	NOUN	B
isoforms	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
between	O	ADP	O
tissues	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
genes	O	NOUN	B
regulated	O	VERB	B
by	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
have	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
our	O	PRON	O
findings	O	NOUN	B
are	O	AUX	O
compatible	O	ADJ	O
with	O	ADP	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
VHL	B-Disease	PROPN	B
-	O	PUNCT	O
mediated	O	VERB	B
control	O	NOUN	B
of	O	ADP	O
transcriptional	O	ADJ	B
elongation	O	NOUN	I
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
role	O	NOUN	O
in	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
development	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
heterogeneity	O	NOUN	I
in	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
:	O	PUNCT	O
role	O	NOUN	O
of	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
common	O	ADJ	O
hereditary	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
have	O	AUX	O
been	O	AUX	O
largely	O	ADV	O
attributed	O	VERB	O
to	O	PART	O
the	O	DET	O
inheritance	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
genes	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
not	O	PART	O
yet	O	ADV	O
clear	O	ADJ	O
what	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
is	O	AUX	O
explained	O	VERB	O
by	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
or	O	CCONJ	O
by	O	ADP	O
some	O	DET	O
other	O	ADJ	O
unidentified	O	ADJ	O
susceptibility	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
explained	O	VERB	O
by	O	ADP	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
North	O	ADJ	B
American	O	ADJ	I
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancers	I-Disease	NOUN	I
and	O	CCONJ	O
assess	O	VERB	B
the	O	DET	O
evidence	O	NOUN	B
for	O	ADP	O
additional	O	ADJ	O
susceptibility	O	NOUN	B
genes	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
confer	O	VERB	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
risk	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	B
-	O	PUNCT	O
three	O	NUM	B
families	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
through	O	ADP	O
two	O	NUM	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
research	O	NOUN	B
programs	O	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
was	O	AUX	O
undertaken	O	VERB	O
to	O	PART	O
establish	O	VERB	O
linkage	O	NOUN	B
between	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
and	O	CCONJ	O
markers	O	NOUN	B
on	O	ADP	O
chromosomes	O	NOUN	B
17q	O	NOUN	I
(	O	PUNCT	O
BRCA1	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
13q	O	NOUN	B
(	O	PUNCT	O
BRCA2	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Mutation	O	NOUN	B
analysis	O	NOUN	I
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
genes	O	NOUN	I
was	O	AUX	O
also	O	ADV	O
undertaken	O	VERB	O
in	O	ADP	O
all	O	DET	O
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
pattern	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
14	O	NUM	O
(	O	PUNCT	O
61	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
23	O	NUM	O
families	O	NOUN	B
studied	O	VERB	O
was	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
BRCA1	O	NOUN	B
by	O	ADP	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
linkage	O	NOUN	B
and	O	CCONJ	O
mutation	O	NOUN	B
analyses	O	NOUN	I
.	O	PUNCT	O


No	O	DET	O
families	O	NOUN	B
were	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
families	O	NOUN	B
(	O	PUNCT	O
22	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
provided	O	VERB	O
evidence	O	NOUN	B
against	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
both	O	CCONJ	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
these	O	DET	O
five	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
BRCA1	O	NOUN	B
or	O	CCONJ	O
BRCA2	O	NOUN	B
status	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
families	O	NOUN	B
(	O	PUNCT	O
17	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
could	O	AUX	O
not	O	PART	O
be	O	AUX	O
determined	O	VERB	O
.	O	PUNCT	O


BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
probably	O	ADV	O
explain	O	VERB	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
that	O	PRON	O
exists	O	VERB	O
in	O	ADP	O
the	O	DET	O
North	O	ADJ	B
American	O	ADJ	I
population	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADV	O
additional	O	ADJ	O
genes	O	NOUN	B
may	O	AUX	O
yet	O	ADV	O
be	O	AUX	O
found	O	VERB	O
that	O	PRON	O
explain	O	VERB	O
some	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


An	O	DET	O
intronic	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
a	O	DET	O
lariat	O	NOUN	B
branchpoint	O	ADJ	I
sequence	O	NOUN	I
is	O	AUX	O
a	O	DET	O
direct	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
an	O	DET	O
inherited	B-Disease	VERB	B
human	I-Disease	ADJ	B
disorder	I-Disease	NOUN	I
(	O	PUNCT	O
fish	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
first	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
the	O	DET	O
splicing	O	NOUN	B
of	O	ADP	O
an	O	DET	O
intron	O	NOUN	B
from	O	ADP	O
nuclear	O	ADJ	B
precursors	O	NOUN	I
of	O	ADP	O
mRNA	O	NOUN	B
results	O	NOUN	O
in	O	ADP	O
the	O	DET	O
formation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
lariat	O	ADJ	B
structure	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
distinct	O	ADJ	O
intronic	O	ADJ	B
nucleotide	O	NOUN	I
sequence	O	NOUN	I
,	O	PUNCT	O
known	O	VERB	O
as	O	ADP	O
the	O	DET	O
branchpoint	O	ADJ	B
region	O	NOUN	I
,	O	PUNCT	O
plays	O	VERB	O
a	O	DET	O
central	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
this	O	DET	O
process	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
here	O	ADV	O
describe	O	VERB	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
such	O	DET	O
a	O	DET	O
sequence	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
sisters	O	NOUN	B
were	O	AUX	O
shown	O	VERB	O
to	O	PART	O
suffer	O	VERB	O
from	O	ADP	O
fish	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
eye	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
FED	B-Disease	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
a	O	DET	O
disorder	O	NOUN	B
which	O	DET	O
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
coding	O	VERB	I
for	O	ADP	O
lecithin	O	NOUN	B
cholesterol	O	NOUN	I
acyltransferase	O	NOUN	I
(	O	PUNCT	O
LCAT	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Sequencing	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LCAT	O	NOUN	B
gene	O	NOUN	I
of	O	ADP	O
all	O	DET	O
three	O	NUM	O
probands	O	NOUN	B
revealed	O	VERB	O
compound	O	NOUN	B
heterozygosity	O	NOUN	I
for	O	ADP	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
which	O	DET	O
is	O	AUX	O
reported	O	VERB	O
to	O	PART	O
underlie	O	VERB	O
the	O	DET	O
FED	B-Disease	PROPN	B
phenotype	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
located	O	ADJ	O
in	O	ADP	O
intron	O	NOUN	B
4	O	NUM	I
(	O	PUNCT	O
IVS4	O	NOUN	B
T	O	NOUN	I
-	O	PUNCT	O
22C	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


By	O	ADP	O
performing	O	VERB	O
in	O	X	B
vitro	O	X	I
expression	O	NOUN	B
of	O	ADP	O
LCAT	O	NOUN	B
minigenes	O	NOUN	B
and	O	CCONJ	O
reverse	O	ADJ	B
transcriptase	O	NOUN	I
PCR	O	NOUN	I
on	O	ADP	O
mRNA	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
leukocytes	O	NOUN	B
of	O	ADP	O
the	O	DET	O
patient	O	NOUN	B
,	O	PUNCT	O
this	O	DET	O
gene	O	NOUN	B
defect	O	NOUN	I
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
cause	O	VERB	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
as	O	ADP	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
complete	O	ADJ	B
intron	O	NOUN	B
retention	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
conclusion	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
demonstrated	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
lariat	O	NOUN	B
branchpoint	O	ADJ	I
consensus	O	NOUN	I
sequence	O	NOUN	I
causes	O	VERB	O
a	O	DET	O
null	O	ADJ	B
allele	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
FED	B-Disease	PROPN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
our	O	PRON	O
finding	O	NOUN	O
illustrates	O	VERB	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
this	O	DET	O
sequence	O	NOUN	B
for	O	ADP	O
normal	O	ADJ	O
human	O	ADJ	B
mRNA	O	NOUN	B
processing	O	NOUN	I
.	O	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
report	O	NOUN	B
provides	O	VERB	O
a	O	DET	O
widely	O	ADV	O
applicable	O	ADJ	O
strategy	O	NOUN	O
which	O	DET	O
ensures	O	VERB	O
fast	O	ADJ	B
and	O	CCONJ	O
effective	O	ADJ	B
screening	O	NOUN	B
for	O	ADP	O
intronic	O	ADJ	B
defects	O	NOUN	I
that	O	PRON	O
underlie	O	VERB	O
differential	O	ADJ	O
gene	O	NOUN	B
expression	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
variant	O	ADJ	B
phenotypes	O	NOUN	B
in	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
identified	O	VERB	O
14	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
less	O	ADV	O
severe	O	ADJ	B
clinical	O	ADJ	B
and	O	CCONJ	O
cellular	O	ADJ	B
phenotype	O	NOUN	I
(	O	PUNCT	O
approximately	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
families	O	NOUN	B
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
United	O	PROPN	B
Kingdom	O	PROPN	I
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
10	O	NUM	O
of	O	ADP	O
these	O	DET	O
families	O	NOUN	B
,	O	PUNCT	O
all	O	DET	O
the	O	DET	O
homozygotes	O	NOUN	B
have	O	AUX	O
a	O	DET	O
137	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
insertion	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
cDNA	O	NOUN	B
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
point	O	NOUN	O
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
sequence	O	NOUN	B
resembling	O	VERB	O
a	O	DET	O
splice	O	NOUN	B
-	O	PUNCT	O
donor	O	NOUN	B
site	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
second	O	ADJ	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
allele	O	NOUN	B
has	O	AUX	O
a	O	DET	O
different	O	ADJ	O
mutation	O	NOUN	B
in	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
less	O	ADV	O
severe	O	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
these	O	DET	O
patients	O	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
some	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	B
splicing	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
occurs	O	VERB	O
as	O	ADP	O
an	O	DET	O
alternative	O	ADJ	B
product	O	NOUN	O
from	O	ADP	O
the	O	DET	O
insertion	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
allele	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
level	O	NOUN	B
of	O	ADP	O
the	O	DET	O
137	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
PCR	O	NOUN	B
product	O	NOUN	O
containing	O	VERB	O
the	O	DET	O
insertion	O	NOUN	B
was	O	AUX	O
lowest	O	ADJ	O
in	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
who	O	PRON	O
showed	O	VERB	O
a	O	DET	O
later	O	ADJ	O
onset	O	NOUN	O
of	O	ADP	O
cerebellar	B-Disease	ADJ	B
ataxia	I-Disease	NOUN	I
.	O	PUNCT	O


A	O	DET	O
further	O	ADJ	O
four	O	NUM	O
families	O	NOUN	B
who	O	PRON	O
do	O	AUX	O
not	O	PART	O
have	O	AUX	O
this	O	DET	O
insertion	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


Mutations	O	NOUN	B
detected	O	VERB	B
in	O	ADP	O
two	O	NUM	O
of	O	ADP	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
are	O	AUX	O
missense	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
normally	O	ADV	O
rare	O	ADJ	B
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
patients	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
demonstration	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
giving	O	VERB	O
rise	O	NOUN	O
to	O	ADP	O
a	O	DET	O
slightly	O	ADV	O
milder	O	ADJ	B
phenotype	O	NOUN	B
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
raises	O	VERB	O
the	O	DET	O
interesting	O	ADJ	O
question	O	NOUN	O
of	O	ADP	O
what	O	DET	O
range	O	NOUN	O
of	O	ADP	O
phenotypes	O	NOUN	B
might	O	AUX	O
occur	O	VERB	O
in	O	ADP	O
individuals	O	NOUN	B
in	O	ADP	O
whom	O	PRON	O
both	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
milder	O	ADJ	B
.	O	PUNCT	O


One	O	NUM	O
possibility	O	NOUN	O
might	O	AUX	O
be	O	AUX	O
that	O	SCONJ	O
individuals	O	NOUN	B
who	O	PRON	O
are	O	AUX	O
compound	O	NOUN	B
heterozygotes	O	NOUN	B
for	O	ADP	O
ATM	O	NOUN	B
mutations	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
than	O	ADP	O
we	O	PRON	O
realize	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
associated	O	VERB	O
exclusively	O	ADV	O
with	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
papillary	I-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
define	O	VERB	O
the	O	DET	O
possible	O	ADJ	O
role	O	NOUN	O
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
sporadic	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
,	O	PUNCT	O
91	O	NUM	O
different	O	ADJ	O
parenchymal	B-Disease	ADJ	B
tumours	I-Disease	NOUN	I
of	I-Disease	ADP	O
the	I-Disease	DET	O
kidney	I-Disease	NOUN	B
have	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
for	O	ADP	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
by	O	ADP	O
single	O	ADJ	B
strand	O	NOUN	I
conformation	O	NOUN	I
polymorphism	O	NOUN	I
(	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
heteroduplex	O	NOUN	B
(	O	PUNCT	O
HD	O	NOUN	B
)	O	PUNCT	O
techniques	O	NOUN	B
.	O	PUNCT	O


Chromosome	O	NOUN	B
3p	O	NOUN	I
deletion	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
98	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
of	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
papillary	I-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
25	O	NUM	O
per	O	ADP	O
cent	O	NOUN	O
of	O	ADP	O
chromophobe	O	NOUN	B
renal	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
22	O	NUM	O
of	O	ADP	O
the	O	DET	O
43	O	NUM	O
non	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
papillary	I-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
,	O	PUNCT	O
abnormally	O	ADV	O
migrating	O	VERB	O
DNA	O	NOUN	B
bands	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
SSCP	O	NOUN	B
and	O	CCONJ	O
/	O	SYM	O
or	O	CCONJ	O
HD	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
mobility	O	NOUN	B
shift	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
23	O	NUM	O
chromophobe	O	NOUN	B
renal	B-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
15	O	NUM	O
papillary	B-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
tumours	I-Disease	NOUN	I
and	O	CCONJ	O
ten	O	NUM	O
renal	B-Disease	ADJ	B
oncocytomas	I-Disease	NOUN	I
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
genetic	O	ADJ	B
changes	O	NOUN	I
other	O	ADJ	O
than	O	ADP	O
loss	O	NOUN	B
of	O	ADP	I
chromosome	O	NOUN	I
3p	O	NOUN	I
sequences	O	NOUN	I
,	O	PUNCT	O
were	O	AUX	O
analysed	O	VERB	B
for	O	ADP	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


None	O	NOUN	O
of	O	ADP	O
these	O	DET	O
tumours	B-Disease	NOUN	B
showed	O	VERB	O
abnormal	O	ADJ	B
migration	O	NOUN	B
patterns	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
mutation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	B-Disease	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
associated	O	VERB	O
exclusively	O	ADV	O
with	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
papillary	I-Disease	ADJ	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
emerin	O	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
nuclear	O	ADJ	B
membrane	O	NOUN	I
protein	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
large	O	ADJ	O
fragment	O	NOUN	B
of	O	ADP	O
emerin	O	NOUN	B
cDNA	O	NOUN	B
was	O	AUX	O
prepared	O	VERB	O
by	O	ADP	O
PCR	O	NOUN	B
and	O	CCONJ	O
expressed	O	VERB	B
as	O	ADP	O
a	O	DET	O
recombinant	O	ADJ	B
protein	O	NOUN	I
in	O	ADP	O
Escherichia	O	X	B
coli	O	X	I
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
as	O	ADP	O
immunogen	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
prepared	O	VERB	O
a	O	DET	O
panel	O	NOUN	O
of	O	ADP	O
12	O	NUM	O
monoclonal	O	ADJ	B
antibodies	O	NOUN	I
which	O	DET	O
recognise	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
four	O	NUM	O
different	O	ADJ	O
epitopes	O	NOUN	B
on	O	ADP	O
emerin	O	NOUN	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
ensure	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
distinguished	O	VERB	O
from	O	ADP	O
non	O	ADJ	B
-	O	PUNCT	O
specific	O	ADJ	B
cross	O	NOUN	B
-	O	PUNCT	O
reacting	O	VERB	B
proteins	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
the	O	DET	O
mAbs	O	NOUN	B
recognised	O	VERB	O
a	O	DET	O
34	O	NUM	O
kDa	O	NOUN	O
protein	O	NOUN	O
in	O	ADP	O
all	O	DET	O
tissues	O	NOUN	B
tested	O	VERB	B
,	O	PUNCT	O
though	O	SCONJ	O
minor	O	ADJ	O
emerin	O	NOUN	B
-	O	PUNCT	O
related	O	VERB	B
bands	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
detected	O	VERB	B
in	O	ADP	O
some	O	DET	O
tissues	O	NOUN	B
.	O	PUNCT	O


Immunofluorescence	O	NOUN	B
microscopy	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
is	O	AUX	O
located	O	ADJ	O
at	O	ADP	O
the	O	DET	O
nuclear	O	ADJ	B
rim	O	NOUN	I
in	O	ADP	O
all	O	DET	O
tissues	O	NOUN	B
examined	O	VERB	B
.	O	PUNCT	O


A	O	DET	O
muscle	O	NOUN	B
biopsy	O	NOUN	I
from	O	ADP	O
an	O	DET	O
Emery	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Dreifuss	I-Disease	PROPN	B
muscular	I-Disease	ADJ	I
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
EMDM	B-Disease	NOUN	B
)	O	PUNCT	O
patient	O	NOUN	B
showed	O	VERB	O
complete	O	ADJ	O
absence	O	NOUN	B
of	O	ADP	O
emerin	O	NOUN	B
by	O	ADP	O
both	O	CCONJ	O
Western	O	NOUN	B
blotting	O	NOUN	I
and	O	CCONJ	O
immunohistochemistry	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
simple	O	ADJ	O
diagnostic	O	ADJ	B
antibody	O	NOUN	I
test	O	NOUN	I
for	O	ADP	O
EDMD	B-Disease	NOUN	B
families	O	NOUN	B
.	O	PUNCT	O


Biochemical	O	ADJ	B
fractionation	O	NOUN	B
of	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
liver	O	NOUN	B
tissues	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
was	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
nuclei	O	NOUN	B
purified	O	VERB	B
by	O	ADP	O
centrifugation	O	NOUN	B
through	O	ADP	O
65	O	NUM	O
%	O	NOUN	O
sucrose	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
absent	O	ADJ	B
from	O	ADP	O
soluble	O	ADJ	B
fractions	O	NOUN	B
(	O	PUNCT	O
post	O	NOUN	B
-	O	PUNCT	O
100	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
g	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


From	O	ADP	O
these	O	DET	O
results	O	NOUN	B
,	O	PUNCT	O
together	O	ADV	O
with	O	ADP	O
sequence	O	NOUN	B
and	O	CCONJ	O
structural	O	ADJ	B
homologies	O	NOUN	I
between	O	ADP	O
emerin	O	NOUN	B
,	O	PUNCT	O
thymopoietins	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
nuclear	O	ADJ	B
lamina	O	NOUN	I
-	O	PUNCT	O
associated	O	VERB	B
protein	O	NOUN	B
,	O	PUNCT	O
LAP2	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
suggest	O	VERB	O
that	O	SCONJ	O
emerin	O	NOUN	B
will	O	AUX	O
prove	O	VERB	O
to	O	PART	O
be	O	AUX	O
one	O	NUM	O
member	O	NOUN	O
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
of	O	ADP	O
inner	O	ADJ	B
nuclear	O	ADJ	I
membrane	O	NOUN	I
proteins	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Mutation	O	NOUN	B
of	O	ADP	O
MSH3	O	NOUN	B
in	O	ADP	O
endometrial	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
evidence	O	NOUN	B
for	O	ADP	O
its	O	PRON	O
functional	O	ADJ	B
role	O	NOUN	O
in	O	ADP	O
heteroduplex	O	NOUN	B
repair	O	NOUN	I
.	O	PUNCT	O


Many	O	ADJ	O
human	O	ADJ	B
tumours	B-Disease	NOUN	I
have	O	AUX	O
length	O	NOUN	O
alterations	O	NOUN	B
in	O	ADP	O
repetitive	O	ADJ	B
sequence	O	NOUN	I
elements	O	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
microsatellite	B-Disease	NOUN	B
instability	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
attributed	O	VERB	O
to	O	PART	O
mutations	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
DNA	O	NOUN	B
mismatch	O	NOUN	I
repair	O	NOUN	I
genes	O	NOUN	I
in	O	ADP	O
hereditary	B-Disease	ADJ	B
nonpolyposis	I-Disease	NOUN	I
colorectal	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
(	O	PUNCT	O
HNPCC	B-Disease	NOUN	B
)	O	PUNCT	O
kindreds	O	NOUN	B
,	O	PUNCT	O
many	O	ADJ	O
sporadic	B-Disease	ADJ	B
tumours	I-Disease	NOUN	I
exhibit	O	VERB	O
instability	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
detectable	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
these	O	DET	O
genes	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
therefore	O	ADV	O
of	O	ADP	O
interest	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
other	O	ADJ	O
genes	O	NOUN	B
that	O	PRON	O
contribute	O	VERB	O
to	O	PART	O
this	O	DET	O
instability	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
yeast	O	NOUN	B
,	O	PUNCT	O
mutations	O	NOUN	B
in	O	ADP	O
several	O	ADJ	O
genes	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
RTH	O	NOUN	B
and	O	CCONJ	O
MSH3	O	NOUN	B
,	O	PUNCT	O
cause	O	VERB	O
microsatellite	O	NOUN	B
instability	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
screened	O	VERB	B
16	O	NUM	O
endometrial	B-Disease	ADJ	B
carcinomas	I-Disease	NOUN	I
with	O	ADP	O
microsatellite	O	NOUN	B
instability	O	NOUN	I
for	O	ADP	O
alterations	O	NOUN	B
in	O	ADP	O
FEN1	O	NOUN	B
(	O	PUNCT	O
the	O	DET	O
human	O	ADJ	B
homolog	O	NOUN	B
of	O	ADP	O
RTH	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
MSH3	O	NOUN	B
(	O	PUNCT	O
refs	O	NOUN	O
12	O	NUM	O
-	O	SYM	O
14	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Although	O	SCONJ	O
we	O	PRON	O
found	O	VERB	O
no	O	DET	O
FEN1	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
MSH3	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
an	O	DET	O
endometrial	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
and	O	CCONJ	O
in	O	ADP	O
an	O	DET	O
endometrial	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
cell	O	NOUN	B
line	O	NOUN	I
.	O	PUNCT	O


Extracts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
line	O	NOUN	I
were	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
repair	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
substrates	O	NOUN	I
containing	O	VERB	O
mismatches	O	NOUN	B
or	O	CCONJ	O
extra	O	ADJ	O
nucleotides	O	NOUN	B
.	O	PUNCT	O


Introducing	O	NOUN	O
chromosome	O	NOUN	O
5	O	NUM	O
,	O	PUNCT	O
encoding	O	VERB	B
the	O	DET	O
MSH3	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
mutant	O	ADJ	B
cell	O	NOUN	I
line	O	NOUN	I
increased	O	VERB	B
the	O	DET	O
stability	O	NOUN	B
of	O	ADP	O
some	O	DET	O
but	O	CCONJ	O
not	O	PART	O
all	O	DET	O
microsatellites	O	NOUN	B
.	O	PUNCT	O


Extracts	O	NOUN	B
of	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
repaired	O	VERB	O
certain	O	ADJ	O
substrates	O	NOUN	B
containing	O	VERB	O
extra	O	ADJ	O
nucleotides	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
were	O	AUX	O
deficient	O	ADJ	B
in	O	ADP	O
repair	O	NOUN	B
of	O	ADP	O
those	O	DET	O
containing	O	VERB	O
mismatches	O	NOUN	B
or	O	CCONJ	O
other	O	ADJ	O
extra	O	ADJ	O
nucleotides	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
subsequent	O	ADJ	O
search	O	NOUN	O
revealed	O	VERB	B
a	O	DET	O
second	O	ADJ	O
gene	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
HHUA	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
MSH6	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Together	O	ADV	O
the	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
MSH3	O	NOUN	B
gene	O	NOUN	O
encodes	O	VERB	B
a	O	DET	O
product	O	NOUN	B
that	O	PRON	O
functions	O	VERB	B
in	O	ADP	O
repair	O	NOUN	B
of	O	ADP	O
some	O	DET	O
but	O	CCONJ	O
not	O	PART	O
all	O	DET	O
pre	O	ADJ	B
-	O	PUNCT	O
mutational	O	ADJ	B
intermediates	O	NOUN	B
,	O	PUNCT	O
its	O	PRON	O
mutation	O	NOUN	B
in	O	ADP	O
tumours	B-Disease	NOUN	B
can	O	AUX	O
result	O	VERB	O
in	O	ADP	O
genomic	O	ADJ	B
instability	O	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
as	O	ADP	O
in	O	ADP	O
yeast	O	NOUN	B
,	O	PUNCT	O
MSH3	O	NOUN	B
and	O	CCONJ	O
MSH6	O	NOUN	B
are	O	AUX	O
partially	O	ADV	O
redundant	O	ADJ	O
for	O	ADP	O
mismatch	O	NOUN	B
repair	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Comparative	O	ADJ	B
genome	O	NOUN	O
mapping	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
region	O	NOUN	O
in	O	ADP	O
mouse	O	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Syrian	O	ADJ	B
hamster	O	NOUN	I
.	O	PUNCT	O


Chromosomal	O	ADJ	B
locations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
Atm	O	NOUN	B
(	O	PUNCT	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
AT	B-Disease	NOUN	B
)	O	PUNCT	O
-	O	PUNCT	O
mutated	O	VERB	B
)	O	PUNCT	O
and	O	CCONJ	O
Acat1	O	NOUN	B
(	O	PUNCT	O
mitochondrial	O	ADJ	B
acetoacetyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
thiolase	O	NOUN	I
)	O	PUNCT	O
genes	O	NOUN	O
in	O	ADP	O
mouse	O	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Syrian	O	ADJ	B
hamster	O	NOUN	I
were	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
direct	O	ADJ	O
R	O	NOUN	B
-	O	PUNCT	O
banding	O	NOUN	B
FISH	O	NOUN	B
.	O	PUNCT	O


Both	O	DET	O
genes	O	NOUN	B
were	O	AUX	O
colocalized	O	VERB	B
to	O	PART	O
the	O	DET	O
C	O	PROPN	B
-	O	PUNCT	O
D	O	NOUN	B
band	O	NOUN	O
of	O	ADP	O
mouse	O	NOUN	O
chromosome	O	NOUN	O
9	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
proximal	O	ADJ	B
end	O	NOUN	O
of	O	ADP	O
q24	O	NOUN	O
.	O	PUNCT	O


1	O	NUM	O
of	O	ADP	O
rat	O	NOUN	B
chromosome	O	NOUN	O
8	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
qa4	O	NUM	B
-	O	PUNCT	O
qa5	O	NUM	B
of	O	ADP	O
Syrian	O	ADJ	B
hamster	O	NOUN	O
chromosome	O	NOUN	O
12	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
regions	O	NOUN	B
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
and	O	CCONJ	O
rat	O	NOUN	B
were	O	AUX	O
homologous	O	ADJ	O
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
11q	O	NOUN	I
.	O	PUNCT	O


Fine	O	ADJ	B
genetic	O	ADJ	B
linkage	O	NOUN	I
mapping	O	NOUN	O
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
AT	B-Disease	ADP	B
region	O	NOUN	I
was	O	AUX	O
performed	O	VERB	O
using	O	VERB	O
the	O	DET	O
interspecific	O	ADJ	B
backcross	O	NOUN	I
mice	O	NOUN	I
.	O	PUNCT	O


Atm	O	NOUN	B
,	O	PUNCT	O
Acat1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Npat	O	PROPN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
a	O	DET	O
new	O	ADJ	O
gene	O	NOUN	B
isolated	O	VERB	B
from	O	ADP	O
the	O	DET	O
AT	O	NOUN	B
region	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
flanking	O	ADJ	B
microsatellite	O	NOUN	I
DNA	O	NOUN	O
markers	O	NOUN	O
were	O	AUX	O
examined	O	VERB	O
.	O	PUNCT	O


No	O	DET	O
recombinations	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
among	O	ADP	O
the	O	DET	O
Atm	O	PROPN	B
,	O	PUNCT	O
Npat	O	PROPN	B
,	O	PUNCT	O
Acat1	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D9Mit6	O	NOUN	B
loci	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
these	O	DET	O
loci	O	NOUN	B
were	O	AUX	O
mapped	O	VERB	B
2	O	NUM	I
.	O	PUNCT	O


0	O	NUM	O
cM	O	NOUN	B
distal	O	ADJ	B
to	O	PART	O
D9Mit99	O	NOUN	O
and	O	CCONJ	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
cM	O	NOUN	O
proximal	O	ADJ	B
to	O	PART	O
D9Mit102	O	NUM	B
.	O	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
linkage	O	NOUN	B
map	O	NOUN	I
of	O	ADP	O
mouse	O	NOUN	B
chromosome	O	NOUN	I
9	O	NUM	I
(	O	PUNCT	O
MMU9	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
that	O	DET	O
of	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
11	O	NUM	I
(	O	PUNCT	O
HSA11	O	NOUN	B
)	O	PUNCT	O
indicates	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
chromosomal	O	ADJ	B
rearrangement	O	NOUN	I
due	O	ADJ	O
to	O	ADP	O
an	O	DET	O
inversion	O	NOUN	B
between	O	ADP	O
Ets1	O	NOUN	B
and	O	CCONJ	O
Atm	O	PROPN	B
-	O	PUNCT	O
Npat	O	PROPN	B
-	O	PUNCT	O
Acat1	O	PROPN	B
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
inversion	O	NOUN	B
of	O	ADP	O
MMU9	O	NOUN	B
originated	O	VERB	O
from	O	ADP	O
the	O	DET	O
chromosomal	O	ADJ	B
breakage	O	NOUN	I
at	O	ADP	O
the	O	DET	O
boundary	O	NOUN	B
between	O	ADP	O
Gria4	O	NOUN	B
and	O	CCONJ	O
Atm	O	PROPN	B
-	O	PUNCT	O
Npat	O	PROPN	B
-	O	PUNCT	O
Acat1	O	NOUN	B
on	O	ADP	O
HSA11	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
type	O	NOUN	O
of	O	ADP	O
inversion	O	NOUN	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
conserved	O	VERB	O
in	O	ADP	O
the	O	DET	O
three	O	NUM	O
rodent	O	ADJ	B
species	O	NOUN	B
,	O	PUNCT	O
mouse	O	NOUN	B
,	O	PUNCT	O
rat	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Syrian	O	ADJ	B
hamster	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
additional	O	ADJ	O
comparative	O	ADJ	O
mapping	O	NOUN	O
data	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Rck	O	NOUN	B
gene	O	NOUN	I


An	O	DET	O
animal	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ND	B-Disease	NOUN	B
)	O	PUNCT	O
:	O	PUNCT	O
gene	O	NOUN	B
targeting	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
ND	B-Disease	NOUN	B
gene	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
cellular	O	ADJ	B
and	O	CCONJ	O
molecular	O	ADJ	B
processes	O	NOUN	I
which	O	DET	O
are	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
Norrie	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
ND	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
used	O	VERB	O
gene	O	NOUN	B
targeting	O	NOUN	B
technology	O	NOUN	B
to	O	PART	O
generate	O	VERB	O
ND	B-Disease	NOUN	B
mutant	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
murine	O	ADJ	B
homologue	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ND	B-Disease	NOUN	B
gene	O	NOUN	I
was	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
shown	O	VERB	O
to	O	PART	O
encode	O	VERB	B
a	O	DET	O
polypeptide	O	NOUN	B
that	O	PRON	O
shares	O	VERB	O
94	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
with	O	ADP	O
its	O	PRON	O
human	O	ADJ	B
counterpart	O	NOUN	B
.	O	PUNCT	O


RNA	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridization	O	NOUN	I
revealed	O	VERB	O
expression	O	NOUN	B
in	O	ADP	O
retina	O	NOUN	B
,	O	PUNCT	O
brain	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
olfactory	O	ADJ	B
bulb	O	NOUN	I
and	O	CCONJ	O
epithelium	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
week	O	NOUN	B
old	O	ADJ	O
mice	O	NOUN	B
.	O	PUNCT	O


Hemizygous	O	ADJ	B
mice	O	NOUN	I
carrying	O	VERB	O
a	O	DET	O
replacement	O	NOUN	B
mutation	O	NOUN	O
in	O	ADP	O
exon	O	NOUN	B
2	O	NUM	I
of	O	ADP	O
the	O	DET	O
ND	B-Disease	NOUN	B
gene	O	NOUN	B
developed	O	VERB	O
retrolental	O	ADJ	B
structures	O	NOUN	I
in	O	ADP	O
the	O	DET	O
vitreous	O	ADJ	B
body	O	NOUN	I
and	O	CCONJ	O
showed	O	VERB	O
an	O	DET	O
overall	O	ADJ	O
disorganization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
retinal	O	ADJ	B
ganglion	O	NOUN	I
cell	O	NOUN	I
layer	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
outer	O	ADJ	O
plexiform	O	NOUN	O
layer	O	NOUN	O
disappears	O	VERB	O
occasionally	O	ADV	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
juxtaposed	O	VERB	B
inner	O	ADJ	B
and	O	CCONJ	O
outer	O	ADJ	O
nuclear	O	ADJ	O
layer	O	NOUN	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
same	O	ADJ	O
regions	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
outer	O	ADJ	B
segments	O	NOUN	I
of	O	ADP	O
the	O	DET	O
photoreceptor	O	NOUN	B
cell	O	NOUN	I
layer	O	NOUN	O
are	O	AUX	O
no	O	ADV	O
longer	O	ADV	O
present	O	ADJ	O
.	O	PUNCT	O


These	O	DET	O
ocular	O	ADJ	B
findings	O	NOUN	I
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
observations	O	NOUN	B
in	O	ADP	O
ND	B-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
generated	O	VERB	O
mouse	O	NOUN	B
line	O	NOUN	I
provides	O	VERB	O
a	O	DET	O
faithful	O	ADJ	O
model	O	NOUN	B
for	O	ADP	O
study	O	NOUN	B
of	O	ADP	O
early	O	ADJ	B
pathogenic	O	ADJ	B
events	O	NOUN	O
in	O	ADP	O
this	O	DET	O
severe	O	ADJ	B
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
recessive	I-Disease	ADJ	B
neurological	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
hybrid	O	ADJ	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
fusion	O	NOUN	B
protein	O	NOUN	I
of	O	ADP	O
alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
transforms	O	VERB	O
fibroblasts	O	NOUN	B
in	O	ADP	O
culture	O	NOUN	B
.	O	PUNCT	O


Pediatric	B-Disease	ADJ	B
alveolar	I-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
a	O	DET	O
chromosomal	O	ADJ	B
translocation	O	NOUN	I
that	O	PRON	O
fuses	O	VERB	O
parts	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAX3	O	NOUN	B
and	O	CCONJ	O
FKHR	O	NOUN	B
genes	O	NOUN	O
.	O	PUNCT	O


PAX3	O	NOUN	B
codes	O	VERB	B
for	O	ADP	O
a	O	DET	O
transcriptional	O	ADJ	B
regulator	O	NOUN	I
that	O	PRON	O
controls	O	VERB	B
developmental	O	ADJ	B
programs	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
FKHR	O	NOUN	B
codes	O	VERB	O
for	O	ADP	O
a	O	DET	O
forkhead	O	NOUN	B
-	O	PUNCT	O
winged	O	VERB	B
helix	O	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
also	O	ADV	O
a	O	DET	O
likely	O	ADJ	O
transcription	O	NOUN	B
factor	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
fusion	O	NOUN	B
product	O	NOUN	I
retains	O	VERB	O
the	O	DET	O
DNA	O	NOUN	B
binding	O	NOUN	I
domains	O	NOUN	I
of	O	ADP	O
the	O	DET	O
PAX3	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
putative	O	ADJ	B
activator	O	NOUN	I
domain	O	NOUN	I
of	O	ADP	O
the	O	DET	O
FKHR	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
protein	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
function	O	VERB	B
as	O	ADP	O
a	O	DET	O
transcriptional	O	ADJ	B
activator	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
the	O	DET	O
RCAS	O	NOUN	B
retroviral	O	ADJ	B
vector	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
introduced	O	VERB	O
the	O	DET	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
gene	O	NOUN	B
into	O	ADP	O
chicken	O	NOUN	B
embryo	O	NOUN	B
fibroblasts	O	NOUN	B
.	O	PUNCT	O


Expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
protein	O	NOUN	O
in	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
transformation	O	VERB	B
the	O	DET	O
cells	O	NOUN	B
become	O	VERB	O
enlarged	O	ADJ	B
,	O	PUNCT	O
grow	O	VERB	B
tightly	O	ADV	O
packed	O	VERB	B
and	O	CCONJ	O
in	O	ADP	O
multiple	O	ADJ	B
layers	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
acquire	O	VERB	B
the	O	DET	O
ability	O	NOUN	B
for	O	ADP	O
anchorage	O	NOUN	B
-	O	PUNCT	O
independent	O	ADJ	B
growth	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
cellular	O	ADJ	B
transformation	O	NOUN	I
in	O	X	B
vitro	O	X	I
will	O	AUX	O
facilitate	O	VERB	O
studies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
mechanism	O	NOUN	B
of	O	ADP	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
oncogenesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Somatic	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
selection	O	NOUN	B
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
determinant	O	NOUN	O
of	O	ADP	O
the	O	DET	O
blood	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
phenotype	O	NOUN	B
in	O	ADP	O
heterozygotes	O	NOUN	B
for	O	ADP	O
glucose	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
mutations	O	NOUN	O
causing	O	VERB	O
severe	O	ADJ	O
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


X	O	NOUN	B
-	O	PUNCT	O
chromosome	O	NOUN	B
inactivation	O	NOUN	B
in	O	ADP	O
mammals	O	NOUN	B
is	O	AUX	O
regarded	O	VERB	O
as	O	ADP	O
an	O	DET	O
essentially	O	ADV	O
random	O	ADJ	B
process	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
resulting	O	VERB	O
somatic	O	ADJ	B
-	O	PUNCT	O
cell	O	NOUN	B
mosaicism	O	NOUN	B
creates	O	VERB	O
the	O	DET	O
opportunity	O	NOUN	O
for	O	ADP	O
cell	O	NOUN	B
selection	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
most	O	ADJ	O
people	O	NOUN	B
with	O	ADP	O
red	O	ADJ	B
-	O	PUNCT	O
blood	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
glucose	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
G6PD	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	O
,	O	PUNCT	O
the	O	DET	O
enzyme	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
phenotype	O	NOUN	B
is	O	AUX	O
only	O	ADV	O
moderately	O	ADV	O
expressed	O	VERB	B
in	O	ADP	O
nucleated	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
small	O	ADJ	O
subset	O	NOUN	O
of	O	ADP	O
hemizygous	O	ADJ	B
males	O	NOUN	B
who	O	PRON	O
suffer	O	VERB	O
from	O	ADP	O
chronic	B-Disease	ADJ	B
nonspherocytic	I-Disease	ADJ	I
hemolytic	I-Disease	ADJ	I
anemia	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
underlying	O	VERB	O
mutations	O	NOUN	B
(	O	PUNCT	O
designated	O	VERB	O
class	O	NOUN	B
I	O	NUM	I
)	O	PUNCT	O
cause	O	VERB	O
more	O	ADV	B
-	O	PUNCT	O
severe	O	ADJ	B
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
this	O	DET	O
might	O	AUX	O
provide	O	VERB	O
an	O	DET	O
opportunity	O	NOUN	O
for	O	ADP	O
selection	O	NOUN	B
in	O	ADP	O
heterozygous	O	ADJ	B
females	O	NOUN	B
during	O	ADP	O
development	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
test	O	VERB	O
this	O	DET	O
possibility	O	NOUN	O
we	O	PRON	O
have	O	AUX	O
analyzed	O	VERB	B
four	O	NUM	O
heterozygotes	O	NOUN	B
for	O	ADP	O
class	O	NOUN	B
I	O	NUM	I
G6PD	O	NOUN	B
mutations	O	NOUN	B
two	O	NUM	O
with	O	ADP	O
G6PD	O	NOUN	B
Portici	O	PROPN	I
(	O	PUNCT	O
1178G	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
A	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
two	O	NUM	O
with	O	ADP	O
G6PD	O	NOUN	B
Bari	O	PROPN	I
(	O	PUNCT	O
1187C	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
fractionated	O	VERB	B
blood	O	NOUN	I
cell	O	NOUN	I
types	O	NOUN	I
(	O	PUNCT	O
including	O	VERB	O
erythroid	O	ADJ	B
,	O	PUNCT	O
myeloid	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
lymphoid	O	ADJ	B
cell	O	NOUN	I
lineages	O	NOUN	O
)	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
excess	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
-	O	PUNCT	O
normal	O	ADJ	B
cells	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
significant	O	ADJ	B
concordance	O	NOUN	B
that	O	PRON	O
we	O	PRON	O
have	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
imbalance	O	NOUN	B
in	O	ADP	O
the	O	DET	O
different	O	ADJ	O
blood	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
lineages	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
selective	O	ADJ	O
mechanism	O	NOUN	B
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
operate	O	VERB	O
at	O	ADP	O
the	O	DET	O
level	O	NOUN	B
of	O	ADP	O
pluripotent	O	ADJ	B
blood	O	NOUN	I
stem	O	NOUN	I
cells	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
it	O	PRON	O
appears	O	VERB	O
that	O	SCONJ	O
severe	O	ADJ	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
affects	O	VERB	O
adversely	O	ADV	O
the	O	DET	O
proliferation	O	NOUN	B
or	O	CCONJ	O
the	O	DET	O
survival	O	NOUN	B
of	O	ADP	O
nucleated	O	ADJ	B
blood	O	NOUN	I
cells	O	NOUN	I
and	O	CCONJ	O
that	O	SCONJ	O
this	O	DET	O
phenotypic	O	ADJ	B
characteristic	O	NOUN	B
is	O	AUX	O
critical	O	ADJ	O
during	O	ADP	O
hematopoiesis	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
meiotic	O	ADJ	B
segregation	O	NOUN	I
,	O	PUNCT	O
using	O	VERB	O
single	O	ADJ	B
-	O	PUNCT	O
sperm	O	NOUN	B
typing	O	NOUN	B
:	O	PUNCT	O
meiotic	O	ADJ	B
drive	O	NOUN	O
at	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
.	O	PUNCT	O


Meiotic	O	ADJ	B
drive	O	NOUN	O
at	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
suggested	O	VERB	O
as	O	ADP	O
being	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
maintaining	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
of	O	ADP	O
DM	B-Disease	NOUN	B
chromosomes	O	NOUN	O
capable	O	ADJ	O
of	O	ADP	O
expansion	O	NOUN	B
to	O	PART	O
the	O	DET	O
disease	O	NOUN	B
state	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
test	O	VERB	O
this	O	DET	O
hypothesis	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
studied	O	VERB	O
samples	O	NOUN	B
of	O	ADP	O
single	O	ADJ	B
sperm	O	NOUN	I
from	O	ADP	O
three	O	NUM	O
individuals	O	NOUN	B
heterozygous	O	ADJ	B
at	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
,	O	PUNCT	O
each	O	DET	O
with	O	ADP	O
one	O	NUM	O
allele	O	NOUN	B
larger	O	ADJ	B
and	O	CCONJ	O
one	O	NUM	O
allele	O	NOUN	B
smaller	O	ADJ	O
than	O	ADP	O
19	O	NUM	O
CTG	O	NOUN	B
repeats	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
guard	O	VERB	B
against	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
problem	O	NOUN	B
of	O	ADP	O
differential	O	ADJ	O
PCR	O	NOUN	B
amplification	O	NOUN	I
rates	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
the	O	DET	O
lengths	O	NOUN	B
of	O	ADP	O
the	O	DET	O
alleles	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
sperm	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
typed	O	VERB	B
at	O	ADP	O
another	O	DET	O
closely	O	ADV	O
linked	O	VERB	O
marker	O	NOUN	B
whose	O	DET	O
allele	O	NOUN	B
size	O	NOUN	I
was	O	AUX	O
unrelated	O	ADJ	O
to	O	PART	O
the	O	DET	O
allele	O	NOUN	B
size	O	NOUN	I
at	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
locus	O	NOUN	I
.	O	PUNCT	O


Using	O	VERB	O
statistical	O	ADJ	B
models	O	NOUN	I
specifically	O	ADV	O
designed	O	VERB	O
to	O	PART	O
study	O	VERB	B
single	O	ADJ	B
-	O	PUNCT	O
sperm	O	NOUN	B
segregation	O	NOUN	B
data	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
find	O	VERB	O
no	O	DET	O
evidence	O	NOUN	O
of	O	ADP	O
meiotic	O	ADJ	B
segregation	O	NOUN	I
distortion	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
upper	O	ADJ	O
limit	O	NOUN	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
-	O	PUNCT	O
sided	O	ADJ	B
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
for	O	ADP	O
the	O	DET	O
estimate	O	NOUN	B
of	O	ADP	O
the	O	DET	O
common	O	ADJ	O
segregation	O	NOUN	B
probability	O	NOUN	B
for	O	ADP	O
the	O	DET	O
three	O	NUM	O
donors	O	NOUN	B
is	O	AUX	O
at	O	ADP	O
or	O	CCONJ	O
below	O	ADV	O
.	O	PUNCT	O


515	O	NUM	O
for	O	ADP	O
all	O	DET	O
models	O	NOUN	B
considered	O	VERB	O
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
from	O	ADP	O
.	O	PUNCT	O


5	O	NUM	O
is	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
models	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
any	O	DET	O
greater	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
segregation	O	NOUN	B
distortion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
must	O	AUX	O
result	O	VERB	O
from	O	ADP	O
events	O	NOUN	B
following	O	VERB	O
sperm	O	NOUN	B
ejaculation	O	NOUN	B
.	O	PUNCT	O


LPP	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
preferred	O	ADJ	O
fusion	O	NOUN	O
partner	O	NOUN	O
gene	O	NOUN	O
of	O	ADP	O
HMGIC	O	NOUN	B
in	O	ADP	O
lipomas	B-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
novel	O	ADJ	O
member	O	NOUN	O
of	O	ADP	O
the	O	DET	O
LIM	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
family	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
major	O	ADJ	O
cytogenetic	O	ADJ	B
subgroup	O	NOUN	I
of	O	ADP	O
lipomas	B-Disease	NOUN	B
is	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
recurrent	O	ADJ	B
chromosome	O	NOUN	I
aberrations	O	NOUN	I
,	O	PUNCT	O
mainly	O	ADV	O
translocations	O	NOUN	B
,	O	PUNCT	O
that	O	PRON	O
involve	O	VERB	O
chromosome	O	NOUN	B
segment	O	NOUN	I
12q13	O	NOUN	I
-	O	PUNCT	O
q15	O	NOUN	B
.	O	PUNCT	O


Multiple	O	ADJ	B
chromosomes	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
as	O	ADP	O
the	O	DET	O
translocation	O	NOUN	B
partners	O	NOUN	B
of	O	ADP	O
chromosome	O	NOUN	O
12	O	NUM	O
but	O	CCONJ	O
3q27	O	NOUN	B
-	O	PUNCT	O
q28	O	NOUN	B
is	O	AUX	O
preferentially	O	ADV	O
involved	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
previous	O	ADJ	O
studies	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
high	O	ADJ	O
mobility	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
HMG	O	NOUN	O
)	O	PUNCT	O
protein	O	NOUN	O
gene	O	NOUN	O
HMGIC	O	NOUN	B
at	O	ADP	O
12q15	O	NOUN	O
is	O	AUX	O
consistently	O	ADV	O
rearranged	O	VERB	B
as	O	ADP	O
a	O	DET	O
consequence	O	NOUN	O
of	O	ADP	O
these	O	DET	O
translocations	O	NOUN	B
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
the	O	DET	O
identification	O	NOUN	B
and	O	CCONJ	O
characterization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
3	O	NUM	I
-	O	PUNCT	O
derived	O	VERB	B
translocation	O	NOUN	B
partner	O	NOUN	O
gene	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
we	O	PRON	O
have	O	AUX	O
designated	O	VERB	O
LPP	O	NOUN	B
(	O	PUNCT	O
lipoma	B-Disease	NOUN	B
preferred	O	ADJ	O
partner	O	NOUN	O
gene	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Using	O	VERB	O
3	O	NUM	O
-	O	PUNCT	O
RACE	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
HMGIC	O	NOUN	B
fusion	O	NOUN	I
transcripts	O	NOUN	I
in	O	ADP	O
lipoma	B-Disease	NOUN	B
cell	O	NOUN	I
line	O	NOUN	I
Li	O	PROPN	B
-	O	PUNCT	O
501	O	NUM	B
/	O	SYM	O
SV40	O	NOUN	B
,	O	PUNCT	O
ectopic	O	ADJ	B
genetic	O	ADJ	O
sequences	O	NOUN	O
were	O	AUX	O
obtained	O	VERB	O
,	O	PUNCT	O
which	O	DET	O
by	O	ADP	O
CASH	O	NOUN	B
(	O	PUNCT	O
chromosome	O	NOUN	B
assignment	O	NOUN	I
using	O	VERB	O
somatic	O	ADJ	B
cell	O	NOUN	I
hybrids	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
FISH	O	NOUN	B
(	O	PUNCT	O
fluorescence	O	NOUN	B
in	O	X	I
situ	O	X	I
hybridization	O	NOUN	I
)	O	PUNCT	O
analysis	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
originate	O	VERB	O
from	O	ADP	O
chromosome	O	NOUN	B
segment	O	NOUN	I
3q27	O	NOUN	I
-	O	PUNCT	O
q28	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
Northern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
mRNA	O	NOUN	B
of	O	ADP	O
over	O	ADP	O
10	O	NUM	O
kb	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
by	O	ADP	O
these	O	DET	O
ectopic	O	ADJ	B
sequences	O	NOUN	I
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
tissues	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
brain	O	NOUN	B
and	O	CCONJ	O
peripheral	O	ADJ	B
blood	O	NOUN	I
leukocytes	O	NOUN	B
.	O	PUNCT	O


Upon	O	SCONJ	O
partial	O	ADJ	B
cDNA	O	NOUN	B
cloning	O	NOUN	I
,	O	PUNCT	O
features	O	NOUN	B
of	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
organization	O	NOUN	I
of	O	ADP	O
LPP	O	NOUN	B
were	O	AUX	O
established	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
span	O	VERB	O
a	O	DET	O
genomic	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
over	O	ADP	O
400	O	NUM	O
kb	O	NOUN	O
.	O	PUNCT	O


Nucleotide	O	NOUN	B
sequence	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
a	O	DET	O
composite	O	ADJ	B
cDNA	O	NOUN	B
of	O	ADP	O
LPP	O	NOUN	B
revealed	O	VERB	O
an	O	DET	O
open	O	ADJ	B
reading	O	NOUN	I
frame	O	NOUN	I
of	O	ADP	O
1836	O	NUM	O
nucleotides	O	NOUN	B
encoding	O	VERB	B
a	O	DET	O
proline	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
protein	O	NOUN	B
containing	O	VERB	O
a	O	DET	O
leucine	O	NOUN	B
-	O	PUNCT	O
zipper	O	NOUN	B
motif	O	NOUN	B
in	O	ADP	O
its	O	PRON	O
amino	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	B
and	O	CCONJ	O
three	O	NUM	O
LIM	O	NOUN	B
domains	O	NOUN	O
in	O	ADP	O
its	O	PRON	O
carboxy	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
LPP	O	PROPN	B
-	O	PUNCT	O
encoded	O	VERB	B
protein	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
classified	O	VERB	O
as	O	ADP	O
a	O	DET	O
novel	O	ADJ	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
group	O	NOUN	B
3	O	NUM	O
proteins	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LIM	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
family	O	NOUN	O
.	O	PUNCT	O


Using	O	VERB	O
reverse	O	ADJ	B
transcriptase	O	NOUN	I
combined	O	VERB	O
with	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reactions	O	NOUN	I
in	O	ADP	O
the	O	DET	O
analysis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
lipoma	B-Disease	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
and	O	CCONJ	O
primary	B-Disease	ADJ	B
lipomas	I-Disease	NOUN	I
,	O	PUNCT	O
it	O	PRON	O
appeared	O	VERB	O
that	O	SCONJ	O
LPP	O	NOUN	B
is	O	AUX	O
frequently	O	ADV	O
rearranged	O	VERB	B
also	O	ADV	O
in	O	ADP	O
cases	O	NOUN	B
without	O	ADP	O
a	O	DET	O
cytogenetically	O	ADV	B
detectable	O	ADJ	B
involvement	O	NOUN	B
of	O	ADP	O
3q27	O	NOUN	B
-	O	PUNCT	O
q28	O	NOUN	B
.	O	PUNCT	O


Two	O	NUM	O
alternative	O	ADJ	B
HMGIC	O	NOUN	B
/	O	SYM	O
LPP	O	NOUN	B
hybrid	O	NOUN	B
transcripts	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
detected	O	VERB	B
;	O	PUNCT	O
the	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
them	O	PRON	O
is	O	AUX	O
mainly	O	ADV	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
either	O	CCONJ	O
two	O	NUM	O
or	O	CCONJ	O
three	O	NUM	O
LIM	O	NOUN	B
domains	O	NOUN	O
in	O	ADP	O
the	O	DET	O
predicted	O	VERB	B
HMGI	O	NOUN	B
-	O	PUNCT	O
C	O	PROPN	B
/	O	SYM	O
LPP	O	NOUN	B
fusion	O	NOUN	B
proteins	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Absence	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
phenotype	O	NOUN	B
and	O	CCONJ	O
intergenerational	O	ADJ	B
stability	O	NOUN	I
of	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
transgenic	O	ADJ	B
mice	O	NOUN	I
expressing	O	VERB	B
the	O	DET	O
human	O	ADJ	B
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
transcript	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
underlying	O	VERB	O
Huntington	B-Disease	NOUN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
HD	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
CAG	O	NOUN	B
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
exon	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
CAG	O	NOUN	B
expansion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
produced	O	VERB	O
transgenic	O	ADJ	B
mice	O	NOUN	I
containing	O	VERB	O
the	O	DET	O
full	O	ADJ	O
length	O	NOUN	O
human	O	ADJ	B
HD	B-Disease	NOUN	B
cDNA	O	NOUN	B
with	O	ADP	O
44	O	NUM	O
CAG	O	NOUN	B
repeats	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
mice	O	NOUN	B
have	O	AUX	O
no	O	DET	O
behavioral	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
and	O	CCONJ	O
morphometric	O	ADJ	B
analysis	O	NOUN	I
at	O	ADP	O
6	O	NUM	O
(	O	PUNCT	O
one	O	NUM	O
animal	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
9	O	NUM	O
(	O	PUNCT	O
two	O	NUM	O
animals	O	NOUN	B
)	O	PUNCT	O
months	O	NOUN	B
age	O	NOUN	B
revealed	O	VERB	O
no	O	DET	O
changes	O	NOUN	O
.	O	PUNCT	O


Despite	O	SCONJ	O
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
mRNA	O	NOUN	B
expression	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
evidence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
gene	O	NOUN	B
product	O	NOUN	I
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
these	O	DET	O
transgenic	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


In	O	X	B
vitro	O	X	I
transfection	O	NOUN	B
studies	O	NOUN	I
indicated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
inclusion	O	NOUN	B
of	O	ADP	O
120	O	NUM	O
bp	O	NOUN	O
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
UTR	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
construct	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
nucleotide	O	NOUN	B
2349	O	NUM	O
prevented	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HD	B-Disease	NOUN	B
cDNA	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
is	O	AUX	O
not	O	PART	O
mediated	O	VERB	O
through	O	ADP	O
DNA	O	NOUN	B
-	O	PUNCT	O
protein	O	NOUN	B
interaction	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
RNA	O	NOUN	B
transcript	O	NOUN	B
with	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
CAG	O	NOUN	B
repeat	O	NOUN	I
is	O	AUX	O
insufficient	O	ADJ	B
to	O	PART	O
cause	O	VERB	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Rather	O	ADV	O
,	O	PUNCT	O
translation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CAG	O	NOUN	B
is	O	AUX	O
crucial	O	ADJ	O
for	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
HD	B-Disease	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
that	O	DET	O
seen	O	VERB	O
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
CAG	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
these	O	DET	O
mice	O	NOUN	B
was	O	AUX	O
remarkably	O	ADV	O
stable	O	ADJ	B
in	O	ADP	O
97	O	NUM	O
meioses	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
suggests	O	VERB	O
that	O	SCONJ	O
genomic	O	ADJ	B
sequences	O	NOUN	I
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
influencing	O	VERB	O
repeat	O	NOUN	O
instability	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


FISH	O	NOUN	B
studies	O	NOUN	I
in	O	ADP	O
a	O	DET	O
patient	O	NOUN	B
with	O	ADP	O
sporadic	B-Disease	ADJ	B
aniridia	I-Disease	NOUN	I
and	O	CCONJ	O
t	O	NOUN	O
(	O	PUNCT	O
7	O	NUM	O
;	O	PUNCT	O
11	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q31	O	NOUN	B
.	O	PUNCT	O
2	O	NUM	O
;	O	PUNCT	O
p13	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
2	O	NUM	O
year	O	NOUN	B
old	O	ADJ	O
female	O	NOUN	B
presenting	O	NOUN	O
with	O	ADP	O
bilateral	B-Disease	ADJ	B
sporadic	I-Disease	ADJ	O
aniridia	I-Disease	NOUN	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
an	O	DET	O
apparently	O	ADV	O
balanced	O	ADJ	O
reciprocal	O	ADJ	B
translocation	O	NOUN	B
with	O	ADP	O
a	O	DET	O
chromosome	O	NOUN	B
11	O	NUM	O
breakpoint	O	NOUN	O
within	O	ADP	O
band	O	NOUN	O
p13	O	NOUN	O
.	O	PUNCT	O


Fluorescence	O	NOUN	B
in	O	X	B
situ	O	X	I
hybridisation	O	NOUN	I
(	O	PUNCT	O
FISH	O	NOUN	B
)	O	PUNCT	O
studies	O	NOUN	B
with	O	ADP	O
distal	O	ADJ	B
11p13	O	NOUN	I
specific	O	ADJ	O
cosmids	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
chromosome	O	NOUN	B
11	O	NUM	I
breakpoint	O	NOUN	I
lay	O	VERB	O
between	O	ADP	O
the	O	DET	O
aniridia	B-Disease	NOUN	B
(	O	PUNCT	O
PAX6	O	NOUN	B
)	O	PUNCT	O
locus	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
region	O	NOUN	B
approximately	O	ADV	B
100	O	NUM	O
kb	O	NOUN	O
distal	O	ADJ	B
to	O	PART	O
PAX6	O	NOUN	B
defined	O	VERB	O
by	O	ADP	O
the	O	DET	O
cosmid	O	NOUN	B
FO2121	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
this	O	DET	O
patient	O	NOUN	B
did	O	AUX	O
not	O	PART	O
have	O	AUX	O
a	O	DET	O
detectable	O	ADJ	B
deletion	O	NOUN	B
within	O	ADP	O
PAX6	O	NOUN	B
,	O	PUNCT	O
her	O	PRON	O
aniridia	B-Disease	NOUN	B
may	O	AUX	O
have	O	AUX	O
resulted	O	VERB	O
from	O	ADP	O
a	O	DET	O
disruption	O	NOUN	B
of	O	ADP	O
the	O	DET	O
distal	O	ADJ	B
chromatin	O	NOUN	O
domain	O	NOUN	O
containing	O	VERB	O
either	O	CCONJ	O
enhancers	O	NOUN	B
or	O	CCONJ	O
regulators	O	NOUN	B
for	O	ADP	O
PAX6	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
case	O	NOUN	B
may	O	AUX	O
therefore	O	ADV	O
be	O	AUX	O
another	O	DET	O
example	O	NOUN	O
of	O	ADP	O
aniridia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
position	O	NOUN	B
effect	O	NOUN	I
as	O	ADP	O
recently	O	ADV	O
described	O	VERB	O
in	O	ADP	O
two	O	NUM	O
familial	B-Disease	ADJ	B
aniridia	I-Disease	NOUN	I
patients	O	NOUN	B
in	O	ADP	O
which	O	DET	O
the	O	DET	O
phenotype	O	NOUN	B
cosegregated	O	VERB	B
with	O	ADP	O
chromosome	B-Disease	NOUN	B
abnormalities	I-Disease	NOUN	I
with	O	ADP	O
11p13	O	NOUN	B
breakpoints	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Muscle	O	NOUN	B
expression	O	NOUN	I
of	O	ADP	O
glucose	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
6	I-Disease	NUM	O
-	I-Disease	PUNCT	O
phosphate	I-Disease	NOUN	B
dehydrogenase	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
in	O	ADP	O
different	O	ADJ	O
variants	O	NOUN	B
.	O	PUNCT	O


Muscle	O	NOUN	B
expression	O	NOUN	I
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
Mediterranean	O	PROPN	B
,	O	PUNCT	O
Seattle	O	PROPN	B
-	O	PUNCT	O
like	O	PROPN	B
and	O	CCONJ	O
A	O	DET	B
-	O	PUNCT	O
variants	O	NOUN	B
.	O	PUNCT	O


G6PD	O	NOUN	B
activity	O	NOUN	B
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
samples	O	NOUN	B
obtained	O	VERB	O
from	O	ADP	O
biopsies	O	NOUN	B
on	O	ADP	O
the	O	DET	O
quadriceps	O	NOUN	B
muscle	O	NOUN	I
of	O	ADP	O
seven	O	NUM	O
males	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
female	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
type	O	NOUN	O
of	O	ADP	O
genetic	O	ADJ	B
variant	O	NOUN	I
was	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
DNA	O	NOUN	B
,	O	PUNCT	O
extracted	O	VERB	O
from	O	ADP	O
blood	O	NOUN	B
samples	O	NOUN	I
.	O	PUNCT	O


All	O	DET	O
variants	O	NOUN	B
showed	O	VERB	O
the	O	DET	O
enzyme	O	NOUN	B
defect	O	NOUN	I
in	O	ADP	O
muscle	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
relationship	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
the	O	DET	O
activity	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
between	O	ADP	O
erythrocytes	O	NOUN	B
and	O	CCONJ	O
muscle	O	NOUN	B
of	O	ADP	O
the	O	DET	O
male	O	ADJ	B
subjects	O	NOUN	O
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
968	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
00008	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
equation	O	NOUN	B
for	O	ADP	O
the	O	DET	O
best	O	ADJ	O
fit	O	ADJ	B
line	O	NOUN	I
was	O	AUX	O
Y	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O


390X	O	NOUN	B
+	O	CCONJ	I
0	O	NUM	I
.	O	PUNCT	O


198	O	NUM	O
198	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
,	O	PUNCT	O
for	O	ADP	O
a	O	DET	O
given	O	VERB	O
variant	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
extent	O	NOUN	O
of	O	ADP	O
the	O	DET	O
enzyme	O	NOUN	B
defect	O	NOUN	I
in	O	ADP	O
muscle	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
determined	O	VERB	O
,	O	PUNCT	O
using	O	VERB	O
this	O	DET	O
equation	O	NOUN	B
,	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
G6PD	O	NOUN	B
activity	O	NOUN	B
of	O	ADP	O
erythrocytes	O	NOUN	B


Gene	O	NOUN	B
therapy	O	NOUN	I
for	O	ADP	O
phenylketonuria	B-Disease	NOUN	B
.	O	PUNCT	O


Classical	O	ADJ	B
phenylketonuria	B-Disease	NOUN	I
(	O	PUNCT	O
PKU	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
a	O	DET	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
hepatic	I-Disease	ADJ	B
phenylalanine	I-Disease	NOUN	I
hydroxylase	I-Disease	NOUN	I
(	O	PUNCT	O
PAH	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Limitations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
current	O	ADJ	B
dietary	O	ADJ	B
treatment	O	NOUN	I
for	O	ADP	O
PKU	B-Disease	NOUN	B
have	O	AUX	O
led	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
potential	O	ADJ	B
treatments	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
somatic	O	ADJ	B
gene	O	NOUN	B
transfer	O	NOUN	I
.	O	PUNCT	O


Three	O	NUM	O
different	O	ADJ	O
vector	O	NOUN	B
systems	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
examined	O	VERB	B
.	O	PUNCT	O


Vectors	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
a	O	DET	O
recombinant	O	ADJ	B
retrovirus	O	NOUN	I
or	O	CCONJ	O
a	O	DET	O
DNA	O	NOUN	B
/	O	SYM	O
protein	O	NOUN	B
complex	O	NOUN	I
can	O	AUX	O
efficiently	O	ADV	O
transduce	O	VERB	B
the	O	DET	O
PAH	O	NOUN	B
cDNA	O	NOUN	B
into	O	ADP	O
PAH	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
hepatocytes	O	NOUN	B
in	O	X	B
vitro	O	X	I
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
application	O	NOUN	B
of	O	ADP	O
these	O	DET	O
vector	O	NOUN	B
systems	O	NOUN	I
is	O	AUX	O
presently	O	ADV	O
limited	O	VERB	O
by	O	ADP	O
their	O	PRON	O
low	O	ADJ	B
transduction	O	NOUN	B
efficiency	O	NOUN	B
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
vector	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
a	O	DET	O
recombinant	O	ADJ	B
adenovirus	O	NOUN	I
can	O	AUX	O
restore	O	VERB	O
10	O	NUM	O
%	O	NOUN	O
-	O	PUNCT	O
80	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
normal	O	ADJ	O
hepatic	O	ADJ	B
PAH	O	NOUN	B
activity	O	NOUN	B
into	O	ADP	O
PAH	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mice	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
completely	O	ADV	O
normalizes	O	VERB	B
serum	O	NOUN	B
phenylalanine	O	NOUN	O
levels	O	NOUN	O
.	O	PUNCT	O


This	O	DET	O
treatment	O	NOUN	B
is	O	AUX	O
transient	O	ADJ	B
and	O	CCONJ	O
cannot	O	ADV	O
be	O	AUX	O
effectively	O	ADV	O
re	O	X	B
-	O	PUNCT	O
administered	O	VERB	B
due	O	ADP	O
to	O	PART	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
neutralizing	O	VERB	B
antibodies	O	NOUN	I
directed	O	VERB	O
against	O	ADP	O
the	O	DET	O
recombinant	O	ADJ	B
adenoviral	O	ADJ	B
vector	O	NOUN	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PKU	B-Disease	NOUN	B
can	O	AUX	O
be	O	AUX	O
completely	O	ADV	O
corrected	O	VERB	O
by	O	ADP	O
somatic	O	ADJ	B
gene	O	NOUN	I
therapy	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
provide	O	VERB	O
some	O	DET	O
direction	O	NOUN	B
for	O	ADP	O
the	O	DET	O
future	O	ADJ	O
development	O	NOUN	B
of	O	ADP	O
adenoviral	O	ADJ	B
vectors	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Exon	O	NOUN	B
-	O	PUNCT	O
intron	O	NOUN	B
structure	O	NOUN	B
of	O	ADP	O
the	O	DET	O
human	O	ADJ	B
neuronal	O	ADJ	O
nicotinic	O	ADJ	O
acetylcholine	O	NOUN	B
receptor	O	NOUN	I
alpha	O	NOUN	I
4	O	NUM	I
subunit	O	NOUN	I
(	O	PUNCT	O
CHRNA4	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
neuronal	O	ADJ	B
nicotinic	O	ADJ	O
acetylcholine	O	NOUN	B
receptor	O	NOUN	I
alpha	O	NOUN	I
4	O	NUM	I
subunit	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
CHRNA4	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
candidate	O	NOUN	B
region	O	NOUN	I
for	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
phenotypes	O	NOUN	B
benign	B-Disease	ADJ	B
familial	I-Disease	ADJ	O
neonatal	I-Disease	ADJ	O
convulsions	I-Disease	NOUN	B
,	O	PUNCT	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
nocturnal	I-Disease	ADJ	B
frontal	I-Disease	ADJ	B
lobe	I-Disease	ADJ	I
epilepsy	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
low	O	ADJ	B
-	O	PUNCT	O
voltage	O	NOUN	B
EEG	O	PROPN	B
.	O	PUNCT	O


Recently	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
missense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
transmembrane	O	ADJ	B
domain	O	NOUN	I
2	O	NUM	I
of	O	ADP	O
CHRNA4	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
nocturnal	I-Disease	ADJ	B
frontal	I-Disease	ADJ	B
lobe	I-Disease	NOUN	I
epilepsy	I-Disease	NOUN	I
in	O	ADP	O
one	O	NUM	O
extended	O	VERB	B
pedigree	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
determined	O	VERB	O
the	O	DET	O
genomic	O	ADJ	B
organization	O	NOUN	I
of	O	ADP	O
CHRNA4	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
consists	O	VERB	O
of	O	ADP	O
six	O	NUM	O
exons	O	NOUN	B
distributed	O	VERB	B
over	O	ADP	O
approximately	O	ADV	O
17	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
nucleotide	O	NOUN	B
sequence	O	NOUN	I
obtained	O	VERB	O
from	O	ADP	O
the	O	DET	O
genomic	O	ADJ	B
regions	O	NOUN	I
adjacent	O	ADJ	B
to	O	PART	O
the	O	DET	O
exon	O	NOUN	B
boundaries	O	NOUN	I
enabled	O	VERB	O
us	O	PRON	O
to	O	PART	O
develop	O	VERB	O
a	O	DET	O
set	O	NOUN	O
of	O	ADP	O
primer	O	NOUN	B
pairs	O	NOUN	B
for	O	ADP	O
PCR	O	NOUN	B
amplification	O	NOUN	I
of	O	ADP	O
the	O	DET	O
complete	O	ADJ	O
coding	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
sequence	O	NOUN	B
analysis	O	NOUN	I
provides	O	VERB	O
the	O	DET	O
basis	O	NOUN	O
for	O	ADP	O
a	O	DET	O
comprehensive	O	ADJ	B
mutation	O	NOUN	B
screening	O	NOUN	O
of	O	ADP	O
CHRNA4	O	NOUN	B
in	O	ADP	O
the	O	DET	O
above	O	ADJ	B
-	O	PUNCT	O
mentioned	O	VERB	B
phenotypes	O	NOUN	B
and	O	CCONJ	O
possibly	O	ADV	O
in	O	ADP	O
other	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
idiopathic	B-Disease	ADJ	B
epilepsies	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
population	O	NOUN	O
frequencies	O	NOUN	B
for	O	ADP	O
common	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
are	O	AUX	O
the	O	DET	O
two	O	NUM	O
major	O	ADJ	O
identified	O	VERB	B
causes	O	NOUN	O
of	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
either	O	DET	O
gene	O	NOUN	B
conferring	O	VERB	I
up	O	ADV	O
to	O	PART	O
80	O	NUM	O
-	O	PUNCT	O
90	O	NUM	O
%	O	NOUN	O
lifetime	O	NOUN	B
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
carrier	O	NOUN	B
females	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
BRCA1	O	NOUN	B
account	O	NOUN	O
for	O	ADP	O
approximately	O	ADV	O
45	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
familial	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
mutations	O	NOUN	B
in	O	ADP	O
BRCA2	O	NOUN	B
account	O	NOUN	O
for	O	ADP	O
a	O	DET	O
comparable	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
.	O	PUNCT	O


Over	O	ADP	O
85	O	NUM	O
distinct	O	ADJ	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
growing	O	VERB	O
list	O	NOUN	O
of	O	ADP	O
BRCA2	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
majority	O	NOUN	O
resulting	O	VERB	O
in	O	ADP	O
protein	O	NOUN	B
truncation	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
specific	O	ADJ	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
185delAG	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
reported	O	VERB	O
increased	O	VERB	B
carrier	O	NOUN	B
frequency	O	NOUN	O
of	O	ADP	O
approximately	O	ADV	O
0	O	NUM	O
.	O	PUNCT	O


9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
population	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
also	O	ADV	O
found	O	VERB	O
in	O	ADP	O
rare	O	ADJ	B
non	O	NOUN	B
-	O	PUNCT	O
Jewish	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
different	O	ADJ	O
haplotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
6174delT	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
BRCA2	O	NOUN	B
was	O	AUX	O
recently	O	ADV	O
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
frequent	O	ADJ	B
mutation	O	NOUN	B
in	O	ADP	O
8	O	NUM	O
out	O	ADP	O
of	O	ADP	O
107	O	NUM	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
women	O	NOUN	B
diagnosed	O	VERB	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
by	O	ADP	O
age	O	NOUN	B
50	O	NUM	O
(	O	PUNCT	O
ref	O	NOUN	O
.	O	PUNCT	O
8	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
three	O	NUM	O
Ashkenazi	O	ADJ	B
male	B-Disease	NOUN	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
conducted	O	VERB	O
a	O	DET	O
large	O	ADJ	B
-	O	PUNCT	O
scale	O	NOUN	B
population	O	NOUN	B
study	O	NOUN	I
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
specific	O	ADJ	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
Ashkenazi	O	ADJ	B
Jewish	O	ADJ	B
individuals	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
unselected	O	ADJ	O
for	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
mutation	O	NOUN	B
screening	O	VERB	B
on	O	ADP	O
approximately	O	ADV	O
3	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
samples	O	NOUN	B
determined	O	VERB	O
a	O	DET	O
carrier	O	NOUN	B
frequency	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


09	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
185delAG	O	NOUN	B
mutation	O	NOUN	B
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


13	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
5382insC	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


BRCA2	O	NOUN	B
analysis	O	NOUN	B
on	O	ADP	O
3	O	NUM	O
,	O	PUNCT	O
085	O	NUM	O
individuals	O	NOUN	B
from	O	ADP	O
the	O	DET	O
same	O	ADJ	O
population	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
carrier	O	NOUN	B
frequency	O	NOUN	O
of	O	ADP	O
1	O	NUM	O
.	O	PUNCT	O


52	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
the	O	DET	O
6174delT	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
expanded	O	VERB	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
study	O	NOUN	B
confirms	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
BRCA1	O	NOUN	B
185delAG	O	NOUN	O
mutation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
BRCA2	O	NOUN	B
6174delT	O	NOUN	O
mutation	O	NOUN	B
constitute	O	VERB	O
the	O	DET	O
two	O	NUM	O
most	O	ADV	O
frequent	O	ADJ	B
mutation	O	NOUN	B
alleles	O	NOUN	B
predisposing	O	VERB	B
to	O	PART	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
among	O	ADP	O
the	O	DET	O
Ashkenazim	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
suggests	O	VERB	O
a	O	DET	O
relatively	O	ADV	O
lower	O	ADJ	O
penetrance	O	NOUN	B
for	O	ADP	O
the	O	DET	O
6174delT	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
BRCA2	O	NOUN	B


Dual	O	ADJ	B
roles	O	NOUN	I
of	O	ADP	O
ATM	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cellular	O	ADJ	B
response	O	NOUN	I
to	O	PART	O
radiation	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
cell	O	NOUN	B
growth	O	NOUN	I
control	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
AT	B-Disease	NOUN	B
)	O	PUNCT	O
patients	O	NOUN	B
,	O	PUNCT	O
denoted	O	VERB	O
ATM	O	NOUN	B
,	O	PUNCT	O
encodes	O	VERB	B
a	O	DET	O
putative	O	ADJ	B
protein	O	NOUN	I
or	O	CCONJ	O
lipid	O	NOUN	B
kinase	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
elucidate	O	VERB	O
the	O	DET	O
functions	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
disrupted	O	VERB	B
the	O	DET	O
mouse	O	NOUN	B
ATM	O	NOUN	B
gene	O	NOUN	I
through	O	ADP	O
homologous	O	ADJ	B
recombination	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
.	O	PUNCT	O


Consistent	O	ADJ	B
with	O	ADP	I
cellular	O	ADJ	B
defects	O	NOUN	I
of	O	ADP	O
AT	B-Disease	ADP	B
patients	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
ATM	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
cells	O	NOUN	B
are	O	AUX	O
hypersensitive	O	ADJ	B
to	O	PART	O
gamma	O	NOUN	B
-	O	PUNCT	O
irradiation	O	NOUN	B
and	O	CCONJ	O
defective	O	ADJ	B
in	O	ADP	O
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
arrest	O	NOUN	I
following	O	VERB	O
radiation	O	NOUN	B
,	O	PUNCT	O
correlating	O	VERB	B
with	O	ADP	O
a	O	DET	O
defective	O	ADJ	B
up	O	ADV	B
-	O	PUNCT	O
regulation	O	NOUN	B
of	O	ADP	O
p53	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
ATM	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mouse	O	NOUN	B
thymocytes	O	NOUN	B
are	O	AUX	O
more	O	ADV	O
resistant	O	ADJ	B
to	O	PART	O
apoptosis	O	NOUN	B
induced	O	VERB	B
by	O	ADP	O
gamma	O	NOUN	B
-	O	PUNCT	O
irradiation	O	NOUN	B
than	O	ADP	O
normal	O	ADJ	O
thymocytes	O	NOUN	B
.	O	PUNCT	O


ATM	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
fibroblasts	O	NOUN	B
are	O	AUX	O
inefficient	O	ADJ	O
in	O	ADP	O
G1	O	NOUN	B
to	O	PART	O
S	O	NOUN	B
-	O	PUNCT	O
phase	O	NOUN	B
progression	O	NOUN	B
following	O	VERB	O
serum	O	NOUN	B
stimulation	O	NOUN	I
and	O	CCONJ	O
senesce	O	VERB	B
after	O	ADP	O
only	O	ADV	O
a	O	DET	O
few	O	ADJ	O
passages	O	NOUN	B
in	O	ADP	O
culture	O	NOUN	B
.	O	PUNCT	O


They	O	PRON	O
have	O	AUX	O
an	O	DET	O
increased	O	VERB	B
constitutive	O	ADJ	B
level	O	NOUN	B
of	O	ADP	O
p21CP1	O	NOUN	B
/	O	SYM	O
WAF1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
therefore	O	ADV	O
critical	O	ADJ	O
both	O	CCONJ	O
for	O	ADP	O
cellular	O	ADJ	B
responses	O	NOUN	I
to	O	PART	O
ionizing	O	VERB	B
radiation	O	NOUN	I
and	O	CCONJ	O
for	O	ADP	O
normal	O	ADJ	B
cell	O	NOUN	I
-	O	PUNCT	O
cycle	O	NOUN	B
progression	O	NOUN	B
.	O	PUNCT	O


ATM	O	NOUN	B
+	O	CCONJ	O
/	O	SYM	B
-	O	PUNCT	O
fibroblasts	O	NOUN	B
and	O	CCONJ	O
thymocytes	O	NOUN	B
showed	O	VERB	O
intermediately	O	ADV	O
defective	O	ADJ	B
responses	O	NOUN	O
to	O	PART	O
irradiation	O	NOUN	B
but	O	CCONJ	O
no	O	DET	O
growth	O	NOUN	B
defect	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
increased	O	VERB	B
cancer	B-Disease	NOUN	B
risk	O	NOUN	I
of	O	ADP	O
AT	B-Disease	ADP	B
heterozygotes	O	NOUN	B
could	O	AUX	O
be	O	AUX	O
attributable	O	ADJ	O
to	O	PART	O
poor	O	ADJ	B
checkpoint	O	NOUN	B
function	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Targeted	O	VERB	B
disruption	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
leads	O	VERB	O
to	O	PART	O
growth	B-Disease	NOUN	B
retardation	I-Disease	NOUN	I
,	O	PUNCT	O
chromosomal	B-Disease	ADJ	B
fragmentation	I-Disease	NOUN	I
during	I-Disease	ADP	O
meiosis	I-Disease	NOUN	B
,	O	PUNCT	O
immune	B-Disease	ADJ	B
defects	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
thymic	B-Disease	ADJ	B
lymphoma	I-Disease	NOUN	I
.	O	PUNCT	O


ATM	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
human	I-Disease	ADJ	O
disease	I-Disease	NOUN	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
member	O	NOUN	O
of	O	ADP	O
a	O	DET	O
family	O	NOUN	B
of	O	ADP	O
kinases	O	NOUN	B
involved	O	VERB	O
in	O	ADP	O
DNA	O	NOUN	B
metabolism	O	NOUN	I
and	O	CCONJ	O
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
checkpoint	O	NOUN	I
control	O	NOUN	I
.	O	PUNCT	O


To	O	PART	O
help	O	VERB	O
clarify	O	VERB	O
the	O	DET	O
physiological	O	ADJ	B
roles	O	NOUN	O
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
disrupted	O	VERB	B
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
mice	O	NOUN	B
through	O	ADP	O
homologous	O	ADJ	B
recombination	O	NOUN	I
.	O	PUNCT	O


Initial	O	ADJ	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
knockout	O	ADJ	B
animals	O	NOUN	I
indicates	O	VERB	O
that	O	SCONJ	O
inactivation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
ATM	O	NOUN	B
gene	O	NOUN	O
recreates	O	VERB	B
much	O	ADV	O
of	O	ADP	O
the	O	DET	O
phenotype	O	NOUN	B
of	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
.	O	PUNCT	O


The	O	DET	O
homozygous	O	ADJ	B
mutant	O	NOUN	I
(	O	PUNCT	O
ATM	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
)	O	PUNCT	O
mice	O	NOUN	B
are	O	AUX	O
viable	O	ADJ	B
,	O	PUNCT	O
growth	O	NOUN	B
-	O	PUNCT	O
retarded	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
infertile	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
infertility	B-Disease	NOUN	B
of	O	ADP	O
ATM	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
results	O	VERB	B
from	O	ADP	O
meiotic	O	ADJ	B
failure	O	NOUN	I
.	O	PUNCT	O


Meiosis	O	NOUN	B
is	O	AUX	O
arrested	O	VERB	B
at	O	ADP	O
the	O	DET	O
zygotene	O	NOUN	B
/	O	PUNCT	O
pachytene	O	NOUN	B
stage	O	NOUN	I
of	O	ADP	O
prophase	O	NOUN	B
I	O	NUM	I
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
abnormal	O	ADJ	B
chromosomal	O	ADJ	B
synapsis	O	NOUN	I
and	O	CCONJ	O
subsequent	O	ADJ	O
chromosome	O	NOUN	B
fragmentation	O	NOUN	I
.	O	PUNCT	O


Immune	B-Disease	ADJ	B
defects	I-Disease	NOUN	I
also	O	ADV	O
are	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
ATM	O	PROPN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
reduced	O	VERB	B
numbers	O	NOUN	I
of	O	ADP	O
B220	O	NOUN	B
+	O	CCONJ	O
CD43	O	NOUN	B
-	O	PUNCT	O
pre	O	ADJ	B
-	O	PUNCT	O
B	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
thymocytes	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
peripheral	O	ADJ	B
T	O	NOUN	I
cells	O	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
functional	O	ADJ	B
impairment	O	NOUN	I
of	O	ADP	O
T	O	NOUN	B
-	O	PUNCT	O
cell	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
immune	O	ADJ	B
responses	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
cerebella	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
-	O	PUNCT	O
/	O	SYM	B
-	O	PUNCT	O
mice	O	NOUN	B
appear	O	VERB	O
normal	O	ADJ	O
by	O	ADP	O
histologic	O	ADJ	B
examination	O	NOUN	I
at	O	ADP	O
3	O	NUM	O
to	O	PART	O
4	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
mice	O	NOUN	B
have	O	AUX	O
no	O	DET	O
gross	O	ADJ	B
behavioral	B-Disease	ADJ	O
abnormalities	I-Disease	NOUN	O
.	O	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
mutant	O	ADJ	B
mice	O	NOUN	I
rapidly	O	ADV	O
develop	O	VERB	O
thymic	B-Disease	ADJ	B
lymphomas	I-Disease	NOUN	I
and	O	CCONJ	O
die	O	VERB	B
before	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
of	O	ADP	O
age	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
plays	O	VERB	O
an	O	DET	O
essential	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
a	O	DET	O
diverse	O	ADJ	B
group	O	NOUN	B
of	O	ADP	O
cellular	O	ADJ	B
processes	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
meiosis	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
normal	O	ADJ	B
growth	O	NOUN	I
of	O	ADP	O
somatic	O	ADJ	B
tissues	O	NOUN	I
,	O	PUNCT	O
immune	O	ADJ	B
development	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
tumor	B-Disease	NOUN	B
suppression	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Cloning	O	NOUN	B
and	O	CCONJ	O
characterization	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenase	O	NOUN	B
cDNA	O	NOUN	B
,	O	PUNCT	O
chromosomal	O	ADJ	B
assignment	O	NOUN	I
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
and	O	CCONJ	O
identification	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
nine	O	NUM	O
different	O	ADJ	O
mutations	O	NOUN	B
within	O	ADP	O
the	O	DET	O
VLCAD	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Very	O	ADV	B
-	O	PUNCT	O
long	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
VLCAD	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
straight	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
dehydrogenase	O	NOUN	I
(	O	PUNCT	O
ACD	O	NOUN	B
)	O	PUNCT	O
enzymes	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
all	O	DET	O
nuclear	O	ADJ	B
encoded	O	VERB	O
mitochondrial	O	ADJ	B
flavoproteins	O	NOUN	I
catalyzing	O	VERB	O
the	O	DET	O
initial	O	ADJ	O
step	O	NOUN	O
in	O	ADP	O
fatty	O	ADJ	B
acid	O	NOUN	I
beta	O	NOUN	I
-	O	PUNCT	O
oxidation	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
used	O	VERB	O
the	O	DET	O
very	O	ADV	O
fast	O	ADV	O
,	O	PUNCT	O
Rapid	O	PROPN	B
Amplification	O	PROPN	B
of	O	ADP	O
cDNA	O	NOUN	B
Ends	O	NOUN	I
(	O	PUNCT	O
RACE	O	NOUN	B
)	O	PUNCT	O
based	O	VERB	O
strategy	O	NOUN	O
to	O	PART	O
obtain	O	VERB	O
the	O	DET	O
sequence	O	NOUN	B
of	O	ADP	O
cDNAs	O	NOUN	B
encoding	O	VERB	B
human	O	ADJ	B
VLCAD	O	NOUN	B
from	O	ADP	O
placenta	O	NOUN	B
and	O	CCONJ	O
fibroblasts	O	NOUN	B
.	O	PUNCT	O


Alignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
predicted	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
VLCAD	O	NOUN	B
with	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
human	O	ADJ	B
ACD	O	NOUN	B
enzymes	O	NOUN	B
revealed	O	VERB	O
extensive	O	ADJ	O
sequence	O	NOUN	O
homology	O	NOUN	O
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
human	O	ADJ	B
VLCAD	O	NOUN	B
and	O	CCONJ	O
human	O	ADJ	B
acyl	O	NOUN	B
-	O	PUNCT	O
CoA	O	NOUN	B
oxidase	O	NOUN	I
showed	O	VERB	O
extensive	O	ADJ	O
sequence	O	NOUN	B
homology	O	NOUN	O
corroborating	O	VERB	O
the	O	DET	O
notion	O	NOUN	O
that	O	SCONJ	O
these	O	DET	O
genes	O	NOUN	B
are	O	AUX	O
evolutionarily	O	ADV	O
related	O	ADJ	O
.	O	PUNCT	O


Southern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
genomic	O	ADJ	B
DNA	O	NOUN	I
from	O	ADP	O
hybrid	O	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
localize	O	VERB	B
the	O	DET	O
VLCAD	O	NOUN	B
gene	O	NOUN	I
to	O	PART	O
human	O	ADJ	B
chromosome	O	NOUN	I
17p11	O	NOUN	I
.	O	PUNCT	O


2	O	NUM	O
-	O	PUNCT	O
p11	O	NOUN	B
.	O	PUNCT	O


13105	O	NUM	O
.	O	PUNCT	O


Using	O	VERB	O
Northern	O	NOUN	B
and	O	CCONJ	O
Western	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
tissue	O	NOUN	B
specific	O	ADJ	O
distribution	O	NOUN	B
of	O	ADP	O
VLCAD	O	NOUN	B
mRNA	O	NOUN	B
and	O	CCONJ	O
protein	O	NOUN	B
in	O	ADP	O
several	O	ADJ	O
human	O	ADJ	B
tissues	O	NOUN	B
we	O	PRON	O
showed	O	VERB	O
that	O	SCONJ	O
VLCAD	O	NOUN	B
is	O	AUX	O
most	O	ADV	O
abundant	O	ADJ	B
in	O	ADP	O
heart	O	NOUN	B
and	O	CCONJ	O
skeletal	O	ADJ	B
muscle	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
agrees	O	VERB	O
well	O	ADV	O
with	O	ADP	O
the	O	DET	O
fact	O	NOUN	O
that	O	SCONJ	O
cardiac	O	NOUN	B
and	O	CCONJ	O
muscle	O	NOUN	B
symptoms	O	NOUN	I
are	O	AUX	O
characteristic	O	ADJ	O
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


Northern	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
and	O	CCONJ	O
sequencing	O	NOUN	B
of	O	ADP	O
cloned	O	VERB	B
PCR	O	NOUN	B
amplified	O	VERB	B
VLCAD	O	NOUN	B
cDNA	O	NOUN	B
from	O	ADP	O
four	O	NUM	O
unrelated	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
VLCAD	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
VLCAD	O	NOUN	B
mRNA	O	NOUN	B
was	O	AUX	O
undetectable	O	ADJ	B
in	O	ADP	O
one	O	NUM	O
patient	O	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
the	O	DET	O
other	O	ADJ	O
three	O	NUM	O
have	O	AUX	O
mutations	O	NOUN	B
in	O	ADP	O
both	O	CCONJ	O
VLCAD	O	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


Western	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
patient	O	NOUN	B
fibroblasts	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
identified	O	VERB	B
mutations	O	NOUN	B
result	O	VERB	O
in	O	ADP	O
severely	O	ADV	B
reduced	O	VERB	B
amounts	O	NOUN	O
of	O	ADP	O
VLCAD	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Molecular	O	ADJ	B
bases	O	NOUN	I
of	O	ADP	O
combined	B-Disease	ADJ	B
subtotal	I-Disease	NOUN	B
deficiencies	I-Disease	NOUN	O
of	I-Disease	ADP	O
C6	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
:	O	PUNCT	O
their	O	PRON	O
effects	O	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
other	O	ADJ	O
C6	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
deficiencies	I-Disease	NOUN	I
.	O	PUNCT	O


Combined	B-Disease	ADJ	B
subtotal	I-Disease	ADJ	B
deficiency	I-Disease	NOUN	I
of	I-Disease	ADP	O
C6	I-Disease	NOUN	B
and	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
which	O	DET	O
both	O	DET	O
proteins	O	NOUN	B
are	O	AUX	O
expressed	O	VERB	B
at	O	ADP	O
very	O	ADV	O
low	O	ADJ	O
levels	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
homozygous	O	ADJ	B
form	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
defect	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
splice	O	NOUN	B
donor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
15	O	NUM	O
of	O	ADP	O
the	O	DET	O
C6	O	NOUN	B
gene	O	NOUN	I
explains	O	VERB	O
the	O	DET	O
low	O	ADJ	O
molecular	O	ADJ	B
weight	O	NOUN	I
of	O	ADP	O
the	O	DET	O
C6	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
probably	O	ADV	O
responsible	O	ADJ	O
for	O	ADP	O
its	O	PRON	O
low	O	ADJ	O
expressed	O	VERB	B
concentration	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
C7	O	NOUN	B
defect	O	NOUN	I
is	O	AUX	O
more	O	ADV	O
enigmatic	O	ADJ	O
the	O	DET	O
protein	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
normal	O	ADJ	O
molecular	O	ADJ	O
weight	O	NOUN	O
,	O	PUNCT	O
low	O	ADJ	B
circulating	O	VERB	B
concentration	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
altered	O	ADJ	O
isoelectric	O	ADJ	B
point	O	NOUN	I
.	O	PUNCT	O


An	O	DET	O
Arg	O	NOUN	B
>	O	NOUN	O
Ser	O	NOUN	B
codon	O	NOUN	I
substitution	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
11	O	NUM	I
is	O	AUX	O
the	O	DET	O
only	O	ADJ	O
molecular	O	ADJ	B
alteration	O	NOUN	I
within	O	ADP	O
the	O	DET	O
mature	O	ADJ	B
C7	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
defects	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
characteristic	O	ADJ	O
set	O	NOUN	O
of	O	ADP	O
polymorphic	O	ADJ	B
DNA	O	NOUN	O
markers	O	NOUN	O
in	O	ADP	O
the	O	DET	O
C6	O	NOUN	B
/	O	PUNCT	O
C7	O	NOUN	B
region	O	NOUN	I
,	O	PUNCT	O
forming	O	VERB	O
a	O	DET	O
distinct	O	ADJ	O
haplotype	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
haplotype	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
other	O	ADJ	O
haplotypes	O	NOUN	B
containing	O	VERB	O
defective	O	ADJ	B
genes	O	NOUN	I
that	O	PRON	O
lead	O	VERB	O
either	O	CCONJ	O
to	O	PART	O
C6	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
C7	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
with	O	ADP	O
different	O	ADJ	O
consequences	O	NOUN	B
.	O	PUNCT	O


Where	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
combined	O	VERB	O
with	O	ADP	O
a	O	DET	O
C6	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
gene	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
serum	O	NOUN	B
C7	O	NOUN	I
levels	O	NOUN	I
can	O	AUX	O
be	O	AUX	O
surprisingly	O	ADV	O
high	O	ADJ	O
,	O	PUNCT	O
possibly	O	ADV	O
because	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
no	O	DET	O
C6	O	NOUN	B
generating	O	VERB	O
C56	O	NOUN	O
to	O	PART	O
consume	O	VERB	O
the	O	DET	O
C7	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
where	O	SCONJ	O
the	O	DET	O
C7	O	NOUN	B
genes	O	NOUN	I
are	O	AUX	O
both	O	CCONJ	O
defective	O	ADJ	B
(	O	PUNCT	O
but	O	CCONJ	O
still	O	ADV	O
partially	O	ADV	O
functional	O	ADJ	B
)	O	PUNCT	O
,	O	PUNCT	O
there	O	PRON	O
may	O	AUX	O
be	O	AUX	O
a	O	DET	O
profound	O	ADJ	O
deficit	O	NOUN	O
of	O	ADP	O
circulating	O	VERB	B
C7	O	NOUN	B
because	O	SCONJ	O
there	O	PRON	O
is	O	AUX	O
ample	O	ADJ	O
C6	O	NOUN	B
to	O	PART	O
produce	O	VERB	O
C56	O	NOUN	B
and	O	CCONJ	O
consume	O	VERB	B
the	O	DET	O
already	O	ADV	O
small	O	ADJ	O
amount	O	NOUN	B
of	O	ADP	O
C7	O	NOUN	B
.	O	PUNCT	O


Each	O	DET	O
molecular	O	ADJ	B
defect	O	NOUN	I
has	O	AUX	O
also	O	ADV	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
isolation	O	NOUN	B
and	O	CCONJ	O
has	O	AUX	O
the	O	DET	O
expected	O	VERB	O
effect	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Genetic	O	ADJ	B
bases	O	NOUN	I
of	O	ADP	O
human	O	ADJ	B
complement	B-Disease	NOUN	O
C7	I-Disease	NOUN	O
deficiency	I-Disease	NOUN	O
.	O	PUNCT	O


Complement	B-Disease	NOUN	B
C7	I-Disease	NOUN	I
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
C7D	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	O
frequently	O	ADV	O
with	O	ADP	O
recurrent	O	ADJ	B
bacterial	B-Disease	ADJ	O
infections	I-Disease	NOUN	O
,	O	PUNCT	O
especially	O	ADV	O
meningitis	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
Neisseria	B-Disease	NOUN	B
meningitidis	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
in	O	ADP	O
this	O	DET	O
work	O	NOUN	O
the	O	DET	O
molecular	O	ADJ	B
bases	O	NOUN	I
of	O	ADP	O
C7D	B-Disease	NOUN	B
in	O	ADP	O
two	O	NUM	O
unrelated	O	ADJ	O
Japanese	O	ADJ	B
males	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
used	O	VERB	O
exon	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
PCR	O	NOUN	B
/	O	SYM	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
analysis	O	NOUN	B
as	O	ADP	O
a	O	DET	O
screening	O	VERB	B
step	O	NOUN	O
for	O	ADP	O
mutations	O	NOUN	B
.	O	PUNCT	O


Subsequent	O	ADJ	O
direct	O	ADJ	O
sequencing	O	NOUN	O
of	O	ADP	O
the	O	DET	O
target	O	NOUN	B
exons	O	NOUN	B
identified	O	VERB	O
homozygous	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
16	O	NUM	O
of	O	ADP	O
case	O	NOUN	O
1	O	NUM	O
and	O	CCONJ	O
in	O	ADP	O
exon	O	NOUN	B
15	O	NUM	I
of	O	ADP	I
case	O	NOUN	I
2	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
case	O	NOUN	O
1	O	NUM	O
was	O	AUX	O
a	O	DET	O
homozygous	O	ADJ	B
T	O	NOUN	I
to	O	PART	O
A	O	NOUN	O
transversion	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
2250	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
third	O	ADJ	O
nucleotide	O	NOUN	O
of	O	ADP	O
the	O	DET	O
codon	O	NOUN	B
TGT	O	NOUN	I
for	O	ADP	O
Cys728	O	NOUN	B
,	O	PUNCT	O
leading	O	VERB	O
to	O	PART	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	O
TGA	O	NOUN	O
(	O	PUNCT	O
C728X	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
case	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
a	O	DET	O
homozygous	O	ADJ	B
2	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
deletion	O	NOUN	B
(	O	PUNCT	O
2137delTG	O	NUM	O
/	O	SYM	O
2138delGT	O	NUM	B
/	O	SYM	O
2139delTG	O	NUM	B
)	O	PUNCT	O
caused	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
,	O	PUNCT	O
generating	O	VERB	O
a	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
codon	O	NOUN	I
4	O	NUM	I
to	O	PART	O
6	O	NUM	O
nucleotides	O	NOUN	B
downstream	O	ADV	B
.	O	PUNCT	O


Family	O	NOUN	B
study	O	NOUN	I
in	O	ADP	O
case	O	NOUN	O
1	O	NUM	O
confirmed	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
nature	O	NOUN	I
of	O	ADP	O
the	O	DET	O
defect	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
detected	O	VERB	B
a	O	DET	O
novel	O	ADJ	O
polymorphism	O	NOUN	B
in	O	ADP	O
intron	O	NOUN	B
11	O	NUM	O
that	O	PRON	O
presumably	O	ADV	O
is	O	AUX	O
linked	O	VERB	O
to	O	PART	O
the	O	DET	O
mutation	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
C7D	B-Disease	NOUN	B
in	O	ADP	O
case	O	NOUN	O
1	O	NUM	O
.	O	PUNCT	O


Our	O	PRON	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
C7D	B-Disease	NOUN	B
is	O	AUX	O
heterogeneous	O	ADJ	B
like	O	ADP	O
most	O	ADJ	O
of	O	ADP	O
the	O	DET	O
other	O	ADJ	O
deficiencies	B-Disease	NOUN	B
of	I-Disease	ADP	O
complement	I-Disease	NOUN	B
components	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


HPRT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
APRT	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mice	O	NOUN	B
are	O	AUX	O
not	O	PART	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
lesch	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
nyhan	I-Disease	NOUN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Complete	B-Disease	ADJ	B
hypoxanthine	I-Disease	NOUN	B
-	I-Disease	PUNCT	O
guanine	I-Disease	NOUN	B
phosphoribosyl	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
transferase	I-Disease	NOUN	B
(	I-Disease	PUNCT	O
HPRT	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
which	O	DET	O
is	O	AUX	O
characterized	O	VERB	B
,	O	PUNCT	O
among	O	ADP	O
other	O	ADJ	O
features	O	NOUN	B
,	O	PUNCT	O
by	O	ADP	O
compulsive	O	ADJ	B
self	O	NOUN	I
-	O	PUNCT	O
injurious	O	ADJ	B
behavior	O	NOUN	O
.	O	PUNCT	O


HPRT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mice	O	NOUN	B
generated	O	VERB	O
using	O	VERB	O
mouse	O	NOUN	B
embryonic	O	ADJ	I
stem	O	NOUN	I
cells	O	NOUN	I
exhibit	O	VERB	O
none	O	NOUN	O
of	O	ADP	O
the	O	DET	O
behavioral	O	ADJ	B
symptoms	O	NOUN	B
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Administration	O	NOUN	B
of	O	ADP	O
drugs	O	NOUN	B
that	O	PRON	O
inhibit	O	VERB	B
adenine	O	NOUN	B
phosphoribosyltransferase	O	NOUN	I
(	O	PUNCT	O
APRT	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
HPRT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mice	O	NOUN	B
has	O	AUX	O
produced	O	VERB	O
the	O	DET	O
suggestion	O	NOUN	O
that	O	SCONJ	O
deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
APRT	I-Disease	NOUN	B
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
HPRT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficiency	I-Disease	NOUN	B
in	O	ADP	O
mice	O	NOUN	B
may	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
self	O	NOUN	B
-	O	PUNCT	O
mutilation	O	NOUN	B
behavior	O	NOUN	O
[	O	PUNCT	O
C	O	PROPN	B
.	O	PUNCT	O
L	O	NOUN	B
.	O	PUNCT	O
Wu	O	NOUN	O
and	O	CCONJ	O
D	O	NOUN	B
.	O	PUNCT	O
W	O	NOUN	O
.	O	PUNCT	O
Melton	O	PROPN	O
(	O	PUNCT	O
1993	O	NUM	O
)	O	PUNCT	O
Nature	O	NOUN	B
Genet	O	PROPN	I
.	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
235	O	NUM	O
-	O	SYM	O
240	O	NUM	O
]	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
test	O	VERB	O
this	O	DET	O
proposition	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
bred	O	VERB	B
HPRT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
APRT	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
doubly	O	ADV	B
-	O	PUNCT	O
deficient	O	ADJ	B
mice	O	NOUN	B
excrete	O	VERB	B
adenine	O	NOUN	B
and	O	CCONJ	O
its	O	PRON	O
highly	O	ADV	O
insoluble	O	ADJ	B
derivative	O	NOUN	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
8	O	NUM	O
-	O	PUNCT	O
dihydroxyadenine	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
human	O	ADJ	B
APRT	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
additional	O	ADJ	O
abnormalities	O	NOUN	B
or	O	CCONJ	O
any	O	DET	O
self	O	NOUN	B
-	O	PUNCT	O
injurious	O	ADJ	B
behavior	O	NOUN	B
were	O	AUX	O
not	O	PART	O
detected	O	VERB	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
APRT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
HPRT	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
mice	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
are	O	AUX	O
devoid	O	ADJ	O
of	O	ADP	O
any	O	DET	O
purine	O	NOUN	B
salvage	O	NOUN	I
pathways	O	NOUN	I
,	O	PUNCT	O
show	O	VERB	O
no	O	DET	O
novel	O	ADJ	O
phenotype	O	NOUN	B
and	O	CCONJ	O
are	O	AUX	O
not	O	PART	O
a	O	DET	O
model	O	NOUN	B
for	O	ADP	O
the	O	DET	O
behavioral	B-Disease	ADJ	B
abnormalities	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
Lesch	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Nyhan	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
as	O	ADP	O
previously	O	ADV	O
suggested	O	VERB	O


Somatic	O	ADJ	B
alterations	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DPC4	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
human	O	ADJ	B
colorectal	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
in	O	X	B
vivo	O	X	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
&	O	CCONJ	O
AIMS	O	ADJ	B
The	O	DET	O
chromosome	O	NOUN	B
region	O	NOUN	I
18q21	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
frequently	O	ADV	O
deleted	O	VERB	O
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
such	O	ADJ	O
frequent	O	ADJ	B
allelic	O	ADJ	B
loss	O	NOUN	I
is	O	AUX	O
a	O	DET	O
hallmark	O	NOUN	O
of	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
tumor	O	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
DPC4	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
located	O	ADJ	O
at	O	ADP	O
18q21	O	NOUN	B
,	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
as	O	ADP	O
a	O	DET	O
tumor	O	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
from	O	ADP	O
examination	O	NOUN	B
of	O	ADP	O
pancreatic	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
it	O	PRON	O
might	O	AUX	O
also	O	ADV	O
be	O	AUX	O
altered	O	VERB	O
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Mutation	O	NOUN	B
analyses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DPC4	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
on	O	ADP	O
complementary	O	ADJ	O
DNA	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
31	O	NUM	O
primary	O	ADJ	B
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
specimens	O	NOUN	B
using	O	VERB	O
a	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
,	O	PUNCT	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Four	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
producing	O	VERB	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
and	O	CCONJ	O
a	O	DET	O
somatic	O	ADJ	B
12	O	NUM	O
-	O	PUNCT	O
base	O	NOUN	B
pair	O	NOUN	I
deletion	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DPC4	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
the	O	DET	O
31	O	NUM	O
cancers	B-Disease	NOUN	B
(	O	PUNCT	O
16	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
5	O	NUM	O
of	O	ADP	O
31	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
DPC4	O	NOUN	B
gene	O	NOUN	I
may	O	AUX	O
play	O	VERB	O
a	O	DET	O
role	O	NOUN	O
as	O	ADP	O
a	O	DET	O
tumor	O	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
a	O	DET	O
fraction	O	NOUN	B
of	O	ADP	O
colorectal	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
allelic	O	ADJ	B
loss	O	NOUN	O
at	O	ADP	O
18q21	O	NOUN	B
is	O	AUX	O
very	O	ADV	O
often	O	ADV	O
seen	O	VERB	O
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancers	I-Disease	NOUN	I
,	O	PUNCT	O
only	O	ADV	O
a	O	DET	O
minority	O	NOUN	B
show	O	VERB	O
DPC4	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
might	O	AUX	O
be	O	AUX	O
another	O	DET	O
tumor	O	NOUN	B
-	O	PUNCT	O
suppressor	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
this	O	DET	O
chromosome	O	NOUN	B
region	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Pleiotropic	O	ADJ	B
defects	O	NOUN	I
in	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
protein	O	NOUN	I
-	O	PUNCT	O
deficient	O	ADJ	B
mice	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
generated	O	VERB	O
a	O	DET	O
mouse	O	NOUN	B
model	O	NOUN	I
for	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
by	O	ADP	O
using	O	VERB	O
gene	O	NOUN	B
targeting	O	VERB	B
to	O	PART	O
generate	O	VERB	O
mice	O	NOUN	B
that	O	PRON	O
do	O	AUX	O
not	O	PART	O
express	O	VERB	O
the	O	DET	O
Atm	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Atm	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
mice	O	NOUN	B
are	O	AUX	O
retarded	O	VERB	B
in	O	ADP	O
growth	O	NOUN	B
,	O	PUNCT	O
do	O	AUX	O
not	O	PART	O
produce	O	VERB	O
mature	O	ADJ	B
sperm	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
exhibit	O	VERB	O
severe	O	ADJ	B
defects	O	NOUN	B
in	O	ADP	O
T	O	NOUN	B
cell	O	NOUN	I
maturation	O	NOUN	B
while	O	SCONJ	O
going	O	VERB	O
on	O	ADP	O
to	O	PART	O
develop	O	VERB	O
thymomas	B-Disease	NOUN	B
.	O	PUNCT	O


Atm	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
fibroblasts	O	NOUN	B
grow	O	VERB	O
poorly	O	ADV	O
in	O	ADP	O
culture	O	NOUN	B
and	O	CCONJ	O
display	O	VERB	B
a	O	DET	O
high	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
double	O	ADJ	B
-	O	PUNCT	O
stranded	O	VERB	B
chromosome	O	NOUN	I
breaks	O	NOUN	I
.	O	PUNCT	O


Atm	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
thymocytes	O	NOUN	B
undergo	O	VERB	O
spontaneous	O	ADJ	B
apoptosis	O	NOUN	B
in	O	X	B
vitro	O	X	I
significantly	O	ADV	O
more	O	ADJ	O
than	O	ADP	O
controls	O	NOUN	B
.	O	PUNCT	O


Atm	O	NOUN	B
-	O	PUNCT	O
deficient	O	ADJ	B
mice	O	NOUN	B
then	O	ADV	O
exhibit	O	VERB	O
many	O	ADJ	O
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
symptoms	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
patients	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
cells	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
them	O	PRON	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Atm	O	NOUN	B
protein	O	NOUN	I
exists	O	VERB	O
as	O	ADP	O
two	O	NUM	O
discrete	O	ADJ	O
molecular	O	ADJ	B
species	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
loss	O	NOUN	B
of	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
of	O	ADP	O
both	O	DET	O
of	O	ADP	O
these	O	DET	O
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
DCC	O	PROPN	B
protein	O	NOUN	I
and	O	CCONJ	O
prognosis	O	NOUN	B
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Allelic	O	ADJ	B
loss	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	O
18q	O	NOUN	O
predicts	O	VERB	O
a	O	DET	O
poor	O	ADJ	B
outcome	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
stage	B-Disease	NOUN	B
II	I-Disease	NUM	I
colorectal	I-Disease	NOUN	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
specific	O	ADJ	O
gene	O	NOUN	B
inactivated	O	VERB	B
by	O	ADP	O
this	O	DET	O
allelic	O	ADJ	B
loss	O	NOUN	O
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
elucidated	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
DCC	O	PROPN	B
(	O	PUNCT	O
deleted	O	VERB	B
in	O	ADP	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
)	O	PUNCT	O
gene	O	NOUN	O
is	O	AUX	O
a	O	DET	O
candidate	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
investigated	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DCC	O	PROPN	B
protein	O	NOUN	I
in	O	ADP	O
tumor	B-Disease	NOUN	B
cells	O	NOUN	I
is	O	AUX	O
a	O	DET	O
prognostic	O	ADJ	B
marker	O	NOUN	I
in	O	ADP	O
colorectal	B-Disease	ADJ	B
carcinoma	I-Disease	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
DCC	O	PROPN	B
was	O	AUX	O
evaluated	O	VERB	B
immunohistochemically	O	ADV	B
in	O	ADP	O
132	O	NUM	O
paraffin	O	NOUN	B
-	O	PUNCT	O
embedded	O	ADJ	B
samples	O	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
curatively	O	ADV	B
resected	O	ADJ	I
stage	B-Disease	NOUN	I
II	I-Disease	NUM	I
and	I-Disease	CCONJ	O
III	I-Disease	NUM	B
colorectal	I-Disease	ADJ	I
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Cox	O	PROPN	B
proportional	O	ADJ	I
-	O	PUNCT	O
hazards	O	NOUN	B
model	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
adjust	O	VERB	O
for	O	ADP	O
covariates	O	NOUN	B
including	O	VERB	O
age	O	NOUN	B
,	O	PUNCT	O
sex	O	NOUN	B
,	O	PUNCT	O
tumor	B-Disease	NOUN	B
site	O	NOUN	I
,	O	PUNCT	O
degree	O	NOUN	B
of	O	ADP	O
tumor	B-Disease	NOUN	B
differentiation	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
use	O	NOUN	O
of	O	ADP	O
adjuvant	O	ADJ	B
therapy	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
expression	O	NOUN	B
of	O	ADP	O
DCC	O	PROPN	B
was	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
positive	O	ADJ	O
predictive	O	ADJ	O
factor	O	NOUN	O
for	O	ADP	O
survival	O	NOUN	B
in	O	ADP	O
both	O	DET	O
stage	B-Disease	NOUN	B
II	I-Disease	NUM	I
and	I-Disease	CCONJ	O
stage	I-Disease	NOUN	B
III	I-Disease	NUM	I
colorectal	I-Disease	NOUN	I
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
stage	O	NOUN	B
II	O	NUM	I
disease	O	NOUN	I
whose	O	DET	O
tumors	B-Disease	NOUN	B
expressed	O	VERB	B
DCC	O	PROPN	B
,	O	PUNCT	O
the	O	DET	O
five	O	NUM	B
-	O	PUNCT	O
year	O	NOUN	B
survival	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
94	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
percent	O	NOUN	O
,	O	PUNCT	O
whereas	O	SCONJ	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
DCC	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
negative	I-Disease	ADJ	B
tumors	I-Disease	NOUN	B
,	O	PUNCT	O
the	O	DET	O
survival	O	NOUN	B
rate	O	NOUN	I
was	O	AUX	O
61	O	NUM	O
.	O	PUNCT	O


6	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0	O	NUM	O
.	O	PUNCT	O
001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
stage	B-Disease	NOUN	B
III	I-Disease	NUM	I
disease	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
respective	O	ADJ	O
survival	O	NOUN	B
rates	O	NOUN	I
were	O	AUX	O
59	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
percent	O	NOUN	O
and	O	CCONJ	O
33	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
percent	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
DCC	O	PROPN	B
is	O	AUX	O
a	O	DET	O
prognostic	O	ADJ	B
marker	O	NOUN	I
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
stage	B-Disease	NOUN	B
II	I-Disease	NUM	I
or	I-Disease	CCONJ	O
stage	I-Disease	NOUN	B
III	I-Disease	NUM	I
colorectal	I-Disease	ADJ	I
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
stage	B-Disease	NOUN	B
II	I-Disease	NUM	I
colorectal	I-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
DCC	O	PROPN	B
identifies	O	VERB	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
lesions	O	NOUN	B
that	O	PRON	O
behave	O	VERB	O
like	O	ADP	O
stage	B-Disease	NOUN	B
III	I-Disease	NUM	I
cancers	I-Disease	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
may	O	AUX	O
thus	O	ADV	O
have	O	AUX	O
therapeutic	O	ADJ	B
implications	O	NOUN	B
in	O	ADP	O
this	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B


Association	O	PROPN	B
of	O	ADP	O
anxiety	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
related	I-Disease	VERB	B
traits	I-Disease	NOUN	B
with	O	ADP	O
a	O	DET	O
polymorphism	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serotonin	O	NOUN	B
transporter	O	NOUN	I
gene	O	NOUN	B
regulatory	O	ADJ	I
region	O	NOUN	I
.	O	PUNCT	O


Transporter	O	NOUN	B
-	O	PUNCT	O
facilitated	O	VERB	B
uptake	O	NOUN	B
of	O	ADP	O
serotonin	O	NOUN	B
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
hydroxytryptamine	O	NOUN	B
or	O	CCONJ	O
5	O	NUM	O
-	O	PUNCT	O
HT	O	PROPN	B
)	O	PUNCT	O
has	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
in	O	ADP	O
anxiety	B-Disease	NOUN	B
in	O	ADP	O
humans	O	NOUN	B
and	O	CCONJ	O
animal	O	NOUN	B
models	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
the	O	DET	O
site	O	NOUN	B
of	O	ADP	O
action	O	NOUN	B
of	O	ADP	O
widely	O	ADV	O
used	O	VERB	O
uptake	O	NOUN	B
-	O	PUNCT	O
inhibiting	O	VERB	B
antidepressant	O	NOUN	B
and	O	CCONJ	O
antianxiety	O	ADJ	B
drugs	O	NOUN	I
.	O	PUNCT	O


Human	O	ADJ	B
5	O	NUM	O
-	O	PUNCT	O
HT	O	NOUN	B
transporter	O	NOUN	I
(	O	PUNCT	O
5	O	NUM	O
-	O	PUNCT	O
HTT	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
transcription	O	NOUN	I
is	O	AUX	O
modulated	O	VERB	B
by	O	ADP	O
a	O	DET	O
common	O	ADJ	O
polymorphism	O	NOUN	B
in	O	ADP	O
its	O	PRON	O
upstream	O	ADJ	B
regulatory	O	ADJ	I
region	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
short	O	ADJ	B
variant	O	NOUN	I
of	O	ADP	O
the	O	DET	O
polymorphism	O	NOUN	B
reduces	O	VERB	B
the	O	DET	O
transcriptional	O	ADJ	B
efficiency	O	NOUN	B
of	O	ADP	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
HTT	O	NOUN	B
gene	O	NOUN	B
promoter	O	NOUN	I
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
decreased	O	VERB	B
5	O	NUM	O
-	O	PUNCT	O
HTT	O	NOUN	B
expression	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	B
-	O	PUNCT	O
HT	O	NOUN	B
uptake	O	NOUN	B
in	O	ADP	O
lymphoblasts	O	NOUN	B
.	O	PUNCT	O


Association	O	NOUN	B
studies	O	NOUN	O
in	O	ADP	O
two	O	NUM	O
independent	O	ADJ	B
samples	O	NOUN	B
totaling	O	VERB	O
505	O	NUM	O
individuals	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
the	O	DET	O
5	O	NUM	O
-	O	PUNCT	O
HTT	O	NOUN	B
polymorphism	O	NOUN	B
accounts	O	VERB	O
for	O	ADP	O
3	O	NUM	O
to	O	PART	O
4	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
total	O	ADJ	O
variation	O	NOUN	B
and	O	CCONJ	O
7	O	NUM	O
to	O	PART	O
9	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
inherited	O	VERB	B
variance	O	NOUN	B
in	O	ADP	O
anxiety	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
related	I-Disease	ADJ	B
personality	I-Disease	NOUN	B
traits	I-Disease	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
sibships	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Phenotypic	O	ADJ	B
and	O	CCONJ	O
genotypic	O	ADJ	B
overlap	O	NOUN	B
between	O	ADP	O
atelosteogenesis	B-Disease	NOUN	B
type	I-Disease	NOUN	I
2	I-Disease	NUM	I
and	O	CCONJ	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
sulfate	O	NOUN	B
transporter	O	NOUN	I
gene	O	NOUN	B
DTDST	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
family	O	NOUN	B
of	O	ADP	O
chondrodysplasias	B-Disease	NOUN	B
that	O	PRON	O
comprises	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
order	O	NOUN	O
of	O	ADP	O
increasing	O	VERB	B
severity	O	NOUN	B
,	O	PUNCT	O
diastrophic	B-Disease	ADJ	B
dysplasia	I-Disease	NOUN	I
(	O	PUNCT	O
DTD	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
atelosteogenesis	B-Disease	NOUN	B
type	I-Disease	NOUN	I
2	I-Disease	NUM	I
(	O	PUNCT	O
AO2	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
achondrogenesis	B-Disease	NOUN	B
type	I-Disease	NOUN	I
1B	I-Disease	NOUN	I
(	O	PUNCT	O
ACG1B	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
learn	O	VERB	O
more	O	ADV	O
about	O	ADP	O
the	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
DTDST	B-Disease	NOUN	B
chondrodysplasias	I-Disease	NOUN	B
and	O	CCONJ	O
about	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
studied	O	VERB	O
fibroblast	O	NOUN	B
cultures	O	NOUN	I
of	O	ADP	O
three	O	NUM	O
new	O	ADJ	O
patients	O	NOUN	B
one	O	NUM	O
with	O	ADP	O
AO	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
2	I-Disease	NUM	O
,	O	PUNCT	O
one	O	NUM	O
with	O	ADP	O
DTD	B-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
with	O	ADP	O
an	O	DET	O
intermediate	O	ADJ	B
phenotype	O	NOUN	B
(	O	PUNCT	O
AO2	B-Disease	NOUN	B
/	O	SYM	O
DTD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Reduced	O	VERB	B
incorporation	O	NOUN	B
of	O	ADP	O
inorganic	O	ADJ	B
sulfate	O	NOUN	I
into	O	ADP	O
macromolecules	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
.	O	PUNCT	O


Each	O	DET	O
of	O	ADP	O
the	O	DET	O
three	O	NUM	O
patients	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
c862t	O	ADJ	B
transition	O	NOUN	B
predicting	O	VERB	B
a	O	DET	O
R279W	O	NOUN	B
substitution	O	NOUN	B
in	O	ADP	O
the	O	DET	O
third	O	ADJ	O
extracellular	O	ADJ	O
loop	O	NOUN	O
of	O	ADP	O
DTDST	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
two	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
DTD	B-Disease	NOUN	B
and	O	CCONJ	O
AO2	B-Disease	NOUN	B
/	O	SYM	O
DTD	B-Disease	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
no	O	DET	O
other	O	ADJ	O
structural	O	ADJ	B
mutation	O	NOUN	O
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
amplification	O	NOUN	I
and	O	CCONJ	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	B
polymorphism	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
fibroblast	O	NOUN	B
cDNA	O	NOUN	I
showed	O	VERB	O
reduced	O	VERB	B
mRNA	O	NOUN	B
levels	O	NOUN	O
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
DTDST	O	NOUN	B
allele	O	NOUN	B
these	O	DET	O
two	O	NUM	O
patients	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
compound	O	ADJ	B
heterozygotes	O	NOUN	B
for	O	ADP	O
the	O	DET	O
"	O	PUNCT	O
Finnish	O	ADJ	B
"	O	PUNCT	O
mutation	O	NOUN	B
(	O	PUNCT	O
as	O	ADP	O
yet	O	ADV	O
uncharacterized	O	VERB	B
at	O	ADP	O
the	O	DET	O
DNA	O	NOUN	B
level	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
causes	O	VERB	O
reduced	O	VERB	B
expression	O	NOUN	B
of	O	ADP	O
DTDST	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
third	O	ADJ	O
patient	O	NOUN	B
(	O	PUNCT	O
with	O	ADP	O
AO2	B-Disease	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
the	O	DET	O
R279W	O	NOUN	B
mutation	O	NOUN	B
compounded	O	VERB	O
with	O	ADP	O
a	O	DET	O
novel	O	ADJ	B
mutation	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
deletion	O	NOUN	B
of	O	ADP	O
cytosine	O	NOUN	B
418	O	NUM	I
(	O	PUNCT	O
delta	O	NOUN	B
c418	O	NOUN	I
)	O	PUNCT	O
,	O	PUNCT	O
predicting	O	VERB	B
a	O	DET	O
frameshift	O	NOUN	B
with	O	ADP	O
premature	O	ADJ	B
termination	O	NOUN	I
.	O	PUNCT	O


Also	O	ADV	O
the	O	DET	O
delta	O	NOUN	B
c418	O	NOUN	I
allele	O	NOUN	B
was	O	AUX	O
underrepresented	O	ADJ	O
in	O	ADP	O
the	O	DET	O
cDNA	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
accordance	O	NOUN	O
with	O	ADP	O
previous	O	ADJ	O
observations	O	NOUN	B
that	O	SCONJ	O
premature	O	ADJ	B
stop	O	VERB	I
codons	O	NOUN	I
reduce	O	VERB	O
mRNA	O	NOUN	B
levels	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
DTDST	O	NOUN	B
R279W	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
a	O	DET	O
total	O	NOUN	O
of	O	ADP	O
11	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
AO2	B-Disease	NOUN	B
or	O	CCONJ	O
DTD	B-Disease	NOUN	B
emphasizes	O	VERB	O
the	O	DET	O
overlap	O	NOUN	B
between	O	ADP	O
these	O	DET	O
conditions	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
has	O	AUX	O
not	O	PART	O
been	O	AUX	O
found	O	VERB	O
so	O	ADV	O
far	O	ADV	O
in	O	ADP	O
8	O	NUM	O
analyzed	O	VERB	B
ACG1B	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
allows	O	VERB	O
some	O	DET	O
residual	O	ADJ	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
sulfate	O	NOUN	B
transporter	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Identification	O	NOUN	B
of	O	ADP	O
WASP	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
mutation	O	NOUN	B
hotspots	O	NOUN	B
and	O	CCONJ	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
disparities	O	NOUN	B
in	O	ADP	O
24	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Wiskott	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Aldrich	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
WAS	B-Disease	PROPN	B
)	O	PUNCT	O
,	O	PUNCT	O
an	O	DET	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
immunodeficiency	I-Disease	NOUN	B
disease	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
recently	O	ADV	O
isolated	O	VERB	B
gene	O	NOUN	B
encoding	O	NOUN	O
WAS	B-Disease	NOUN	B
protein	O	NOUN	I
(	O	PUNCT	O
WASP	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
extensive	O	ADJ	O
clinical	O	ADJ	B
heterogeneity	O	NOUN	O
.	O	PUNCT	O


Cumulative	O	ADJ	B
mutation	O	NOUN	B
data	O	NOUN	B
have	O	AUX	O
revealed	O	VERB	O
that	O	SCONJ	O
WASP	O	NOUN	B
genotypes	O	NOUN	B
are	O	AUX	O
also	O	ADV	O
highly	O	ADV	O
variable	O	ADJ	B
among	O	ADP	O
WAS	B-Disease	AUX	B
patients	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
relationship	O	NOUN	B
of	O	ADP	O
phenotype	O	NOUN	B
with	O	ADP	O
genotype	O	NOUN	B
in	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
remains	O	VERB	O
unclear	O	ADJ	B
.	O	PUNCT	O


To	O	PART	O
address	O	VERB	O
this	O	DET	O
issue	O	NOUN	B
we	O	PRON	O
characterized	O	VERB	B
WASP	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
24	O	NUM	O
unrelated	O	ADJ	O
WAS	B-Disease	AUX	B
patients	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
18	O	NUM	O
boys	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
classical	O	ADJ	O
WAS	B-Disease	PROPN	B
and	O	CCONJ	O
6	O	NUM	O
boys	O	NOUN	B
expressing	O	VERB	B
mild	O	ADJ	B
forms	O	NOUN	I
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
examined	O	VERB	B
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
correlation	O	NOUN	B
of	O	ADP	O
these	O	DET	O
as	O	ADV	O
well	O	ADV	O
as	O	ADV	O
all	O	DET	O
previously	O	ADV	O
published	O	VERB	B
WASP	O	NOUN	B
mutations	O	NOUN	B
with	O	ADP	O
disease	O	NOUN	B
severity	O	NOUN	I
.	O	PUNCT	O


By	O	ADP	O
analysis	O	NOUN	B
of	O	ADP	O
these	O	DET	O
compiled	O	VERB	O
mutation	O	NOUN	B
data	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
demonstrated	O	VERB	O
clustering	O	NOUN	B
of	O	ADP	O
WASP	O	NOUN	B
mutations	O	NOUN	B
within	O	ADP	O
the	O	DET	O
four	O	NUM	O
most	O	ADJ	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
exons	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
and	O	CCONJ	O
also	O	ADV	O
identified	O	VERB	O
several	O	ADJ	O
sites	O	NOUN	B
within	O	ADP	O
this	O	DET	O
region	O	NOUN	O
as	O	ADP	O
hotspots	O	NOUN	B
for	O	ADP	O
WASP	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
characteristics	O	NOUN	B
were	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
both	O	CCONJ	O
severe	O	ADJ	B
and	O	CCONJ	O
mild	O	ADJ	B
cases	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
cumulative	O	ADJ	B
data	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
predominance	O	NOUN	O
of	O	ADP	O
missense	O	NOUN	B
mutations	O	NOUN	I
among	O	ADP	O
the	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
lesions	O	NOUN	O
observed	O	VERB	B
in	O	ADP	O
boys	O	NOUN	B
with	O	ADP	O
isolated	B-Disease	VERB	B
thrombocytopenia	I-Disease	NOUN	O
,	O	PUNCT	O
missense	O	NOUN	B
mutations	O	NOUN	I
were	O	AUX	O
not	O	PART	O
exclusively	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
milder	O	ADJ	O
WAS	B-Disease	AUX	B
phenotypes	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
also	O	ADV	O
comprised	O	VERB	O
a	O	DET	O
substantial	O	ADJ	B
portion	O	NOUN	I
(	O	PUNCT	O
38	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
WASP	O	NOUN	B
gene	O	NOUN	I
defects	O	NOUN	B
found	O	VERB	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
severe	O	ADJ	B
disease	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
identical	O	ADJ	B
WASP	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
disparate	O	ADJ	O
phenotypes	O	NOUN	B
,	O	PUNCT	O
reveal	O	VERB	O
a	O	DET	O
lack	O	NOUN	B
of	O	ADP	O
phenotype	O	NOUN	B
concordance	O	NOUN	B
with	O	ADP	O
genotype	O	NOUN	B
in	O	ADP	O
WAS	B-Disease	PROPN	B
and	O	CCONJ	O
thus	O	ADV	O
imply	O	VERB	O
that	O	SCONJ	O
phenotypic	O	ADJ	B
outcome	O	NOUN	O
in	O	ADP	O
this	O	DET	O
disease	O	NOUN	B
cannot	O	AUX	O
be	O	AUX	O
reliably	O	ADV	O
predicted	O	VERB	B
solely	O	ADV	O
on	O	ADP	O
the	O	DET	O
basis	O	NOUN	O
of	O	ADP	O
WASP	O	NOUN	B
genotypes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
'	O	PART	O
part	O	NOUN	O
of	O	ADP	O
APC	B-Disease	NOUN	B
exon	O	NOUN	O
15	O	NUM	O
do	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
truncated	O	VERB	B
proteins	O	NOUN	I
and	O	CCONJ	O
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
attenuated	O	VERB	B
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	NOUN	I
.	O	PUNCT	O


Familial	B-Disease	ADJ	B
adenomatous	I-Disease	ADJ	I
polyposis	I-Disease	NOUN	I
(	O	PUNCT	O
FAP	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
inherited	O	VERB	B
predisposition	O	NOUN	B
to	O	PART	O
colorectal	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
characterized	O	VERB	B
by	O	ADP	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
numerous	O	ADJ	B
adenomatous	B-Disease	ADJ	B
polyps	I-Disease	NOUN	I
predominantly	O	ADV	O
in	O	ADP	O
the	O	DET	O
colorectal	O	ADJ	B
region	O	NOUN	I
.	O	PUNCT	O


Germline	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
adenomatous	B-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
APC	B-Disease	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	B
are	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
most	O	ADJ	O
cases	O	NOUN	B
of	O	ADP	O
FAP	B-Disease	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
5	O	NUM	O
end	O	NOUN	O
of	O	ADP	O
APC	B-Disease	NOUN	B
are	O	AUX	O
known	O	VERB	O
to	O	PART	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
relatively	O	ADV	O
mild	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
,	O	PUNCT	O
called	O	VERB	O
attenuated	B-Disease	VERB	B
adenomatous	I-Disease	ADJ	B
polyposis	I-Disease	NOUN	I
coli	I-Disease	X	I
(	O	PUNCT	O
AAPC	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
part	O	NOUN	O
of	O	ADP	O
exon	O	NOUN	B
15	O	NUM	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
at	O	ADP	O
1862	O	NUM	O
,	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Dutch	O	ADJ	B
kindred	O	NOUN	I
with	O	ADP	O
AAPC	B-Disease	NOUN	B
.	O	PUNCT	O


Western	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
lymphoblastoid	O	ADJ	B
cell	O	NOUN	I
lines	O	NOUN	I
derived	O	VERB	O
from	O	ADP	O
affected	O	VERB	B
family	O	NOUN	B
members	O	NOUN	I
from	O	ADP	O
this	O	DET	O
kindred	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
from	O	ADP	O
a	O	DET	O
previously	O	ADV	O
reported	O	VERB	O
Swiss	O	ADJ	B
family	O	NOUN	I
carrying	O	VERB	O
a	O	DET	O
frameshift	O	NOUN	B
mutation	O	NOUN	I
at	O	ADP	O
codon	O	NOUN	B
1987	O	NUM	I
and	O	CCONJ	O
displaying	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
attenuated	O	VERB	B
phenotype	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
only	O	ADV	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
APC	B-Disease	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


Our	O	PRON	O
study	O	NOUN	B
indicates	O	VERB	O
that	O	SCONJ	O
chain	O	NOUN	B
-	O	PUNCT	O
terminating	O	VERB	B
mutations	O	NOUN	B
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
part	O	NOUN	O
of	O	ADP	O
APC	B-Disease	NOUN	B
do	O	AUX	O
not	O	PART	O
result	O	VERB	O
in	O	ADP	O
detectable	O	ADJ	B
truncated	O	VERB	B
polypeptides	O	NOUN	O
and	O	CCONJ	O
we	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
this	O	DET	O
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
basis	O	NOUN	O
for	O	ADP	O
the	O	DET	O
observed	O	VERB	B
AAPC	B-Disease	NOUN	B
phenotype	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Complete	O	ADJ	B
genomic	O	ADJ	B
sequence	O	NOUN	I
and	O	CCONJ	O
analysis	O	NOUN	B
of	O	ADP	O
117	O	NUM	O
kb	O	NOUN	O
of	O	ADP	O
human	O	ADJ	B
DNA	O	NOUN	B
containing	O	VERB	O
the	O	DET	O
gene	O	NOUN	B
BRCA1	O	NOUN	I
.	O	PUNCT	O


Over	O	ADP	O
100	O	NUM	O
distinct	O	ADJ	O
disease	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
gene	O	NOUN	I
BRCA1	O	NOUN	B
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
in	O	ADP	O
>	O	NOUN	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
tumors	B-Disease	NOUN	B
from	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
inherited	O	VERB	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
indicates	O	VERB	O
tumor	B-Disease	NOUN	B
suppressive	O	ADJ	I
function	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
somatic	O	ADJ	B
mutations	O	NOUN	I
suggests	O	VERB	O
that	O	SCONJ	O
BRCA1	O	NOUN	B
inactivation	O	NOUN	B
in	O	ADP	O
sporadic	O	ADJ	B
tumors	B-Disease	NOUN	I
occurs	O	VERB	O
by	O	ADP	O
alternative	O	ADJ	B
mechanisms	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
interstitial	O	ADJ	B
chromosomal	O	ADJ	O
deletion	O	NOUN	O
or	O	CCONJ	O
reduced	O	VERB	B
transcription	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
identify	O	VERB	O
possible	O	ADJ	O
features	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
genomic	O	ADJ	B
region	O	NOUN	I
that	O	PRON	O
may	O	AUX	O
contribute	O	VERB	O
to	O	PART	O
chromosomal	O	ADJ	B
instability	O	NOUN	I
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
potential	O	ADJ	O
transcriptional	O	ADJ	B
regulatory	O	ADJ	O
elements	O	NOUN	O
,	O	PUNCT	O
a	O	DET	O
117	O	NUM	O
,	O	PUNCT	O
143	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
DNA	O	NOUN	B
sequence	O	NOUN	I
encompassing	O	VERB	O
BRCA1	O	NOUN	B
was	O	AUX	O
obtained	O	VERB	O
by	O	ADP	O
random	O	ADJ	B
sequencing	O	NOUN	I
of	O	ADP	O
four	O	NUM	O
cosmids	O	NOUN	B
identified	O	VERB	B
from	O	ADP	O
a	O	DET	O
human	O	ADJ	B
chromosome	O	NOUN	I
17	O	NUM	O
specific	O	ADJ	O
library	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
24	O	NUM	O
exons	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
span	O	VERB	O
an	O	DET	O
81	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	B
region	O	NOUN	I
that	O	PRON	O
has	O	AUX	O
an	O	DET	O
unusually	O	ADV	O
high	O	ADJ	B
density	O	NOUN	I
of	O	ADP	O
Alu	O	NOUN	B
repetitive	O	ADJ	I
DNA	O	NOUN	I
(	O	PUNCT	O
41	O	NUM	O
.	O	PUNCT	O
5	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
but	O	CCONJ	O
relatively	O	ADV	O
low	O	ADJ	B
density	O	NOUN	I
(	O	PUNCT	O
4	O	NUM	O
.	O	PUNCT	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
other	O	ADJ	O
repetitive	O	ADJ	B
sequences	O	NOUN	I
.	O	PUNCT	O


BRCA1	O	NOUN	B
intron	O	NOUN	B
lengths	O	NOUN	B
range	O	VERB	O
in	O	ADP	O
size	O	NOUN	B
from	O	ADP	O
403	O	NUM	O
bp	O	NOUN	O
to	O	PART	O
9	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
kb	O	NOUN	O
and	O	CCONJ	O
contain	O	VERB	O
the	O	DET	O
intragenic	O	ADJ	B
microsatellite	O	NOUN	O
markers	O	NOUN	O
D17S1323	O	NOUN	B
,	O	PUNCT	O
D17S1322	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
D17S855	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
localize	O	VERB	O
to	O	PART	O
introns	O	NOUN	B
12	O	NUM	O
,	O	PUNCT	O
19	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
20	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
contig	O	NOUN	B
contains	O	VERB	O
two	O	NUM	O
complete	O	ADJ	O
genes	O	NOUN	B
Rho7	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
rho	O	ADJ	O
family	O	NOUN	B
of	O	ADP	O
GTP	O	NOUN	B
binding	O	NOUN	I
proteins	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
VAT1	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
abundant	O	ADJ	B
membrane	O	NOUN	B
protein	O	NOUN	I
of	O	ADP	O
cholinergic	O	ADJ	B
synaptic	O	ADJ	B
vesicles	O	NOUN	I
.	O	PUNCT	O


Partial	O	ADJ	B
sequences	O	NOUN	I
of	O	ADP	O
the	O	DET	O
1A1	O	NOUN	B
-	O	PUNCT	O
3B	O	PROPN	B
B	O	NOUN	B
-	O	PUNCT	O
box	O	NOUN	B
protein	O	NOUN	I
pseudogene	O	NOUN	I
and	O	CCONJ	O
IFP	O	PROPN	B
35	O	NUM	O
,	O	PUNCT	O
an	O	DET	O
interferon	O	NOUN	B
induced	O	ADJ	B
leucine	O	NOUN	B
zipper	O	NOUN	I
protein	O	NOUN	I
,	O	PUNCT	O
reside	O	VERB	O
within	O	ADP	O
the	O	DET	O
contig	O	NOUN	B
.	O	PUNCT	O


An	O	DET	O
L21	O	NOUN	B
ribosomal	O	ADJ	I
protein	O	NOUN	I
pseudogene	O	NOUN	I
is	O	AUX	O
embedded	O	ADJ	O
in	O	ADP	O
BRCA1	O	NOUN	B
intron	O	NOUN	B
13	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
order	O	NOUN	O
of	O	ADP	O
genes	O	NOUN	B
on	O	ADP	O
the	O	DET	O
chromosome	O	NOUN	B
is	O	AUX	O
centromere	O	NOUN	B
-	O	PUNCT	O
1FP	O	NUM	O
35	O	NUM	O
-	O	PUNCT	O
VAT1	O	NOUN	B
-	O	PUNCT	O
Rho7	O	NOUN	B
-	O	PUNCT	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
1A1	O	PROPN	B
-	O	PUNCT	O
3B	O	PROPN	B
-	O	PUNCT	O
telomere	O	NOUN	B


Identification	O	NOUN	B
of	O	ADP	O
a	O	DET	O
RING	O	NOUN	B
protein	O	NOUN	I
that	O	PRON	O
can	O	AUX	O
interact	O	VERB	B
in	O	X	B
vivo	O	X	I
with	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
gene	O	NOUN	B
,	O	PUNCT	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
encodes	O	VERB	B
a	O	DET	O
large	O	ADJ	O
polypeptide	O	NOUN	B
that	O	PRON	O
contains	O	VERB	O
the	O	DET	O
cysteine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
RING	O	NOUN	B
motif	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
zinc	O	NOUN	B
-	O	PUNCT	O
binding	O	VERB	B
domain	O	NOUN	O
found	O	VERB	O
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
regulatory	O	ADJ	B
proteins	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
describe	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
protein	O	NOUN	B
that	O	PRON	O
interacts	O	VERB	O
in	O	X	B
vivo	O	X	I
with	O	ADP	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
region	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
BRCA1	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
RING	O	NOUN	B
domain	O	NOUN	I
(	O	PUNCT	O
BARD1	O	NOUN	B
)	O	PUNCT	O
protein	O	NOUN	B
contains	O	VERB	O
an	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
RING	O	NOUN	B
motif	O	NOUN	B
,	O	PUNCT	O
three	O	NUM	O
tandem	O	ADJ	B
ankyrin	O	NOUN	I
repeats	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
C	O	NOUN	B
-	O	PUNCT	O
terminal	O	ADJ	B
sequence	O	NOUN	B
with	O	ADP	O
significant	O	ADJ	O
homology	O	NOUN	B
to	O	PART	O
the	O	DET	O
phylogenetically	O	ADV	B
conserved	O	VERB	I
BRCT	O	NOUN	B
domains	O	NOUN	I
that	O	PRON	O
lie	O	VERB	O
near	O	ADP	B
the	O	DET	O
C	O	NOUN	O
terminus	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
BARD1	O	NOUN	B
/	O	PUNCT	O
BRCA1	O	NOUN	B
interaction	O	NOUN	B
is	O	AUX	O
disrupted	O	VERB	B
by	O	ADP	O
BRCA1	O	NOUN	B
missense	O	NOUN	B
mutations	O	NOUN	I
that	O	PRON	O
segregate	O	VERB	O
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
susceptibility	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
BARD1	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
mediating	O	VERB	O
tumour	B-Disease	NOUN	B
suppression	O	NOUN	B
by	O	ADP	O
BRCA1	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
heterozygous	O	ADJ	B
mutations	O	NOUN	O
in	O	ADP	O
BRCA1	O	NOUN	B
using	O	VERB	O
high	O	ADJ	B
density	O	NOUN	I
oligonucleotide	O	NOUN	I
arrays	O	NOUN	I
and	O	CCONJ	O
two	O	NUM	B
-	O	PUNCT	O
colour	O	NOUN	B
fluorescence	O	NOUN	B
analysis	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ability	O	NOUN	O
to	O	PART	O
scan	O	VERB	B
a	O	DET	O
large	O	ADJ	O
gene	O	NOUN	B
rapidly	O	ADV	O
and	O	CCONJ	O
accurately	O	ADV	B
for	O	ADP	O
all	O	DET	O
possible	O	ADJ	O
heterozygous	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
large	O	ADJ	O
numbers	O	NOUN	O
of	O	ADP	O
patient	O	NOUN	B
samples	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
critical	O	ADJ	O
for	O	ADP	O
the	O	DET	O
future	O	NOUN	B
of	O	ADP	O
medicine	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
designed	O	VERB	O
high	O	ADJ	B
-	O	PUNCT	O
density	O	NOUN	B
arrays	O	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
over	O	ADP	O
96	O	NUM	O
,	O	PUNCT	O
600	O	NUM	O
oligonucleotides	O	NOUN	B
20	O	NUM	O
-	O	PUNCT	O
nucleotides	O	NOUN	B
(	O	PUNCT	O
nt	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
length	O	NOUN	O
to	O	PART	O
screen	O	VERB	B
for	O	ADP	O
a	O	DET	O
wide	O	ADJ	O
range	O	NOUN	O
of	O	ADP	O
heterozygous	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
.	O	PUNCT	O


45	O	NUM	O
-	O	PUNCT	O
kilobases	O	NOUN	B
(	O	PUNCT	O
kb	O	NOUN	O
)	O	PUNCT	O
exon	O	NOUN	O
11	O	NUM	O
of	O	ADP	O
the	O	DET	O
hereditary	B-Disease	ADJ	B
breast	I-Disease	NOUN	I
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
gene	O	NOUN	B
BRCA1	O	NOUN	B
.	O	PUNCT	O


Reference	O	NOUN	B
and	O	CCONJ	O
test	O	NOUN	O
samples	O	NOUN	B
were	O	AUX	O
co	O	PART	B
-	O	PUNCT	O
hybridized	O	VERB	B
to	O	ADP	O
these	O	DET	O
arrays	O	NOUN	B
and	O	CCONJ	O
differences	O	NOUN	B
in	O	ADP	O
hybridization	O	NOUN	B
patterns	O	NOUN	B
quantitated	O	VERB	B
by	O	ADP	O
two	O	NUM	O
-	O	PUNCT	O
colour	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


Fourteen	O	NUM	O
of	O	ADP	O
fifteen	O	NUM	O
patient	O	NOUN	B
samples	O	NOUN	I
with	O	ADP	O
known	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
accurately	O	ADV	O
diagnosed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
no	O	DET	O
false	O	ADJ	O
positive	O	ADJ	O
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
20	O	NUM	O
control	O	NOUN	B
samples	O	NOUN	I
.	O	PUNCT	O


Eight	O	NUM	O
single	O	ADJ	O
nucleotide	O	NOUN	O
polymorphisms	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
readily	O	ADV	O
detected	O	VERB	B
.	O	PUNCT	O


DNA	O	NOUN	B
chip	O	NOUN	I
-	O	PUNCT	O
based	O	VERB	B
assays	O	NOUN	B
may	O	AUX	O
provide	O	VERB	O
a	O	DET	O
valuable	O	ADJ	O
new	O	ADJ	O
technology	O	NOUN	B
for	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
throughput	O	NOUN	B
cost	O	NOUN	B
-	O	PUNCT	O
efficient	O	ADJ	B
detection	O	NOUN	B
of	O	ADP	O
genetic	O	ADJ	B
alterations	O	NOUN	I
.	O	PUNCT	O


Autosomal	O	ADJ	B
dominant	O	ADJ	B
primary	O	ADJ	B
hyperparathyroidism	B-Disease	NOUN	I
and	I-Disease	CCONJ	O
jaw	I-Disease	NOUN	B
tumor	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
associated	O	VERB	B
with	O	ADP	I
renal	B-Disease	ADJ	B
hamartomas	I-Disease	NOUN	I
and	O	CCONJ	O
cystic	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
:	O	PUNCT	O
linkage	O	NOUN	B
to	O	PART	O
1q21	O	NOUN	B
-	O	PUNCT	O
q32	O	NOUN	B
and	O	CCONJ	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
type	O	NOUN	I
allele	O	NOUN	B
in	O	ADP	O
renal	B-Disease	ADJ	B
hamartomas	I-Disease	NOUN	I
.	O	PUNCT	O


Hereditary	B-Disease	ADJ	B
hyperparathyroidism	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
jaw	I-Disease	NOUN	B
tumor	I-Disease	NOUN	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
HPT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
JT	I-Disease	PROPN	B
)	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
disease	I-Disease	NOUN	O
(	O	PUNCT	O
OMIM	O	NOUN	B
145001	O	NUM	O
)	O	PUNCT	O
that	O	PRON	O
has	O	AUX	O
recently	O	ADV	O
been	O	AUX	O
mapped	O	VERB	O
to	O	PART	O
chromosomal	O	ADJ	B
region	O	NOUN	I
1q21	O	NOUN	B
-	O	PUNCT	O
q32	O	NOUN	B
(	O	PUNCT	O
HRPT2	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
two	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
HPT	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
JT	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
in	O	ADP	O
which	O	DET	O
adult	B-Disease	ADJ	B
renal	I-Disease	ADJ	B
hamartomas	I-Disease	NOUN	I
or	O	CCONJ	O
cystic	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
were	O	AUX	O
prominent	O	ADJ	O
associated	O	VERB	O
features	O	NOUN	B
,	O	PUNCT	O
possibly	O	ADV	O
representing	O	VERB	O
a	O	DET	O
new	O	ADJ	O
phenotypic	O	ADJ	B
variant	O	NOUN	B
of	O	ADP	O
the	O	DET	O
HPT	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
JT	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
first	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
renal	B-Disease	ADJ	B
lesions	I-Disease	NOUN	I
were	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
five	O	NUM	O
out	O	ADP	O
of	O	ADP	O
six	O	NUM	O
affected	O	VERB	B
individuals	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
HPT	B-Disease	NOUN	B
and	O	CCONJ	O
JT	B-Disease	NOUN	B
were	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
four	O	NUM	O
and	O	CCONJ	O
two	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
second	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
JT	B-Disease	NOUN	B
was	O	AUX	O
found	O	VERB	O
in	O	ADP	O
three	O	NUM	O
of	O	ADP	O
the	O	DET	O
five	O	NUM	O
affected	O	VERB	B
individuals	O	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
affected	O	VERB	B
members	O	NOUN	B
also	O	ADV	O
exhibited	O	VERB	O
polycystic	B-Disease	ADJ	B
kidney	I-Disease	NOUN	I
disease	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
possibility	O	NOUN	O
of	O	ADP	O
the	O	DET	O
latter	O	ADJ	O
cosegregating	O	NOUN	B
as	O	ADP	O
a	O	DET	O
separate	O	ADJ	O
autosomal	O	ADJ	B
dominant	O	ADJ	O
gene	O	NOUN	O
can	O	AUX	O
not	O	PART	O
be	O	AUX	O
ruled	O	VERB	O
out	O	ADP	O
.	O	PUNCT	O


A	O	DET	O
sex	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
penetrance	O	NOUN	B
of	O	ADP	O
primary	B-Disease	ADJ	B
HPT	I-Disease	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
predominantly	O	ADV	O
male	O	NOUN	B
-	O	PUNCT	O
affected	O	VERB	B
cases	O	NOUN	B
was	O	AUX	O
evident	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
families	O	NOUN	B
.	O	PUNCT	O


Twenty	O	NUM	O
microsatellite	O	NOUN	B
markers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
HRPT2	O	NOUN	B
region	O	NOUN	O
were	O	AUX	O
typed	O	VERB	B
,	O	PUNCT	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
markers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
multiple	B-Disease	ADJ	B
endocrine	I-Disease	ADJ	I
neoplasia	I-Disease	NOUN	I
(	I-Disease	PUNCT	O
MEN	I-Disease	NOUN	B
)	I-Disease	PUNCT	O
types	I-Disease	NOUN	O
1	I-Disease	NUM	O
and	I-Disease	CCONJ	O
2	I-Disease	NUM	O
regions	O	NOUN	B
at	O	ADP	O
11q13	O	NOUN	B
and	O	CCONJ	O
10q11	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
disease	O	NOUN	B
in	O	ADP	O
these	O	DET	O
two	O	NUM	O
kindreds	O	NOUN	B
was	O	AUX	O
linked	O	VERB	O
to	O	PART	O
five	O	NUM	O
markers	O	NOUN	B
in	O	ADP	O
the	O	DET	O
1q21	O	NOUN	B
-	O	PUNCT	O
q32	O	NOUN	B
region	O	NOUN	I
(	O	PUNCT	O
logarithm	O	NOUN	B
-	O	PUNCT	O
of	O	ADP	B
-	O	PUNCT	O
odds	O	NOUN	B
scores	O	VERB	I
3	O	NUM	I
.	O	PUNCT	O
2	O	NUM	O
-	O	SYM	O
4	O	NUM	O
2	O	NUM	O
-	O	SYM	O
4	O	NUM	O
.	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
whereas	O	SCONJ	O
linkage	O	NOUN	B
to	O	PART	O
the	O	DET	O
MEN1	B-Disease	NOUN	B
and	O	CCONJ	O
MEN2	B-Disease	NOUN	B
regions	O	NOUN	B
was	O	AUX	O
excluded	O	VERB	O
.	O	PUNCT	O


Meiotic	O	ADJ	B
recombinations	O	NOUN	I
detected	O	VERB	B
in	O	ADP	O
affected	O	VERB	B
individuals	O	NOUN	B
placed	O	VERB	O
the	O	DET	O
locus	O	NOUN	B
telomeric	O	NOUN	B
of	O	ADP	O
D1S215	O	NOUN	B
,	O	PUNCT	O
thus	O	ADV	O
narrowing	O	VERB	B
the	O	DET	O
HRPT2	O	NOUN	B
region	O	NOUN	B
from	O	ADP	O
>	O	X	O
60	O	NUM	O
to	O	PART	O
approximately	O	ADV	O
34	O	NUM	O
centimorgans	O	NOUN	B
.	O	PUNCT	O


Loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
seven	O	NUM	O
renal	B-Disease	ADJ	B
hamartomas	I-Disease	NOUN	I
from	O	ADP	O
two	O	NUM	O
affected	O	VERB	B
individuals	O	NOUN	B
in	O	ADP	O
the	O	DET	O
first	O	ADJ	O
family	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
a	O	DET	O
jaw	B-Disease	NOUN	B
tumor	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
parathyroid	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
from	O	ADP	O
the	O	DET	O
second	O	ADJ	O
family	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
renal	B-Disease	ADJ	B
hamartomas	I-Disease	NOUN	I
showed	O	VERB	O
loss	O	NOUN	B
of	O	ADP	O
heterozygosity	O	NOUN	B
at	O	ADP	O
the	O	DET	O
1q21	O	NOUN	B
-	O	PUNCT	O
q32	O	NOUN	B
region	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
losses	O	NOUN	B
invariably	O	ADV	O
involved	O	VERB	O
the	O	DET	O
wild	O	ADJ	B
type	O	NOUN	I
allele	O	NOUN	B
derived	O	VERB	O
from	O	ADP	O
the	O	DET	O
unaffected	O	ADJ	B
parent	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
the	O	DET	O
inactivation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
in	O	ADP	O
this	O	DET	O
region	O	NOUN	B


Independent	O	ADJ	B
origin	O	NOUN	B
of	O	ADP	O
single	O	ADJ	O
and	O	CCONJ	O
double	O	ADJ	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
glucose	O	NOUN	I
6	O	NUM	O
-	O	PUNCT	O
phosphate	O	NOUN	B
dehydrogenase	O	NOUN	I
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
vast	O	ADJ	O
majority	O	NOUN	O
of	O	ADP	O
both	O	CCONJ	O
polymorphic	O	ADJ	B
and	O	CCONJ	O
sporadic	O	ADJ	B
G6PD	O	NOUN	B
variants	O	NOUN	B
are	O	AUX	O
due	O	ADJ	O
to	O	PART	O
single	O	ADJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
four	O	NUM	O
polymorphic	O	ADJ	B
variants	O	NOUN	B
that	O	PRON	O
have	O	AUX	O
two	O	NUM	O
point	O	NOUN	O
mutations	O	NOUN	B
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
mutations	O	NOUN	B
is	O	AUX	O
always	O	ADV	O
376	O	NUM	O
A	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
G	O	NOUN	B
(	O	PUNCT	O
126	O	NUM	O
Asn	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
Asp	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
which	O	DET	O
on	O	ADP	O
its	O	PRON	O
own	O	ADJ	O
gives	O	VERB	O
rise	O	NOUN	O
to	O	PART	O
the	O	DET	O
nondeficient	O	ADJ	B
polymorphic	O	ADJ	B
variant	O	NOUN	I
,	O	PUNCT	O
G6PD	O	NOUN	B
A	O	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
a	O	DET	O
study	O	NOUN	B
of	O	ADP	O
G6PD	B-Disease	NOUN	B
deficient	I-Disease	ADJ	B
patients	O	NOUN	B
who	O	PRON	O
presented	O	VERB	O
with	O	ADP	O
clinical	O	ADJ	B
favism	B-Disease	NOUN	I
in	O	ADP	O
Spain	O	PROPN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
found	O	VERB	O
a	O	DET	O
new	O	ADJ	O
polymorphic	O	ADJ	B
variant	O	NOUN	O
that	O	SCONJ	O
we	O	PRON	O
have	O	AUX	O
called	O	VERB	O
G6PD	O	NOUN	B
Malaga	O	PROPN	I
,	O	PUNCT	O
whose	O	DET	O
only	O	ADJ	O
abnormality	O	NOUN	B
is	O	AUX	O
a	O	DET	O
542	O	NUM	O
A	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
(	O	PUNCT	O
181	O	NUM	O
Asp	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	PROPN	O
Val	O	NOUN	B
)	O	PUNCT	I
mutation	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
same	O	ADJ	O
mutation	O	NOUN	B
as	O	ADP	O
previously	O	ADV	O
found	O	VERB	O
in	O	ADP	O
association	O	NOUN	B
with	O	ADP	I
the	O	DET	O
mutation	O	NOUN	B
of	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
in	O	ADP	O
the	O	DET	O
double	O	ADJ	B
mutant	O	NOUN	I
,	O	PUNCT	O
G6PD	O	NOUN	B
Santamaria	O	PROPN	B
.	O	PUNCT	O


G6PD	O	PROPN	B
Malaga	O	PROPN	I
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
enzyme	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
(	O	PUNCT	O
class	O	NOUN	B
III	O	NUM	I
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
enzymic	O	ADJ	B
properties	O	NOUN	O
of	O	ADP	O
G6PD	O	NOUN	B
Malaga	O	PROPN	I
and	O	CCONJ	O
G6PD	O	NOUN	B
Santamaria	O	PROPN	B
are	O	AUX	O
quite	O	ADV	O
similar	O	ADJ	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
this	O	DET	O
case	O	NOUN	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
additive	O	ADJ	O
rather	O	ADV	O
than	O	ADP	O
synergistic	O	ADJ	B
.	O	PUNCT	O


G6PD	O	NOUN	B
Santamaria	O	PROPN	B
might	O	AUX	O
have	O	AUX	O
been	O	AUX	O
produced	O	VERB	O
by	O	ADP	O
recombination	O	NOUN	B
between	O	ADP	O
G6PD	O	NOUN	B
A	O	NOUN	O
and	O	CCONJ	O
G6PD	O	NOUN	B
Malaga	O	PROPN	I
;	O	PUNCT	O
however	O	ADV	O
haplotype	O	NOUN	B
analysis	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
silent	O	ADJ	B
polymorphism	O	NOUN	B
,	O	PUNCT	O
suggests	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
same	O	ADJ	O
542	O	NUM	O
A	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
mutation	O	NOUN	I
has	O	AUX	O
taken	O	VERB	O
place	O	NOUN	O
independently	O	ADV	O
in	O	ADP	O
a	O	DET	O
G6PD	O	NOUN	B
B	O	NOUN	I
gene	O	NOUN	I
to	O	PART	O
give	O	VERB	O
G6PD	O	NOUN	B
Malaga	O	PROPN	I
and	O	CCONJ	O
in	O	ADP	O
a	O	DET	O
G6PD	O	NOUN	B
A	O	NOUN	I
gene	O	NOUN	I
to	O	PART	O
give	O	VERB	O
G6PD	O	NOUN	B
Santamaria	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
help	O	VERB	O
to	O	PART	O
outline	O	VERB	O
the	O	DET	O
relationship	O	NOUN	B
and	O	CCONJ	O
evolution	O	NOUN	B
of	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
G6PD	O	NOUN	B
locus	O	NOUN	O
.	O	PUNCT	O
.	O	PUNCT	O


BRCA1	O	NOUN	B
R841W	O	NOUN	O
:	O	PUNCT	O
a	O	DET	O
strong	O	ADJ	O
candidate	O	NOUN	O
for	O	ADP	O
a	O	DET	O
common	O	ADJ	O
mutation	O	NOUN	B
with	O	ADP	O
moderate	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


BRCA1	O	NOUN	B
mutations	O	NOUN	B
cause	O	VERB	O
increased	O	VERB	B
risk	O	NOUN	B
for	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
frequently	O	ADV	O
of	O	ADP	O
early	O	ADJ	B
onset	O	NOUN	I
.	O	PUNCT	O


Many	O	ADJ	O
different	O	ADJ	O
mutations	O	NOUN	B
occur	O	VERB	O
in	O	ADP	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
several	O	ADJ	O
examples	O	NOUN	O
of	O	ADP	O
recurrent	O	ADJ	B
mutations	O	NOUN	I
,	O	PUNCT	O
each	O	DET	O
of	O	ADP	O
which	O	DET	O
accounts	O	VERB	O
for	O	ADP	O
a	O	DET	O
significant	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
heritable	O	ADJ	B
cancer	B-Disease	NOUN	O
predisposition	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
common	O	ADJ	O
mutations	O	NOUN	B
have	O	AUX	O
an	O	DET	O
etiological	O	ADJ	B
role	O	NOUN	O
in	O	ADP	O
many	O	ADJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
and	O	CCONJ	O
provide	O	VERB	O
the	O	DET	O
opportunity	O	NOUN	O
to	O	PART	O
examine	O	VERB	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
and	O	CCONJ	O
genotype	O	NOUN	B
-	O	PUNCT	O
environment	O	NOUN	B
interactions	O	NOUN	B
in	O	ADP	O
individuals	O	NOUN	B
with	O	ADP	O
the	O	DET	O
identical	O	ADJ	B
BRCA1	O	NOUN	B
lesion	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
missense	O	NOUN	B
change	O	NOUN	I
in	O	ADP	O
BRCA1	O	NOUN	B
,	O	PUNCT	O
2640	O	NUM	O
C	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
(	O	PUNCT	O
R841W	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
found	O	VERB	O
in	O	ADP	O
3	O	NUM	O
cases	O	NOUN	B
from	O	ADP	O
a	O	DET	O
subject	O	ADJ	B
group	O	NOUN	I
of	O	ADP	O
305	O	NUM	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
79	I-Disease	NUM	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
from	O	ADP	O
Orange	O	PROPN	B
County	O	PROPN	I
,	O	PUNCT	O
CA	O	PROPN	B
.	O	PUNCT	O


These	O	DET	O
are	O	AUX	O
consecutive	O	ADJ	B
,	O	PUNCT	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
cases	O	NOUN	B
not	O	PART	O
selected	O	VERB	O
for	O	ADP	O
age	O	NOUN	B
or	O	CCONJ	O
family	O	NOUN	B
history	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
three	O	NUM	O
cases	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
is	O	AUX	O
a	O	DET	O
strong	O	ADJ	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
breast	B-Disease	NOUN	B
,	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
,	I-Disease	PUNCT	O
or	I-Disease	CCONJ	O
other	I-Disease	ADJ	O
cancers	I-Disease	NOUN	B
possibly	O	ADV	O
related	O	ADJ	O
to	O	PART	O
a	O	DET	O
BRCA1	O	NOUN	B
defect	O	NOUN	B
and	O	CCONJ	O
family	O	NOUN	B
members	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
high	O	ADJ	O
concordance	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
incidence	O	NOUN	B
with	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
R841W	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
age	O	NOUN	B
of	O	ADP	O
cancer	B-Disease	NOUN	B
onset	O	NOUN	I
was	O	AUX	O
not	O	PART	O
always	O	ADV	O
distinct	O	ADJ	O
from	O	ADP	O
typical	O	ADJ	O
sporadic	O	ADJ	B
cases	O	NOUN	B
.	O	PUNCT	O


Testing	O	NOUN	B
of	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
413	O	NUM	O
unrelated	O	ADJ	O
individuals	O	NOUN	B
to	O	PART	O
examine	O	VERB	O
the	O	DET	O
hypothesis	O	NOUN	B
that	O	SCONJ	O
R841W	O	NOUN	B
might	O	AUX	O
be	O	AUX	O
a	O	DET	O
rare	O	ADJ	B
polymorphism	O	NOUN	B
detected	O	VERB	B
one	O	NUM	O
additional	O	ADJ	O
instance	O	NOUN	O
in	O	ADP	O
a	O	DET	O
woman	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
diagnosed	O	VERB	B
at	O	ADP	O
age	O	NOUN	B
77	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
cancer	B-Disease	NOUN	B
in	O	ADP	O
one	O	NUM	O
parent	O	NOUN	B
.	O	PUNCT	O


R841W	O	NOUN	B
is	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
an	O	DET	O
etiologically	O	ADV	B
significant	O	ADJ	I
lesion	O	NOUN	B
with	O	ADP	O
involvement	O	NOUN	B
in	O	ADP	O
close	O	ADJ	O
to	O	PART	O
1	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
of	O	ADP	O
0	O	NUM	O
-	O	SYM	O
1	O	NUM	O
.	O	PUNCT	O
7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
all	O	DET	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancers	I-Disease	NOUN	I
in	O	ADP	O
this	O	DET	O
population	O	NOUN	B
.	O	PUNCT	O


Ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
:	O	PUNCT	O
founder	O	NOUN	B
effect	O	NOUN	B
among	O	ADP	O
north	O	ADJ	B
African	O	ADJ	I
Jews	O	PROPN	I
.	O	PUNCT	O


The	O	DET	O
ATM	O	NOUN	B
gene	O	NOUN	I
is	O	AUX	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
autosomal	B-Disease	ADJ	B
recessive	I-Disease	ADJ	I
disorder	I-Disease	NOUN	I
ataxia	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
characterized	O	VERB	B
by	O	ADP	O
cerebellar	B-Disease	ADJ	B
degeneration	I-Disease	NOUN	I
,	O	PUNCT	O
immunodeficiency	B-Disease	NOUN	B
and	O	CCONJ	O
cancer	B-Disease	NOUN	B
predisposition	I-Disease	NOUN	I
.	O	PUNCT	O


A	B-Disease	DET	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
carriers	O	NOUN	B
were	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
moderately	O	ADV	O
cancer	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
prone	I-Disease	ADJ	B
.	O	PUNCT	O


A	O	DET	O
wide	O	ADJ	O
variety	O	NOUN	O
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
most	O	ADJ	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
unique	O	ADJ	O
to	O	PART	O
single	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
various	O	ADJ	O
ethnic	O	ADJ	B
groups	O	NOUN	I
,	O	PUNCT	O
precluding	O	VERB	O
carrier	O	NOUN	B
screening	O	NOUN	O
with	O	ADP	O
mutation	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
assays	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
single	O	ADJ	O
mutation	O	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
32	O	NUM	O
/	O	SYM	O
33	O	NUM	O
defective	O	ADJ	B
ATM	O	NOUN	B
alleles	O	NOUN	B
in	O	ADP	O
Jewish	O	ADJ	B
A	B-Disease	PROPN	I
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
families	O	NOUN	B
of	O	ADP	O
North	O	ADJ	B
African	O	ADJ	I
origin	O	NOUN	B
,	O	PUNCT	O
coming	O	VERB	O
from	O	ADP	O
various	O	ADJ	O
regions	O	NOUN	B
of	O	ADP	O
Morocco	O	PROPN	B
and	O	CCONJ	O
Tunisia	O	PROPN	B
.	O	PUNCT	O


This	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
103C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
,	O	PUNCT	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
stop	O	NOUN	B
codon	O	NOUN	B
at	O	ADP	O
position	O	NOUN	O
35	O	NUM	O
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
keeping	O	NOUN	O
with	O	ADP	O
the	O	DET	O
nature	O	NOUN	O
of	O	ADP	O
this	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
various	O	ADJ	O
antibodies	O	NOUN	B
directed	O	VERB	O
against	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
failed	O	VERB	B
to	O	PART	O
defect	O	VERB	B
this	O	DET	O
protein	O	NOUN	B
in	O	ADP	O
patient	O	NOUN	B
cells	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
rapid	O	ADJ	O
carrier	O	NOUN	O
detection	O	NOUN	O
assay	O	NOUN	O
detected	O	VERB	B
this	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
out	O	ADP	O
of	O	ADP	O
488	O	NUM	O
ATM	O	NOUN	B
alleles	O	NOUN	B
of	O	ADP	O
Jewish	O	ADJ	B
Moroccan	O	ADJ	I
or	O	CCONJ	O
Tunisian	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
founder	O	NOUN	B
effect	O	NOUN	B
provides	O	VERB	O
a	O	DET	O
unique	O	ADJ	B
opportunity	O	NOUN	O
for	O	ADP	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
screening	O	NOUN	B
for	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
carriers	O	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
Jewish	O	ADJ	B
community	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutation	O	NOUN	B
analysis	O	NOUN	I
of	O	ADP	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
in	O	ADP	O
a	O	DET	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
population	O	NOUN	O
.	O	PUNCT	O


A	O	DET	O
population	O	NOUN	B
-	O	PUNCT	O
based	O	VERB	B
series	O	NOUN	B
of	O	ADP	O
54	O	NUM	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
from	O	ADP	O
Southern	O	PROPN	B
California	O	PROPN	I
were	O	AUX	O
analyzed	O	VERB	B
for	O	ADP	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
inherited	B-Disease	VERB	B
breast	I-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
genes	O	NOUN	O
,	O	PUNCT	O
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


Nine	O	NUM	O
(	O	PUNCT	O
17	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relative	O	ADJ	B
.	O	PUNCT	O


A	O	DET	O
further	O	ADJ	O
seven	O	NUM	O
(	O	PUNCT	O
13	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
reported	O	VERB	O
breast	B-Disease	NOUN	B
/	I-Disease	SYM	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
at	O	ADP	O
least	O	ADJ	O
one	O	NUM	O
second	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relative	O	ADJ	B
and	O	CCONJ	O
in	O	ADP	O
no	O	DET	O
first	O	ADJ	O
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	O
.	O	PUNCT	O


No	O	DET	O
germ	O	NOUN	B
-	O	PUNCT	O
line	O	NOUN	B
BRCA1	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


Two	O	NUM	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
(	O	PUNCT	O
4	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
total	O	NOUN	O
)	O	PUNCT	O
were	O	AUX	O
found	O	VERB	O
to	O	PART	O
carry	O	VERB	O
novel	O	ADJ	O
truncating	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA2	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Only	O	ADV	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
two	O	NUM	O
male	B-Disease	NOUN	B
breast	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
carrying	O	VERB	O
a	O	DET	O
BRCA2	O	NOUN	B
mutation	O	NOUN	B
had	O	AUX	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
cancer	B-Disease	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
one	O	NUM	O
case	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relative	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
remaining	O	VERB	O
eight	O	NUM	O
cases	O	NOUN	B
(	O	PUNCT	O
89	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
male	B-Disease	ADJ	B
breast	I-Disease	NOUN	O
cancer	I-Disease	NOUN	O
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
breast	B-Disease	NOUN	B
/	I-Disease	PUNCT	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	B
remain	O	VERB	O
unaccounted	O	ADJ	O
for	O	ADP	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
either	O	CCONJ	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
or	O	CCONJ	O
the	O	DET	O
BRCA2	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
basis	O	NOUN	I
for	O	ADP	O
Duarte	B-Disease	PROPN	B
and	I-Disease	CCONJ	O
Los	I-Disease	PROPN	B
Angeles	I-Disease	PROPN	I
variant	I-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
.	O	PUNCT	O


Human	O	ADJ	B
orythrocytes	O	NOUN	B
that	O	PRON	O
are	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
Duarte	B-Disease	PROPN	B
enzyme	I-Disease	NOUN	B
variant	I-Disease	NOUN	I
of	I-Disease	ADP	O
galactosemia	I-Disease	NOUN	O
(	O	PUNCT	O
D	O	NOUN	B
/	O	SYM	O
D	O	NOUN	B
)	O	PUNCT	O
have	O	AUX	O
a	O	DET	O
characteristic	O	ADJ	O
isoform	O	NOUN	B
on	O	ADP	O
isoelectric	O	ADJ	B
focusing	O	NOUN	O
and	O	CCONJ	O
50	O	NUM	O
%	O	NOUN	O
reduction	O	NOUN	B
in	O	ADP	O
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Duarte	O	PROPN	B
biochemical	O	ADJ	B
phenotype	O	NOUN	B
has	O	AUX	O
a	O	DET	O
molecular	O	ADJ	B
genotype	O	NOUN	I
of	O	ADP	O
N314D	O	NOUN	B
/	O	SYM	O
N314D	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
characteristic	O	ADJ	O
Duarte	O	PROPN	B
isoform	O	NOUN	I
is	O	AUX	O
also	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
variant	O	NOUN	B
called	O	VERB	O
the	O	DET	O
"	O	PUNCT	O
Los	O	PROPN	B
Angeles	O	PROPN	I
(	O	PUNCT	O
LA	O	PROPN	B
)	O	PUNCT	O
phenotype	O	NOUN	B
,	O	PUNCT	O
"	O	PUNCT	O
which	O	DET	O
has	O	AUX	O
increased	O	VERB	B
GALT	O	NOUN	B
enzyme	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
evaluated	O	VERB	B
GALT	O	NOUN	B
enzyme	O	NOUN	B
activity	O	NOUN	I
and	O	CCONJ	O
screened	O	VERB	B
the	O	DET	O
GALT	O	NOUN	B
genes	O	NOUN	B
of	O	ADP	O
145	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
one	O	NUM	O
or	O	CCONJ	O
more	O	ADJ	O
N314D	O	NOUN	B
-	O	PUNCT	O
containing	O	VERB	B
alleles	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
seven	O	NUM	O
with	O	ADP	O
the	O	DET	O
LA	O	NOUN	B
biochemical	O	ADJ	B
phenotype	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
had	O	AUX	O
a	O	DET	O
1721C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
in	O	ADP	O
cis	O	NOUN	O
with	O	ADP	O
the	O	DET	O
N314D	O	NOUN	B
missense	O	NOUN	B
mutation	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
1721C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
is	O	AUX	O
a	O	DET	O
neutral	O	ADJ	O
polymorphism	O	NOUN	B
for	O	ADP	O
leucine	O	NOUN	B
at	O	ADP	O
amino	O	NOUN	B
acid	O	NOUN	I
218	O	NUM	I
(	O	PUNCT	O
L218L	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
pedigree	O	NOUN	B
analyses	O	NOUN	I
,	O	PUNCT	O
this	O	DET	O
1721C	O	PROPN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transition	O	NOUN	I
segregated	O	VERB	B
with	O	ADP	O
the	O	DET	O
LA	O	NOUN	B
phenotype	O	NOUN	B
of	O	ADP	O
increased	O	VERB	B
GALT	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
three	O	NUM	O
different	O	ADJ	O
biochemical	O	ADJ	B
phenotypes	O	NOUN	B
(	O	PUNCT	O
LA	O	PROPN	B
/	O	SYM	O
N	O	PROPN	B
,	O	PUNCT	O
LA	O	PROPN	B
/	O	SYM	O
G	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
LA	O	PROPN	B
/	O	SYM	O
D	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
mechanism	O	NOUN	B
for	O	ADP	O
increased	O	VERB	B
activity	O	NOUN	B
of	O	ADP	O
the	O	DET	O
LA	O	NOUN	B
variant	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
compared	O	VERB	O
GALT	O	NOUN	B
mRNA	O	NOUN	B
,	O	PUNCT	O
protein	O	NOUN	B
abundance	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
enzyme	O	VERB	B
thermal	O	ADJ	I
stability	O	NOUN	I
in	O	ADP	O
lymphoblast	O	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
of	O	ADP	O
D	O	NOUN	B
and	O	CCONJ	O
LA	O	NOUN	B
phenotypes	O	NOUN	B
with	O	ADP	O
comparable	O	ADJ	O
genotypes	O	NOUN	B
.	O	PUNCT	O


GALT	O	NOUN	B
protein	O	NOUN	O
abundance	O	NOUN	B
was	O	AUX	O
increased	O	VERB	B
in	O	ADP	O
LA	O	NOUN	B
compared	O	VERB	B
to	O	PART	O
D	O	NOUN	B
alleles	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
mRNA	O	NOUN	B
was	O	AUX	O
similar	O	ADJ	O
among	O	ADP	O
all	O	DET	O
genotypes	O	NOUN	B
.	O	PUNCT	O


When	O	SCONJ	O
LA	O	PROPN	B
/	O	SYM	O
D	O	PROPN	B
and	O	CCONJ	O
D	O	NOUN	B
/	O	SYM	O
D	O	NOUN	B
GALT	O	NOUN	B
biochemical	O	ADJ	B
phenotypes	O	NOUN	B
were	O	AUX	O
compared	O	VERB	O
to	O	PART	O
N	O	NOUN	B
/	O	SYM	O
N	O	NOUN	B
GALT	O	NOUN	B
phenotypes	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
had	O	AUX	O
50	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
compared	O	VERB	O
to	O	ADP	O
21	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
reduction	O	NOUN	B
in	O	ADP	O
GALT	O	NOUN	B
activity	O	NOUN	B
in	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
type	O	NOUN	I
(	O	PUNCT	O
N	O	NOUN	B
/	O	SYM	O
N	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
exposure	O	NOUN	B
at	O	ADP	O
identical	O	ADJ	B
initial	O	ADJ	O
enzyme	O	NOUN	B
activity	O	NOUN	I
to	O	PART	O
50	O	NUM	O
degrees	O	NOUN	B
C	O	NOUN	O
for	O	ADP	O
15	O	NUM	O
min	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
codon	O	NOUN	B
change	O	NOUN	O
N314D	O	NOUN	B
in	O	ADP	O
cis	O	NOUN	O
with	O	ADP	O
the	O	DET	O
base	O	NOUN	B
-	O	PUNCT	O
pair	O	NOUN	B
transition	O	NOUN	O
1721C	O	PROPN	O
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
produces	O	VERB	O
the	O	DET	O
LA	B-Disease	NOUN	B
variant	I-Disease	NOUN	B
of	I-Disease	ADP	O
galactosemia	I-Disease	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
this	O	DET	O
nucleotide	O	NOUN	B
change	O	NOUN	I
increases	O	VERB	B
GALT	O	NOUN	B
activity	O	NOUN	B
by	O	ADP	O
increasing	O	VERB	B
GALT	O	NOUN	B
protein	O	NOUN	O
abundance	O	NOUN	B
without	O	ADP	O
increasing	O	VERB	B
transcription	O	NOUN	B
or	O	CCONJ	O
decreasing	O	VERB	B
thermal	O	ADJ	B
lability	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
favorable	O	ADJ	O
codon	O	NOUN	B
bias	O	NOUN	I
for	O	ADP	O
the	O	DET	O
mutated	O	VERB	B
codon	O	NOUN	B
with	O	ADP	O
consequently	O	ADV	O
increased	O	VERB	B
translation	O	NOUN	B
rates	O	NOUN	I
is	O	AUX	O
postulated	O	VERB	O
as	O	ADP	O
the	O	DET	O
mechanism	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
TSG101	O	NOUN	B
tumor	B-Disease	NOUN	B
susceptibility	O	NOUN	I
gene	O	NOUN	I
is	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
chromosome	O	NOUN	B
11	O	NUM	I
band	O	NOUN	I
p15	O	NOUN	I
and	O	CCONJ	O
is	O	AUX	O
mutated	O	VERB	B
in	O	ADP	O
human	O	ADJ	B
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


Recent	O	ADJ	O
work	O	NOUN	O
has	O	AUX	O
identified	O	VERB	B
a	O	DET	O
mouse	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
tsg101	O	NOUN	B
)	O	PUNCT	O
whose	O	DET	O
inactivation	O	NOUN	B
in	O	ADP	O
fibroblasts	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
cellular	O	ADJ	B
transformation	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
ability	O	NOUN	O
to	O	PART	O
produce	O	VERB	O
metastatic	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
in	O	ADP	O
nude	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
human	O	ADJ	B
homolog	O	NOUN	B
,	O	PUNCT	O
TSG101	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
we	O	PRON	O
isolated	O	VERB	B
and	O	CCONJ	O
mapped	O	VERB	B
to	O	PART	O
chromosome	O	NOUN	O
11	O	NUM	O
,	O	PUNCT	O
bands	O	VERB	O
15	O	NUM	O
.	O	PUNCT	O


1	O	NUM	O
-	O	SYM	O
15	O	NUM	O
1	O	NUM	O
-	O	SYM	O
15	O	NUM	O
.	O	PUNCT	O


2	O	NUM	O
,	O	PUNCT	O
a	O	DET	O
region	O	NOUN	B
proposed	O	VERB	O
to	O	PART	O
contain	O	VERB	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
s	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
mutated	O	VERB	B
at	O	ADP	O
high	O	ADJ	O
frequency	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
.	O	PUNCT	O


In	O	ADP	O
7	O	NUM	O
of	O	ADP	O
15	O	NUM	O
uncultured	O	ADJ	B
primary	O	ADJ	O
human	O	ADJ	B
breast	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
,	O	PUNCT	O
intragenic	O	ADJ	B
deletions	O	NOUN	B
were	O	AUX	O
shown	O	VERB	O
in	O	ADP	O
TSG101	O	NOUN	B
genomic	O	ADJ	B
DNA	O	NOUN	I
and	O	CCONJ	O
transcripts	O	NOUN	B
by	O	ADP	O
gel	O	NOUN	B
and	O	CCONJ	O
sequence	O	NOUN	B
analysis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
mutations	O	NOUN	B
affecting	O	VERB	B
two	O	NUM	O
TSG101	O	NOUN	B
alleles	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
cancers	B-Disease	NOUN	B
.	O	PUNCT	O


No	O	DET	O
TSG101	O	NOUN	B
defects	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
matched	O	VERB	B
normal	O	ADJ	O
breast	O	NOUN	B
tissue	O	NOUN	I
from	O	ADP	O
the	O	DET	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
strongly	O	ADV	O
implicate	O	VERB	O
TSG101	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O


Moderate	O	ADJ	B
intergenerational	O	ADJ	B
and	O	CCONJ	O
somatic	O	ADJ	B
instability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
55	O	NUM	O
-	O	PUNCT	O
CTG	O	NOUN	B
repeat	O	NOUN	O
in	O	ADP	O
transgenic	O	ADJ	B
mice	O	NOUN	I
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
the	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
trinucleotide	O	NOUN	B
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	O
region	O	NOUN	O
(	O	PUNCT	O
UTR	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
DM	B-Disease	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
DMPK	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
is	O	AUX	O
polymorphic	O	ADJ	B
and	O	CCONJ	O
varies	O	VERB	O
in	O	ADP	O
size	O	NOUN	B
between	O	ADP	O
5	O	NUM	O
and	O	CCONJ	O
37	O	NUM	O
repeats	O	NOUN	B
in	O	ADP	O
unaffected	O	ADJ	O
individuals	O	NOUN	B
whereas	O	SCONJ	O
in	O	ADP	O
affected	O	VERB	B
patients	O	NOUN	B
there	O	PRON	O
are	O	AUX	O
between	O	ADP	O
50	O	NUM	O
and	O	CCONJ	O
4	O	NUM	O
,	O	PUNCT	O
000	O	NUM	O
CTGs	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
size	O	NOUN	B
of	O	ADP	O
the	O	DET	O
(	O	PUNCT	O
CTG	O	NOUN	B
)	O	PUNCT	O
n	O	NOUN	O
repeat	O	NOUN	O
,	O	PUNCT	O
which	O	DET	O
increases	O	VERB	B
through	O	ADP	O
generations	O	NOUN	B
,	O	PUNCT	O
generally	O	ADV	O
correlates	O	VERB	O
with	O	ADP	O
clinical	O	ADJ	B
severity	O	NOUN	I
and	O	CCONJ	O
age	O	NOUN	B
of	O	ADP	O
onset	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
instability	O	NOUN	B
of	O	ADP	O
the	O	DET	O
CTG	O	NOUN	B
repeat	O	NOUN	O
appears	O	VERB	O
to	O	PART	O
depend	O	VERB	O
on	O	ADP	O
its	O	PRON	O
size	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
on	O	ADP	O
the	O	DET	O
sex	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transmitting	O	VERB	B
parent	O	NOUN	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
mitotic	O	ADJ	B
instability	O	NOUN	I
analysis	O	NOUN	I
of	O	ADP	O
different	O	ADJ	O
human	O	ADJ	B
DM	B-Disease	NOUN	B
tissues	O	NOUN	I
shows	O	VERB	O
length	O	NOUN	B
mosaicism	O	NOUN	B
between	O	ADP	O
different	O	ADJ	O
cell	O	NOUN	B
lineages	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
mechanisms	O	NOUN	I
of	O	ADP	O
triplet	O	NOUN	B
instability	O	NOUN	I
remain	O	VERB	O
elusive	O	ADJ	O
.	O	PUNCT	O


To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
genomic	O	ADJ	B
sequences	O	NOUN	I
in	O	ADP	O
instability	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
produced	O	VERB	O
transgenic	O	ADJ	B
mice	O	NOUN	I
containing	O	VERB	O
a	O	DET	O
45	O	NUM	O
-	O	PUNCT	O
kb	O	NOUN	O
genomic	O	ADJ	B
segment	O	NOUN	I
with	O	ADP	O
a	O	DET	O
55	O	NUM	O
-	O	PUNCT	O
CTG	O	NOUN	B
repeat	O	NOUN	O
cloned	O	VERB	B
from	O	ADP	O
a	O	DET	O
mildly	O	ADV	B
affected	O	VERB	B
patient	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
other	O	ADJ	O
mouse	O	NOUN	B
models	O	NOUN	I
containing	O	VERB	O
CAG	O	NOUN	B
repeats	O	NOUN	I
within	O	ADP	O
cDNAs	O	NOUN	B
,	O	PUNCT	O
these	O	DET	O
mice	O	NOUN	B
showed	O	VERB	O
both	O	CCONJ	O
intergenerational	O	ADJ	B
and	O	CCONJ	O
somatic	O	ADJ	B
repeat	O	NOUN	I
instability	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Missense	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
Fas	O	NOUN	B
gene	O	NOUN	I
resulting	O	VERB	O
in	O	ADP	O
autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
:	O	PUNCT	O
a	O	DET	O
molecular	O	ADJ	B
and	O	CCONJ	O
immunological	O	ADJ	B
analysis	O	NOUN	I
.	O	PUNCT	O


Programmed	O	ADJ	B
cell	O	NOUN	I
death	O	NOUN	I
(	O	PUNCT	O
or	O	CCONJ	O
apoptosis	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
physiological	O	ADJ	B
process	O	NOUN	I
essential	O	ADJ	B
to	O	PART	O
the	O	DET	O
normal	O	ADJ	B
development	O	NOUN	I
and	O	CCONJ	O
homeostatic	O	ADJ	B
maintenance	O	NOUN	B
of	O	ADP	O
the	O	DET	O
immune	O	ADJ	B
system	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Fas	O	NOUN	B
/	O	SYM	O
Apo	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
receptor	O	NOUN	B
plays	O	VERB	O
a	O	DET	O
crucial	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
regulation	O	NOUN	B
of	O	ADP	O
apoptosis	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
lymphoproliferation	O	NOUN	B
in	O	ADP	O
MRL	O	NOUN	B
-	O	PUNCT	O
lpr	O	NOUN	B
/	O	PUNCT	O
lpr	O	NOUN	B
mice	O	NOUN	I
and	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
recently	O	ADV	O
described	O	VERB	O
autoimmune	B-Disease	ADJ	B
lymphoproliferative	I-Disease	ADJ	I
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
ALPS	B-Disease	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
humans	O	NOUN	B
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
due	O	ADJ	O
to	O	PART	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
Fas	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
a	O	DET	O
novel	O	ADJ	O
family	O	NOUN	B
with	O	ADP	O
ALPS	B-Disease	NOUN	B
in	O	ADP	O
which	O	DET	O
three	O	NUM	O
affected	O	VERB	B
siblings	O	NOUN	B
carry	O	VERB	O
two	O	NUM	O
distinct	O	ADJ	O
missense	O	NOUN	B
mutations	O	NOUN	I
on	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
Fas	O	NOUN	B
gene	O	NOUN	I
alleles	O	NOUN	O
and	O	CCONJ	O
show	O	VERB	O
lack	O	NOUN	B
of	O	ADP	O
Fas	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
children	O	NOUN	B
share	O	VERB	O
common	O	ADJ	O
clinical	O	ADJ	B
features	O	NOUN	I
including	O	VERB	O
splenomegaly	B-Disease	NOUN	B
and	O	CCONJ	O
lymphadenopathy	B-Disease	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
only	O	ADV	O
one	O	NUM	O
developed	O	VERB	O
severe	O	ADJ	B
autoimmune	B-Disease	ADJ	B
manifestations	I-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
all	O	DET	O
three	O	NUM	O
siblings	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
demonstrated	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
anergic	O	ADJ	B
CD3	O	NOUN	I
+	O	CCONJ	O
CD4	O	NOUN	B
-	O	PUNCT	O
CD8	O	NOUN	B
-	O	PUNCT	O
(	O	PUNCT	O
double	O	ADJ	B
negative	O	ADJ	I
,	O	PUNCT	O
[	O	PUNCT	O
DN	O	PROPN	B
]	O	PUNCT	O
)	O	PUNCT	O
T	O	NOUN	B
cells	O	NOUN	I
;	O	PUNCT	O
moreover	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
chronic	O	ADJ	B
lymphocyte	O	NOUN	I
activation	O	NOUN	I
was	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
as	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
HLA	O	NOUN	B
-	O	PUNCT	O
DR	O	NOUN	B
expression	O	NOUN	B
on	O	ADP	O
peripheral	O	ADJ	B
CD3	O	NOUN	B
+	O	CCONJ	I
cells	O	NOUN	B
and	O	CCONJ	O
by	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
high	O	ADJ	B
levels	O	NOUN	B
of	O	ADP	O
serum	O	NOUN	B
activation	O	NOUN	O
markers	O	NOUN	B
such	O	ADJ	O
as	O	ADP	O
soluble	O	ADJ	B
interleukin	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
receptor	O	NOUN	I
(	O	PUNCT	O
slL	O	NOUN	B
-	O	PUNCT	O
2R	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
soluble	O	ADJ	B
CD30	O	NOUN	B
(	O	PUNCT	O
sCD30	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
constitutively	O	ADV	B
expressed	O	VERB	B
nuclear	O	ADJ	B
protein	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
not	O	PART	O
up	O	ADV	O
-	O	PUNCT	O
regulated	O	VERB	B
following	O	VERB	O
genome	O	NOUN	B
damage	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
product	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
ATM	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
identified	O	VERB	B
by	O	ADP	O
using	O	VERB	O
an	O	DET	O
antiserum	O	NOUN	B
developed	O	VERB	O
to	O	PART	O
a	O	DET	O
peptide	O	NOUN	B
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
deduced	O	VERB	B
amino	O	NOUN	B
acid	O	NOUN	I
sequence	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
is	O	AUX	O
a	O	DET	O
single	O	ADJ	O
,	O	PUNCT	O
high	O	ADJ	B
-	O	PUNCT	O
molecular	O	ADJ	B
weight	O	NOUN	I
protein	O	NOUN	I
predominantly	O	ADV	O
confined	O	VERB	O
to	O	PART	O
the	O	DET	O
nucleus	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
fibroblasts	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
is	O	AUX	O
present	O	ADJ	O
in	O	ADP	O
both	O	CCONJ	O
nuclear	O	ADJ	B
and	O	CCONJ	O
microsomal	O	ADJ	B
fractions	O	NOUN	I
from	O	ADP	O
human	O	ADJ	B
lymphoblast	O	NOUN	O
cells	O	NOUN	O
and	O	CCONJ	O
peripheral	O	ADJ	B
blood	O	NOUN	I
lymphocytes	O	NOUN	I
.	O	PUNCT	O


ATM	O	NOUN	B
protein	O	NOUN	I
levels	O	NOUN	O
and	O	CCONJ	O
localization	O	NOUN	B
remain	O	VERB	O
constant	O	ADJ	B
throughout	O	ADP	O
all	O	DET	O
stages	O	NOUN	B
of	O	ADP	O
the	O	DET	O
cell	O	NOUN	B
cycle	O	NOUN	I
.	O	PUNCT	O


Truncated	O	VERB	B
ATM	O	NOUN	B
protein	O	NOUN	I
was	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
lymphoblasts	O	NOUN	B
from	O	ADP	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
patients	O	NOUN	B
homozygous	O	ADJ	B
for	O	ADP	O
mutations	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
premature	O	ADJ	B
protein	O	NOUN	I
termination	O	NOUN	I
.	O	PUNCT	O


Exposure	O	NOUN	B
of	O	ADP	I
normal	O	ADJ	O
human	O	ADJ	B
cells	O	NOUN	I
to	O	PART	O
gamma	O	NOUN	B
-	O	PUNCT	O
irradiation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
radiomimetic	O	ADJ	B
drug	O	NOUN	I
neocarzinostatin	O	NOUN	O
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
ATM	O	NOUN	B
protein	O	NOUN	I
levels	O	NOUN	O
,	O	PUNCT	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
a	O	DET	O
noted	O	ADJ	O
rise	O	NOUN	O
in	O	ADP	O
p53	O	NOUN	B
levels	O	NOUN	B
over	O	ADP	O
the	O	DET	O
same	O	ADJ	O
time	O	NOUN	B
interval	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
are	O	AUX	O
consistent	O	ADJ	B
with	O	ADP	I
a	O	DET	O
role	O	NOUN	O
for	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
in	O	ADP	O
ensuring	O	VERB	O
the	O	DET	O
fidelity	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
repair	O	NOUN	I
and	O	CCONJ	O
cell	O	NOUN	B
cycle	O	NOUN	I
regulation	O	NOUN	I
following	O	VERB	O
genome	O	NOUN	B
damage	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Type	O	NOUN	B
III	O	NUM	I
collagen	O	NOUN	I
is	O	AUX	O
crucial	O	ADJ	O
for	O	ADP	O
collagen	O	NOUN	B
I	O	NOUN	I
fibrillogenesis	O	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
normal	O	ADJ	O
cardiovascular	O	ADJ	B
development	O	NOUN	B
.	O	PUNCT	O


Type	O	NOUN	B
III	O	NUM	I
collagen	O	NOUN	I
is	O	AUX	O
a	O	DET	O
fibrillar	O	ADJ	B
forming	O	VERB	O
collagen	O	NOUN	B
comprising	O	VERB	O
three	O	NUM	O
alpha1	O	NOUN	B
(	O	PUNCT	O
III	O	NUM	O
)	O	PUNCT	O
chains	O	NOUN	O
and	O	CCONJ	O
is	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
early	O	ADJ	B
embryos	O	NOUN	B
and	O	CCONJ	O
throughout	O	ADP	O
embryogenesis	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
adult	O	NOUN	B
,	O	PUNCT	O
type	O	NOUN	B
III	O	NUM	I
collagen	O	NOUN	I
is	O	AUX	O
a	O	DET	O
major	O	ADJ	O
component	O	NOUN	O
of	O	ADP	O
the	O	DET	O
extracellular	O	ADJ	B
matrix	O	NOUN	I
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
internal	O	ADJ	B
organs	O	NOUN	I
and	O	CCONJ	O
skin	O	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
COL3A1	O	NOUN	B
gene	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
implicated	O	VERB	O
as	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
type	B-Disease	NOUN	B
IV	I-Disease	NUM	I
Ehlers	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Danlos	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
disease	O	NOUN	B
leading	O	VERB	O
to	O	PART	O
aortic	B-Disease	ADJ	B
rupture	I-Disease	NOUN	I
in	O	ADP	O
early	O	ADJ	B
adult	O	ADJ	I
life	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
directly	O	ADV	O
study	O	VERB	B
the	O	DET	O
role	O	NOUN	O
of	O	ADP	O
Col3a1	O	NOUN	B
in	O	ADP	O
development	O	NOUN	B
and	O	CCONJ	O
disease	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
inactivated	O	VERB	B
the	O	DET	O
Col3a1	O	NOUN	B
gene	O	NOUN	I
in	O	ADP	O
embryonic	O	ADJ	B
stem	O	NOUN	I
cells	O	NOUN	I
by	O	ADP	O
homologous	O	ADJ	B
recombination	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
mutated	O	VERB	B
allele	O	NOUN	O
was	O	AUX	O
transmitted	O	VERB	B
through	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
germ	O	NOUN	B
line	O	NOUN	I
and	O	CCONJ	O
homozygous	O	ADJ	B
mutant	O	ADJ	O
animals	O	NOUN	O
were	O	AUX	O
derived	O	VERB	O
from	O	ADP	O
heterozygous	O	ADJ	B
intercrosses	O	NOUN	B
.	O	PUNCT	O


About	O	ADV	O
10	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
homozygous	O	ADJ	B
mutant	O	ADJ	B
animals	O	NOUN	O
survived	O	VERB	O
to	O	PART	O
adulthood	O	NOUN	B
but	O	CCONJ	O
have	O	AUX	O
a	O	DET	O
much	O	ADV	O
shorter	O	ADJ	B
life	O	NOUN	O
span	O	NOUN	O
compared	O	VERB	B
with	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
mice	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
major	O	ADJ	O
cause	O	NOUN	O
of	O	ADP	O
death	O	NOUN	B
of	O	ADP	O
mutant	O	ADJ	B
mice	O	NOUN	I
was	O	AUX	O
rupture	O	NOUN	B
of	O	ADP	O
the	O	DET	O
major	O	ADJ	B
blood	O	NOUN	I
vessels	O	NOUN	I
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
patients	O	NOUN	B
with	O	ADP	O
type	B-Disease	NOUN	B
IV	I-Disease	NUM	I
Ehlers	I-Disease	PROPN	B
-	I-Disease	PUNCT	O
Danlos	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
.	O	PUNCT	O


Ultrastructural	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
tissues	O	NOUN	B
from	O	ADP	O
mutant	O	ADJ	B
mice	O	NOUN	I
revealed	O	VERB	O
that	O	SCONJ	O
type	O	NOUN	B
III	O	NUM	I
collagen	O	NOUN	I
is	O	AUX	O
essential	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	O
collagen	O	NOUN	B
I	O	NOUN	I
fibrillogenesis	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cardiovascular	O	ADJ	B
system	O	NOUN	I
and	O	CCONJ	O
other	O	ADJ	O
organs	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Nonsense	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
3	O	NUM	I
of	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
an	O	DET	O
unusual	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
a	O	DET	O
G	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
A	O	NOUN	O
transition	O	NOUN	B
at	O	ADP	O
nucleotide	O	NOUN	B
431	O	NUM	O
of	O	ADP	O
the	O	DET	O
proteolipid	O	NOUN	B
protein	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
PLP	O	NOUN	B
)	O	PUNCT	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
nonsense	O	ADJ	B
codon	O	NOUN	I
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
with	O	ADP	O
an	O	DET	O
unusual	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
Pelizaeus	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Merzbacher	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
(	O	PUNCT	O
PMD	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
mutation	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
creates	O	VERB	O
a	O	DET	O
second	O	ADJ	O
AluI	O	NOUN	B
restriction	O	NOUN	I
site	O	NOUN	I
,	O	PUNCT	O
results	O	VERB	B
in	O	ADP	O
a	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
PLP	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
clinical	O	ADJ	B
picture	O	NOUN	I
resembles	O	VERB	O
somewhat	O	ADV	O
that	O	DET	O
of	O	ADP	O
X	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
linked	I-Disease	VERB	B
spastic	I-Disease	ADJ	B
paraplegia	I-Disease	NOUN	I
(	O	PUNCT	O
SPG	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


It	O	PRON	O
differs	O	VERB	O
from	O	ADP	O
this	O	DET	O
and	O	CCONJ	O
both	O	CCONJ	O
the	O	DET	O
classical	O	ADJ	B
and	O	CCONJ	O
connatal	O	ADJ	B
forms	O	NOUN	O
of	O	ADP	O
PMD	B-Disease	NOUN	B
in	O	ADP	O
that	O	SCONJ	O
it	O	PRON	O
is	O	AUX	O
relatively	O	ADV	O
mild	O	ADJ	B
in	O	ADP	O
form	O	NOUN	O
,	O	PUNCT	O
onset	O	NOUN	O
is	O	AUX	O
delayed	O	VERB	B
beyond	O	ADP	O
age	O	NOUN	B
2	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
nystagmus	B-Disease	NOUN	B
is	O	AUX	O
absent	O	ADJ	B
,	O	PUNCT	O
tremors	B-Disease	NOUN	B
are	O	AUX	O
prominent	O	ADJ	O
,	O	PUNCT	O
mental	B-Disease	ADJ	B
retardation	I-Disease	NOUN	I
is	O	AUX	O
not	O	PART	O
severe	O	ADJ	B
,	O	PUNCT	O
some	O	DET	O
patients	O	NOUN	B
show	O	VERB	O
dementia	B-Disease	NOUN	B
or	O	CCONJ	O
personality	B-Disease	NOUN	B
disorders	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
disease	O	NOUN	B
is	O	AUX	O
progressive	O	ADJ	B
rather	O	ADV	O
than	O	ADP	O
static	O	ADJ	B
in	O	ADP	O
some	O	DET	O
,	O	PUNCT	O
and	O	CCONJ	O
several	O	ADJ	O
females	O	NOUN	B
show	O	VERB	O
signs	O	NOUN	B
of	O	ADP	I
disease	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
nonsense	O	ADJ	B
mutation	O	NOUN	I
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
in	O	ADP	O
exon	O	NOUN	B
3B	O	NOUN	I
,	O	PUNCT	O
should	O	AUX	O
block	O	VERB	B
the	O	DET	O
synthesis	O	NOUN	B
of	O	ADP	O
normal	O	ADJ	O
PLP	O	NOUN	B
but	O	CCONJ	O
spare	O	ADJ	O
DM20	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
isoform	O	NOUN	B
whose	O	DET	O
persistence	O	NOUN	B
has	O	AUX	O
been	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
mild	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
PLP	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
associated	I-Disease	VERB	B
disease	I-Disease	NOUN	O
in	O	ADP	O
both	O	CCONJ	O
humans	O	NOUN	B
and	O	CCONJ	O
mice	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Common	O	ADJ	O
BRCA1	O	NOUN	B
variants	O	NOUN	B
and	O	CCONJ	O
susceptibility	O	NOUN	B
to	O	PART	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


Most	O	ADV	O
multiple	O	ADJ	B
case	O	NOUN	B
families	O	NOUN	I
of	O	ADP	O
young	O	ADJ	B
onset	O	NOUN	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
are	O	AUX	O
thought	O	VERB	O
to	O	PART	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
highly	O	ADV	O
penetrant	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
predisposing	O	VERB	B
genes	O	NOUN	I
BRCA1	O	NOUN	B
and	O	CCONJ	O
BRCA2	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
uncommon	O	ADJ	O
in	O	ADP	O
the	O	DET	O
population	O	NOUN	B
and	O	CCONJ	O
they	O	PRON	O
probably	O	ADV	O
account	O	VERB	O
for	O	ADP	O
only	O	ADV	O
a	O	DET	O
few	O	ADJ	O
percent	O	NOUN	O
of	O	ADP	O
all	O	DET	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
incidence	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
much	O	ADV	O
larger	O	ADJ	O
fraction	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
might	O	AUX	O
,	O	PUNCT	O
in	O	ADP	O
principle	O	NOUN	O
,	O	PUNCT	O
be	O	AUX	O
due	O	ADJ	O
to	O	PART	O
common	O	ADJ	O
variants	O	NOUN	B
which	O	DET	O
confer	O	VERB	O
more	O	ADV	O
modest	O	ADJ	O
individual	O	ADJ	B
risks	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
are	O	AUX	O
several	O	ADJ	O
common	O	ADJ	O
polymorphisms	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
which	O	DET	O
generate	O	VERB	O
amino	O	NOUN	B
acid	O	NOUN	I
substitutions	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
examined	O	VERB	O
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
of	O	ADP	O
these	O	DET	O
polymorphisms	O	NOUN	B
Gln356Arg	O	NOUN	B
,	O	PUNCT	O
Pro871Leu	O	NOUN	B
,	O	PUNCT	O
Glu1038Gly	O	NOUN	B
and	O	CCONJ	O
Ser1613Gly	O	NOUN	B
in	O	ADP	O
large	O	ADJ	O
series	O	NOUN	O
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
cases	O	NOUN	B
and	O	CCONJ	O
matched	O	VERB	B
controls	O	NOUN	I
.	O	PUNCT	O


Due	O	ADP	O
to	O	ADP	O
strong	O	ADJ	O
linkage	O	NOUN	B
disequilibrium	O	NOUN	I
,	O	PUNCT	O
these	O	DET	O
four	O	NUM	O
sites	O	NOUN	B
generate	O	VERB	O
only	O	ADV	O
three	O	NUM	O
haplotypes	O	NOUN	B
with	O	ADP	O
a	O	DET	O
frequency	O	NOUN	B
>	O	NOUN	O
1	O	NUM	O
.	O	PUNCT	O


3	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
haplotypes	O	NOUN	B
,	O	PUNCT	O
defined	O	VERB	O
by	O	ADP	O
the	O	DET	O
alleles	O	NOUN	B
Gln356Pro871Glu1038Ser1613	O	NOUN	B
and	O	CCONJ	O
Gln356Leu871Gly1038Gly1613	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
frequencies	O	NOUN	B
of	O	ADP	O
0	O	NUM	O
.	O	PUNCT	O


57	O	NUM	O
and	O	CCONJ	O
0	O	NUM	O
.	O	PUNCT	O


32	O	NUM	O
respectively	O	ADV	O
,	O	PUNCT	O
and	O	CCONJ	O
these	O	DET	O
frequencies	O	NOUN	B
do	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
patient	O	NOUN	B
and	O	CCONJ	O
control	O	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
polymorphisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	O
do	O	AUX	O
not	O	PART	O
make	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
contribution	O	NOUN	O
to	O	PART	O
breast	B-Disease	NOUN	B
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
risk	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
our	O	PRON	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Arg356	O	NOUN	B
allele	O	NOUN	I
may	O	AUX	O
have	O	AUX	O
a	O	DET	O
different	O	ADJ	O
genotype	O	NOUN	B
distribution	O	NOUN	B
in	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
from	O	ADP	O
that	O	DET	O
in	O	ADP	O
controls	O	NOUN	B
(	O	PUNCT	O
Arg356	O	NOUN	B
homozygotes	O	NOUN	I
are	O	AUX	O
more	O	ADV	O
frequent	O	ADJ	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0	O	NUM	O
.	O	PUNCT	O
01	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
it	O	PRON	O
may	O	AUX	O
be	O	AUX	O
protective	O	ADJ	O
against	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


If	O	SCONJ	O
this	O	DET	O
finding	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
confirmed	O	VERB	O
,	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
provide	O	VERB	O
an	O	DET	O
insight	O	NOUN	O
into	O	ADP	O
the	O	DET	O
structural	O	ADJ	B
features	O	NOUN	O
of	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
protein	O	NOUN	I
that	O	PRON	O
are	O	AUX	O
important	O	ADJ	O
for	O	ADP	O
its	O	PRON	O
function	O	NOUN	B
.	O	PUNCT	O


Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
:	O	PUNCT	O
Dr	O	PROPN	B
.	O	PUNCT	O
W	O	PROPN	O
.	O	PUNCT	O


Kniest	O	NOUN	B
,	O	PUNCT	O
his	O	PRON	O
patient	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
molecular	O	ADJ	B
defect	O	NOUN	I
.	O	PUNCT	O


Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
is	O	AUX	O
a	O	DET	O
severe	O	ADJ	B
chondrodysplasia	B-Disease	NOUN	B
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
defective	B-Disease	ADJ	B
formation	I-Disease	NOUN	B
of	I-Disease	ADP	O
type	I-Disease	NOUN	B
II	I-Disease	NUM	I
collagen	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
about	O	ADP	O
Dr	O	PROPN	B
.	O	PUNCT	O
Kniest	O	PROPN	B
,	O	PUNCT	O
who	O	PRON	O
first	O	ADV	O
described	O	VERB	O
the	O	DET	O
condition	O	NOUN	B
in	O	ADP	O
1952	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
his	O	PRON	O
patient	O	NOUN	B
,	O	PUNCT	O
who	O	PRON	O
,	O	PUNCT	O
at	O	ADP	O
the	O	DET	O
age	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
years	O	NOUN	B
is	O	AUX	O
severely	B-Disease	ADV	B
handicapped	I-Disease	VERB	B
with	O	ADP	O
short	B-Disease	ADJ	B
stature	I-Disease	NOUN	I
,	O	PUNCT	O
restricted	B-Disease	ADJ	B
joint	I-Disease	ADJ	B
mobility	I-Disease	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
blindness	B-Disease	NOUN	B
but	O	CCONJ	O
is	O	AUX	O
mentally	O	ADV	B
alert	O	ADJ	I
and	O	CCONJ	O
leads	O	VERB	O
an	O	DET	O
active	O	ADJ	B
life	O	NOUN	I
.	O	PUNCT	O


Molecular	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
DNA	O	NOUN	B
showed	O	VERB	O
a	O	DET	O
single	O	ADJ	B
base	O	NOUN	I
(	O	PUNCT	O
G	O	NOUN	O
)	O	PUNCT	O
deletion	O	NOUN	B
involving	O	VERB	O
the	O	DET	O
GT	O	NOUN	B
dinucleotide	O	NOUN	I
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
intron	O	NOUN	B
18	O	NUM	O
destroying	O	VERB	B
a	O	DET	O
splice	O	NOUN	B
site	O	NOUN	I
of	O	ADP	O
the	O	DET	O
COL2A1	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
in	O	ADP	O
accordance	O	NOUN	O
with	O	ADP	O
molecular	O	ADJ	B
findings	O	NOUN	I
in	O	ADP	O
other	O	ADJ	O
patients	O	NOUN	B
with	O	ADP	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
and	O	CCONJ	O
confirms	O	VERB	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
original	O	ADJ	B
patient	O	NOUN	B
,	O	PUNCT	O
that	O	SCONJ	O
the	O	DET	O
disorder	O	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
small	O	ADJ	O
inframe	O	ADJ	B
deletions	O	NOUN	B
often	O	ADV	O
due	O	ADJ	O
to	O	PART	O
exon	O	NOUN	B
skipping	O	NOUN	I
as	O	ADP	O
a	O	DET	O
result	O	NOUN	O
of	O	ADP	O
COL2A1	O	NOUN	B
splice	O	NOUN	I
site	O	NOUN	I
mutations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Cloning	O	NOUN	B
of	O	ADP	O
the	O	DET	O
homogentisate	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
dioxygenase	O	NOUN	B
gene	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
key	O	ADJ	O
enzyme	O	NOUN	B
of	O	ADP	O
alkaptonuria	B-Disease	NOUN	B
in	O	ADP	O
mouse	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
determined	O	VERB	O
48	O	NUM	O
amino	O	NOUN	B
acid	O	NOUN	I
residues	O	NOUN	I
from	O	ADP	O
five	O	NUM	O
peptides	O	NOUN	B
from	O	ADP	O
the	O	DET	O
homogeneous	O	ADJ	B
monomer	O	NOUN	I
of	O	ADP	O
homogentisate	O	NOUN	B
1	O	NUM	I
,	O	PUNCT	O
2	O	NUM	B
-	O	PUNCT	O
dioxygenase	O	NOUN	B
(	O	PUNCT	O
HGO	O	NOUN	B
;	O	PUNCT	O
E	O	NOUN	B
.	O	PUNCT	O
C	O	NOUN	O
.	O	PUNCT	O
1	O	X	O
.	O	PUNCT	O
13	O	NUM	O
.	O	PUNCT	O
11	O	NUM	O
.	O	PUNCT	O
15	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
mouse	O	NOUN	B
liver	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
digestion	O	NOUN	B
with	O	ADP	O
trypsin	O	NOUN	B
,	O	PUNCT	O
peptides	O	NOUN	B
were	O	AUX	O
separated	O	VERB	O
by	O	ADP	O
reversed	O	VERB	B
phase	O	NOUN	I
chromatography	O	NOUN	I
and	O	CCONJ	O
amino	O	NOUN	B
acid	O	NOUN	I
sequenced	O	VERB	I
.	O	PUNCT	O


The	O	DET	O
deduced	O	VERB	O
codon	O	NOUN	B
sequence	O	NOUN	I
of	O	ADP	O
three	O	NUM	O
peptides	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
derive	O	VERB	O
degenerated	O	ADJ	B
oligomeres	O	NOUN	B
.	O	PUNCT	O


By	O	ADP	O
combining	O	VERB	O
these	O	DET	O
oligos	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
were	O	AUX	O
able	O	ADJ	O
to	O	PART	O
amplify	O	VERB	B
fragments	O	NOUN	B
from	O	ADP	O
100	O	NUM	O
to	O	PART	O
300	O	NUM	O
bases	O	NOUN	B
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
from	O	ADP	O
mouse	O	NOUN	B
liver	O	NOUN	B
cDNA	O	NOUN	I
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
after	O	ADP	O
reverse	O	ADJ	B
transcription	O	NOUN	I
(	O	PUNCT	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
fragment	O	NOUN	B
of	O	ADP	O
200	O	NUM	O
b	O	NOUN	O
was	O	AUX	O
cloned	O	VERB	B
and	O	CCONJ	O
used	O	VERB	O
as	O	ADP	O
a	O	DET	O
probe	O	NOUN	B
to	O	PART	O
screen	O	VERB	O
a	O	DET	O
mouse	O	NOUN	B
liver	O	NOUN	B
cDNA	O	NOUN	I
library	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
clone	O	NOUN	B
from	O	ADP	O
this	O	DET	O
library	O	NOUN	B
contained	O	VERB	O
the	O	DET	O
complete	O	ADJ	B
cDNA	O	NOUN	B
-	O	PUNCT	O
insert	O	NOUN	B
for	O	ADP	O
HGO	O	NOUN	B
as	O	ADP	O
determined	O	VERB	O
by	O	ADP	O
sequencing	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
cDNA	O	NOUN	B
encodes	O	VERB	B
for	O	ADP	O
a	O	DET	O
protein	O	NOUN	B
of	O	ADP	O
50	O	NUM	O
kDa	O	NOUN	O
,	O	PUNCT	O
as	O	ADP	O
predicted	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
cDNA	O	NOUN	B
of	O	ADP	O
mouse	O	NOUN	B
HGO	O	NOUN	B
has	O	AUX	O
an	O	DET	O
overall	O	ADJ	O
identity	O	NOUN	B
of	O	ADP	O
41	O	NUM	O
%	O	NOUN	O
to	O	ADP	O
the	O	DET	O
corresponding	O	ADJ	O
gene	O	NOUN	B
hmgA	O	NOUN	O
from	O	ADP	O
Aspergillus	O	NOUN	B
.	O	PUNCT	O


Sequence	O	NOUN	B
similarities	O	NOUN	B
to	O	PART	O
human	O	ADJ	B
expressed	O	VERB	O
sequence	O	NOUN	O
tags	O	NOUN	O
(	O	PUNCT	O
EST	O	NOUN	B
)	O	PUNCT	O
clones	O	NOUN	B
ranged	O	VERB	O
from	O	ADP	O
70	O	NUM	O
%	O	NOUN	O
to	O	PART	O
20	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
positions	O	NOUN	B
of	O	ADP	O
122	O	NUM	O
conserved	O	VERB	O
amino	O	NOUN	B
acids	O	NOUN	I
could	O	AUX	O
be	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
multiple	O	ADJ	B
sequence	O	NOUN	I
alignment	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
one	O	NUM	O
first	O	ADJ	O
intron	O	NOUN	B
of	O	ADP	O
928	O	NUM	O
b	O	NOUN	O
in	O	ADP	O
the	O	DET	O
mouse	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
gene	O	NOUN	B
for	O	ADP	O
HGO	O	NOUN	B
seems	O	VERB	O
to	O	PART	O
be	O	AUX	O
expressed	O	VERB	B
in	O	ADP	O
various	O	ADJ	O
tissues	O	NOUN	B
,	O	PUNCT	O
as	O	ADP	O
shown	O	VERB	O
by	O	ADP	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
on	O	ADP	O
different	O	ADJ	O
cDNAs	O	NOUN	B
.	O	PUNCT	O


FISH	O	NOUN	B
experiments	O	NOUN	B
with	O	ADP	O
the	O	DET	O
whole	O	ADJ	O
murine	O	ADJ	B
cDNA	O	NOUN	B
as	O	ADP	O
probe	O	NOUN	B
clearly	O	ADV	O
revealed	O	VERB	O
signals	O	NOUN	B
at	O	ADP	O
the	O	DET	O
human	O	ADJ	B
chromosomal	O	ADJ	O
band	O	NOUN	O
3q13	O	NOUN	O
.	O	PUNCT	O


3	O	NUM	O
-	O	PUNCT	O
q21	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
corresponds	O	VERB	O
well	O	ADV	O
to	O	ADP	O
the	O	DET	O
previous	O	ADJ	O
assignment	O	NOUN	B
of	O	ADP	O
the	O	DET	O
locus	O	NOUN	B
for	O	ADP	O
the	O	DET	O
human	O	ADJ	B
alkaptonuria	B-Disease	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
AKU	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
the	O	DET	O
same	O	ADJ	O
chromosomal	O	ADJ	B
region	O	NOUN	I
by	O	ADP	O
multipoint	O	ADJ	B
linkage	O	NOUN	I
analysis	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
therefore	O	ADV	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
HGO	O	NOUN	B
cDNA	O	NOUN	B
encodes	O	VERB	B
the	O	DET	O
gene	O	NOUN	B
responsible	O	ADJ	O
for	O	ADP	O
alkaptonuria	B-Disease	NOUN	B
.	O	PUNCT	O


PTEN	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
putative	O	ADJ	B
protein	O	NOUN	I
tyrosine	O	NOUN	I
phosphatase	O	NOUN	I
gene	O	NOUN	I
mutated	O	VERB	B
in	O	ADP	O
human	O	ADJ	B
brain	B-Disease	NOUN	B
,	I-Disease	PUNCT	O
breast	I-Disease	NOUN	B
,	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
prostate	I-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Mapping	O	NOUN	B
of	O	ADP	O
homozygous	O	ADJ	B
deletions	O	NOUN	B
on	O	ADP	O
human	O	ADJ	B
chromosome	O	NOUN	I
10q23	O	NOUN	I
has	O	AUX	O
led	O	VERB	O
to	O	PART	O
the	O	DET	O
isolation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
candidate	O	NOUN	O
tumor	B-Disease	NOUN	B
suppressor	O	NOUN	I
gene	O	NOUN	I
,	O	PUNCT	O
PTEN	O	NOUN	B
,	O	PUNCT	O
that	O	PRON	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
mutated	O	VERB	B
at	O	ADP	O
considerable	O	ADJ	O
frequency	O	NOUN	B
in	O	ADP	O
human	O	ADJ	B
cancers	B-Disease	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
preliminary	O	ADJ	O
screens	O	NOUN	B
,	O	PUNCT	O
mutations	O	NOUN	B
of	O	ADP	O
PTEN	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
31	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
13	O	NUM	O
/	O	SYM	O
42	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
glioblastoma	B-Disease	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
and	O	CCONJ	O
xenografts	O	NOUN	B
,	O	PUNCT	O
100	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
/	O	SYM	O
4	O	NUM	B
)	O	PUNCT	O
of	O	ADP	O
prostate	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
cell	O	NOUN	B
lines	O	NOUN	I
,	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
/	O	SYM	O
65	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
cell	O	NOUN	B
lines	O	NOUN	I
and	O	CCONJ	O
xenografts	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
17	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
3	O	NUM	O
/	O	SYM	O
18	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
primary	B-Disease	ADJ	B
glioblastomas	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
predicted	O	VERB	O
PTEN	O	NOUN	B
product	O	NOUN	B
has	O	AUX	O
a	O	DET	O
protein	O	NOUN	B
tyrosine	O	NOUN	I
phosphatase	O	NOUN	I
domain	O	NOUN	I
and	O	CCONJ	O
extensive	O	ADJ	O
homology	O	NOUN	B
to	O	PART	O
tensin	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
protein	O	NOUN	B
that	O	PRON	O
interacts	O	VERB	O
with	O	ADP	O
actin	O	NOUN	B
filaments	O	NOUN	I
at	O	ADP	O
focal	O	ADJ	B
adhesions	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
homologies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
PTEN	O	NOUN	B
may	O	AUX	O
suppress	O	VERB	B
tumor	B-Disease	NOUN	B
cell	O	NOUN	I
growth	O	NOUN	O
by	O	ADP	O
antagonizing	O	VERB	O
protein	O	NOUN	B
tyrosine	O	NOUN	I
kinases	O	NOUN	I
and	O	CCONJ	O
may	O	AUX	O
regulate	O	VERB	B
tumor	B-Disease	NOUN	B
cell	O	NOUN	I
invasion	O	NOUN	O
and	O	CCONJ	O
metastasis	B-Disease	NOUN	B
through	O	ADP	O
interactions	O	NOUN	B
at	O	ADP	O
focal	O	ADJ	B
adhesions	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Heterogeneity	O	NOUN	B
in	O	ADP	O
Schwartz	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Jampel	I-Disease	PROPN	B
chondrodystrophic	I-Disease	ADJ	B
myotonia	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
Schwartz	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Jampel	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
SJS	B-Disease	NOUN	B
;	O	PUNCT	O
chondrodystrophic	B-Disease	ADJ	B
myotonia	I-Disease	NOUN	I
;	O	PUNCT	O
McK	O	NOUN	B
255	O	NUM	O
,	O	PUNCT	O
800	O	NUM	O
)	O	PUNCT	O
is	O	AUX	O
a	O	DET	O
recessively	B-Disease	ADV	O
inherited	I-Disease	VERB	B
condition	I-Disease	NOUN	B
defined	O	VERB	O
by	O	ADP	O
myotonia	B-Disease	NOUN	B
,	O	PUNCT	O
short	B-Disease	ADJ	B
stature	I-Disease	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
bone	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
linkage	O	NOUN	I
between	O	ADP	O
SJS	B-Disease	NOUN	B
and	O	CCONJ	O
chromosomal	O	ADJ	B
region	O	NOUN	I
1q36	O	NUM	B
-	O	PUNCT	O
34	O	NUM	O
has	O	AUX	O
been	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
several	O	ADJ	O
families	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
gene	O	NOUN	B
has	O	AUX	O
not	O	PART	O
yet	O	ADV	O
been	O	AUX	O
identified	O	VERB	B
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
and	O	CCONJ	O
radiological	O	ADJ	B
features	O	NOUN	O
in	O	ADP	O
81	O	NUM	O
patients	O	NOUN	B
from	O	ADP	O
the	O	DET	O
literature	O	NOUN	B
and	O	CCONJ	O
5	O	NUM	O
own	O	ADJ	O
patients	O	NOUN	B
trying	O	VERB	O
to	O	PART	O
identify	O	VERB	O
distinct	O	ADJ	O
subgroups	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
tested	O	VERB	O
genetic	O	ADJ	B
linkage	O	NOUN	I
to	O	PART	O
the	O	DET	O
SJS	B-Disease	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
1	O	NUM	I
in	O	ADP	O
one	O	NUM	O
family	O	NOUN	B
with	O	ADP	O
two	O	NUM	O
affected	O	VERB	B
sibs	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
have	O	AUX	O
mild	O	ADJ	B
skeletal	O	ADJ	B
changes	O	NOUN	O
which	O	DET	O
may	O	AUX	O
be	O	AUX	O
secondary	O	ADJ	B
consequences	O	NOUN	B
of	O	ADP	I
myotonia	B-Disease	NOUN	B
,	O	PUNCT	O
while	O	SCONJ	O
another	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
primary	O	ADJ	B
bone	B-Disease	NOUN	I
dysplasia	I-Disease	NOUN	I
with	O	ADP	O
myotonia	B-Disease	NOUN	B
.	O	PUNCT	O


Within	O	ADP	O
this	O	DET	O
latter	O	ADJ	O
group	O	NOUN	B
,	O	PUNCT	O
there	O	PRON	O
are	O	AUX	O
differences	O	NOUN	B
in	O	ADP	O
age	O	NOUN	B
of	O	ADP	O
manifestation	O	NOUN	B
,	O	PUNCT	O
clinical	O	ADJ	B
course	O	NOUN	I
and	O	CCONJ	O
pattern	O	NOUN	B
of	O	ADP	O
bone	O	NOUN	B
changes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
tentatively	O	ADV	O
isolate	O	VERB	B
three	O	NUM	O
different	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
SJS	B-Disease	NOUN	B
type	I-Disease	NOUN	B
1A	I-Disease	NOUN	I
,	O	PUNCT	O
usually	O	ADV	O
recognized	O	VERB	O
in	O	ADP	O
childhood	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
moderate	O	ADJ	B
bone	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	PART	O
the	O	DET	O
original	O	ADJ	B
descriptions	O	NOUN	B
of	O	ADP	O
Schwartz	O	PROPN	B
,	O	PUNCT	O
Jampel	O	PROPN	B
and	O	CCONJ	O
Aberfeld	O	PROPN	B
;	O	PUNCT	O
type	O	NOUN	B
1B	O	NOUN	I
,	O	PUNCT	O
similar	O	ADJ	O
to	O	PART	O
type	O	NOUN	B
1A	O	NOUN	I
but	O	CCONJ	O
recognizable	O	ADJ	O
at	O	ADP	O
birth	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
more	O	ADV	O
pronounced	O	ADJ	O
bone	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
resembling	O	VERB	O
Kniest	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
;	O	PUNCT	O
and	O	CCONJ	O
type	O	NOUN	B
2	O	NUM	I
,	O	PUNCT	O
manifest	O	ADJ	B
at	O	ADP	O
birth	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
increased	O	VERB	B
mortality	O	NOUN	B
and	O	CCONJ	O
bone	B-Disease	NOUN	B
dysplasia	I-Disease	NOUN	I
resembling	O	VERB	O
Pyle	B-Disease	PROPN	B
disease	I-Disease	NOUN	I
.	O	PUNCT	O


Genetic	O	ADJ	B
analysis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
family	O	NOUN	B
with	O	ADP	O
two	O	NUM	O
sibs	O	NOUN	B
affected	O	VERB	B
by	O	ADP	O
SJS	B-Disease	NOUN	B
type	I-Disease	NOUN	O
2	I-Disease	NUM	O
showed	O	VERB	O
evidence	O	NOUN	B
against	O	ADP	O
linkage	O	NOUN	B
to	O	PART	O
chromosome	O	NOUN	B
1p36	O	NOUN	I
-	O	PUNCT	O
34	O	NUM	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
SJS	B-Disease	NOUN	B
is	O	AUX	O
clinically	O	ADV	B
and	O	CCONJ	O
radiologically	O	ADV	B
heterogeneous	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
causes	O	NOUN	O
of	O	ADP	O
heterogeneity	O	NOUN	B
are	O	AUX	O
not	O	PART	O
known	O	VERB	O
yet	O	ADV	O
but	O	CCONJ	O
are	O	AUX	O
likely	O	ADJ	O
to	O	PART	O
include	O	VERB	O
both	O	CCONJ	O
different	O	ADJ	O
mutations	O	NOUN	B
at	O	ADP	O
the	O	DET	O
SJS	B-Disease	NOUN	B
locus	O	NOUN	B
on	O	ADP	O
chromosome	O	NOUN	B
1	O	NUM	I
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
second	O	ADJ	O
SJS	B-Disease	NOUN	B
locus	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
tentative	O	ADJ	O
clinico	O	NOUN	B
-	O	PUNCT	O
radiological	O	ADJ	B
classification	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
useful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
characterization	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
development	O	NOUN	B
of	O	ADP	O
genotype	O	NOUN	B
-	O	PUNCT	O
phenotype	O	NOUN	B
correlations	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
clinical	O	ADJ	B
overview	O	NOUN	I
of	O	ADP	O
WT1	O	NOUN	B
gene	O	NOUN	B
mutations	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
WT1	O	NOUN	B
gene	O	NOUN	I
were	O	AUX	O
anticipated	O	VERB	B
to	O	PART	O
explain	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
basis	O	NOUN	O
of	O	ADP	O
the	O	DET	O
childhood	O	NOUN	B
kidney	B-Disease	NOUN	I
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
Wilms	B-Disease	NOUN	B
tumour	I-Disease	NOUN	I
(	O	PUNCT	I
WT	B-Disease	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Six	O	NUM	O
years	O	NOUN	B
on	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
review	O	VERB	B
100	O	NUM	O
reports	O	NOUN	B
of	O	ADP	O
intragenic	O	ADJ	B
WT1	O	NOUN	B
mutations	O	NOUN	B
and	O	CCONJ	O
examine	O	VERB	O
the	O	DET	O
accompanying	O	VERB	O
clinical	O	ADJ	B
phenotypes	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
only	O	ADV	O
5	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
sporadic	B-Disease	ADJ	B
Wilms	I-Disease	NOUN	B
tumours	I-Disease	NOUN	I
have	O	AUX	O
intragenic	O	ADJ	B
WT1	O	NOUN	B
mutations	O	NOUN	B
,	O	PUNCT	O
>	O	X	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
the	O	DET	O
Denys	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Drash	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
(	O	PUNCT	O
renal	B-Disease	ADJ	B
nephropathy	I-Disease	NOUN	I
,	O	PUNCT	O
gonadal	B-Disease	ADJ	B
anomaly	I-Disease	NOUN	I
,	O	PUNCT	O
predisposition	B-Disease	NOUN	B
to	I-Disease	PART	O
WT	I-Disease	NOUN	B
)	O	PUNCT	O
carry	O	VERB	O
constitutional	O	ADJ	B
intragenic	O	ADJ	O
WT1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


WT1	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
also	O	ADV	O
been	O	AUX	O
reported	O	VERB	O
in	O	ADP	O
juvenile	B-Disease	ADJ	B
granulosa	I-Disease	NOUN	I
cell	I-Disease	NOUN	I
tumour	I-Disease	NOUN	I
,	O	PUNCT	O
non	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
asbestos	I-Disease	NOUN	B
related	I-Disease	ADJ	O
mesothelioma	I-Disease	NOUN	B
,	O	PUNCT	O
desmoplastic	B-Disease	ADJ	B
small	I-Disease	ADJ	I
round	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
tumour	I-Disease	NOUN	I
and	O	CCONJ	O
,	O	PUNCT	O
most	O	ADV	O
recently	O	ADV	O
,	O	PUNCT	O
acute	B-Disease	ADJ	B
myeloid	I-Disease	ADJ	I
leukemia	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
myotonia	I-Disease	NOUN	B
congenita	I-Disease	NOUN	I
affects	O	VERB	O
pore	O	NOUN	B
properties	O	NOUN	B
of	O	ADP	O
the	O	DET	O
muscle	O	NOUN	B
chloride	O	NOUN	I
channel	O	NOUN	I
.	O	PUNCT	O


Autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
myotonia	I-Disease	NOUN	B
congenita	I-Disease	NOUN	I
is	O	AUX	O
an	O	DET	O
inherited	B-Disease	VERB	B
disorder	I-Disease	NOUN	B
of	I-Disease	ADP	O
skeletal	I-Disease	ADJ	B
muscle	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
mutations	O	NOUN	B
in	O	ADP	O
a	O	DET	O
voltage	O	NOUN	B
-	O	PUNCT	O
gated	O	VERB	B
Cl	O	NOUN	B
-	O	PUNCT	O
channel	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
CLCN1	O	NOUN	B
,	O	PUNCT	O
7q35	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Here	O	ADV	O
,	O	PUNCT	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
mutation	O	NOUN	B
predicting	O	VERB	B
the	O	DET	O
substitution	O	NOUN	B
of	O	ADP	O
Gly	O	NOUN	B
230	O	NUM	O
by	O	ADP	O
glutamic	O	ADJ	B
acid	O	NOUN	I
(	O	PUNCT	O
G230E	O	NOUN	B
)	O	PUNCT	O
between	O	ADP	O
segments	O	NOUN	B
D3	O	NOUN	I
and	O	CCONJ	O
D4	O	NOUN	B
dramatically	O	ADV	O
alters	O	VERB	O
the	O	DET	O
pore	O	NOUN	B
properties	O	NOUN	B
of	O	ADP	O
a	O	DET	O
recombinant	O	ADJ	B
human	O	ADJ	B
muscle	O	NOUN	O
Cl	O	NOUN	B
-	O	PUNCT	O
channel	O	NOUN	B
(	O	PUNCT	O
hCIC	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
expressed	O	VERB	B
in	O	ADP	O
a	O	DET	O
mammalian	O	ADJ	B
cell	O	NOUN	O
line	O	NOUN	O
(	O	PUNCT	O
tsA201	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
G230E	O	NOUN	B
mutation	O	NOUN	B
causes	O	VERB	O
substantial	O	ADJ	O
changes	O	NOUN	O
in	O	ADP	O
anion	O	NOUN	B
and	O	CCONJ	O
cation	O	NOUN	B
selectivity	O	NOUN	B
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
a	O	DET	O
fundamental	O	ADJ	O
change	O	NOUN	O
in	O	ADP	O
rectification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
current	O	ADJ	B
-	O	PUNCT	O
voltage	O	NOUN	B
relationship	O	NOUN	B
.	O	PUNCT	O


Whereas	O	SCONJ	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
channels	O	NOUN	I
are	O	AUX	O
characterized	O	VERB	B
by	O	ADP	O
pronounced	O	ADJ	O
inward	O	ADV	B
rectification	O	NOUN	O
and	O	CCONJ	O
a	O	DET	O
Cl	O	NOUN	B
>	O	NOUN	O
thiocyanate	O	NOUN	B
>	O	X	O
Br	O	X	B
>	O	X	O
NO	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
>	O	X	O
I	O	NOUN	B
>	O	X	O
CH	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
SO	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
selectivity	O	NOUN	B
,	O	PUNCT	O
G230E	O	NOUN	B
exhibits	O	VERB	O
outward	O	ADV	B
rectification	O	NOUN	I
at	O	ADP	O
positive	O	ADJ	B
potentials	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
thiocyanate	O	NOUN	B
>	O	X	O
NO	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
>	O	X	O
I	O	NOUN	B
>	O	X	O
Br	O	X	B
>	O	X	O
Cl	O	NOUN	B
>	O	NOUN	O
CH	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
SO	O	NOUN	B
(	O	PUNCT	O
3	O	NUM	O
)	O	PUNCT	O
selectivity	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
cation	O	NOUN	B
-	O	PUNCT	O
to	O	ADP	O
-	O	PUNCT	O
anion	O	NOUN	B
permeability	O	NOUN	O
ratio	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutant	O	NOUN	B
is	O	AUX	O
much	O	ADV	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
of	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
channel	O	NOUN	B
.	O	PUNCT	O


Voltage	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
blocks	O	NOUN	B
by	O	ADP	O
intracellular	O	ADJ	B
and	O	CCONJ	O
extracellular	O	ADJ	B
iodide	O	NOUN	O
help	O	NOUN	O
to	O	PART	O
distinguish	O	VERB	O
two	O	NUM	O
distinct	O	ADJ	O
ion	O	NOUN	B
binding	O	NOUN	I
sites	O	NOUN	I
within	O	ADP	O
the	O	DET	O
hClC	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
conduction	O	NOUN	B
pathway	O	NOUN	I
.	O	PUNCT	O


Both	O	CCONJ	O
binding	O	VERB	B
sites	O	NOUN	I
are	O	AUX	O
preserved	O	VERB	O
in	O	ADP	O
the	O	DET	O
mutant	O	NOUN	B
but	O	CCONJ	O
have	O	AUX	O
decreased	O	VERB	B
affinities	O	NOUN	B
for	O	ADP	O
iodide	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
Gly	O	NOUN	B
230	O	NUM	O
is	O	AUX	O
critical	O	ADJ	O
for	O	ADP	O
normal	O	ADJ	B
ion	O	NOUN	I
conductance	O	NOUN	I
in	O	ADP	O
hClC	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
and	O	CCONJ	O
that	O	SCONJ	O
this	O	DET	O
residue	O	NOUN	B
resides	O	VERB	B
within	O	ADP	O
the	O	DET	O
channel	O	NOUN	B
pore	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
PAX6	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
simple	O	ADJ	O
aniridia	B-Disease	NOUN	B
:	O	PUNCT	O
an	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
mutation	O	NOUN	B
detection	O	NOUN	B
in	O	ADP	O
12	O	NUM	O
cases	O	NOUN	B
.	O	PUNCT	O


Twelve	O	NUM	O
aniridia	B-Disease	NOUN	B
patients	O	NOUN	B
,	O	PUNCT	O
five	O	NUM	O
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
and	O	CCONJ	O
seven	O	NUM	O
presumed	O	VERB	O
to	O	PART	O
be	O	AUX	O
sporadic	O	ADJ	B
,	O	PUNCT	O
were	O	AUX	O
exhaustively	O	ADV	O
screened	O	VERB	B
in	O	ADP	O
order	O	NOUN	O
to	O	PART	O
test	O	VERB	B
what	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
people	O	NOUN	B
with	O	ADP	O
aniridia	B-Disease	NOUN	B
,	O	PUNCT	O
uncomplicated	O	ADJ	B
by	O	ADP	O
associated	O	VERB	O
anomalies	O	NOUN	B
,	O	PUNCT	O
carry	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
PAX6	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
90	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
cases	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
mutation	O	NOUN	B
detection	O	NOUN	O
techniques	O	NOUN	O
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
determine	O	VERB	O
if	O	SCONJ	O
one	O	NUM	O
method	O	NOUN	B
was	O	AUX	O
superior	O	ADJ	O
for	O	ADP	O
this	O	DET	O
gene	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
protein	O	NOUN	B
truncation	O	NOUN	I
test	O	NOUN	I
(	O	PUNCT	O
PTT	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
used	O	VERB	O
on	O	ADP	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	NOUN	B
products	O	NOUN	O
,	O	PUNCT	O
SSCP	O	NOUN	B
on	O	ADP	O
genomic	O	ADJ	B
PCR	O	NOUN	I
amplifications	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
chemical	O	ADJ	B
cleavage	O	NOUN	I
of	O	ADP	O
mismatch	O	NOUN	B
on	O	ADP	O
both	O	DET	O
RT	O	NOUN	B
-	O	PUNCT	O
PCR	O	NOUN	B
and	O	CCONJ	O
genomic	O	ADJ	B
amplifications	O	NOUN	I
.	O	PUNCT	O


For	O	ADP	O
RT	O	PROPN	B
-	O	PUNCT	O
PCR	O	NOUN	B
products	O	NOUN	B
,	O	PUNCT	O
only	O	ADV	O
the	O	DET	O
translated	O	VERB	B
portion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
was	O	AUX	O
screened	O	VERB	B
.	O	PUNCT	O


On	O	ADP	O
genomic	O	ADJ	B
products	O	NOUN	I
exons	O	NOUN	B
1	O	NUM	O
to	O	PART	O
13	O	NUM	O
(	O	PUNCT	O
including	O	VERB	O
740	O	NUM	O
bp	O	NOUN	O
of	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
sequence	O	NOUN	I
and	O	CCONJ	O
all	O	DET	O
intron	O	NOUN	B
/	O	SYM	O
exon	O	NOUN	B
boundaries	O	NOUN	I
)	O	PUNCT	O
were	O	AUX	O
screened	O	VERB	B
,	O	PUNCT	O
as	O	ADP	O
was	O	AUX	O
a	O	DET	O
neuroretina	O	ADJ	B
specific	O	ADJ	O
enhancer	O	NOUN	O
in	O	ADP	O
intron	O	NOUN	B
4	O	NUM	O
.	O	PUNCT	O


Ten	O	NUM	O
of	O	ADP	O
the	O	DET	O
possible	O	ADJ	O
12	O	NUM	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
five	O	NUM	O
familial	O	ADJ	B
cases	O	NOUN	B
and	O	CCONJ	O
five	O	NUM	O
of	O	ADP	O
the	O	DET	O
sporadic	O	ADJ	B
patients	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
,	O	PUNCT	O
all	O	DET	O
of	O	ADP	O
which	O	DET	O
conformed	O	VERB	O
to	O	PART	O
a	O	DET	O
functional	O	ADJ	B
outcome	O	NOUN	I
of	O	ADP	O
haploinsufficiency	O	NOUN	B
.	O	PUNCT	O


Five	O	NUM	O
were	O	AUX	O
splice	O	NOUN	B
site	O	NOUN	I
mutations	O	NOUN	B
(	O	PUNCT	O
one	O	NUM	O
in	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
two	O	NUM	O
in	O	ADP	O
the	O	DET	O
donor	O	NOUN	B
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
one	O	NUM	O
in	O	ADP	O
each	O	DET	O
of	O	ADP	O
the	O	DET	O
acceptor	O	NOUN	B
sites	O	NOUN	I
of	O	ADP	O
introns	O	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
9	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
five	O	NUM	O
were	O	AUX	O
nonsense	O	ADJ	B
mutations	O	NOUN	I
in	O	ADP	O
exons	O	NOUN	B
8	O	NUM	O
,	O	PUNCT	O
9	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
,	O	PUNCT	O
11	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
12	O	NUM	O
.	O	PUNCT	O


SSCP	O	NOUN	B
analysis	O	NOUN	B
of	O	ADP	O
individually	O	ADV	O
amplified	O	VERB	B
exons	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
which	O	DET	O
nine	O	NUM	O
of	O	ADP	O
the	O	DET	O
10	O	NUM	O
mutations	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
,	O	PUNCT	O
was	O	AUX	O
the	O	DET	O
most	O	ADV	O
useful	O	ADJ	O
detection	O	NOUN	B
method	O	NOUN	I
for	O	ADP	O
PAX6	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Insulin	O	NOUN	B
gene	O	NOUN	I
region	O	NOUN	I
contributes	O	VERB	O
to	O	PART	O
genetic	O	ADJ	B
susceptibility	O	NOUN	I
to	O	PART	O
,	O	PUNCT	O
but	O	CCONJ	O
may	O	AUX	O
not	O	PART	O
to	O	PART	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
,	O	PUNCT	O
insulin	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
dependent	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
in	O	ADP	O
Japanese	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
Caucasian	O	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
has	O	AUX	O
been	O	AUX	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
insulin	O	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
INS	O	NOUN	B
)	O	PUNCT	O
region	O	NOUN	O
contains	O	VERB	O
the	O	DET	O
insulin	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
dependent	I-Disease	ADJ	B
diabetes	I-Disease	NOUN	B
mellitus	I-Disease	NOUN	I
locus	O	NOUN	I
(	O	PUNCT	O
IDDM2	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
Japanese	O	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
has	O	AUX	O
been	O	AUX	O
no	O	DET	O
report	O	NOUN	O
demonstrating	O	VERB	O
the	O	DET	O
contribution	O	NOUN	B
of	O	ADP	O
IDDM2	O	NOUN	B
to	O	PART	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
IDDM	B-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
conducted	O	VERB	O
an	O	DET	O
association	O	NOUN	B
study	O	NOUN	I
of	O	ADP	O
IDDM	B-Disease	NOUN	B
in	O	ADP	O
a	O	DET	O
large	O	ADJ	O
number	O	NOUN	O
of	O	ADP	O
Japanese	O	ADJ	B
subjects	O	NOUN	B
with	O	ADP	O
multiple	O	ADJ	O
polymorphisms	O	NOUN	B
in	O	ADP	O
INS	O	NOUN	B
region	O	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
association	O	NOUN	B
of	O	ADP	O
the	O	DET	O
INS	O	NOUN	B
region	O	NOUN	O
with	O	ADP	O
IDDM	B-Disease	NOUN	B
.	O	PUNCT	O


Alleles	O	NOUN	B
positively	O	ADV	B
associated	O	VERB	B
with	O	ADP	I
IDDM	B-Disease	NOUN	B
in	O	ADP	O
INS	O	NOUN	B
region	O	NOUN	O
were	O	AUX	O
the	O	DET	O
same	O	ADJ	O
as	O	ADP	O
those	O	DET	O
positively	O	ADV	B
-	O	PUNCT	O
associated	O	VERB	B
with	O	ADP	I
IDDM	B-Disease	NOUN	B
in	O	ADP	O
Caucasian	O	ADJ	B
population	O	NOUN	B
,	O	PUNCT	O
although	O	SCONJ	O
positively	O	ADV	B
-	O	PUNCT	O
associated	O	VERB	B
alleles	O	NOUN	B
are	O	AUX	O
very	O	ADV	O
common	O	ADJ	O
(	O	PUNCT	O
allele	O	NOUN	B
frequencies	O	NOUN	B
>	O	VERB	O
0	O	NUM	O
.	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
Japanese	O	ADJ	B
general	O	ADJ	B
population	O	NOUN	I
.	O	PUNCT	O


These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
IDDM2	O	NOUN	B
is	O	AUX	O
involved	O	VERB	O
in	O	ADP	O
the	O	DET	O
genetic	O	ADJ	B
susceptibility	O	NOUN	I
to	O	PART	O
IDDM	B-Disease	NOUN	B
in	O	ADP	O
Japanese	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
high	O	ADJ	O
frequencies	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
-	O	PUNCT	O
associated	O	VERB	B
alleles	O	NOUN	B
in	O	ADP	O
the	O	DET	O
general	O	ADJ	B
population	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
IDDM2	O	NOUN	B
locus	O	NOUN	B
is	O	AUX	O
not	O	PART	O
responsible	O	ADJ	O
for	O	ADP	O
the	O	DET	O
low	O	ADJ	B
incidence	O	NOUN	B
of	O	ADP	O
IDDM	B-Disease	NOUN	B
in	O	ADP	O
Japanese	O	PROPN	B
.	O	PUNCT	O


The	O	DET	O
human	O	ADJ	B
complement	O	NOUN	B
C9	O	NOUN	I
gene	O	NOUN	I
:	O	PUNCT	O
identification	O	NOUN	B
of	O	ADP	O
two	O	NUM	O
mutations	O	NOUN	B
causing	O	VERB	O
deficiency	O	NOUN	B
and	O	CCONJ	O
revision	O	NOUN	B
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
structure	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ninth	O	ADJ	O
component	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
complement	O	NOUN	O
(	O	PUNCT	O
C9	O	NOUN	B
)	O	PUNCT	O
is	O	AUX	O
the	O	DET	O
last	O	ADJ	O
of	O	ADP	O
the	O	DET	O
terminal	O	ADJ	B
complement	O	NOUN	O
components	O	NOUN	O
creating	O	VERB	O
the	O	DET	O
membrane	O	NOUN	B
attack	O	NOUN	I
complex	O	NOUN	I
.	O	PUNCT	O


C9	O	NOUN	B
is	O	AUX	O
a	O	DET	O
single	O	ADJ	B
-	O	PUNCT	O
chain	O	NOUN	B
serum	O	NOUN	I
protein	O	NOUN	I
that	O	PRON	O
is	O	AUX	O
encoded	O	VERB	B
by	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
located	O	ADJ	O
on	O	ADP	O
chromosome	O	NOUN	B
5p	O	NOUN	I
.	O	PUNCT	O


Deficiency	B-Disease	NOUN	B
of	I-Disease	ADP	O
terminal	I-Disease	ADJ	B
complement	I-Disease	NOUN	O
components	I-Disease	NOUN	O
is	O	AUX	O
generally	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
recurrent	O	ADJ	B
neisseria	B-Disease	NOUN	O
infections	I-Disease	NOUN	O
.	O	PUNCT	O


We	O	PRON	O
studied	O	VERB	O
a	O	DET	O
previously	O	ADV	O
described	O	VERB	O
Swiss	O	ADJ	B
family	O	NOUN	I
with	O	ADP	O
inherited	B-Disease	VERB	B
C9	I-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
.	O	PUNCT	O


To	O	PART	O
identify	O	VERB	O
the	O	DET	O
genetic	O	ADJ	B
basis	O	NOUN	O
of	O	ADP	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
developed	O	VERB	O
an	O	DET	O
approach	O	NOUN	O
using	O	VERB	O
exon	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
PCR	O	NOUN	B
and	O	CCONJ	O
direct	O	ADJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
.	O	PUNCT	O


As	O	ADP	O
a	O	DET	O
cause	O	NOUN	O
of	O	ADP	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
found	O	VERB	O
two	O	NUM	O
different	O	ADJ	O
point	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
both	O	DET	O
generating	O	VERB	O
TGA	O	NOUN	B
stop	O	VERB	I
codons	O	NOUN	B
in	O	ADP	O
the	O	DET	O
coding	O	VERB	B
sequence	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
mutation	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
C	O	NOUN	O
to	O	PART	O
A	O	DET	O
exchange	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
exon	O	NOUN	B
2	O	NUM	I
at	O	ADP	O
cDNA	O	NOUN	B
position	O	NOUN	O
166	O	NUM	O
,	O	PUNCT	O
the	O	DET	O
other	O	ADJ	O
,	O	PUNCT	O
a	O	DET	O
C	O	NOUN	O
to	O	PART	O
T	O	NOUN	B
exchange	O	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
exon	O	NOUN	B
4	O	NUM	I
(	O	PUNCT	O
cDNA	O	NOUN	B
position	O	NOUN	O
464	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
family	O	NOUN	B
studies	O	NOUN	I
of	O	ADP	O
three	O	NUM	O
first	O	ADJ	B
-	O	PUNCT	O
degree	O	NOUN	B
relatives	O	NOUN	B
with	O	ADP	O
heterozygous	O	ADJ	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
demonstrated	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
two	O	NUM	O
mutations	O	NOUN	B
are	O	AUX	O
segregating	O	VERB	B
independently	O	ADV	O
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
mutations	O	NOUN	B
are	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
explain	O	VERB	O
the	O	DET	O
complete	O	ADJ	O
deficiency	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
the	O	DET	O
probands	O	NOUN	B
studied	O	VERB	O
.	O	PUNCT	O


DNA	O	NOUN	B
sequencing	O	NOUN	I
of	O	ADP	O
the	O	DET	O
exon	O	NOUN	B
-	O	PUNCT	O
intron	O	NOUN	B
junctions	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
revisions	O	NOUN	B
regarding	O	VERB	O
the	O	DET	O
boundaries	O	NOUN	B
between	O	ADP	O
exons	O	NOUN	B
4	O	NUM	O
,	O	PUNCT	O
5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
6	O	NUM	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
between	O	ADP	O
exons	O	NOUN	B
10	O	NUM	O
and	O	CCONJ	O
11	O	NUM	O
.	O	PUNCT	O


No	O	DET	O
additional	O	ADJ	O
introns	O	NOUN	B
were	O	AUX	O
detected	O	VERB	B
in	O	ADP	O
exons	O	NOUN	B
6	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
DNA	O	NOUN	B
marker	O	NOUN	I
studies	O	NOUN	I
were	O	AUX	O
conducted	O	VERB	O
using	O	VERB	O
known	O	VERB	O
polymorphisms	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C6	O	NOUN	B
,	O	PUNCT	O
C7	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
C9	O	NOUN	B
genes	O	NOUN	I
,	O	PUNCT	O
confirming	O	VERB	O
the	O	DET	O
linkage	O	NOUN	B
of	O	ADP	O
the	O	DET	O
observed	O	VERB	B
C9	O	NOUN	B
mutations	O	NOUN	I
with	O	ADP	O
defined	O	VERB	O
haplotypes	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


BRCA1	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
women	O	NOUN	B
attending	O	VERB	B
clinics	O	NOUN	B
that	O	PRON	O
evaluate	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
To	O	PART	O
define	O	VERB	O
the	O	DET	O
incidence	O	NOUN	B
of	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
among	O	ADP	O
patients	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
clinics	O	NOUN	B
that	O	PRON	O
evaluate	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
DNA	O	NOUN	B
samples	O	NOUN	I
from	O	ADP	O
women	O	NOUN	B
seen	O	VERB	O
in	O	ADP	O
this	O	DET	O
setting	O	NOUN	O
and	O	CCONJ	O
constructed	O	VERB	O
probability	O	NOUN	B
tables	O	NOUN	B
to	O	PART	O
provide	O	VERB	O
estimates	O	NOUN	B
of	O	ADP	O
the	O	DET	O
likelihood	O	NOUN	B
of	O	ADP	O
finding	O	VERB	B
a	O	DET	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
individual	O	ADJ	O
families	O	NOUN	B
.	O	PUNCT	O


METHODS	O	VERB	O
Clinical	O	ADJ	B
information	O	NOUN	I
,	O	PUNCT	O
family	O	NOUN	B
histories	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
blood	O	NOUN	B
for	O	ADP	O
DNA	O	NOUN	B
analysis	O	NOUN	I
were	O	AUX	O
obtained	O	VERB	O
from	O	ADP	O
263	O	NUM	O
women	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Conformation	O	NOUN	B
-	O	PUNCT	O
sensitive	O	ADJ	B
gel	O	NOUN	B
electrophoresis	O	NOUN	I
and	O	CCONJ	O
DNA	O	NOUN	B
sequencing	O	NOUN	I
were	O	AUX	O
used	O	VERB	O
to	O	PART	O
identify	O	VERB	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	VERB	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
identified	O	VERB	B
in	O	ADP	O
16	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Only	O	ADV	O
7	O	NUM	O
percent	O	NOUN	O
of	O	ADP	O
women	O	NOUN	B
from	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
but	O	CCONJ	O
not	O	PART	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
had	O	AUX	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
rates	O	NOUN	B
were	O	AUX	O
higher	O	ADJ	O
among	O	ADP	O
women	O	NOUN	B
from	O	ADP	O
families	O	NOUN	B
with	O	ADP	O
a	O	DET	O
history	O	NOUN	B
of	O	ADP	O
both	O	CCONJ	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


Among	O	ADP	O
family	O	NOUN	B
members	O	NOUN	I
,	O	PUNCT	O
an	O	DET	O
average	O	ADJ	O
age	O	NOUN	B
of	O	ADP	O
less	O	ADJ	O
than	O	ADP	O
55	O	NUM	O
years	O	NOUN	B
at	O	ADP	O
the	O	DET	O
diagnosis	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
the	O	DET	O
same	O	ADJ	O
woman	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
Ashkenazi	O	PROPN	B
Jewish	O	ADJ	B
ancestry	O	NOUN	B
were	O	AUX	O
all	O	DET	O
associated	O	VERB	B
with	O	ADP	I
an	O	DET	O
increased	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
detecting	O	VERB	B
a	O	DET	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
.	O	PUNCT	O


No	O	DET	O
association	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
between	O	ADP	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
bilateral	O	ADJ	B
breast	B-Disease	NOUN	O
cancer	I-Disease	NOUN	O
or	O	CCONJ	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
breast	B-Disease	NOUN	B
cancers	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
detection	O	NOUN	B
of	O	ADP	O
a	O	DET	O
BRCA1	O	NOUN	B
mutation	O	NOUN	B
,	O	PUNCT	O
or	O	CCONJ	O
between	O	ADP	O
the	O	DET	O
position	O	NOUN	B
of	O	ADP	O
the	O	DET	O
mutation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
BRCA1	O	NOUN	B
gene	O	NOUN	I
and	O	CCONJ	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
ovarian	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
in	O	ADP	O
a	O	DET	O
family	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Among	O	ADP	O
women	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
the	O	DET	I
disease	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
percentage	O	NOUN	B
with	O	ADP	O
BRCA1	O	NOUN	B
coding	O	NOUN	B
-	O	PUNCT	O
region	O	NOUN	B
mutations	O	NOUN	B
is	O	AUX	O
less	O	ADJ	O
than	O	ADP	O
the	O	DET	O
45	O	NUM	O
percent	O	NOUN	O
predicted	O	VERB	B
by	O	ADP	O
genetic	O	ADJ	B
-	O	PUNCT	O
linkage	O	NOUN	B
analysis	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
even	O	ADV	O
in	O	ADP	O
a	O	DET	O
referral	O	NOUN	B
clinic	O	NOUN	I
specializing	O	VERB	O
in	O	ADP	O
screening	O	VERB	B
women	O	NOUN	B
from	O	ADP	O
high	O	ADJ	B
-	O	PUNCT	O
risk	O	NOUN	B
families	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
tests	O	NOUN	B
for	O	ADP	O
BRCA1	O	NOUN	B
mutations	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
negative	O	ADJ	B
and	O	CCONJ	O
therefore	O	ADV	O
uninformative	O	ADJ	B
.	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
arginine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
protein	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ARP	O	PROPN	B
)	O	PUNCT	O
in	O	ADP	O
pancreatic	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
ARP	O	PROPN	B
gene	O	NOUN	O
encodes	O	VERB	B
a	O	DET	O
highly	O	ADV	O
conserved	O	VERB	O
arginine	O	NOUN	B
-	O	PUNCT	O
rich	O	ADJ	B
protein	O	NOUN	I
from	O	ADP	O
chromosomal	O	ADJ	B
band	O	NOUN	I
3p21	O	NOUN	I
.	O	PUNCT	O


1	O	NUM	O
1	O	NUM	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
cytogenetic	O	ADJ	B
level	O	NOUN	O
this	O	DET	O
region	O	NOUN	B
is	O	AUX	O
frequently	O	ADV	O
deleted	O	VERB	O
in	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
different	O	ADJ	O
solid	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
,	O	PUNCT	O
although	O	SCONJ	O
not	O	PART	O
in	O	ADP	O
pancreatic	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
reported	O	VERB	O
the	O	DET	O
presence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
specific	O	ADJ	O
mutation	O	NOUN	B
(	O	PUNCT	O
ATG50	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
AGG	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
deletion	O	NOUN	B
of	O	ADP	O
codon	O	NOUN	B
50	O	NUM	O
of	O	ADP	O
the	O	DET	O
ARP	O	PROPN	B
gene	O	NOUN	O
in	O	ADP	O
different	O	ADJ	O
tumor	B-Disease	NOUN	B
types	I-Disease	NOUN	I
(	O	PUNCT	O
Shridhar	O	PROPN	O
et	O	X	O
al	O	PROPN	O
.	O	PUNCT	O
,	O	PUNCT	O
1996	O	NUM	O
,	O	PUNCT	O
1996a	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
observed	O	VERB	O
mutations	O	NOUN	B
involving	O	VERB	O
codon	O	NOUN	B
50	O	NUM	O
in	O	ADP	O
11	O	NUM	O
of	O	ADP	O
37	O	NUM	O
pancreatic	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


The	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
codon	O	NOUN	B
50	O	NUM	O
mutation	O	NOUN	B
is	O	AUX	O
roughly	O	ADV	O
the	O	DET	O
same	O	ADJ	O
in	O	ADP	O
pancreatic	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
other	O	ADJ	O
types	O	NOUN	O
of	O	ADP	O
tumors	B-Disease	NOUN	B
previously	O	ADV	O
examined	O	VERB	O
.	O	PUNCT	O


In	O	ADP	O
addition	O	NOUN	O
,	O	PUNCT	O
we	O	PRON	O
have	O	AUX	O
detected	O	VERB	B
mutations	O	NOUN	B
at	O	ADP	O
codon	O	NOUN	B
51	O	NUM	O
in	O	ADP	O
multiple	O	ADJ	O
PCR	O	NOUN	B
subclones	O	NOUN	B
in	O	ADP	O
two	O	NUM	O
other	O	ADJ	O
pancreatic	B-Disease	ADJ	B
tumors	I-Disease	NOUN	I
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ARP	O	PROPN	B
gene	O	NOUN	I
are	O	AUX	O
thus	O	ADV	O
commonly	O	ADV	O
observed	O	VERB	B
in	O	ADP	O
pancreatic	B-Disease	ADJ	B
cancer	I-Disease	NOUN	I
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
many	O	ADJ	O
other	O	ADJ	O
cancers	B-Disease	NOUN	B
.	O	PUNCT	O


Difficulties	O	NOUN	B
in	O	ADP	O
the	O	DET	O
ascertainment	O	NOUN	B
of	O	ADP	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
lessons	O	NOUN	O
to	O	PART	O
be	O	AUX	O
drawn	O	VERB	O
from	O	ADP	O
a	O	DET	O
compound	O	NOUN	B
heterozygote	O	NOUN	I
C9	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
subject	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
group	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
long	O	ADV	B
-	O	PUNCT	O
surviving	O	VERB	B
mismatched	O	ADJ	B
kidney	O	NOUN	I
allografts	O	NOUN	I
were	O	AUX	O
investigated	O	VERB	B
for	O	ADP	O
complement	O	NOUN	B
function	O	NOUN	I
using	O	VERB	O
haemolytic	O	ADJ	B
assays	O	NOUN	I
in	O	ADP	O
agarose	O	NOUN	B
gels	O	NOUN	I
.	O	PUNCT	O


One	O	NUM	O
patient	O	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
have	O	AUX	O
no	O	DET	O
alternative	O	ADJ	O
pathway	O	NOUN	O
activity	O	NOUN	O
but	O	CCONJ	O
a	O	DET	O
low	O	ADJ	O
normal	O	ADJ	O
classical	O	ADJ	O
pathway	O	NOUN	O
.	O	PUNCT	O


Surprisingly	O	ADV	O
,	O	PUNCT	O
investigation	O	NOUN	B
revealed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
patients	O	NOUN	B
complement	O	NOUN	O
was	O	AUX	O
normal	O	ADJ	O
for	O	ADP	O
all	O	DET	O
components	O	NOUN	B
except	O	SCONJ	O
C9	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
was	O	AUX	O
functionally	O	ADV	O
absent	O	ADJ	B
.	O	PUNCT	O


The	O	DET	O
patient	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
DNA	O	NOUN	B
markers	O	NOUN	I
in	O	ADP	O
the	O	DET	O
C6	O	NOUN	B
,	O	PUNCT	O
C7	O	NOUN	B
and	O	CCONJ	O
C9	O	NOUN	B
region	O	NOUN	I
of	O	ADP	O
chromosome	O	NOUN	B
5	O	NUM	I
and	O	CCONJ	O
therefore	O	ADV	O
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
a	O	DET	O
compound	O	NOUN	B
heterozygote	O	NOUN	I
for	O	ADP	O
two	O	NUM	O
uncharacterized	O	ADJ	B
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
genes	O	NOUN	I
.	O	PUNCT	O


Serological	O	ADJ	B
analysis	O	NOUN	I
by	O	ADP	O
ELISA	O	NOUN	B
revealed	O	VERB	B
that	O	SCONJ	O
he	O	PRON	O
has	O	AUX	O
trace	O	NOUN	B
concentrations	O	NOUN	I
of	O	ADP	O
a	O	DET	O
non	O	ADJ	B
-	O	PUNCT	O
functional	O	ADJ	B
C9	O	NOUN	B
molecule	O	NOUN	I
.	O	PUNCT	O


Western	O	NOUN	B
blot	O	NOUN	I
analysis	O	NOUN	I
was	O	AUX	O
not	O	PART	O
sufficiently	O	ADV	O
sensitive	O	ADJ	B
to	O	PART	O
permit	O	VERB	O
detection	O	NOUN	B
of	O	ADP	O
this	O	DET	O
molecule	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
hypothesize	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
patient	O	NOUN	B
is	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
complete	B-Disease	ADJ	O
deficiency	I-Disease	NOUN	B
of	I-Disease	ADP	O
C9	I-Disease	NOUN	B
and	O	CCONJ	O
for	O	ADP	O
a	O	DET	O
gene	O	NOUN	B
directing	O	VERB	O
hyposynthesis	O	NOUN	B
of	O	ADP	O
a	O	DET	O
defective	O	ADJ	B
C9	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
also	O	ADV	O
suggest	O	VERB	O
that	O	SCONJ	O
C9	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
may	O	AUX	O
be	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
among	O	ADP	O
Caucasians	O	PROPN	B
than	O	ADP	O
has	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O
.	O	PUNCT	O


Screening	O	VERB	B
for	O	ADP	O
ESR	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
patients	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
leukocyte	O	NOUN	B
DNA	O	NOUN	I
from	O	ADP	O
143	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
familial	O	ADJ	B
clustering	O	NOUN	I
of	O	ADP	O
breast	B-Disease	NOUN	B
and	I-Disease	CCONJ	O
/	I-Disease	SYM	O
or	I-Disease	CCONJ	O
ovarian	I-Disease	ADJ	B
cancer	I-Disease	NOUN	I
and	O	CCONJ	O
tumour	B-Disease	NOUN	B
DNA	O	NOUN	I
from	O	ADP	O
96	O	NUM	O
breast	B-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
were	O	AUX	O
screened	O	VERB	B
for	O	ADP	O
base	O	NOUN	B
mutations	O	NOUN	I
in	O	ADP	O
the	O	DET	O
estrogen	O	NOUN	B
receptor	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
ESR	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Three	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
a	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
cancer	B-Disease	NOUN	I
were	O	AUX	O
carrying	O	VERB	O
a	O	DET	O
Gly160Cys	O	VERB	B
germline	O	NOUN	B
substitution	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
alteration	O	NOUN	B
was	O	AUX	O
also	O	ADV	O
detected	O	VERB	B
in	O	ADP	O
eight	O	NUM	O
(	O	PUNCT	O
four	O	NUM	O
females	O	NOUN	B
and	O	CCONJ	O
four	O	NUM	O
males	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
729	O	NUM	O
controls	O	NOUN	B
(	O	PUNCT	O
366	O	NUM	O
female	O	NOUN	B
,	O	PUNCT	O
363	O	NUM	O
males	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
substitution	O	NOUN	B
probably	O	ADV	O
represents	O	VERB	O
a	O	DET	O
polymorphism	O	NOUN	B
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
229	O	NUM	O
female	O	ADJ	B
controls	O	NOUN	I
in	O	ADP	O
whom	O	DET	O
family	O	NOUN	B
history	O	NOUN	I
of	O	ADP	I
cancer	B-Disease	NOUN	I
was	O	AUX	O
known	O	VERB	O
,	O	PUNCT	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
who	O	PRON	O
had	O	AUX	O
a	O	DET	O
sister	O	NOUN	B
with	O	ADP	O
breast	B-Disease	NOUN	B
cancer	I-Disease	NOUN	I
was	O	AUX	O
carrying	O	VERB	O
the	O	DET	O
variant	O	ADJ	B
allele	O	NOUN	B
.	O	PUNCT	O


Hence	O	ADV	O
,	O	PUNCT	O
a	O	DET	O
possible	O	ADJ	O
clinical	O	ADJ	B
significance	O	NOUN	I
of	O	ADP	O
the	O	DET	O
glycine	O	NOUN	B
into	O	ADP	O
cysteine	O	NOUN	B
cannot	O	NOUN	O
be	O	AUX	O
completely	O	ADV	O
ruled	O	VERB	O
out	O	ADP	O
and	O	CCONJ	O
should	O	AUX	O
be	O	AUX	O
further	O	ADV	O
investigated	O	VERB	B
.	O	PUNCT	O


Somatic	O	ADJ	B
mutations	O	NOUN	O
were	O	AUX	O
not	O	PART	O
detected	O	VERB	B
in	O	ADP	O
any	O	DET	O
of	O	ADP	O
the	O	DET	O
tumours	B-Disease	NOUN	B
studied	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
present	O	ADJ	O
data	O	NOUN	B
do	O	AUX	O
not	O	PART	O
provide	O	VERB	O
support	O	NOUN	O
for	O	ADP	O
somatic	O	ADJ	B
ESR	O	NOUN	B
base	O	NOUN	O
mutations	O	NOUN	O
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
mechanism	O	NOUN	B
for	O	ADP	O
hormonal	O	ADJ	B
therapy	O	NOUN	I
resistance	O	NOUN	B
in	O	ADP	O
estrogen	B-Disease	NOUN	B
receptor	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
positive	I-Disease	ADJ	B
breast	I-Disease	NOUN	B
carcinomas	I-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
bases	O	NOUN	I
of	O	ADP	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
:	O	PUNCT	O
three	O	NUM	O
different	O	ADJ	O
defects	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
molecular	O	ADJ	B
basis	O	NOUN	I
of	O	ADP	O
C7	B-Disease	NOUN	B
deficiency	I-Disease	NOUN	I
has	O	AUX	O
been	O	AUX	O
investigated	O	VERB	B
in	O	ADP	O
two	O	NUM	O
Irish	O	ADJ	B
families	O	NOUN	B
and	O	CCONJ	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
Israeli	O	ADJ	B
families	O	NOUN	B
of	O	ADP	O
Moroccan	O	ADJ	B
Sephardic	O	ADJ	B
Jewish	O	ADJ	B
origin	O	NOUN	B
.	O	PUNCT	O


Exon	O	NOUN	B
PCR	O	NOUN	I
and	O	CCONJ	O
sequencing	O	NOUN	B
revealed	O	VERB	O
a	O	DET	O
heterozygous	O	ADJ	B
point	O	NOUN	O
mutation	O	NOUN	O
at	O	ADP	O
the	O	DET	O
3	O	NUM	O
splice	O	NOUN	B
acceptor	O	NOUN	I
site	O	NOUN	I
of	O	ADP	O
intron	O	NOUN	B
1	O	NUM	O
in	O	ADP	O
one	O	NUM	O
Irish	O	ADJ	B
family	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
other	O	ADJ	O
Irish	O	ADJ	B
family	O	NOUN	B
,	O	PUNCT	O
exons	O	NOUN	B
7	O	NUM	O
and	O	CCONJ	O
8	O	NUM	O
failed	O	VERB	B
to	O	PART	O
amplify	O	VERB	B
and	O	CCONJ	O
they	O	PRON	O
were	O	AUX	O
shown	O	VERB	O
to	O	PART	O
be	O	AUX	O
deleted	O	VERB	B
.	O	PUNCT	O


Marker	O	NOUN	B
haplotype	O	NOUN	B
studies	O	NOUN	B
of	O	ADP	O
the	O	DET	O
C6	O	NOUN	B
and	O	CCONJ	O
C7	O	NOUN	B
gene	O	NOUN	I
region	O	NOUN	I
and	O	CCONJ	O
Southern	O	NOUN	B
blots	O	NOUN	I
show	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
Irish	O	ADJ	B
family	O	NOUN	O
with	O	ADP	O
the	O	DET	O
splice	O	NOUN	B
defect	O	NOUN	I
also	O	ADV	O
segregate	O	VERB	O
for	O	ADP	O
the	O	DET	O
deletion	O	NOUN	B
,	O	PUNCT	O
which	O	DET	O
is	O	AUX	O
not	O	PART	O
easily	O	ADV	O
detected	O	VERB	B
in	O	ADP	O
heterozygotes	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Israeli	O	ADJ	B
C7	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
deficient	I-Disease	ADJ	B
cases	O	NOUN	B
all	O	DET	O
share	O	VERB	O
a	O	DET	O
C7	O	NOUN	B
haplotype	O	NOUN	I
and	O	CCONJ	O
are	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
a	O	DET	O
mis	O	X	B
-	O	PUNCT	O
sense	O	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
exon	O	NOUN	B
9	O	NUM	I
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
one	O	NUM	O
individual	O	NOUN	B
is	O	AUX	O
heterozygous	O	ADJ	B
for	O	ADP	O
markers	O	NOUN	B
at	O	ADP	O
adjacent	O	ADJ	B
C6	O	NOUN	B
loci	O	NOUN	I
,	O	PUNCT	O
showing	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
has	O	AUX	O
been	O	AUX	O
an	O	DET	O
intergenic	O	ADJ	B
recombination	O	NOUN	I
and	O	CCONJ	O
suggesting	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
deficiency	O	NOUN	B
mutation	O	NOUN	B
is	O	AUX	O
of	O	ADP	O
appreciable	O	ADJ	O
antiquity	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Molecular	O	ADJ	B
heterogeneity	O	NOUN	B
of	O	ADP	O
classical	B-Disease	ADJ	O
and	I-Disease	CCONJ	O
Duarte	I-Disease	PROPN	B
galactosemia	I-Disease	NOUN	I
:	O	PUNCT	O
mutation	O	NOUN	B
analysis	O	NOUN	I
by	O	ADP	O
denaturing	O	VERB	B
gradient	O	NOUN	O
gel	O	NOUN	B
electrophoresis	O	NOUN	I
.	O	PUNCT	O


Classical	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
is	O	AUX	O
caused	O	VERB	O
by	O	ADP	O
one	O	NUM	O
common	O	ADJ	O
missense	O	NOUN	B
mutation	O	NOUN	I
(	O	PUNCT	O
Q188R	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
by	O	ADP	O
several	O	ADJ	O
rare	O	ADJ	B
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
galactose	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
-	O	PUNCT	O
phosphate	O	NOUN	B
uridyltransferase	O	NOUN	I
(	O	PUNCT	O
GALT	O	NOUN	B
)	O	PUNCT	O
gene	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
variant	O	NOUN	B
of	O	ADP	O
GALT	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
Duarte	O	PROPN	B
variant	O	NOUN	B
,	O	PUNCT	O
occurs	O	VERB	O
as	O	ADP	O
two	O	NUM	O
types	O	NOUN	O
,	O	PUNCT	O
Duarte	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
(	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
Duarte	O	PROPN	B
-	O	PUNCT	O
2	O	NUM	O
(	O	PUNCT	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
both	O	DET	O
of	O	ADP	O
which	O	DET	O
carry	O	VERB	O
the	O	DET	O
sequence	O	NOUN	B
change	O	NOUN	O
N314D	O	NOUN	B
.	O	PUNCT	O


D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
increases	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	O
decreases	O	VERB	B
GALT	O	NOUN	B
activity	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
the	O	DET	O
molecular	O	ADJ	B
genetics	O	NOUN	I
of	O	ADP	O
classical	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
Duarte	I-Disease	PROPN	B
galactosemia	I-Disease	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
analyzed	O	VERB	B
the	O	DET	O
GALT	O	NOUN	B
mutations	O	NOUN	B
in	O	ADP	O
30	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
classical	B-Disease	ADJ	O
galactosemia	I-Disease	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
10	O	NUM	O
families	O	NOUN	B
with	O	ADP	O
the	O	DET	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
variant	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
3	O	NUM	O
individuals	O	NOUN	B
carrying	O	VERB	O
the	O	DET	O
D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	O
allele	O	NOUN	B
by	O	ADP	O
denaturing	O	VERB	B
gradient	O	NOUN	O
gel	O	NOUN	O
electrophoresis	O	NOUN	O
(	O	PUNCT	O
DGGE	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


DGGE	O	NOUN	B
detected	O	VERB	B
59	O	NUM	O
of	O	ADP	O
the	O	DET	O
60	O	NUM	O
classical	O	ADJ	O
galactosemia	B-Disease	NOUN	B
alleles	O	NOUN	B
.	O	PUNCT	O


Q188R	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
60	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
K285N	O	NOUN	B
accounted	O	VERB	O
for	O	ADP	O
28	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
these	O	DET	O
alleles	O	NOUN	B
.	O	PUNCT	O


Eight	O	NUM	O
novel	O	ADJ	O
candidate	O	NOUN	O
galactosemia	B-Disease	NOUN	B
mutations	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
.	O	PUNCT	O


On	O	ADP	O
all	O	DET	O
D	O	NOUN	B
-	O	PUNCT	O
2	O	NUM	B
alleles	O	NOUN	B
N314D	O	NOUN	B
occurred	O	VERB	O
in	O	ADP	O
cis	O	NOUN	O
with	O	ADP	O
two	O	NUM	O
intronic	O	ADJ	B
sequence	O	NOUN	I
changes	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
D	O	NOUN	B
-	O	PUNCT	O
1	O	NUM	B
alleles	O	NOUN	B
in	O	ADP	O
cis	O	NOUN	O
with	O	ADP	O
a	O	DET	O
neutral	O	ADJ	B
mutation	O	NOUN	I
in	O	ADP	O
exon	O	NOUN	B
7	O	NUM	I
.	O	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
mutations	O	NOUN	B
causing	O	VERB	O
galactosemia	B-Disease	NOUN	B
are	O	AUX	O
highly	O	ADV	O
heterogeneous	O	ADJ	B
and	O	CCONJ	O
that	O	SCONJ	O
K285N	O	NOUN	B
is	O	AUX	O
a	O	DET	O
second	O	ADV	O
common	O	ADJ	O
galactosemia	B-Disease	NOUN	B
mutation	O	NOUN	B
in	O	ADP	O
our	O	PRON	O
population	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Isolation	O	NOUN	B
of	O	ADP	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
ATM	O	NOUN	B
cDNA	O	NOUN	B
and	O	CCONJ	O
correction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
cellular	O	ADJ	B
phenotype	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
gene	O	NOUN	B
mutated	O	VERB	I
in	O	ADP	O
the	O	DET	O
human	O	ADJ	B
genetic	B-Disease	ADJ	B
disorder	I-Disease	NOUN	I
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
(	O	PUNCT	O
A	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
ATM	O	NOUN	B
,	O	PUNCT	O
was	O	AUX	O
recently	O	ADV	O
identified	O	VERB	B
by	O	ADP	O
positional	O	ADJ	B
cloning	O	NOUN	I
.	O	PUNCT	O


ATM	O	NOUN	B
is	O	AUX	O
a	O	DET	O
member	O	NOUN	B
of	O	ADP	O
the	O	DET	O
phosphatidylinositol	O	NOUN	B
-	O	PUNCT	O
3	O	NUM	B
-	O	PUNCT	O
kinase	O	NOUN	B
superfamily	O	NOUN	B
,	O	PUNCT	O
some	O	DET	O
of	O	ADP	O
which	O	DET	O
are	O	AUX	O
protein	O	NOUN	B
kinases	O	NOUN	I
and	O	CCONJ	O
appear	O	VERB	O
to	O	PART	O
have	O	AUX	O
important	O	ADJ	O
roles	O	NOUN	O
in	O	ADP	O
cell	O	NOUN	B
cycle	O	NOUN	I
control	O	NOUN	I
and	O	CCONJ	O
radiation	O	NOUN	B
signal	O	NOUN	I
transduction	O	NOUN	I
.	O	PUNCT	O


We	O	PRON	O
describe	O	VERB	O
herein	O	ADV	O
,	O	PUNCT	O
to	O	ADP	O
our	O	PRON	O
knowledge	O	NOUN	B
,	O	PUNCT	O
for	O	ADP	O
the	O	DET	O
first	O	ADJ	O
time	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
cloning	O	NOUN	B
of	O	ADP	O
a	O	DET	O
full	O	ADJ	B
-	O	PUNCT	O
length	O	NOUN	B
cDNA	O	NOUN	B
for	O	ADP	O
ATM	O	NOUN	B
and	O	CCONJ	O
correction	O	NOUN	B
of	O	ADP	O
multiple	O	ADJ	O
aspects	O	NOUN	O
of	O	ADP	O
the	O	DET	O
radio	O	NOUN	B
-	O	PUNCT	O
sensitive	O	ADJ	B
phenotype	O	NOUN	B
of	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
cells	O	NOUN	I
by	O	ADP	O
transfection	O	NOUN	B
with	O	ADP	O
this	O	DET	O
cDNA	O	NOUN	B
.	O	PUNCT	O


Overexpression	O	NOUN	B
of	O	ADP	O
ATM	O	NOUN	B
cDNA	O	NOUN	B
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
cells	O	NOUN	I
enhanced	O	VERB	B
the	O	DET	O
survival	O	NOUN	B
of	O	ADP	O
these	O	DET	O
cells	O	NOUN	B
in	O	ADP	O
response	O	NOUN	B
to	O	PART	O
radiation	O	NOUN	B
exposure	O	NOUN	I
,	O	PUNCT	O
decreased	O	VERB	B
radiation	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
chromosome	O	NOUN	B
aberrations	O	NOUN	I
,	O	PUNCT	O
reduced	O	VERB	B
radio	O	NOUN	B
-	O	PUNCT	O
resistant	O	ADJ	B
DNA	O	NOUN	B
synthesis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
partially	O	ADV	O
corrected	O	VERB	O
defective	O	ADJ	O
cell	O	NOUN	O
cycle	O	NOUN	O
checkpoints	O	NOUN	O
and	O	CCONJ	O
induction	O	NOUN	B
of	O	ADP	O
stress	O	NOUN	B
-	O	PUNCT	O
activated	O	VERB	B
protein	O	NOUN	B
kinase	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
correction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
defects	O	NOUN	B
in	O	ADP	O
A	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
T	I-Disease	NOUN	B
cells	O	NOUN	I
provides	O	VERB	O
further	O	ADJ	O
evidence	O	NOUN	B
of	O	ADP	O
the	O	DET	O
multiplicity	O	NOUN	B
of	O	ADP	O
effector	O	NOUN	B
functions	O	NOUN	I
of	O	ADP	O
the	O	DET	O
ATM	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
suggests	O	VERB	O
possible	O	ADJ	O
approaches	O	NOUN	B
to	O	PART	O
gene	O	NOUN	B
therapy	O	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Fusion	O	NOUN	B
genes	O	NOUN	I
resulting	O	VERB	O
from	O	ADP	O
alternative	O	ADJ	B
chromosomal	O	ADJ	B
translocations	O	NOUN	I
are	O	AUX	O
overexpressed	O	VERB	B
by	O	ADP	O
gene	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mechanisms	O	NOUN	B
in	O	ADP	O
alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
.	O	PUNCT	O


Chromosomal	O	ADJ	B
translocations	O	NOUN	I
identified	O	VERB	B
in	O	ADP	O
hematopoietic	B-Disease	ADJ	B
and	I-Disease	CCONJ	O
solid	I-Disease	ADJ	B
tumors	I-Disease	NOUN	I
result	O	VERB	O
in	O	ADP	O
deregulated	O	ADJ	B
expression	O	NOUN	B
of	O	ADP	O
protooncogenes	O	NOUN	B
or	O	CCONJ	O
creation	O	NOUN	B
of	O	ADP	O
chimeric	O	ADJ	B
proteins	O	NOUN	I
with	O	ADP	O
tumorigenic	O	ADJ	B
potential	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
pediatric	O	ADJ	B
solid	B-Disease	ADJ	B
tumor	I-Disease	NOUN	I
alveolar	B-Disease	ADJ	I
rhabdomyosarcoma	I-Disease	NOUN	I
,	O	PUNCT	O
a	O	DET	O
consistent	O	ADJ	O
t	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
;	O	PUNCT	O
13	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
q35	O	NOUN	B
;	O	PUNCT	O
q14	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
variant	O	ADJ	B
t	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
13	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
p36	O	NOUN	B
;	O	PUNCT	O
q14	O	NOUN	B
)	O	PUNCT	O
translocation	O	NOUN	B
generates	O	VERB	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
or	O	CCONJ	O
PAX7	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
fusion	O	NOUN	B
proteins	O	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
report	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
demonstrate	O	VERB	O
that	O	SCONJ	O
in	O	ADP	O
addition	O	NOUN	O
to	O	PART	O
functional	O	ADJ	B
alterations	O	NOUN	B
these	O	DET	O
translocations	O	NOUN	B
are	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
fusion	O	NOUN	B
product	O	NOUN	I
overexpression	O	NOUN	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
and	O	CCONJ	O
PAX7	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
overexpression	O	NOUN	B
occurs	O	VERB	O
by	O	ADP	O
distinct	O	ADJ	O
mechanisms	O	NOUN	B
.	O	PUNCT	O


Transcription	O	NOUN	B
of	O	ADP	O
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
is	O	AUX	O
increased	O	VERB	B
relative	O	ADJ	O
to	O	ADP	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
PAX3	O	NOUN	B
by	O	ADP	O
a	O	DET	O
copy	O	NOUN	B
number	O	NOUN	I
-	O	PUNCT	O
independent	O	ADJ	B
process	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
PAX7	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
overexpression	O	NOUN	B
results	O	VERB	B
from	O	ADP	O
fusion	O	NOUN	B
gene	O	NOUN	I
amplification	O	NOUN	I
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
gene	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
mechanisms	O	NOUN	B
were	O	AUX	O
selected	O	VERB	O
to	O	PART	O
overexpress	O	VERB	B
PAX3	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
and	O	CCONJ	O
PAX7	O	NOUN	B
-	O	PUNCT	O
FKHR	O	NOUN	B
in	O	ADP	O
alveolar	B-Disease	ADJ	B
rhabdomyosarcoma	I-Disease	NOUN	I
,	O	PUNCT	O
presumably	O	ADV	O
due	O	ADJ	O
to	O	PART	O
differences	O	NOUN	B
in	O	ADP	O
regulation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
loci	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
postulate	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
overexpression	O	NOUN	B
mechanisms	O	NOUN	B
ensure	O	VERB	O
a	O	DET	O
critical	O	ADJ	O
level	O	NOUN	B
of	O	ADP	O
gene	O	NOUN	B
product	O	NOUN	I
for	O	ADP	O
the	O	DET	O
oncogenic	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
these	O	DET	O
fusions	O	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


atm	O	NOUN	O
and	O	CCONJ	O
p53	O	NOUN	B
cooperate	O	VERB	B
in	O	ADP	O
apoptosis	O	NOUN	B
and	O	CCONJ	O
suppression	O	NOUN	B
of	O	ADP	O
tumorigenesis	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
in	O	ADP	O
resistance	O	NOUN	B
to	O	PART	O
acute	B-Disease	ADJ	B
radiation	I-Disease	NOUN	B
toxicity	I-Disease	NOUN	B
.	O	PUNCT	O


Mutations	O	NOUN	B
in	O	ADP	O
atm	O	NOUN	O
and	O	CCONJ	O
p53	O	NOUN	B
cause	O	VERB	O
the	O	DET	O
human	O	ADJ	B
cancer	B-Disease	NOUN	I
-	I-Disease	PUNCT	O
associated	I-Disease	VERB	B
diseases	I-Disease	NOUN	B
ataxia	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
telangiectasia	I-Disease	NOUN	B
and	O	CCONJ	O
Li	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
Fraumeni	I-Disease	PROPN	B
syndrome	I-Disease	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
two	O	NUM	O
genes	O	NOUN	B
are	O	AUX	O
believed	O	VERB	O
to	O	PART	O
interact	O	VERB	B
in	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
pathways	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
regulation	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
damage	O	NOUN	I
-	O	PUNCT	O
induced	O	VERB	B
cell	O	NOUN	B
-	O	PUNCT	O
cycle	O	NOUN	B
checkpoints	O	NOUN	I
,	O	PUNCT	O
apoptosis	O	NOUN	B
and	O	CCONJ	O
radiation	O	NOUN	B
sensitivity	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
cellular	O	ADJ	B
proliferation	O	NOUN	I
.	O	PUNCT	O


Atm	O	PROPN	B
-	O	PUNCT	O
null	O	ADJ	B
mice	O	NOUN	O
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
those	O	DET	O
null	O	NOUN	B
for	O	ADP	O
p53	O	NOUN	B
,	O	PUNCT	O
develop	O	VERB	O
mainly	O	ADV	O
T	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
lymphomas	I-Disease	NOUN	I
,	O	PUNCT	O
supporting	O	VERB	O
the	O	DET	O
view	O	NOUN	O
that	O	SCONJ	O
these	O	DET	O
genes	O	NOUN	B
have	O	AUX	O
similar	O	ADJ	O
roles	O	NOUN	O
in	O	ADP	O
thymocyte	O	NOUN	B
development	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
study	O	VERB	B
the	O	DET	O
interactions	O	NOUN	B
of	O	ADP	O
these	O	DET	O
two	O	NUM	O
genes	O	NOUN	B
on	O	ADP	O
an	O	DET	O
organismal	O	ADJ	B
level	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
bred	O	VERB	B
mice	O	NOUN	O
heterozygous	O	ADJ	B
for	O	ADP	O
null	O	ADJ	B
alleles	O	NOUN	I
of	O	ADP	O
both	O	CCONJ	O
atm	O	NOUN	B
and	O	CCONJ	O
p53	O	NOUN	B
to	O	PART	O
produce	O	VERB	O
all	O	DET	O
genotypic	O	ADJ	B
combinations	O	NOUN	I
.	O	PUNCT	O


Mice	O	NOUN	B
doubly	O	ADV	O
null	O	ADJ	O
for	O	ADP	O
atm	O	NOUN	B
and	O	CCONJ	O
p53	O	NOUN	B
exhibited	O	VERB	O
a	O	DET	O
dramatic	O	ADJ	O
acceleration	O	NOUN	B
of	O	ADP	O
tumour	B-Disease	NOUN	B
formation	O	NOUN	I
relative	O	ADJ	O
to	O	PART	O
singly	O	ADV	O
null	O	ADJ	O
mice	O	NOUN	O
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
both	O	DET	O
genes	O	NOUN	B
collaborate	O	VERB	O
in	O	ADP	O
a	O	DET	O
significant	O	ADJ	B
manner	O	NOUN	O
to	O	PART	O
prevent	O	VERB	B
tumorigenesis	O	NOUN	B
.	O	PUNCT	O


With	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
their	O	PRON	O
roles	O	NOUN	O
in	O	ADP	O
apoptosis	O	NOUN	B
,	O	PUNCT	O
loss	O	NOUN	B
of	O	ADP	O
atm	O	NOUN	O
rendered	O	VERB	O
thymocytes	O	NOUN	B
only	O	ADV	O
partly	O	ADV	O
resistant	O	ADJ	B
to	O	PART	O
irradiation	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
apoptosis	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
additional	O	ADJ	O
loss	O	NOUN	B
of	O	ADP	O
p53	O	NOUN	B
engendered	O	VERB	O
complete	O	ADJ	O
resistance	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
implies	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
irradiation	O	NOUN	B
-	O	PUNCT	O
induced	O	VERB	B
atm	O	NOUN	O
and	O	CCONJ	O
p53	O	NOUN	B
apoptotic	O	ADJ	B
pathways	O	NOUN	I
are	O	AUX	O
not	O	PART	O
completely	O	ADV	O
congruent	O	ADJ	B
.	O	PUNCT	O


Finally	O	ADV	O
-	O	PUNCT	O
and	O	CCONJ	O
in	O	ADP	O
contrast	O	NOUN	O
to	O	PART	O
prior	O	ADJ	O
predictions	O	NOUN	B
-	O	PUNCT	O
atm	O	NOUN	B
and	O	CCONJ	O
p53	O	NOUN	B
do	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
interact	O	VERB	B
in	O	ADP	O
acute	B-Disease	ADJ	B
radiation	I-Disease	NOUN	O
toxicity	I-Disease	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
a	O	DET	O
separate	O	ADJ	O
atm	O	NOUN	O
effector	O	NOUN	O
pathway	O	NOUN	O
for	O	ADP	O
this	O	DET	O
DNA	O	NOUN	B
damage	O	NOUN	I
response	O	NOUN	I
and	O	CCONJ	O
having	O	VERB	O
implications	O	NOUN	O
for	O	ADP	O
the	O	DET	O
prognosis	O	NOUN	B
and	O	CCONJ	O
treatment	O	NOUN	B
of	O	ADP	O
human	O	ADJ	B
tumours	B-Disease	NOUN	I
.	O	PUNCT	O
.	O	PUNCT	O


Trinucleotide	O	NOUN	B
repeat	O	NOUN	I
expansion	O	NOUN	B
at	O	ADP	O
the	O	DET	O
myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
locus	O	NOUN	I
reduces	O	VERB	O
expression	O	NOUN	B
of	O	ADP	O
DMAHP	O	NOUN	B
.	O	PUNCT	O


Myotonic	B-Disease	ADJ	B
dystrophy	I-Disease	NOUN	I
,	O	PUNCT	O
or	O	CCONJ	O
dystrophia	B-Disease	ADJ	B
myotonica	I-Disease	NOUN	I
(	O	PUNCT	O
DM	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
autosomal	B-Disease	ADJ	B
dominant	I-Disease	ADJ	O
multisystem	I-Disease	NOUN	B
disorder	I-Disease	NOUN	I
caused	O	VERB	O
by	O	ADP	O
the	O	DET	O
expansion	O	NOUN	B
of	O	ADP	O
a	O	DET	O
CTG	O	NOUN	B
trinucleotide	O	NOUN	I
repeat	O	NOUN	I
in	O	ADP	O
the	O	DET	O
3	O	NUM	O
untranslated	O	ADJ	B
region	O	NOUN	I
of	O	ADP	O
the	O	DET	O
DMPK	O	NOUN	B
protein	O	NOUN	I
kinase	O	NOUN	I
gene	O	NOUN	I
on	O	ADP	O
chromosome	O	NOUN	B
19q13	O	NOUN	I
.	O	PUNCT	O


3	O	NUM	O
(	O	PUNCT	O
refs	O	NOUN	O
1	O	NUM	O
-	O	SYM	O
3	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Although	O	SCONJ	O
the	O	DET	O
DM	B-Disease	NOUN	B
mutation	O	NOUN	B
was	O	AUX	O
identified	O	VERB	O
more	O	ADJ	O
than	O	ADP	O
five	O	NUM	O
years	O	NOUN	B
ago	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
pathogenic	O	ADJ	B
mechanisms	O	NOUN	B
underlying	O	VERB	O
this	O	DET	O
most	O	ADV	O
prevalent	O	ADJ	O
form	O	NOUN	O
of	O	ADP	O
hereditary	O	ADJ	B
adult	O	ADJ	O
neuromuscular	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
remain	O	VERB	O
elusive	O	ADJ	O
.	O	PUNCT	O


Previous	O	ADJ	O
work	O	NOUN	O
from	O	ADP	O
our	O	PRON	O
laboratory	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
DNase	O	NOUN	B
l	O	NOUN	O
-	O	PUNCT	O
hypersensitive	O	ADJ	B
site	O	NOUN	B
located	O	ADJ	O
adjacent	O	ADJ	B
to	O	PART	O
the	O	DET	O
repeats	O	NOUN	B
on	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
is	O	AUX	O
eliminated	O	VERB	O
by	O	ADP	O
repeat	O	NOUN	O
expansion	O	NOUN	B
,	O	PUNCT	O
indicating	O	VERB	O
that	O	SCONJ	O
large	O	ADJ	O
CTG	O	NOUN	B
-	O	PUNCT	O
repeat	O	NOUN	B
arrays	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
local	O	ADJ	B
chromatin	O	NOUN	B
environment	O	NOUN	I
that	O	PRON	O
represses	O	VERB	B
gene	O	NOUN	B
expression	O	NOUN	I
.	O	PUNCT	O


Here	O	ADV	O
we	O	PRON	O
report	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
hypersensitive	O	ADJ	B
site	O	NOUN	I
contains	O	VERB	O
an	O	DET	O
enhancer	O	NOUN	B
element	O	NOUN	I
that	O	PRON	O
regulates	O	VERB	B
transcription	O	NOUN	B
of	O	ADP	O
the	O	DET	O
adjacent	O	ADJ	B
DMAHP	O	NOUN	B
homeobox	O	NOUN	B
gene	O	NOUN	I
.	O	PUNCT	O


Analysis	O	NOUN	B
of	O	ADP	O
DMAHP	O	NOUN	B
expression	O	NOUN	B
in	O	ADP	O
the	O	DET	O
cells	O	NOUN	B
of	O	ADP	O
DM	B-Disease	NOUN	B
patients	O	NOUN	B
with	O	ADP	O
loss	O	NOUN	B
of	O	ADP	O
the	O	DET	O
hypersensitive	O	ADJ	B
site	O	NOUN	I
revealed	O	VERB	B
a	O	DET	O
two	O	NUM	O
-	O	PUNCT	O
to	O	PART	O
fourfold	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
DMAHP	O	NOUN	B
transcript	O	NOUN	B
levels	O	NOUN	B
relative	O	ADJ	O
to	O	PART	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
controls	O	NOUN	B
.	O	PUNCT	O


Allele	O	NOUN	B
-	O	PUNCT	O
specific	O	ADJ	B
analysis	O	NOUN	B
of	O	ADP	O
DMAHP	O	NOUN	B
expression	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
steady	O	ADJ	B
-	O	PUNCT	O
state	O	NOUN	B
transcript	O	NOUN	B
levels	O	NOUN	B
from	O	ADP	O
the	O	DET	O
expanded	O	VERB	O
allele	O	NOUN	B
were	O	AUX	O
greatly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
comparison	O	NOUN	B
to	O	PART	O
those	O	DET	O
from	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
allele	O	NOUN	B
.	O	PUNCT	O


Together	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
results	O	NOUN	B
demonstrate	O	VERB	O
that	O	SCONJ	O
CTG	O	NOUN	B
-	O	PUNCT	O
repeat	O	NOUN	B
expansions	O	NOUN	B
can	O	AUX	O
suppress	O	VERB	B
local	O	ADJ	B
gene	O	NOUN	B
expression	O	NOUN	I
and	O	CCONJ	O
implicate	O	VERB	O
DMAHP	O	NOUN	B
in	O	ADP	O
DM	B-Disease	NOUN	B
pathogenesis	O	NOUN	B
.	O	PUNCT	O


Constitutively	O	ADV	B
methylated	O	VERB	I
CpG	O	NOUN	B
dinucleotides	O	NOUN	I
as	O	ADP	O
mutation	O	NOUN	B
hot	O	ADJ	B
spots	O	NOUN	I
in	O	ADP	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
RB1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
wide	O	ADJ	O
spectrum	O	NOUN	O
of	O	ADP	O
mutations	O	NOUN	B
,	O	PUNCT	O
ranging	O	VERB	O
from	O	ADP	O
point	O	NOUN	O
mutations	O	NOUN	B
to	O	ADP	O
large	O	ADJ	O
deletions	O	NOUN	B
,	O	PUNCT	O
have	O	AUX	O
been	O	AUX	O
described	O	VERB	O
in	O	ADP	O
the	O	DET	O
retinoblastoma	B-Disease	NOUN	B
gene	O	NOUN	I
(	O	PUNCT	O
RB1	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
throughout	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
these	O	DET	O
genetic	O	ADJ	B
alterations	O	NOUN	I
do	O	AUX	O
not	O	PART	O
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
homogeneously	O	ADV	B
distributed	O	VERB	B
.	O	PUNCT	O


In	O	ADP	O
particular	O	ADJ	O
,	O	PUNCT	O
a	O	DET	O
significant	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
disease	O	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
mutations	O	NOUN	B
results	O	VERB	B
in	O	ADP	O
the	O	DET	O
premature	O	ADJ	B
termination	O	NOUN	I
of	O	ADP	O
protein	O	NOUN	B
synthesis	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
majority	O	NOUN	O
of	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
occur	O	VERB	O
as	O	ADP	O
C	O	NOUN	B
-	O	PUNCT	O
-	O	PUNCT	O
>	O	X	O
T	O	NOUN	B
transitions	O	NOUN	I
at	O	ADP	O
CpG	O	NOUN	B
dinucleotides	O	NOUN	I
(	O	PUNCT	O
CpGs	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Such	O	ADJ	O
recurrent	O	ADJ	B
CpG	O	NOUN	B
mutations	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
those	O	DET	O
found	O	VERB	O
in	O	ADP	O
RB1	O	NOUN	B
,	O	PUNCT	O
are	O	AUX	O
likely	O	ADJ	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
the	O	DET	O
deamination	O	NOUN	B
of	O	ADP	O
5	O	NUM	O
-	O	PUNCT	O
methylcytosine	O	NOUN	B
within	O	ADP	O
these	O	DET	O
CpGs	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
used	O	VERB	O
the	O	DET	O
sodiumbisulfite	O	ADJ	B
conversion	O	NOUN	B
method	O	NOUN	O
to	O	PART	O
detect	O	VERB	B
cytosine	O	NOUN	B
methylation	O	NOUN	B
in	O	ADP	O
representative	O	ADJ	O
exons	O	NOUN	B
of	O	ADP	O
RB1	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
analyzed	O	VERB	B
DNA	O	NOUN	B
from	O	ADP	O
a	O	DET	O
variety	O	NOUN	O
of	O	ADP	O
tissues	O	NOUN	B
and	O	CCONJ	O
specifically	O	ADV	O
targeted	O	VERB	O
CGA	O	NOUN	B
codons	O	NOUN	B
in	O	ADP	O
RB1	O	NOUN	B
,	O	PUNCT	O
where	O	SCONJ	O
recurrent	O	ADJ	B
premature	O	ADJ	I
termination	O	NOUN	I
mutations	O	NOUN	I
have	O	AUX	O
been	O	AUX	O
reported	O	VERB	O
.	O	PUNCT	O


We	O	PRON	O
found	O	VERB	O
that	O	SCONJ	O
DNA	O	NOUN	B
methylation	O	NOUN	I
within	O	ADP	O
RB1	O	NOUN	B
exons	O	NOUN	B
8	O	NUM	O
,	O	PUNCT	O
14	O	NUM	O
,	O	PUNCT	O
25	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
27	O	NUM	O
appeared	O	VERB	O
to	O	PART	O
be	O	AUX	O
restricted	O	ADJ	O
to	O	PART	O
CpGs	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
six	O	NUM	O
CGA	O	NOUN	B
codons	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
codons	O	NOUN	B
containing	O	VERB	O
methylated	O	VERB	B
cytosines	O	NOUN	B
have	O	AUX	O
not	O	PART	O
been	O	AUX	O
reported	O	VERB	O
to	O	PART	O
be	O	AUX	O
mutated	O	VERB	B
.	O	PUNCT	O


Therefore	O	ADV	O
,	O	PUNCT	O
disease	O	NOUN	B
-	O	PUNCT	O
causing	O	VERB	B
mutations	O	NOUN	B
at	O	ADP	O
CpGs	O	NOUN	B
in	O	ADP	O
RB1	O	NOUN	B
appear	O	VERB	O
to	O	PART	O
be	O	AUX	O
determined	O	VERB	O
by	O	ADP	O
several	O	ADJ	O
factors	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
the	O	DET	O
constitutive	O	ADJ	B
presence	O	NOUN	B
of	O	ADP	O
DNA	O	NOUN	B
methylation	O	NOUN	I
at	O	ADP	O
cytosines	O	NOUN	B
within	O	ADP	O
CpGs	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
specific	O	ADJ	O
codon	O	NOUN	B
within	O	ADP	O
which	O	DET	O
the	O	DET	O
methylated	O	VERB	B
cytosine	O	NOUN	I
is	O	AUX	O
located	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
particular	O	ADJ	O
region	O	NOUN	O
of	O	ADP	O
the	O	DET	O
gene	O	NOUN	B
within	O	ADP	O
which	O	DET	O
that	O	DET	O
codon	O	NOUN	B
resides	O	VERB	B
.	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
von	B-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	NOUN	B
tumor	I-Disease	NOUN	I
suppressor	O	NOUN	I
gene	O	NOUN	I
product	O	NOUN	I
interacts	O	VERB	O
with	O	ADP	O
Sp1	O	NOUN	B
to	O	PART	O
repress	O	VERB	B
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
promoter	O	NOUN	B
activity	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
von	B-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	NOUN	B
tumor	I-Disease	NOUN	I
suppressor	O	NOUN	I
gene	O	NOUN	I
(	O	PUNCT	O
VHL	O	NOUN	B
)	O	PUNCT	O
has	O	AUX	O
a	O	DET	O
critical	O	ADJ	O
role	O	NOUN	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
clear	B-Disease	ADJ	B
-	I-Disease	PUNCT	O
cell	I-Disease	NOUN	B
renal	I-Disease	ADJ	I
cell	I-Disease	NOUN	I
carcinoma	I-Disease	NOUN	I
(	O	PUNCT	O
RCC	B-Disease	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
VHL	O	NOUN	B
mutations	O	NOUN	B
have	O	AUX	O
been	O	AUX	O
found	O	VERB	O
in	O	ADP	O
both	O	CCONJ	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
associated	I-Disease	VERB	B
and	I-Disease	CCONJ	O
sporadic	I-Disease	ADJ	B
RCCs	I-Disease	NOUN	B
.	O	PUNCT	O


Recent	O	ADJ	O
studies	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
vascular	O	ADJ	B
endothelial	O	ADJ	I
growth	O	NOUN	I
factor	O	NOUN	I
(	O	PUNCT	O
VEGF	O	NOUN	B
)	O	PUNCT	O
mRNA	O	NOUN	B
is	O	AUX	O
upregulated	O	VERB	B
in	O	ADP	O
RCC	B-Disease	NOUN	B
-	I-Disease	PUNCT	O
and	I-Disease	CCONJ	O
von	I-Disease	PROPN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
-	I-Disease	PUNCT	O
associated	I-Disease	VERB	B
tumors	I-Disease	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
have	O	AUX	O
therefore	O	ADV	O
assessed	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VHL	O	NOUN	B
gene	O	NOUN	I
product	O	NOUN	I
on	O	ADP	O
VEGF	O	NOUN	B
expression	O	NOUN	B
.	O	PUNCT	O


VEGF	O	NOUN	B
promoter	O	NOUN	B
-	O	PUNCT	O
luciferase	O	NOUN	B
constructs	O	NOUN	B
were	O	AUX	O
transiently	O	ADV	O
cotransfected	O	VERB	B
with	O	ADP	O
a	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
VHL	O	NOUN	B
(	O	PUNCT	O
wt	O	PROPN	O
-	O	PUNCT	O
VHL	O	NOUN	B
)	O	PUNCT	O
vector	O	NOUN	O
in	O	ADP	O
several	O	ADJ	O
cell	O	NOUN	B
lines	O	NOUN	I
,	O	PUNCT	O
including	O	VERB	O
293	O	NUM	O
embryonic	O	ADJ	B
kidney	O	NOUN	I
and	O	CCONJ	O
RCC	B-Disease	NOUN	B
cell	O	NOUN	I
lines	O	NOUN	I
.	O	PUNCT	O


wt	O	NOUN	O
-	O	PUNCT	O
VHL	O	NOUN	B
protein	O	NOUN	I
inhibited	O	VERB	B
VEGF	O	NOUN	B
promoter	O	NOUN	B
activity	O	NOUN	I
in	O	ADP	O
a	O	DET	O
dose	O	NOUN	B
-	O	PUNCT	O
dependent	O	ADJ	B
manner	O	NOUN	O
up	O	ADV	O
to	O	PART	O
5	O	NUM	O
-	O	PUNCT	O
to	O	PART	O
10	O	NUM	O
-	O	PUNCT	O
fold	O	NOUN	B
.	O	PUNCT	O


Deletion	O	NOUN	B
analysis	O	NOUN	I
defined	O	VERB	O
a	O	DET	O
144	O	NUM	O
-	O	PUNCT	O
bp	O	NOUN	B
region	O	NOUN	B
of	O	ADP	O
the	O	DET	O
VEGF	O	NOUN	B
promoter	O	NOUN	B
necessary	O	ADJ	O
for	O	ADP	O
VHL	O	NOUN	B
repression	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
VHL	O	NOUN	B
-	O	PUNCT	O
responsive	O	ADJ	B
element	O	NOUN	B
is	O	AUX	O
GC	O	NOUN	B
rich	O	ADJ	O
and	O	CCONJ	O
specifically	O	ADV	O
binds	O	VERB	B
the	O	DET	O
transcription	O	NOUN	B
factor	O	NOUN	I
Sp1	O	NOUN	B
in	O	ADP	O
crude	O	ADJ	B
nuclear	O	ADJ	I
extracts	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
Drosophila	O	NOUN	B
cells	O	NOUN	I
,	O	PUNCT	O
cotransfected	O	VERB	B
VHL	O	NOUN	B
represses	O	VERB	O
Sp1	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
activation	O	NOUN	B
but	O	CCONJ	O
not	O	PART	O
basal	O	ADJ	B
activity	O	NOUN	I
of	O	ADP	O
the	O	DET	O
VEGF	O	NOUN	B
promoter	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
next	O	ADV	O
demonstrated	O	VERB	O
in	O	ADP	O
coimmunoprecipitates	O	NOUN	B
that	O	SCONJ	O
VHL	O	NOUN	B
and	O	CCONJ	O
Sp1	O	NOUN	B
were	O	AUX	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
same	O	ADJ	O
complex	O	NOUN	B
and	O	CCONJ	O
,	O	PUNCT	O
by	O	ADP	O
using	O	VERB	O
a	O	DET	O
glutathione	O	NOUN	B
-	O	PUNCT	O
S	O	PROPN	B
-	O	PUNCT	O
transferase	O	NOUN	B
-	O	PUNCT	O
VHL	O	NOUN	B
fusion	O	NOUN	B
protein	O	NOUN	I
and	O	CCONJ	O
purified	O	VERB	B
Sp1	O	NOUN	B
,	O	PUNCT	O
that	O	SCONJ	O
VHL	O	NOUN	B
and	O	CCONJ	O
Sp1	O	NOUN	B
directly	O	ADV	O
interact	O	VERB	B
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
endogenous	O	ADJ	B
VEGF	O	NOUN	B
mRNA	O	NOUN	B
levels	O	NOUN	O
were	O	AUX	O
suppressed	O	VERB	B
in	O	ADP	O
permanent	O	ADJ	B
RCC	B-Disease	NOUN	B
cell	O	NOUN	B
lines	O	NOUN	I
expressing	O	VERB	B
wt	O	NOUN	O
-	O	PUNCT	O
VHL	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
nuclear	O	ADJ	B
run	O	NOUN	I
-	O	PUNCT	O
on	O	ADP	O
studies	O	NOUN	B
indicated	O	VERB	O
that	O	SCONJ	O
VHL	O	NOUN	B
regulation	O	NOUN	B
of	O	ADP	O
VEGF	O	NOUN	B
occurs	O	VERB	O
at	O	ADP	O
least	O	ADJ	O
partly	O	ADV	O
at	O	ADP	O
the	O	DET	O
transcriptional	O	ADJ	B
level	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
observations	O	NOUN	B
support	O	VERB	O
a	O	DET	O
new	O	ADJ	O
mechanism	O	NOUN	B
for	O	ADP	O
VHL	O	NOUN	B
-	O	PUNCT	O
mediated	O	VERB	B
transcriptional	O	ADJ	B
repression	O	NOUN	I
via	O	ADP	O
a	O	DET	O
direct	O	ADJ	O
inhibitory	O	ADJ	B
action	O	NOUN	O
on	O	ADP	O
Sp1	O	NOUN	B
and	O	CCONJ	O
suggest	O	VERB	O
that	O	SCONJ	O
loss	O	NOUN	B
of	O	ADP	O
Sp1	O	NOUN	B
inhibition	O	NOUN	B
may	O	AUX	O
be	O	AUX	O
important	O	ADJ	O
in	O	ADP	O
the	O	DET	O
pathogenesis	O	NOUN	B
of	O	ADP	O
von	B-Disease	NOUN	B
Hippel	I-Disease	PROPN	I
-	I-Disease	PUNCT	O
Lindau	I-Disease	PROPN	B
disease	I-Disease	NOUN	I
and	O	CCONJ	O
RCC	B-Disease	NOUN	B
.	O	PUNCT	O
.	O	PUNCT	O


Adult	B-Disease	ADJ	B
onset	I-Disease	NOUN	O
globoid	I-Disease	NOUN	O
cell	I-Disease	NOUN	O
leukodystrophy	I-Disease	NOUN	O
(	O	PUNCT	O
Krabbe	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
)	O	PUNCT	O
:	O	PUNCT	O
analysis	O	NOUN	B
of	O	ADP	O
galactosylceramidase	O	NOUN	B
cDNA	O	NOUN	B
from	O	ADP	O
four	O	NUM	O
Japanese	O	ADJ	B
patients	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
examined	O	VERB	B
galactosylceramidase	O	NOUN	B
(	O	PUNCT	O
GALC	O	NOUN	B
)	O	PUNCT	O
cDNA	O	NOUN	B
in	O	ADP	O
four	O	NUM	O
Japanese	O	ADJ	B
patients	O	NOUN	B
with	O	ADP	O
adult	B-Disease	ADJ	B
onset	I-Disease	NOUN	O
globoid	I-Disease	NOUN	B
cell	I-Disease	NOUN	I
leukodystrophy	I-Disease	NOUN	I
(	O	PUNCT	O
Krabbe	B-Disease	ADJ	B
disease	I-Disease	NOUN	I
;	O	PUNCT	O
AO	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
GLD	I-Disease	PROPN	B
)	O	PUNCT	O
by	O	ADP	O
polymerase	O	NOUN	B
chain	O	NOUN	I
reaction	O	NOUN	I
/	O	SYM	O
single	O	ADJ	B
-	O	PUNCT	O
strand	O	NOUN	B
conformation	O	NOUN	O
polymorphism	O	NOUN	B
(	O	PUNCT	O
PCR	O	NOUN	B
-	O	PUNCT	O
SSCP	O	NOUN	B
)	O	PUNCT	O
analysis	O	NOUN	B
,	O	PUNCT	O
subsequent	O	ADJ	O
sequence	O	NOUN	B
determination	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
restriction	O	NOUN	B
enzyme	O	NOUN	O
digestion	O	NOUN	O
of	O	ADP	O
PCR	O	NOUN	B
products	O	NOUN	I
,	O	PUNCT	O
initial	O	ADJ	B
symptoms	O	NOUN	B
were	O	AUX	O
the	O	DET	O
onset	O	NOUN	O
of	O	ADP	O
slowly	O	ADV	O
progressive	O	ADJ	B
spastic	B-Disease	ADJ	B
paraplegia	I-Disease	NOUN	I
from	O	ADP	O
the	O	DET	O
middle	O	NOUN	B
of	O	ADP	O
the	O	DET	O
second	O	ADJ	O
decade	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
diminished	B-Disease	VERB	B
GALC	I-Disease	NOUN	B
activity	I-Disease	NOUN	O
in	O	ADP	O
their	O	PRON	O
leukocytes	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
identified	O	VERB	B
three	O	NUM	O
missense	O	NOUN	B
mutations	O	NOUN	I
(	O	PUNCT	O
I66M	O	NOUN	B
,	O	PUNCT	O
G270D	O	NOUN	B
,	O	PUNCT	O
L618S	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
exon	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
skipping	O	NOUN	B
(	O	PUNCT	O
535	O	NUM	O
-	O	PUNCT	O
573del	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Two	O	NUM	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
had	O	AUX	O
only	O	ADV	O
the	O	DET	O
I66M	O	NOUN	B
mutant	O	ADJ	I
mRNA	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
only	O	ADV	O
the	O	DET	O
G27OD	O	NOUN	B
mutant	O	ADJ	I
mRNA	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
fourth	O	ADJ	O
patient	O	NOUN	B
carried	O	VERB	O
a	O	DET	O
compound	O	NOUN	B
heterozygous	O	ADJ	B
mutation	O	NOUN	B
of	O	ADP	O
535	O	NUM	O
-	O	PUNCT	O
573del	O	NOUN	B
and	O	CCONJ	O
L618S	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
determine	O	VERB	O
the	O	DET	O
enzymatic	O	ADJ	B
activities	O	NOUN	I
produced	O	VERB	O
by	O	ADP	O
these	O	DET	O
mutations	O	NOUN	B
,	O	PUNCT	O
we	O	PRON	O
constructed	O	VERB	O
mutated	O	VERB	B
GALC	O	NOUN	B
cDNAs	O	NOUN	O
and	O	CCONJ	O
expressed	O	VERB	B
them	O	PRON	O
in	O	ADP	O
COS	O	PROPN	B
-	O	PUNCT	O
1	O	NUM	O
cells	O	NOUN	B
.	O	PUNCT	O


Three	O	NUM	O
mutations	O	NOUN	B
,	O	PUNCT	O
viz	O	ADJ	O
.	O	PUNCT	O
,	O	PUNCT	O
G270D	O	NOUN	B
,	O	PUNCT	O
L618S	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
exon	O	NOUN	B
-	O	PUNCT	O
6	O	NUM	O
skipping	O	NOUN	B
(	O	PUNCT	O
535	O	NUM	O
-	O	PUNCT	O
573del	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
produced	O	VERB	O
diminished	B-Disease	VERB	B
GALC	I-Disease	NOUN	B
activity	I-Disease	NOUN	B
as	O	ADP	O
expected	O	VERB	O
.	O	PUNCT	O


The	O	DET	O
I66M	O	NOUN	B
mutation	O	NOUN	I
in	O	ADP	O
the	O	DET	O
wild	O	ADJ	B
-	O	PUNCT	O
type	O	NOUN	B
GALC	O	NOUN	B
cDNA	O	NOUN	O
(	O	PUNCT	O
I289	O	NOUN	B
)	O	PUNCT	O
had	O	AUX	O
normal	O	ADJ	B
activity	O	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
when	O	SCONJ	O
this	O	DET	O
mutation	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
V289	O	NOUN	B
polymorphism	O	NOUN	B
were	O	AUX	O
introduced	O	VERB	O
into	O	ADP	O
the	O	DET	O
same	O	ADJ	O
allele	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
had	O	AUX	O
decreased	O	VERB	B
activity	O	NOUN	B
.	O	PUNCT	O


Thus	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
a	O	DET	O
unique	O	ADJ	B
mutation	O	NOUN	B
and	O	CCONJ	O
polymorphism	O	NOUN	B
causes	O	VERB	O
conformational	O	ADJ	B
change	O	NOUN	I
in	O	ADP	O
the	O	DET	O
GALC	O	NOUN	B
enzyme	O	NOUN	B
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
low	O	ADJ	O
enzymatic	O	ADJ	B
activity	O	NOUN	I
.	O	PUNCT	O


AO	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
GLD	I-Disease	PROPN	B
mutations	O	NOUN	B
,	O	PUNCT	O
including	O	VERB	O
those	O	DET	O
found	O	VERB	O
here	O	ADV	O
,	O	PUNCT	O
are	O	AUX	O
located	O	ADJ	O
in	O	ADP	O
the	O	DET	O
N	O	NOUN	B
-	O	PUNCT	O
terminus	O	NOUN	B
(	O	PUNCT	O
I66M	O	NOUN	B
,	O	PUNCT	O
G270D	O	NOUN	B
,	O	PUNCT	O
535	O	NUM	O
-	O	PUNCT	O
573del	O	NOUN	B
)	O	PUNCT	O
or	O	CCONJ	O
C	O	NOUN	B
-	O	PUNCT	O
terminus	O	NOUN	B
(	O	PUNCT	O
L618S	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
the	O	DET	O
GALC	O	NOUN	B
enzyme	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
reported	O	VERB	O
mutations	O	NOUN	B
in	O	ADP	O
the	O	DET	O
infantile	O	ADJ	B
form	O	NOUN	I
(	O	PUNCT	O
IF	B-Disease	PROPN	B
-	I-Disease	PUNCT	O
GLD	I-Disease	PROPN	B
)	O	PUNCT	O
are	O	AUX	O
in	O	ADP	O
the	O	DET	O
central	O	ADJ	B
domain	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
difference	O	NOUN	O
in	O	ADP	O
mutation	O	NOUN	B
sites	O	NOUN	I
may	O	AUX	O
affect	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
features	O	NOUN	I
of	O	ADP	O
GLD	B-Disease	NOUN	B
.	O	PUNCT	O


